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Poor medicines adherence in children is one of the common problems 
in the health care system. Knowing the medicines adherence rate in 
individual children is important to understand the consequences of 
non-adherence. Different factors can contribute to poor adherence 
such as forgetting, lack of understanding about the treatment or 
disease, age of child, socioeconomic status, medicines schedule and 
taste. Strategies that target these factors may improve medicines 
adherence. This research explores methods of measuring medicines 
adherence and the barriers and facilitators to medicines adherence in 
children with diverse diseases.   
A systematic review of measures of medicines adherence in children 
was conducted. Six databases were searched to identify studies 
published in the last ten years and therefore to focus on the methods 
recently used to assess medicines adherence in children. Inclusion 
criteria were original research studies measuring medicines adherence 
in children. Only 31 articles met the inclusion criteria and were 
included. The review identified seven methods which had been used to 
measure adherence; self-report, Electronic Monitoring Devices (EMD), 
dose count, canister weight, plasma level, checking medical records or 
pharmacy refill data, and contact by mobile phone. Currently, no gold 
standard method to measure adherence to medicines in children exists 
as each method has its own advantages and disadvantages. 
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A systematic review of the barriers and facilitators to medicines 
adherence in children was also conducted. Six databases were 
searched to identify the most common barriers and facilitators in the 
last ten years. Inclusion criteria were original research studies with 
stated objectives of identifying barriers and/or facilitators of medicines 
adherence in children. This review identified 177 articles that met the 
inclusion criteria. Reported barriers included forgetfulness, weak 
patient-provider relationships, stigma and discrimination, drug 
regimen complexity and lack of support from families. Factors reported 
to facilitate adherence include linking of medicine taking with daily life 
routines, using reminders to avoid forgetfulness, a higher level of 
caregivers and parental education and good communication between 
healthcare professionals, patients and parents. 
Based on the findings from the two systematic reviews, two exploratory 
studies were conducted to measure medicines adherence in children in 
Saudi Arabia and the UK, and to explore the barriers to and facilitators 
of medicines adherence in these children. After confirming eligibility for 
inclusion in the two studies, the patients and their parents or guardians 
were asked to participate in the studies. The researcher provided them 
with written and verbal information about the study in age-appropriate 
language. In both studies, the patient or parent/guardian were asked 
to answer all questions in the Beliefs about Medicines Questionnaire 
(BMQ) and our own designed questionnaire, in order to measure 
medicines adherence and explore the barriers to and facilitators of 
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medicines adherence in children. One hundred children and their 
parents/guardians were recruited for each study. The study conducted 
in Saudi Arabia found substantial agreement between the study’s two 
adherence measurement methods of self-report and Medication 
possession ratio (MPR) calculation. Additionally, this study identified 
that changes in daily routine, many doses each day, unpleasant 
medicine taste and fear of side effects were the most common barriers 
to medicines adherence. Using reminders, implementing a scheduled 
routine for taking medicines, measures to address poor taste, pain 
caused by administration or taking big tablets, and adequate family 
support were the most common facilitators for medicine adherence in 
children.  
The study conducted in the UK found changes in daily routine, poor 
medicine taste, many doses each day, and being busy were the most 
common barriers to medicine adherence. This study similarly found 
that using reminders, measures to address poor taste, pain caused by 
administration or taking big tablets, following a scheduled routine for 
taking medicines, and family support were the most common 
facilitators in children’s medicine adherence. Both studies found a 
statistically significant association between the participants’ beliefs 
about medicines and adherence rates and between adherence rates 
and the education level of the patients’ parents. However, there was 
no statistically significant association between adherence rates, age 
and gender in either study. 
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This project contributes to the field of medicines adherence in children 
by confirming that there is currently no gold standard method of 
measuring it, but that there is good agreement between the two 
adherence measurements of MPR and self-report. Additionally, 
parental education level and BMQ differential scores are factors 
significantly associated with medicines adherence.  In addition, this 
project highlights the most common barriers to and facilitators of 
medicines adherence in children with diverse diseases in children’s 
hospitals in Saudi Arabia and the UK.  
vii 
 
Publications and presentations related to this thesis  
 
Oral presentations:  
• Medicines adherence in children, 18 months presentation event in 
Clinical Sciences building, City Hospital, 29th October 2019, 
Nottingham, UK.  
 
Poster presentations:  
• Systematic review of measuring medicines adherence in children. 24th 
Neonatal and Paediatric Pharmacists Group (NPPG) Annual Professional 
Conference & Exhibition (9 – 11 November 2018), Mercure Grand 
Hotel, Bristol.  
• Aldosari M, Oliveira A, Conroy S. Measuring Medicines Adherence 
in Children: A Systematic Review. Arch Dis Child. 2019;104: e2. 
Available from: https://adc.bmj.com/content/104/7/e2.10.  
(Published abstract) 
• Systematic review of barriers and facilitators to medicines adherence 
in children. 25th NPPG Annual Professional Conference & Exhibition (8 




First and above all, I praise Allah, the almighty for guiding me in my 
life and during my study. I would like to express my deepest gratitude 
to Dr Sharon Conroy and Dr Ana Oliveira for their enthusiastic 
encouragement, guidance and effort to organise this project.  
I wish to also extend special thanks to Coral Smith and Janine 
Abramson for their double-checking of the data from the two 
systematic reviews.  
My appreciation is also extended to Coral Smith and the paediatric 
clinical nurses of the Royal Derby hospital for helping me in the 
recruitment of families in the UK questionnaire study. I would also like 
to thank Dr Alanoud Al Marri, the pharmacy staff and the paediatric 
nurses of King Fahad Medical City for helping me in the recruitment of 
families in the Saudi study. 
I would like also to offer special thanks to Dr Andrea Venn for her 
support and help while consulting and explaining the statistical 
methods. I would also like to thank my supervisors who gave advices 
concerning qualitative analysis.  
I would like also to thank Dr Lorraine Pinnington Director of 
Postgraduate Education, Karen Kirkland and all office staff at the 
Division of Medical Sciences and Graduate Entry Medicine for their 
guidance and help during my academic study.  
I would like also to acknowledge the support provided by my wife, 




ADHD           Attention Deficit Hyperactivity Disorder 
BMQ             Beliefs About Medicines Questionnaire 
CINAHL        Cumulative Index to Nursing and Allied Literature 
EMD             Electronic Monitoring Device 
GH Growth Hormone 
GORD Gastro-Oesophageal Reflux Disease 
HEDCs High Economic Developed Countries 
HDAS Healthcare Databases Advanced Search 
IBD             Inflammatory bowel disease 
IPA International Pharmaceutical Abstracts 
IRB Institutional Review Board 
KFMC King Fahad Medical City 
LEDCs         Low Economic Developed Countries 
MAM   Medical Adherence Measure 
MARS Medication Adherence Rate Scale 
MEMS Medication Event Monitoring System 
MPR Medication Possession Ratio 
PIS          Participant Information Sheet 
RCT Randomised Controlled Study 
STROBE Strengthening the Reporting of observational studies in           
Epidemiology 
TABS Talking About Medicines Study 
TB Tuberculosis 
VAS Visual Analogue Scale 




 Chapter 1: Introduction .................................................................... 1 
1.1 Background .......................................................................... 2 
1.2 Consequences and costs of medicines non-adherence .................. 5 
1.3 Medicines adherence measures ................................................ 7 
1.3.1 Direct methods ................................................................ 7 
1.3.2 Indirect methods .............................................................. 8 
1.4 Types of nonadherence ......................................................... 11 
1.4.1 Intentional nonadherence ................................................ 11 
1.4.2 Unintentional nonadherence ............................................. 13 
1.5 Barriers to medicines adherence ............................................. 14 
1.5.1 Patient-related factors ..................................................... 15 
1.5.2 Healthcare team and system-related factors ....................... 17 
1.5.3 Condition-related factors ................................................. 18 
1.5.4 Socioeconomic-related factors .......................................... 19 
1.5.5 Medicine-related factors .................................................. 20 
1.6 Facilitators of medicines adherence ......................................... 22 
1.7 Research question, aims and objectives of this research ............. 25 
1.7.1 Research question .......................................................... 25 
1.7.2 Aims of this research ...................................................... 25 
1.7.3 Objectives of this research ............................................... 25 
 Chapter 2: Measuring medicines adherence in children: A systematic 
review .......................................................................................... 28 
2.1 Introduction ........................................................................ 29 
2.2 Methods ............................................................................. 30 
2.2.1 Search strategy .............................................................. 30 
2.2.2 Justification of search strategy.......................................... 31 
2.2.3 Inclusion criteria ............................................................ 32 
2.2.4 Exclusion criteria ............................................................ 32 
2.2.5 Data collection and analysis ............................................. 33 
2.2.6 Quality assessment ......................................................... 33 
2.3 Results ............................................................................... 34 
2.3.1 Number of studies .......................................................... 34 
2.3.2 Quality of studies ........................................................... 36 
A. Observational studies ........................................................... 36 
B. RCT ................................................................................... 36 
xi 
 
2.3.3 Countries ...................................................................... 36 
2.3.4 Study design ................................................................. 36 
2.3.5 Type of assessment tools used to measure adherence .......... 37 
A. Self-report .......................................................................... 37 
B. Electronic monitoring devices (EMDs) ...................................... 41 
C. Pill or dose count ................................................................. 42 
D. Medical record or pharmacy refill data ..................................... 42 
E. Medicine plasma level ........................................................... 43 
F. Daily telephone calls ............................................................ 44 
G. Canister weight ................................................................... 44 
2.3.6 Type of diseases............................................................. 46 
A. HIV/AIDS ........................................................................... 47 
B. Asthma .............................................................................. 52 
C. Inflammatory Bowel Disease (IBD) ......................................... 54 
D. Diabetes ............................................................................. 56 
E. Epilepsy ............................................................................. 58 
F. Other diseases .................................................................... 60 
2.4 Discussion .......................................................................... 63 
2.5 Limitations .......................................................................... 72 
2.6 Conclusion .......................................................................... 72 
 Chapter 3: Barriers and facilitators to medicines adherence in children: A 
systematic review ........................................................................... 74 
3.1 Introduction ........................................................................ 75 
3.2 Methods ............................................................................. 76 
3.2.1 Search strategy .............................................................. 76 
3.2.2 Justification of search strategy.......................................... 77 
3.2.3 Inclusion criteria ............................................................ 78 
3.2.4 Exclusion criteria ............................................................ 78 
3.2.5 Data collection ............................................................... 78 
3.2.6 Quality assessment ......................................................... 79 
3.2.7 Data analysis ................................................................. 80 
3.3 Results ............................................................................... 80 
3.3.1 Number of studies .......................................................... 80 
3.3.2 Quality of studies ........................................................... 82 
A. Observational studies ........................................................ 82 
B. RCT ................................................................................ 82 
xii 
 
3.3.3 Countries ...................................................................... 82 
A. Studies from HEDCs (n=130) .............................................. 83 
B. Studies from LEDCs (n=47) ................................................ 83 
3.3.4 Study design ................................................................. 84 
3.3.5 Tools used to identify barriers and facilitators ..................... 84 
A. Patients’ medical data ........................................................... 84 
B. Self-report ....................................................................... 85 
3.3.6 Types of diseases ........................................................... 89 
A. HIV/AIDS ......................................................................... 90 
B. Asthma .......................................................................... 110 
C. Kidney or liver diseases and solid organ transplant patients .... 120 
D. Psychiatric disorders ......................................................... 127 
E. Inflammatory bowel diseases (IBD) ....................................... 133 
F. Epilepsy ............................................................................ 137 
G. Studies conducted with patients with different diseases .......... 142 
H. Sickle cell disease ............................................................ 145 
I. Cystic Fibrosis .................................................................... 148 
J. Diabetes ............................................................................ 150 
K. Tuberculosis .................................................................... 152 
L. Chronic rheumatic diseases .................................................. 154 
M. Multiple Sclerosis ............................................................. 156 
N. Cancer ........................................................................... 158 
O. (GH) deficiency ................................................................ 160 
P. Thalassemia ....................................................................... 162 
Q. Other diseases ................................................................. 164 
3.4 Discussion ......................................................................... 166 
3.4.1 Barriers to medicines adherence in children ....................... 167 
A. Patient-related factors ...................................................... 168 
B. Socioeconomic-related factors ............................................ 170 
C. Medicine-related factors .................................................... 171 
D. Condition related factors ................................................... 173 
E. Healthcare professional- and system-related factors .............. 174 
3.4.2 Facilitators to medicines adherence .................................. 176 
3.4.3 HEDC vs LEDC .............................................................. 177 
3.4.4 Limitations ................................................................... 179 
3.5 Conclusion ......................................................................... 179 
xiii 
 
 Chapter 4: Exploratory study on the barriers and facilitators of medicines 
adherence in a Saudi Arabia children’s hospital ................................... 181 
4.1 Introduction ....................................................................... 182 
4.1.1 Aims ........................................................................... 183 
4.2 Method ............................................................................. 183 
4.2.1 Inclusion criteria ........................................................... 183 
4.2.2 Exclusion criteria ........................................................... 184 
4.2.3 Recruitment ................................................................. 184 
4.2.4 Justification of the questionnaires .................................... 185 
A. Beliefs about Medicines Questionnaire (BMQ) ........................ 186 
B. Purpose-designed questionnaire ......................................... 188 
4.2.5 Thematic analysis .......................................................... 193 
4.2.6 Statistical analysis ......................................................... 197 
4.2.7 Sample size and justification ........................................... 197 
4.3 Results .............................................................................. 199 
4.3.1 Demographic and clinical characteristics ............................ 199 
4.3.2 Barriers to medicines adherence ...................................... 201 
4.3.3 Facilitators to medicines adherence .................................. 203 
4.3.4 Adherence rates ............................................................ 205 
4.3.5 Statistical analysis ......................................................... 210 
4.3.6 Barriers and facilitators to medicines adherence ................. 214 
4.3.7 Thematic analysis .......................................................... 219 
A. Barriers to medicines adherence ......................................... 220 
B. Facilitators of medicines adherence ..................................... 225 
4.3.8 Beliefs about Medicines Questionnaire (BMQ) ..................... 230 
4.4 Discussion ......................................................................... 236 
4.4.1 Adherence rates ............................................................ 237 
4.4.2 Barriers to medicines adherence ...................................... 239 
4.4.3 Facilitators of medicines adherence .................................. 244 
4.4.4 Implications for practice ................................................. 247 
4.4.5 Limitations ................................................................... 248 
4.5 Conclusions ....................................................................... 249 
 Chapter 5: Exploratory study on the barriers and facilitators of medicines 
adherence in a UK children’s hospital ................................................ 251 
5.1 Introduction ....................................................................... 252 
5.1.1 Aims ........................................................................... 253 
xiv 
 
5.2 Method ............................................................................. 253 
5.2.1 Inclusion criteria ........................................................... 254 
5.2.2 Exclusion criteria ........................................................... 254 
5.2.3 Recruitment ................................................................. 254 
5.2.4 Justification of the questionnaires .................................... 256 
5.2.5 Thematic analysis .......................................................... 256 
5.2.6 Statistical analysis ......................................................... 257 
5.2.7 Sample size and justification ........................................... 257 
5.3 Results .............................................................................. 257 
5.3.1 Demographic and clinical characteristics ............................ 257 
5.3.2 Most common barriers to medicines adherence .................. 260 
5.3.3 Most common facilitators to medicines adherence ............... 262 
5.3.4 Adherence rates ............................................................ 264 
5.3.5 Statistical analysis ......................................................... 268 
5.3.6 Barriers and facilitators to medicines adherence ................. 270 
5.3.7 Thematic analysis .......................................................... 276 
A. Barriers to medicines adherence ......................................... 277 
B. Facilitators of medicines adherence ..................................... 284 
5.3.8 Questionnaire (BMQ) ...................................................... 289 
5.4 Discussion ......................................................................... 295 
5.4.1 Adherence rates ............................................................ 296 
5.4.2 Barriers to medicines adherence ...................................... 298 
5.4.3 Facilitators of medicines adherence .................................. 303 
5.4.4 Implications for practice ................................................. 305 
5.4.5 Limitations ................................................................... 306 
5.5 Conclusion ......................................................................... 308 
 Chapter 6: Barriers to and facilitators of medicines adherence in children 
with diverse diseases “a comparison” ................................................ 309 
6.1 Introduction ....................................................................... 310 
6.2 Methods ............................................................................ 310 
6.2.1 Saudi and UK studies (Chapters 4 and 5) – Key differences .. 310 
6.2.2 Previous studies conducted with children with diverse diseases
 311 
6.2.3 Data analysis ................................................................ 311 
6.3 Results .............................................................................. 312 
6.3.1 Countries ..................................................................... 312 
xv 
 
6.3.2 Most common barriers and facilitators in all studies ............. 312 
6.4 Discussion ......................................................................... 317 
6.5 Conclusion ......................................................................... 322 
 Chapter 7: General conclusion ........................................................ 324 
7.1 Introduction ....................................................................... 325 
7.2 Key findings ....................................................................... 326 
7.3 Key practice implications ...................................................... 329 
7.4 Limitations ......................................................................... 330 
7.5 Challenges ......................................................................... 331 
7.6 Future research .................................................................. 332 
7.7 Conclusion ......................................................................... 333 
 References .................................................................................. 335 
 Appendices .................................................................................. 384 
9.1 Ethical approval in Saudi Arabia ............................................ 385 
9.2 Participant information sheets and consent forms ..................... 386 
9.3 BMQ questionnaire Arabic and English forms ........................... 403 
9.4 Designed questionnaire Arabic and English forms ..................... 408 
9.5 Summary table for Chapter 4 ................................................ 415 
9.6 Ethical approval in the UK (Chapter 5) ................................... 420 
9.7 Certificate for Research Integrity course ................................. 425 
9.8 Summary table for Chapter 5 ................................................ 426 
 
List of Figures 
Figure 1-1 Relationship between medicine non-adherence and associated 
health care costs. Adapted from Aurel O Luga. ...................................... 6 
Figure 1-2 The five factors affecting medicine adherence. Adapted from 
WHO 2003. .................................................................................... 15 
Figure 1-3  Flow chart showing the relationship between the works 
involved in this thesis ...................................................................... 27 
Figure 2-1  Flow chart of the literature search performed (PRISMA flow 
diagram). ...................................................................................... 35 
xvi 
 
Figure 3-1 Flow chart of the literature search performed (PRISMA flow 
diagram). ...................................................................................... 81 
List of Tables 
Table 2-1 Summary of self-report tools used. .................................... 39 
Table 2-2 Summary of measures of adherence by medical or pharmacy 
refill data. ..................................................................................... 43 
Table 2-3 Summary of the strengths and weaknesses of the assessment 
tools ............................................................................................. 45 
Table 2-4 Studies measuring medicines adherence in HIV/AIDS patients 49 
Table 2-5 Studies measuring medicines adherence in patients with Asthma
 ................................................................................................... 53 
Table 2-6 Studies measuring medicines adherence in patients with IBD . 55 
Table 2-7 Studies measuring medicines adherence in patients with diabetes
 ................................................................................................... 57 
Table 2-8 Studies measuring medicines adherence in patients with epilepsy
 ................................................................................................... 59 
Table 2-9 Studies measuring medicines adherence in patients with different 
diseases ........................................................................................ 61 
Table 3-1 Summary of validated questionnaires used to identify barriers 
and facilitators. .............................................................................. 86 
Table 3-2  Studies reporting barriers and facilitators to medicines 
adherence in HIV/AIDS patients. For barriers and facilitators numbers are 
reported as % or significant association (if no numbers given numbers not 
reported in study). .......................................................................... 95 
Table 3-3 Studies reporting barriers and facilitators to medicines 
adherence in patients with asthma. For barriers and facilitators numbers are 
xvii 
 
reported as % or significant association (if no numbers given, numbers not 
reported in study). ......................................................................... 113 
Table 3-4 Studies reporting barriers and facilitators to medicines 
adherence in patients with kidney or liver diseases or solid organ transplant. 
For barriers and facilitators numbers are reported as % or significant 
association (if no numbers given numbers not reported in study). ......... 122 
Table 3-5 Studies reporting barriers and facilitators to medicines 
adherence in patients with psychiatric disorders. For barriers and facilitators 
numbers are reported as % or significant association (if no numbers given 
numbers not reported in study). ...................................................... 129 
Table 3-6 Studies reporting barriers and facilitators to medicines 
adherence in patients with IBD. For barriers and facilitators numbers are 
reported as % or significant association (if no numbers given numbers not 
reported in study). ......................................................................... 134 
Table 3-7  Studies reporting barriers and facilitators to medicines 
adherence in patients with epilepsy. For barriers and facilitators numbers 
are reported as % or significant association (if no numbers given numbers 
not reported in study). ................................................................... 139 
Table 3-8  Studies reporting barriers and facilitators to medicines 
adherence in patients with different diseases. For barriers and facilitators 
numbers are reported as % or significant association (if no numbers given 
numbers not reported in study). ...................................................... 143 
Table 3-9 Studies reporting barriers and facilitators to medicines 
adherence in patients with sickle cell disease. For barriers and facilitators 
numbers are reported as % or significant association (if no numbers given 
numbers not reported in study). ...................................................... 146 
xviii 
 
Table 3-10 Studies reporting barriers and facilitators to medicines 
adherence in patients with cystic fibrosis diseases. For barriers and 
facilitators numbers are reported as % or significant association (if no 
numbers given numbers not reported in study). ................................. 149 
Table 3-11  Studies reporting barriers and facilitators to medicines 
adherence in patients with diabetes. For barriers and facilitators numbers 
are reported as % or significant association (if no numbers given numbers 
not reported in study). ................................................................... 151 
Table 3-12  Studies reporting barriers and facilitators to medicines 
adherence in patients with tuberculosis. For barriers and facilitators 
numbers are reported as % or significant association (if no numbers given 
numbers not reported in study). ...................................................... 153 
Table 3-13  Studies reporting barriers and facilitators to medicines 
adherence in patients with chronic rheumatic disease. For barriers and 
facilitators numbers are reported as % or significant association (if no 
numbers given numbers not reported in study). ................................. 155 
Table 3-14  Studies reporting barriers and facilitators to medicines 
adherence in patients with multiple sclerosis. For barriers and facilitators 
numbers are reported as % or significant association (if no numbers given 
numbers not reported in study). ...................................................... 157 
Table 3-15  Studies reporting barriers and facilitators to medicines 
adherence in patients with cancer. For barriers and facilitators numbers are 
reported as % or significant association (if no numbers given numbers not 
reported in study). ......................................................................... 159 
Table 3-16  Studies that reported barriers and facilitators to medicines 
adherence in patients with GH deficiency. For barriers and facilitators 
xix 
 
numbers are reported as % or significant association (if no numbers given 
numbers not reported in study). ...................................................... 161 
Table 3-17  Studies reporting barriers and facilitators to medicines 
adherence in patients with thalassemia. For barriers and facilitators 
numbers are reported as % or significant association (if no numbers given 
numbers not reported in study). ...................................................... 163 
Table 3-18 Studies reporting barriers and facilitators to medicines 
adherence in patients with other diseases. For barriers and facilitators 
numbers are reported as % or significant association (if no numbers given 
numbers not reported in study). ...................................................... 165 
Table 4-1  Examples of coding ........................................................ 195 
Table 4-2  Examples of turning codes into themes ............................. 195 
Table 4-3 Demographic and clinical characteristics of the study population 
(n = 100) ..................................................................................... 200 
Table 4-4 Barriers to Medicines adherence as perceived by the study 
population. ................................................................................... 202 
Table 4-5 Facilitators to medicines adherence as perceived by the study 
population .................................................................................... 204 
Table 4-6  Medicines adherence, as reported by the study population and 
measured by the MPR..................................................................... 205 
Table 4-7 Self-reported vs. MPR level of agreement of medicines 
adherence. ................................................................................... 207 
Table 4-8 Distribution of children’s adherence to medicines by disease .. 209 
Table 4-9 Stratification of the study participants’ characteristics and 
children’s adherence to medicine (MPR) ............................................ 211 
xx 
 
Table 4-10 Stratification of the study participants’ characteristics and self-
report adherence to medicine .......................................................... 213 
Table 4-11  Questions about barriers and facilitators to medicines 
adherence .................................................................................... 217 
Table 4-12 Barriers and facilitators themes. ..................................... 219 
Table 4-13 Barriers to medicines adherence as reported by study 
participants .................................................................................. 220 
Table 4-14 Facilitators of medicines adherence as reported by study 
participants .................................................................................. 225 
Table 4-15 Beliefs about Medicines among Saudi participants. ............. 231 
Table 4-16 Mean BMQ necessity and concerns scales in different groups.
 .................................................................................................. 232 
Table 4-17 Mean BMQ necessity and concerns scales ......................... 233 
Table 4-18 Correlation between BMQ differential scores and MPR 
adherence .................................................................................... 234 
Table 4-19 Correlation between BMQ differential scores and self-reported 
adherence .................................................................................... 235 
Table 5-1 Demographic and clinical characteristics of the study population 
(n = 100) ..................................................................................... 258 
Table 5-2 Barriers to Medicines adherence as perceived by the study 
population .................................................................................... 261 
Table 5-3 Facilitators to medicines adherence as perceived by the study 
population .................................................................................... 263 
Table 5-4 Adherence rate for 14 participants who took more than one 
medicine and reported different adherence rates. ............................... 265 
Table 5-5 Self-reported adherence rates .......................................... 266 
xxi 
 
Table 5-6 Distribution of children’s adherence to medicines by disease .. 267 
Table 5-7 Stratification of the study participants’ characteristics and 
children’s adherence to medicine ...................................................... 269 
Table 5-8 Questions about barriers and facilitators to medicines adherence
 .................................................................................................. 273 
Table 5-9  Examples of experienced side effects. ............................... 275 
Table 5-10 Barriers and facilitators themes. ..................................... 276 
Table 5-11  Barriers to medicines adherence as reported by study 
participants .................................................................................. 277 
Table 5-12 Facilitators of medicines adherence as reported by study 
participants .................................................................................. 284 
Table 5-13  Beliefs about Medicines among participants. .................... 290 
Table 5-14 Mean BMQ necessity and concerns scales in different groups.
 .................................................................................................. 291 
Table 5-15 Mean BMQ necessity and concerns scales ......................... 292 
Table 5-16 Correlation between BMQ differential scores and adherence rate
 .................................................................................................. 294 
Table 6-1 Studies reporting barriers and facilitators to medicines 
adherence in patients with diverse diseases. For barriers and facilitators 
numbers are reported as % or significant association (if no numbers given 



























Around 400 BCE, Hippocrates was the first to note that some patients 
do not take their medicines as prescribed, and then complain that they 
do not work (1). In 1882, Robert Koch described noncompliant patients 
with tuberculosis (TB) as irresponsible and/or careless (1). McMaster 
University Medical Centre initiated the groundwork on patient 
compliance at the beginning of the 1970s, resulting in a book entitled 
Compliance with Therapeutic Regimens by Sackett and Haynes (2). 
According to Sackett and Haynes (1976), compliance is defined as “the 
extent to which the patient’s behaviour coincides with the clinical 
prescription, regardless of how the latter was generated” (2). 
Thus, the groundwork for the present adherence research was laid at 
the end of the 1970s. At that time, only the term compliance was used, 
and research studies concentrated on the influence of noncompliance 
on therapeutic results in clinical studies. Patients’ perspectives had not 
yet been considered (3). 
Later studies addressed how patients were affected, and how 
medicines were integrated into patients’ daily routines (3). Parallel to 
this evolution, the term adherence was increasingly used instead of 
compliance (4). Medicines adherence and patient compliance have 
often been used synonymously. However, compliance has recently 
been associated with the negative connotation that patients are 
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subservient to healthcare professionals and now, the preferred 
terminology is ‘adherence with medication’ (3). 
These changes led a joint working group convened by the Royal 
Pharmaceutical Society of Great Britain to suggest using the new term 
concordance in 1995 (5). In 1997, adherence was defined by the 
American Heart Association as: “a behavioural process, strongly 
affected by the environment in which the patient lives, including health 
care practices and systems” (6). This definition assumed that optimal 
adherence depends on patients having the motivation, skills, resources 
and knowledge required to follow healthcare professionals’ instructions 
(6). 
In 2003, adherence was defined by the World Health Organisation 
(WHO) as “the extent to which a person’s behaviour—taking 
medication, following a diet and/or executing lifestyle changes 
corresponds with agreed recommendations from a healthcare 
provider” (7). Progressively, the idea of agreement and cooperation 
between patient and healthcare provider became associated with the 
idea of adherence, while ‘compliance’ referred only to following a 
healthcare provider’s recommendations (7). 
Concordance refers to involving patients in the treatment process to 
improve adherence. It is not synonymous with either adherence or 
compliance. It refers to the interaction between patients and 
healthcare providers, but it does not relate directly to a patients’ 
medication-taking behaviour (8). 
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To achieve high levels of concordance patients should be involved in 
the decision of prescribing medicines. If a therapeutic partnership is 
not established non-concordance may occur and therefore may lead to 
failure of the interaction (9). Concordance is based on the assumption 
that discussion between patients and healthcare providers is a 
negotiation between equals. As such, how patients value the benefits 
and risks of a particular medicine may differ from the values 
determined by their healthcare providers (10). One of the differences 
between concordance and adherence or compliance is that adherence 
and compliance can be measured by pharmacy dispensing data, 
electric pill counters, prescription claim records or other validated 
survey instruments; however, concordance cannot be measured in 
these ways (9).  
Persistence is another term associated with the optimal use of 
medicines by patients, however it is purely related to long-term 
therapy. The definition of persistence is “the length of time between 
the first and last dose, being applicable in the event that a patient 
discontinues treatment” (11). Whereas persistence refers to how long 
patients remain on therapy, adherence and compliance refer to how 
well patients follow the treatment (11).  
Treatment outcomes are affected not only by how well patients follow 
the treatment but also by how long they remain on the treatment. Thus 
adherence and persistence should be measured and defined separately 
to achieve good outcomes of treatment (11). Patients’ desire to take a 
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medicine plays an important role in adherence. Thus, compliance, 
persistence and adherence, but not concordance, are terminologies 
that may detect the level of inadequate medicine use (12). In 2009, 
medicine adherence was added as a MeSH term (13). 
Medicines non-adherence is a multidimensional health care issue. 
Patients may be non-adherent during different stages of therapy; they 
may decide not to have their medicines dispensed and even not to start 
taking them at all. Furthermore, patients may take their medicines at 
the wrong times, or use less or more than the prescribed amounts. 
Patients may also discontinue treatment prematurely (12) . 
1.2 Consequences and costs of medicines non-adherence 
According to Chappell et al., 30 to 70% of children prescribed long-
term medicines exhibit poor adherence (14). The consequences of 
medicines non-adherence may be disease progression, lower quality of 
life, wasted medicines, and increased use of medical resources, e.g., 
hospital visits, and increased admissions to nursing homes (15). Figure 
1-1 shows the relationship between medicines non-adherence and 
associated health care costs. The risk of hospitalisation for non-
adherent patients with congestive heart failure, hypercholesterolemia, 
diabetes mellitus, or hypertension is more than double that of the 
adherent patients (16). Non-adherence to medicines may also have 
negative consequences for healthcare providers, and medical 




       
Figure 1-1 Relationship between medicine non-adherence and 
associated health care costs. Adapted from Aurel O Luga (17). 
The health concern is that poor adherence can result in unsuccessful 
or inadequate therapies and unnecessarily prolonged therapies. It can 
also lead to additional visits to doctors or changed prescriptions (18). 
Premature discontinuation of treatment may lead to delayed recovery, 
and this may result in patients contracting additional diseases and 
more hospitalisation and costs. Additionally lack of adherence places 
patients at risk of complicating the doctor-patient relationship as well 
as extending periods of treatment (19). Non-adherence to antibiotic 
courses may lead to bacterial resistance and the increased probability 
of recurrent infections (18). When patients take extra doses of 
medicines without medical supervision, the possibility of toxicity 
increases, and this may lead to increased rates of mortality and 













1.3 Medicines adherence measures 
Knowing the degree to which patients adhere to medicines is important 
both in clinical practice and in medical research. Assessing medicine 
adherence in pharmaceutical trials is necessary to examine the dose–
response relationship and enable an accurate analysis of treatment 
efficacy and toxicity (20). Inaccurate assessment may cause problems 
that are dangerous and costly, e.g. if an adolescent patient’s adherence 
to antidiabetic medicines is estimated incorrectly to be high but their 
blood glucose is still high, the doctor may increase the dose of the 
prescribed medicines or add other antidiabetic medicines in addition 
(21). Many different methods are used to measure adherence to 
medicines (20). These methods may be categorised as either direct or 
indirect (22). Currently, no gold standard method exists, as each 
method has its own advantages and disadvantages (22). 
1.3.1  Direct methods 
Direct methods include: 
• Measurement of the concentration of the medicine or a metabolite 
in a body fluid, usually urine or blood. 
• Direct observation of the patient taking the medicine. 
These methods can be used at specific intervals or randomly (20). The 
measurement of the drug plasma level is a good technique to assess 
adherence (22). For example, with some anti-epileptic drugs, such as 
valproic acid or phenytoin, the drug plasma level should reflect regimen 
8 
 
adherence with these medicines. Although these direct methods are 
considered more accurate than indirect methods, direct methods also 
have some disadvantages (22). Direct methods are difficult to perform, 
invasive, expensive, and may be susceptible to distortion by the 
patients, e.g., a patient may take a double dose of the medicine before 
the blood test and, thus, can give a false impression of adherence (23). 
1.3.2  Indirect methods 
Indirect methods are more commonly used to assess medicine 
adherence than direct methods. The most commonly used indirect 
methods are highlighted below: 
A. Patient self-reports 
To assess adherence to medicines clinicians traditionally rely on self-
reports. Direct questions for patients regarding medicine use may be 
asked during consultations (24). Clinicians may ask judgmental, single 
closed-ended questions, such as, ‘Do you take your medications as 
prescribed?’ and because of worries in sharing difficulties associated 
with drug use, patients may answer ‘yes’. This type of direct 
questioning has been suggested to be unreliable (25). More reliable 
and complete information may be obtained through alternative 
questioning (26). By posing non-judgmental, open-ended questions, 
such as ‘Will you tell me how you take your medications?’, patients 
may actually be encouraged by interviewers to share their difficulties 
with medicine use (26). Also, questions could be focused on how many 
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times a patient forgot to take their medicines and the reasons why a 
patient might not take his or her medicine (27). Medicines adherence 
in children can be assessed by asking the opinion of a caregiver 
(parents, school nurse or teacher) (16). Although self-report is easy to 
use and inexpensive, it is thought to be the least accurate method 
(28,29). 
B. Dose counting 
This method involves counting the number of doses that have been 
taken between two clinic visits or scheduled appointments, and 
comparing this number with the total number of doses dispensed for 
the patient in order to assess medicine adherence in research settings 
(30). For inhaler devices doses may be counted by weighing inhaler 
devices at the beginning of treatment and at each subsequent clinical 
visit until the devices are empty (24,31). This method is easy to use 
and inexpensive compared with other methods. The main 
disadvantages of this method are overestimates of the adherence rate, 
families may forget to bring their medicine containers to each visit, it 
counts the number of doses gone but this does not guarantee medicine 
ingestion, and it fails to provide information on the times that doses 
are taken which may be important in determining clinical outcomes 
(23). In addition, patients can manipulate the data, e.g., a patient may 




C. Electronic monitoring devices (EMDs) 
The EMD is a device that fits on a medicine bottle and contains 
microelectronics that record the time and date the bottle is opened. It 
can also record how many hours since it was last opened and how 
many times the bottle has been opened (24). Use of EMDs in practice 
and research is increasing because of their ability to provide adherence 
data to clinicians  (28,33). Although EMDs may be considered to be the 
best method to assess adherence of medicines, EMDs are expensive, 
patients need to understand how to use the device, the opening of the 
medicine bottle does not necessarily mean that the dose was taken, 
and the presence of an electronic monitoring device may remind 
patients that they are under surveillance, which may affect their 
medicine-taking behaviour, thereby inflating their adherence rates 
(33,34).  
D. Pharmacy refill data 
Prescription data and data on pharmacy refills may be used to assess 
patient adherence. These data can show the frequency of refills and 
whether or not patients’ prescriptions have been filled (35).  Pharmacy 
refill data can measure adherence by calculating the medication 
possession ratio (MPR), which is defined as “the number of doses 





The MPR is calculated by this equation: 
MPR = 
total days’ supply for medicine dispensed 
the number of days that the patient should have been taking the medicine
 
The MPR will equal 1, representing the highest adherence, when the 
total days’ supply is equal to the number of days between two 
prescription refill times. Assuming that the number of days of the 
supply is constant, the longer the duration between two prescription 
refills, the lower the MPR value, reflecting lower adherence (36). The 
disadvantages of this method are that patients may order refills but 
possess a large amount of unopened medicine, the method is useful to 
assess adherence for chronic diseases but not for acute diseases, and 
this method does not account for the timing of the doses (38).  
1.4 Types of nonadherence 
Nonadherence to medicines may be intentional or unintentional. 
1.4.1  Intentional nonadherence 
Intention is characterised as the determination to act in a certain 
way and is an element of human behaviour, including health 
behaviour (39). Intentional nonadherence can be described as “a 
process in which the patient decides not to follow therapy 
instructions or not to use medication” (40). This generally reflects a 
decision-making process in which patients weigh the advantages and 
disadvantages of therapy (40). It is important to understand the 
cognitive factors (e.g., preferences and beliefs) that may affect 
medicines adherence (41). 
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The beliefs affecting patients’ adherence to medicines can be divided 
into two groups: concerns about possible adverse effects (Concern 
beliefs) and perceptions about the need for medicines (Necessity 
beliefs) (42). This ‘Necessity-Concerns Framework’ may help 
healthcare providers elicit and address key beliefs that support 
patients’ attitudes and decisions about medicines (41). Horne et al. 
developed a validated questionnaire (Beliefs about Medicines 
Questionnaire (BMQ)) to quantify patients’ Concerns and Necessity 
beliefs and  to assess their relationship with medicines adherence 
(42). A meta-analysis of 94 studies of patients with chronic diseases 
was then performed by Horne et al. to examine the value of the BMQ 
in predicting medicines adherence.  It was concluded that the BMQ 
is useful for understanding patients’ perspectives on their medicines 
and medicines adherence can be improved by addressing patients’ 
concerns and explaining to them the importance of their medicines 
(41). 
Beliefs about the necessity of medicines is assumed to be determined 
by quality of life, the severity of disease and patients’ behaviours 
(43). There are many behavioural theories that are believed to have 
an impact on patients’ beliefs about their medicines. For example, if 
the patients think that their disease can be controlled by the 
medicines, they are more likely to be adherent. This is guided by 
Weiner’s attribution theory that is concerned how individuals’ 
behaviour and thinking are related to how their interpret events 
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(44). Patients’ beliefs about their medicines may have a greater 
impact on their adherence if they have a psychological need for 
autonomy (45). Self-determination theory (which refers to each 
patient’s ability to make choices for their treatment) is another 
behavioural theory that argues that treatment environments that 
support confidence and affords autonomy for patients are likely to 
improve medicines adherence (45). 
The health locus of control is another psychological construct that 
has been studied in relationship to adherence (46). Locus of control 
contributes to understanding health behaviours in chronic diseases 
(46). Locus of control is divided into two categories: internal (a belief 
that a person can have control over their health and refers to traits 
and behaviours) and external (a belief that results from outside 
factors which are independent of their own action) (47). It has been 
found that medicines adherence may be influenced by patients’ 
health locus of control (47). For example, adherence rates may be 
improved by interventions that target patients’ internal locus of 
control such as providing a positive feedback to the patient for their 
small success (48).  
1.4.2 Unintentional nonadherence 
Unintentional nonadherence refers to passive or unplanned 
behaviour and is less strongly related to individual cognition and 
beliefs than intentional nonadherence. It may be the consequence of 
not knowing precisely how to take medicine or of forgetfulness (49). 
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Patients may either not remember the instructions for medicine use 
or forget to take the medicines at the recommended times (39). 
The use of multiple medicines is related to an increased chance of 
complex dosing schemes. The necessity to manage potential drug–
drug interactions may also increase the risk of complex dosing 
schemes, such as the need to take bisphosphonates or tetracycline 
separately from iron salts, aluminium, magnesium or calcium. Other 
examples include the need to take thyroid hormones and 
bisphosphonates at least 30 minutes before breakfast. In contrast, 
some medicines should be taken with a meal, not on an empty 
stomach, leading to a complex dosing scheme that patients then 
have to follow (3). 
1.5 Barriers to medicines adherence 
Poor adherence may cause suboptimal results of treatment and 
increased morbidity and mortality (50). Enhancing medicine adherence 
for chronic conditions such as diabetes, hyperlipidaemia and 
hypertension creates significant economic and health benefits (7,50). 
To enhance adherence, the multifactorial causes of poor adherence 
should be understood. As shown in Figure 1-2, the World Health 
Organisation (WHO) classifies these factors into five categories: 
condition-related, social and economic, healthcare team and system-







Figure 1-2 The five factors affecting medicine adherence. Adapted 
from WHO 2003 (7). 
1.5.1  Patient-related factors 
A. Patient-related factors: adults 
Many patient-related factors, including suboptimal health literacy, lack 
of involvement in the therapy decision-making process, and lack of 
understanding of the disease, contribute to non-adherence to medicine 
(50–52). Health literacy is defined as “the degree to which patients 
have the ability to understand basic health information and services 
needed to make appropriate health decisions”  (50,53). In 2000 in the 
United States alone, an estimated 90 million adults had low health 























rates of hospitalisation (54). In 2015 in England 42 % of adults were 
unable to make use of and understand everyday health information 
(55).  
Medicines adherence in adults may be affected by patients’ experiences 
with pharmacological treatment, their attitudes and beliefs about the 
effectiveness of the therapy, low self-efficacy, lack of knowledge about 
the disease, and lack of motivation (56). In older adults, cognitive 
limitations and physical impairments, e.g., the patient may be unable 
to open the medicine bottle, may further increase the risk of medicine 
non-adherence (56). 
B. Patient-related factors: children 
Medicines adherence in children is also an important topic for health 
care professionals. Lack of adherence may cause complications in 
children with chronic or acute diseases (19). For many children, the 
administration of medicine is a parent’s responsibility, and parents’ 
knowledge, beliefs and attitudes may also affect the timing and dosing 
of medicines (57). Clinical experience indicates that for children with 
chronic diseases, e.g. diabetes, asthma, epilepsy and cystic fibrosis, 
poor adherence is common (14,57). 
One factor that affects adherence is age. Younger children appear to 
have higher rates of medicines adherence than adolescents (7,58). 
When children enter school, they spend less time with their family at 
home and they may be more influenced by the social environment and 
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their peers (7,58). Poor adherence is common in school-aged or 
adolescent patients who are taking multiple doses of medicine per day 
because of difficulty of using medicines at school (58,59). Children who 
are usually reminded by their parents to take their medicines may 
forget the doses during school time (49,58).  Family conflict and stress 
for children and parents have been suggested to be some of the most 
significant reasons for medicine non-adherence (60). Other barriers 
reported by parents include not understanding the instructions of the 
treatment, changes in usual routine, being busy and forgetting 
(59,61,62).  
1.5.2  Healthcare team and system-related factors 
Healthcare providers may not only fail to recognise non-adherence to 
medicines in their patients, but they may also contribute to increasing 
the risk of non-adherence by inadequately considering the financial 
cost of medicines to the patient (in some countries some patients do 
not have health insurance and may have to buy their medicines) (63). 
In addition failing to explain the medicine’s side effects and benefits, 
or prescribing complex medicine regimens may contribute to non-
adherence (22,64). Communication between healthcare providers and 
patients may be inadequate and may also contribute to poor adherence 
(64).  
Healthcare system-related factors that have a negative effect on 
medicines adherence include (37,38): 
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• Provider-patient relationships, as weak relationships between care 
providers and patients may lead to decreased medicine adherence. 
• Lack of training and knowledge for healthcare providers. 
• Overworked healthcare providers. 
• Lack of  provider knowledge about medicine adherence and how to 
improve adherence. 
1.5.3  Condition-related factors 
In some patients with chronic diseases requiring long-term 
administration of medicines, adherence may decline significantly over 
time (67). This poor adherence may happen when symptoms of the 
disease are few or disappear; the absence of symptoms may be a 
barrier for patients to follow their treatment. Some patients with few 
disease symptoms may believe they are healing, discontinue their 
treatments and thus have poor medicine adherence, e.g., if an 
asthmatic child begins to feel better and their symptoms have 
improved, the parent may stop administering daily inhaled steroids, 
believing this will prevent the medicine’s side effects (68). It is 
imperative that patients understand the disease and the risks if they 
do not follow the treatment (56). 
Severity of the disease and rate of progression may affect adherence 
to medicines; when the severity of a disease is high, the medicine 
adherence of the patient with the disease may reduce because the 
patients may lose trust in their treatment (69,70).    
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1.5.4  Socioeconomic-related factors 
Family support is important for patients, especially children, who 
cannot be relied up on to take their medicines properly and may not 
realise the importance of the medicine or the seriousness of their 
disease. Patients who have less social support from caregivers, friends 
or family to assist with medicine regimens tend to have less medicines 
adherence (50,56).  
In some countries, limited access to healthcare facilities or greater 
distance from medical centres has been reported as a barrier to 
adherence especially for patients who do not have enough money for 
transportation (71,72). Patient adherence to medicines can also be 
affected by the fear of stigma or discrimination, especially among 
adolescent patients (73,74). Adolescents with diseases such as HIV 
may be afraid to take their medicines in front of others because of fear 
of disclosure of their disease status and subsequent discrimination, 
stigma, rejection and isolation (49,58,72). This could cause 
adolescents to hide their medicines from others or not take them at all 
when out with friends, which may result in not taking medicines at the 
right time or missing doses (73). 
High cost of medicine is another socioeconomic barrier to adherence in 
some countries, especially if patients do not have health insurance and 
have to pay for their medicine. In some cases, patients try to reduce 
the cost of medicine by decreasing the dosage and/or the frequency of 
a recommended treatment (56).  
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1.5.5  Medicine-related factors 
Some medicines have different routes of administration. The oral route 
is the preferred and most frequently used route of administration for 
children (75). The most commonly acceptable dosage form for 
children’s oral formulations is liquid, which also has the advantage of 
dosage flexibility. However, when the volumes to be administered are 
small, accuracy of measurement may become difficult and can confuse 
caregivers and parents (76). Furthermore, when the medicine is 
prescribed in a liquid formulation, parents may remember the volume 
of the dose but not necessarily the dosage in units. If a bottle is empty 
or broken, a different strength of medicine may be provided as a 
replacement e.g. many unlicensed products such as phenobarbital 
liquid are available on the market from different companies and in 
different strengths. Parents may continue to administer the original 
volume, resulting in the dose administered being up to tenfold lower 
or higher than prescribed (14). For example, in Sheffield, a four-
month-old baby died after a GP prescribed furosemide liquid which was 
ten times stronger than the formulation previously prescribed by the 
hospital (77). The GP correctly prescribed a reduced volume 
(decreased from 5 ml to 0.5 ml), but the mother gave the baby 5 ml 
by mistake in accordance with the first volume prescribed (77).  
Solid oral formulations have limited dose flexibility. In cases where no 
liquid formulation is available, carers and parents may be asked to 
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modify formulations, which can be difficult. For example, they may be 
asked to dissolve a capsule’s content in a certain volume of water or to 
crush and disperse a tablet in water. Such drug manipulations may 
lead to inaccurate dosing and reduce desired drug effectiveness or 
cause toxicity (78). The need for complex manipulations, poor drug 
efficacy or side effects may negatively affect patient adherence 
(61,69). 
Complexity of the medicine regimen is another medicine related barrier 
to adherence. When the number of medicines prescribed or the number 
of daily doses is increased, the possibilty of missing a doses increases 
(70,79). In addition, the longer the duration of treatment the less likely 
proper medicines adherence is maintained (80,81). Acute conditions 
are associated with greater adherence to medicine than chronic 
conditions (80).  
In asthmatic patients, especially children, ensuring continued use of 
inhaled medicines can be difficult (82). A number of factors may 
influence adherence to inhaled medicines, such as difficulties with 
inhaler devices (e.g., inhalers can be difficult to use and mistakes in 
the technique can mean that little or no dose is inhaled by the patient) 
and regimen complexity (83,84). 
Adverse effects of medicine have also been reported as a reason for 
discontinuing daily medicines (51,83). Adverse side effects can cause 
physical discomfort and decrease trust in doctors, causing scepticism 
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about the efficacy of the treatment (e.g. side effects have been 
reported as one of the most common reasons for non-adherence in 
children with chronic disease) (85). 
1.6 Facilitators of medicines adherence 
Understanding reasons for poor adherence and addressing them is 
important for improving medicines adherence (7). There are also 
factors that may help to improve medicines adherence, especially in 
children, such as family support, using reminders, establishing a 
routine, good knowledge about disease and treatment and masking 
poor taste/big tablet of medicine (50,75,86,87).  
Knowledge of the possible outcomes of non-adherence to the medicine 
and a comprehensive understanding of the importance of the medicine 
have been reported among children with HIV, asthma, ADHD and their 
parents who were adherent (86,88–90). This knowledge and 
understanding of the disease and importance of treatment, combined 
with patients’ desire to be healthy, motivated them to take their 
medicines as prescribed (86,88–90). 
Some patients establish a routine and use reminder tools so they do 
not forget to take their medicine (87). Linking the medicines regimen 
with daily life routines and taking the drugs at the same time every 
day (e.g., before a meal or after brushing teeth) may reduce the 
probability of missed doses (87,88). Patients use different reminder 
tools to remember their medicines, such as marking a calendar, 
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keeping a tally sheet of doses, setting an alarm (phone, tablet device 
or clock) or using note reminders (e.g., notes on the refrigerator) 
(70,87,91). 
The bad taste of some medicines is one of the reasons for poor 
adherence in children (92). Sweet tasting medicines can minimise 
resistance and enhance adherence for children as many have a low 
tolerance for disagreeable tasting medicines (75). However, these 
sweet medicines can cause problems with dental caries, especially if 
they are required on a long-term basis. 
Family support is one of the most important factors that can help 
patients, especially children, adhere to medicine (50,56). Family 
members can help the child by reminding them it is time to take their 
medicine, helping them take their medicine and encouraging them to 
continue with adherence to the medicine (93–95). In addition, 
reinforcing medicine taking with rewards can motivate children to 
adhere to their medicine (59). 
Healthcare providers can help improve adherence in children by 
clearly instructing the children and their parents on how to take 
their medicine, explaining any possible undesired aspects of taking 
their medicine and discussing options with them (e.g. some 
patients may prefer syrup formulations more than tablets) 
(59,96,97). In addition, discussing the rationale for the treatment 
and the benefits of adherence and offering written or verbal 
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information (e.g., telephone calls or home visits by nurses or 
educational books) about the nature of the medicines and the 
























1.7 Research question, aims and objectives of this research 
Most studies concerning medicines adherence have focused on adult 
patients rather than on children because of the practical difficulties and 
ethical issues in children’s studies (98). Most previous paediatric 
studies have focused on children with a particular disease, for example 
HIV, asthma, epilepsy or diabetes. Only a few studies included children 
with any and therefore diverse diseases. Most of these did not explore 
both barriers to and facilitators of medicines adherence.  
1.7.1  Research question  
What are the most common barriers to and facilitators of medicines 
adherence in children with diverse diseases?  
1.7.2  Aims of this research 
We aimed to fill gaps in knowledge of the barriers to and facilitators of 
medicines adherence in children with diverse diseases in the UK and 
Saudi Arabia.  
1.7.3  Objectives of this research 
1. To identify and explore the strengths and weaknesses of methods 
of measuring medicines adherence in children (Chapter 2). 
2. To identify barriers to and facilitators of medicines adherence in 




3. To measure medicines adherence in children in Saudi Arabia and 
to explore all barriers to and facilitators of their adherence 
(Chapter 4). 
4. To measure medicines adherence in children in the UK and to 
explore all barriers to and facilitators of their adherence 
(Chapter 5). 
5. To summarise current knowledge on barriers to and facilitators 
of medicines adherence in children with diverse diseases 
(Chapter 6), including the knowledge gained from our own 
work.  
6. To describe implications for practice and recommendations for 
future research (Chapter 7). 
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As previously mentioned, for many children, the administration of 
medicine is a parent’s responsibility, and parents’ knowledge, beliefs 
and attitudes may affect the timing and dosing of medicines (57). 
Reasons for poor medicines adherence in children include concerns 
about treatment effectiveness, forgetfulness, parents’ lack of 
understanding of the diagnosis, and fear of medicine side effects. 
Knowing the degree of medicines adherence in children is important to 
provide information on the consequences of non-adherence and to 
develop strategies to improve adherence (50). We wanted to find out 
the best method to measure adherence in children to inform the 
subsequent studies in this PhD project.  
An ideal measure of medicines adherence should be easy to carry out 
and inexpensive, user friendly, highly reliable, flexible, and practical. 
It has been suggested however, that no single standard measure 
meeting all these criteria has been identified (99). We looked for a 
systematic review exploring measures of medicines adherence in 
children and could not find one. We therefore performed a systematic 
review to identify the measures of medicines adherence which have 
been used with children and to explore the strengths and weaknesses 




2.2.1  Search strategy 
A systematic literature search was performed to identify all papers 
describing methods used to measure medicines adherence in children. 
Six databases were searched from March 2008 to July 2020 to focus 
on the methods recently used to assess medicines adherence in 
children. The initial search was performed using the Healthcare 
Databases Advanced Search (HDAS) platform, which allows the 
combination of several databases.  




• Cumulative Index to Nursing and Allied Health Literature (CINAHL) 
The search was also conducted separately using the Cochrane library 
and International Pharmaceutical Abstracts (IPA). 
A hand search of the bibliographies of relevant papers was also 
performed in order to identify all studies related to our inclusion 
criteria. 
The resulting studies were exported to Endnote and combined together 
to remove duplications.  
The databases were searched for all studies which used a measure of 
medicines adherence and included paediatric patients aged ≤18 years 
of age. The following keywords were used: measure* or scale* or 
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assess* or screen* AND adhere* or complian* or nonadhere* 
or noncomplian* or patient compliance* or medication 
adherence* AND children* or child* or pediatrics* or 
paediatric* or adolescent* or infant* or newborn*or neonate*. 
2.2.2  Justification of search strategy 
In this systematic review, the specific keywords above were selected 
to integrate a wide variety of terms that met our aims and purposes.  
The first part of the search strategy covered the methods used to 
measure medicines adherence that we wanted to explore. Terms were 
selected to cover different permutations of plural, noun, singular and 
adjectives using asterisks (*). The keywords for the first part we 
selected were ‘measure* or scale* or assess* or screen*’. Measure* 
and scale* were used as recommended by the BioMed Central Medical 
Research Methodology for systematic reviews which contained 
searches about measuring medicine adherence (100). In addition we 
added assess* and screen* from previous systematic reviews (101–
103).  
In the second part of the keywords, we covered terms for medicines 
adherence. The keywords that we used were ‘adhere* or complian* or 
nonadhere* or noncomplian* or patient compliance* or medication 
adherence*’. These terms were taken from  systematic reviews related 
to the subject of medicines adherence which were published in 
reputable journals (97,104–106).  
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The third part covered the paediatric age group. The keywords that we 
used were ‘children* or child* or pediatrics* or infant* or neonate* or 
newborn* or adolescent*’ to cover all paediatric patients aged ≤18 
years. These terms were used as recommended by search strategies 
for MEDLINE (107). The English spelling ‘paediatric’ was not included 
as we were of the understanding that the term ‘pediatrics*’ covered 
this variation in spelling. We recognise now however that this is not 
the case and is therefore an omission in our search strategy.  
2.2.3  Inclusion criteria 
Inclusion criteria were original research studies measuring medicines 
adherence in children (age from birth to 18 years) and included all 
countries and all languages. To be included, the assessment tool used 
to measure adherence in each study needed to be clearly identified or 
discussed in some detail.  
2.2.4  Exclusion criteria 
Exclusion criteria included: 
• Review articles, editorials, conference papers, reports. 
• Studies reporting only adherence outcomes/rates without reporting 
methods of how these were measured. 
• Studies that did not separately identify the methods which were 
used to measure medicines adherence in children. 
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2.2.5  Data collection and analysis 
One reviewer (Aldosari M) examined all titles and abstracts identified 
by the search according to the inclusion and exclusion criteria. Where 
relevance was not clear from the title or abstract, full papers were 
obtained and reviewed. As a reliability measure, 5% of titles and 
abstracts were assessed independently by another researcher from our 
group (Smith C) and after discussion, Aldosari M and Smith C reached 
full consensus on which studies were relevant. All studies using 
methods to measure medicines adherence in children were analysed. 
The following data were extracted into a table:  
• Name of authors. 
• Publication year. 
• Country where study was completed. 
• Type of study.  
• Number and age of participants. 
• Type of measurement tool used to assess adherence. 
• Type of disease. 
•  Reported outcome. 
2.2.6  Quality assessment 
Quality assessment is done in order to identify studies with a high risk 
of bias. The quality of the included observational cohort studies and 
observational cross-sectional studies was rated independently by two 
researchers (Aldosari M and Smith C) using the Strengthening the 
34 
 
Reporting of Observational studies in Epidemiology (STROBE) checklist 
(108). STROBE is a comprehensive quality tool which is designed to 
assess the quality of cohort and cross-sectional studies (108). The 
maximum STROBE score is 100% and the score required for inclusion 
was 70% as used in a previous systematic review by our research 
group published in a peer reviewed reputable journal (109). The 
STROBE checklist was appropriate because 25 of the included studies 
were observational cohort studies, six observational cross-sectional 
studies, and one was a randomised controlled trial (RCT).   
The quality of the included RCT was assessed using the Cochrane 
collaborations tool for assessing risk of bias in randomised controlled 
trials (110). The Cochrane process involves assessing the article 
against seven criteria and if the study shows a high risk of bias on two 
or more criteria then it should be excluded. 
2.3 Results 
2.3.1  Number of studies 
9,747 studies were identified after searching the six databases. After 
removing duplication, 7051 papers were identified. Aldosari M screened 
these studies and in total 7,020 of them were excluded. Only 31 articles 
met the inclusion criteria and were included (Figure 2-1). All of the 
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2.3.2 Quality of studies 
Quality assessment of all studies was performed independently by the 
two researchers (Aldosari M and Smith C) and any discrepancies were 
resolved by discussion.  
A. Observational studies 
Quality assessment of the 25 cohort and the six cross-sectional 
studies was done using the STROBE checklist. All studies met the 
standard for inclusion and scored ≥ 70%.  
B. RCT 
Quality assessment for the one RCT study was done using the 
Cochrane collaboration tool. This study had three criteria with a 
high risk of bias, and  was therefore excluded from the results 
(112).  
2.3.3  Countries 
Thirteen studies were conducted in the United States, four in South 
Africa and three in Kenya. Two studies were conducted in two countries 
Jordan and Northern Ireland and the remaining nine studies in the 
United Kingdom, Jordan, Australia, Ethiopia, Senegal, Uganda, France, 
Brazil and Netherlands. 
2.3.4  Study design 




2.3.5  Type of assessment tools used to measure adherence 
Various assessment tools were used in the studies. These are described 
below: 
A. Self-report  
Twenty-five studies used self-report tools to measure adherence 
(28,29,120–129,31,130–134,113–119).  
These self-report tools consisted of multi-item questionnaires to 
identify the children’s adherence with medicine regimens during a 
stated previous period of time. The self-report tools differed in their 
formats and questions, depending on which diseases and populations 
were being targeted. They were used to assess medicines adherence 
in HIV, asthma, inflammatory bowel disease (IBD), epilepsy, diabetes, 
migraine, thalassemia, malaria, and major depressive disorder 
patients. The validity of self-report was assessed in some studies by 
comparing results with those of other adherence-measurement tools, 
including pill counting, Medication Event Monitoring System (MEMS), 
pharmacy-refill data and plasma medicine levels (28,29,124–
126,128,129,132,31,113,115–118,121,122). For children using liquid 
drug formulations, self-report was found to be an easier method of 
assessing adherence than pill counting due to difficulties in measuring 
returned liquid medicines (117). 
Many studies found that self-report appears to overestimate the rate 
of adherence (29,31,117,118,122–124,126,129,132). Only two 
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studies suggested that self-reported adherence rates were lower than 
those measured by EMD and drug plasma level (128,134). 
One study conducted anonymous self-report by which caregivers 
completed self-report without writing the patients’ name (122).  














Table 2-1 Summary of self-report tools used. 
Study 
(Condition, year, country) 
Details of self-reports used 
HIV 2008 
United States (114) 
➢ Questionnaire began with identification of medicine. Asked about missed doses during past 3 days. 
➢ Patients classified as adherent if no doses missed during past 3 days. 
HIV. 2008 
South Africa (117) 
➢ Caregivers asked to rate medicine giving adherence on VAS. 
➢ VAS covered range from 0% to 100% in steps of 10%. 
➢ Higher scores indicated greater adherence. 
HIV 2009 
United States (119) 
HIV 2009 
United States (28) 
➢ 3 days recall questionnaire-based interview by clinic staff with older children and caregivers at routine clinic 
visit. 
➢ Questions included dosing schedule, time of last dose and number of missed doses in last 3 days. 
➢ Adherence calculated as percentage of doses taken over previous 3 days. 
HIV 2010 
South Africa (120) 
➢ 3 days recall questionnaire-based interview by clinic staff with caregivers at routine clinic visit. 
➢ VAS used to rate adherence for the last 30 days, ranging from 0 to 100% in steps of 10%. 
➢ Higher scores indicate greater adherence. 
HIV 2010 
United States (121) 
➢ Caregivers asked single question to identify child’s adherence to medicines as missed taking or never missed 
during last 6 months. 
➢ Children classified as adherent when caregiver reported never missed taking or non-adherent when caregiver 
reported missed taking. 
HIV 2012 
Uganda (29) 
➢ Adherence related questions requested information about patients’ adherence. Completed by adolescents. 
➢ No other details reported. 
HIV 2013 
Ethiopia (113) 
➢ Nine questions used to assess adherence, completed by caregivers. Each question scored from 0 to 1. 
➢ Median score taken as cut-off to classify adherence as good or poor. 
➢ Adherence reported as good when median score >4.  





➢ VAS used to assess number of doses taken in last month. Parents indicated doses taken on horizontal line; 
leftmost side indicated no doses taken, rightmost side indicated all doses taken. 
HIV 2015 
South Africa (115) 
➢ Structured questionnaire to obtain information about infant adherence from mothers. 
➢ Questions included whether infants missed doses since previous visit, reason for missed doses and number 
of days missed. 
➢ Mothers reporting missing two or more doses classified as non-adherent.  
Asthma 2008 
Australia (122) 
➢ At consultation visit caregivers asked about child’s use of medicine: ‘In the last month what percentage of 
the time would your child have taken their medication?’ 
➢ Physician wrote down estimate of medicine adherence based on caregiver answer. 
Asthma 2008 
Brazil (31) 
➢ Self-report performed by filling out diary in which parents wrote time and date of medicine use. 




(Condition, year, country) 
Details of self-reports used 
Major Depressive Disorder 
2010, United States (132)  
➢ Adherence rate identified by calculating percentage of doses taken during period of treatment. 
Asthma 2016  
Netherlands (123)  
Epilepsy 2013 
United Kingdom (126) 
➢ Medication Adherence Report (or Rating) Scale (MARS) questionnaire used. Consisted of 10 questions to 
evaluate patient’s behaviour towards medicines during past week.  
➢ Each item scored from 1 to 5. 
➢ Higher scores indicated higher adherence. 
Inflammatory Bowel 
Disease 2009 
United States (124) 
➢ Medical Adherence Measure (MAM) questionnaire used. 
➢ Measured adherence across 4 domains: adherence behaviour, knowledge, barriers to medicine adherence, 
and organisational system.  
Epilepsy 2010 
United States (125) 
➢ Caregivers asked how many doses their child missed in past week. 
➢ Adherence rate calculated by: 
[(number of doses prescribed per week - number of doses missed)/number of doses prescribed per week)]* 
100. Range 0-100%. 
Diabetes 2011 
United States (127) 
➢ Diabetes Self-Management Questionnaire (DSMQ) used. 25-item, validated, semi-structured interview 
assessing adherence to diabetes medicines. 
➢ Higher scores indicate greater adherence. 
Migraine 2016 
United States (128) 
➢ Self-report performed using diary in iMigraine Application via iPod touch where patients answered questions. 




➢ Adolescents asked ‘How do you rate your adherence to medicine in last four weeks from 0% to 100%?’ 





➢ Interview conducted with parents. 
➢ Adherence scored on basis of 3 items: length of treatment, number of doses per day, and method of 
administration. 
➢ Complete adherence defined as adherence to all 3 items; non-adherent as non-adherent to at least one 
item. 
➢ No other details reported. 
Malaria 2009 
Senegal (131). 
➢ 3 days recall questionnaire-based interview by clinic staff with caregivers at routine clinic visit. 
➢ Questions included dosing schedule, time of last dose, and number of missed doses in last 3 days. 
➢ Adherence calculated as percentage of doses taken over previous 3 days. 
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B. Electronic monitoring devices (EMDs)  
Fourteen studies used an EMD to measure adherence 
(28,29,125,128,132,135,31,34,116–118,120,122,123). The EMD is a 
device that fits on a medicine bottle and contains microelectronics that 
record the time and date the bottle or inhaler device is opened (24). Even 
though different models exist, the basic principle of this system is that 
whenever the medicine bottle is opened, a microprocessor embedded in the 
device records the exact dates and times (24).  
Ten studies used an EMD called a Medication Event Monitoring System 
(MEMS) device, two studies used a Smartinhaler device, one study used a 
DOSER, and one study used an eCAPs device. When using these devices to 
measure adherence an assumption has to be made that the patient takes 
the medicine each time the bottle opened.  
An EMD was used to assess medicines adherence in HIV, asthma, IBD, 
epilepsy, migraine, and major depressive disorder patients. At each visit, 
the data was downloaded from the EMD by the staff responsible for the 
study. Several studies found the EMD more accurate and reliable than other 
measures of adherence, including self-report, pill counting and pharmacy-
refill records (28,29,31,116–118,120,122,132). In addition, several studies 
have considered the EMD to be highly accurate and used it as a reference 




C. Pill or dose count  
Eight studies used pill or dose counting methods to measure adherence 
(28,29,113–115,124,132,136). With this method patients are required to 
bring their remaining medicine to each visit. The staff responsible for the 
study then count the number of doses (number of tablets for solid dose 
forms and volume of medicine for liquid dose forms) that have been taken 
between two clinic visits and compare this number with the total number of 
doses dispensed for the patient for that time interval. The percentage by 
volume of medicine consumed, or the percentage of pills taken, is calculated 
by dividing the actual volume or number of pills taken by the expected 
volume or number of pills, then multiplying by 100. This method has been 
used to assess medicines adherence in HIV, IBD and major depressive 
disorder. Several studies found the dose count less accurate than EMDs and 
medicine plasma level and more accurate than self-report (28,29,124). 
D. Medical record or pharmacy refill data  
Seven studies used medical record or pharmacy refill data to measure 
adherence (31,119–121,129,133,137). This method measures adherence 
by calculating the number of doses dispensed from pharmacy or the number 
of appointment visits in relation to the dispensing period or the appointment 
period (31,120,121,137). This method assumes that the medicine is taken 
exactly as prescribed. One study defined non-adherence as any missed 
refills or appointments, and adherence is defined as no missed refills or 
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appointments (121). This method has been used to assess medicines 
adherence in HIV, asthma, thalassemia, and sickle cell disease patients. 
Table 2.2 shows a summary of studies measuring adherence by medical or 
pharmacy refill data. 
 Table 2-2 Summary of measures of adherence by medical or pharmacy 
refill data. 
Study 
(Condition, year, country) 
Adherence calculated as: 
HIV 2009 
United States (119) 
Asthma 2008 Brazil (31) 
Number of all doses taken/ Number of doses prescribed 
*100 
HIV 2010 
South Africa (120) 
Occasions when medicine was dispensed/ occasions when 
medicine was supposed to be dispensed * 100 
HIV 2010 
United States (121) 
No missing refill classified as adherent 
Any missed refill classified as non-adherent 
Thalassemia 2014 
Jordan (129) 
Frequency of consistency of attendance to appointments 
rated 1-10. Higher frequency of consistency reported as 
higher level of adherence. 
Sickle cell disease 2010 
United States (137) 
Ratio of number of expected days between refill periods 
(numerator) and observed days between refill periods for 
patient (denominator). 
 
E. Medicine plasma level  
Seven studies used medicine plasma level to measure adherence 
(115,124,126,129,134–136). In these studies, the concentration of 
medicine in plasma was measured and compared with the expected 
concentration. When the concentration of medicine in plasma was as 
expected, the patient was classified as adherent to medicine. This method 
was used to assess medicines adherence in HIV, IBD, epilepsy and 
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thalassemia patients. Several studies have suggested this method to be 
more accurate than other measures of adherence except EMD 
(124,126,135,136). Plasma drug concentrations have also been used as a 
reference standard by which to validate other adherence measurements 
(115,131) 
F. Daily telephone calls  
Two studies used daily telephone calls to measure adherence in asthma and 
diabetes patients (138,139). Patients were called daily to assess disease 
symptoms and rates of medicine adherence and it was found to be feasible 
for assessing both (138,139). The method was not compared with other 
methods to verify its efficacy. This method was more expensive than self-
reporting and was difficult to perform (138). In addition, this method was 
susceptible to bias because a daily call may remind patients that they are 
under surveillance, which may affect their adherence rates (138). 
G. Canister weight  
One study used canister weight to measure adherence (31). This method is 
similar to dose count and involves weighing medicine devices such as 
inhalers, at the beginning of treatment and at each subsequent clinical visit 
until the devices are empty (31). This method was used to assess adherence 
only in asthma patients. The adherence rate was calculated by dividing the 
actual weight by the expected weight, then multiplying by 100. This method 
has been found to have the same efficacy as using an EMD and to be less 
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expensive, suggesting that the canister-weight method could be an 
alternative to expensive electronic devices for assessing medicine 
adherence in patients with asthma (31).  
Each method had strengths and weaknesses. Table 2-3 Shows a summary 
of the strengths and weaknesses of the assessment tools. 
Table 2-3 Summary of the strengths and weaknesses of the assessment 
tools  
Assessment tools Strengths Weaknesses 
Self-report ➢ Flexible.  
➢ Most practical method.  
➢ Less burdensome for staff.  
➢ Inexpensive.  
➢ Time saving. 
➢ Least accurate.  
➢ Overestimated adherence rates.  
➢ Does not guarantee actual 
ingestion of medicines. 
EMDs ➢ More accurate than self-
report, pill count & 
pharmacy refill data. 
➢ Expensive.  
➢ Time consuming.  
➢ Not easily available. 
➢ Does not guarantee actual 
ingestion of medicines. 
Pill count ➢ Easy to use.  
➢ Inexpensive. 
 
➢ Overestimated adherence rate. 
➢ Less accurate than EMDs and 
medicine plasma level. 
➢ Does not guarantee actual 




➢ More accurate than self-
report and pill count. 
➢ Less accurate than MEMS and 
medicine plasma level. 
➢ Does not guarantee actual 
ingestion of medicines. 
Medicine plasma 
level 
➢ More accurate than self-
report, pill count and 
pharmacy refill data.  
➢ Does guarantee actual 
ingestion of medicines. 
➢ Costly. 
➢ Time consuming. 








➢ Difficult to perform. 
➢ Does not guarantee actual 
ingestion of medicines. 
Canister weight ➢ Same efficacy as using 
EMDs  
➢ Less expensive than EMDs. 
 
➢ Only applicable to inhalation 
devices. 
➢ Does not guarantee actual 
ingestion of medicines. 
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2.3.6 Type of diseases 
The studies measured medicine adherence for several diseases, which were, 
in order of frequency: 
• HIV/AIDS (n=13) 
• Asthma (n=4) 
• Inflammatory bowel disease (IBD) (n=3) 
• Epilepsy (n=2) 
• Type 1 diabetes (n=2) 
• Migraine (n=1) 
• Thalassemia (n=1) 
• Malaria (n=1) 
• Major depressive disorder (n=1) 
• Sickle cell disease (n=1). 
• Kidney transplant (n=1). 
• One study measured medicine adherence in all patients discharged from 
a French paediatric emergency department with at least one oral drug 
prescription, regardless of diagnosis. 
The following sections summarise the included studies and are divided into 






Thirteen studies measured medicines adherence in HIV/AIDS patients 
(28,29,121,135,136,113–120)(Table 2-4).  
Self-report tools were used with both children and caregivers in three 
studies (28,114,119). In six studies, they were only administered to 
caregivers (113,115–118,120), and in one study were only given to 
adolescents (29). Good agreement was found between the reports from 
children and their caregivers (28,114,119). 
Eight studies used viral load assessment as a confirmation of measures of 
adherence, and there was a significant association between viral response 
and  full adherence measured by self-report, pill count, EMD and pharmacy 
refill data (28,114,116,117,119–121,136). Two studies used EMD, self-
report, and plasma level without a validated measure  (viral load) 
(118,135). They suggested that viral load assessment should be used in 
future studies for confirming adherence measures (118,135). One study 
used plasma nevirapine concentrations for confirming self-report and dose-
count measures (115). 
The EMD was directly compared with the self-report, pill counts, and 
pharmacy refill data in six studies (28,29,116–118,120), and in each study, 
the EMD was considered to be more reliable.  
Five studies (28,113,116–118) found that self-reports were the least 
accurate method as they appeared to overestimate adherence rates when 
compared to other measures such as dose count and EMDs and it was 
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suggested that they should therefore not be used alone to assess 
adherence. Another study compared pill count, self-report measures and 
EMD and found that pill counts and self-reports both overestimated 
adherence rates (29).  
Only one study reported that adherence rates measured by pill counts were 
very low; this study used unannounced home-based pill counts to avoid 



















Table 2-4 Studies measuring medicines adherence in HIV/AIDS patients 
Study Brief study 
description 









Ages 8-19 years. 
1 - Self-report, completed by 146 parents and 
132 children. 
2 - Dose count; liquid formulation measured in 
millilitres and powder in scoops to count actual 
number of doses. 
3 - Viral load assessment used as confirmation 
of measures of adherence. 
Self-report useful for measuring adherence over longer 
period. 
Significant association between missed dose count and 









Ages 51 ± 2.7 
months 
1 - Self-report, completed by 73 caregivers. 
2 – EMD. 
3 - Viral load assessment used as confirmation 
of measures of adherence. 
Adherence rate measured by caregiver reports higher than 
that measured by EMD.  
Self-reporting classified 91% patients as >95% adherent; 
EMD classified 36% patients as >95% adherent. 
Comparing EMD and self-report adherence measures to 










Ages 0-18 years 
1 - Self-report, completed by 127 parents and 
50 children over 13 years old. 
2 - Pharmacy refill data; pharmacy records for 
previous 12 months obtained from clinical 
database. 
3 - Viral load assessment used as confirmation 
of measures of adherence. 
Despite potential for overestimating adherence, study 
supports use of self-report as efficient tool for measuring 
adherence. 
Good agreement between adult caregiver reports and child 
reports. 
Significant association between self-reported, pharmacy 








Ages 8-18 years 
1 - Self-report, completed by 24 parents and 
24 children. 
2 - EMD recorded dates and times when bottle 
was opened. 
3 - Pill counts, clinician calculated percentage 
of pills taken over dispensing period. 
4 - Viral load assessment used as confirmation 
of measures of adherence. 
Pill counts inexpensive and relatively easy method of 
assessing adherence. 
EMD most effective method. 
Good agreement between adult caregiver reports and child 
reports. 
Adherence rates obtained: pill counts 86%, EMD 78%, 
caregiver reports 99%, and child reports 98%. 
Comparing both EMD and self-report adherence measures 




Study Brief study 
description 









Ages 6-18 years 
1 - Self-report, completed by caregivers. 
2 - Pharmacy refill data; zero missing refills 
over previous 6 months classed as ‘adherent’. 
3 - Viral load assessment used as confirmation 
of measures of adherence. 
 
No significant association between viral response and full 
adherence as defined by caregiver reports and pharmacy 
refill data. 








Median age 3.7 
years 
1 - Self-report completed by caregivers. 
2 - EMD which defined adherence by 
percentage of doses taken. 
3 - Pharmacy refill data. 
4 - Viral load assessment used as confirmation 
of measures of adherence. 
 
No significant differences between adherence rates 
measured by self-reports 100%, EMD 92%, and pharmacy 
refill data 100% (p>0.1). 
Despite high cost of EMD, it was best method for 
measuring adherence. 
More effort should be directed towards development of 









Ages 12-17 years 
1 - Self-report completed by adolescents. 
2 - EMD, missed doses identified by non-
opening events. 
3 - Pill counts. 
Pill counts and self-reporting appeared to overestimate 
adherence rate. 
Adherence rates obtained: self-report 99%, pill count 
97%, and EMD 88%. 










Ages 8-13 years 
1 - Self-report, completed by caregivers. 
2 - Pill count; home-based unannounced pill 
count conducted to avoid bias.  
Unacceptably low adherence level estimated by pill counts. 
Using unannounced home-based pill count, only 34.8% of 
sample had adherence rate of at least 95%. 
Agreement between unannounced pill count and caregiver 











Mean age 8.2 
years 
1 - Self-report, completed by caregivers. 




Adherence rates differed between measures. 






Study Brief study 
description 












1 - Self-report, completed by mothers. 
2 - Dose count by assessment of unused 
returned medicine. 
3 - Plasma level by measuring concentration in 
plasma and comparing with expected 
concentration used as confirmation of other 
measures. 
Self-reporting could be useful in assessing adherence to 
antiretroviral treatment in infants < 6 weeks. 
Good agreement between self-report and dose count. 
Using multiple measures of adherence more useful than 
single measure. 
Plasma nevirapine concentrations used as objective 
measure to verify other measures: plasma level 85.6%, 









Ages 0-14 years 
1 - Self-report, completed by caregivers. 
2 - EMD. 
3 - Viral load assessment used as confirmation 
of measures of adherence. 
Self-reporting appeared to overestimate adherence rates. 
High correlation between viral load levels and adherence 
rate measured by EMD. 









Ages 6 months- 
13 years 
1 - Pill count, calculating percentage of doses 
taken over dispensing period. 
2 - Viral load assessment used as confirmation 
of measures of adherence. 
Adherence of ≥95%, measured by pill count is not an ideal 
predictor of treatment outcomes. 
Low correlations between pill count and viral load 
measures were reported. 







Mean age 7.7 
years 
1 - Plasma level measuring concentration in 
plasma and comparing with expected 
concentration. 
2 - EMD. 
No differences between adherence rates measured by 
plasma level and EMD. 
Study suggested that viral load should be used as 






Four studies measured medicine adherence in patients with asthma 
(31,122,123,138) (Table 2-5).  
Three studies (31,122,123) found that self-reports overestimated 
adherence rates and were the least accurate in assessing adherence. 
Pharmacy refill data also overestimated adherence, but less so than self-
reporting (31).  
Daily calls to patients’/parents’ mobile phones were reported to have an 
effectiveness close to that of self-reporting, but were more expensive and 
susceptible to bias because a daily call may remind patients that they are 
under surveillance, which may affect their medicine-taking behaviour, 
thereby inflating their adherence rates (138). 
Two studies (31,122) reported that an EMD was the best method for 
assessing adherence rates for asthmatic patients, compared with self-
report, pharmacy refill data, and daily telephone calls. One study (31) 
found that measuring canister weights had the same effectiveness as EMD 
and was less expensive.
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Table 2-5 Studies measuring medicines adherence in patients with Asthma 
Study Brief study 
description 








Ages 18 months-7 
years 
1 - Self-report completed by 51 caregivers. 
2 - EMD with an electronic monitoring 
device (Smartinhaler). 
Poor correlation between adherence rates measured 
by self-report and EMD (r=0.31). 








Ages 3-14 years 
1 - Self-report, completed by 102 parents. 
2 - Canister weight. 
3 - Pharmacy refill data. 
4 - EMD (DOSER). 
High discrepancy between self-reporting and other 
methods. Adherence rates obtained: self-report 
96.4%, pharmacy refill data 70%, canister weight 
46.3%, and EMD 51.5%.  
Adherence rate by pharmacy refill data also 
overestimated, but to a lesser degree than self-
reporting. 
EMD and canister weight were most reliable methods. 
Significant agreement (p<0.01) suggests that 









Ages 12-18 years 
daily telephone call; participants called 
daily to report symptoms and missed 
doses. 
daily telephone call is a feasible method of assessing 
asthma symptoms and adherence. 
More expensive than self-reporting while still 
susceptible to bias. 
Garcia-







Ages 2-13 years 
1 - Self-report, completed by 133 parents. 
2 - EMD used as reference standard 
(Smartinhaler). 
Self-reporting overestimated adherence and was too 
inaccurate when validated using EMD. 
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C. Inflammatory Bowel Disease (IBD) 
Three studies measured medicines adherence in patients with IBD 
(34,124,134) (Table 2-6).  
Plasma level was reported to be the most reliable method of measuring 
adherence for patients with IBD, compared to self-report and pill count 
(124).  
It was suggested that EMD may overestimate adherence as the devices 
document the time that a bottle was opened but cannot document actual 
ingestion of medicine or if the correct number of pills was taken (34). 
Additionally, participants enrolled in the study who are aware of being 
monitored may have had an increased adherence rate because of this 
awareness (34). 
Alsous et al. found that adherence rates measured by self-report (39.4% 
classified as non-adherent) was lower than adherence rates measured by 










Table 2-6 Studies measuring medicines adherence in patients with IBD 
Study Brief study 
description 









Ages 13-17 years 
1 - Self-report, completed by 42 parents and 42 
children. 
2 - Pill count; percentage of pills taken over 
dispensing period. 
3 - Plasma level; medicine concentration in plasma 
compared with expected concentration. 
No statistically significant correlation between 
measures of adherence 
(p>0.05). 
Measuring drug plasma levels most reliable method. 









Ages 8-17.5 years 
1 - EMD. 
2 - IBD symptoms used as confirmation of measure 
of adherence. 
 
By comparing adherence rate reported by EMD and 
IBD symptoms, EMD monitoring appeared to 
overestimate medicine adherence rates. 









Ages 13-17 years 
1 - Self-report completed by 33 children and 47 
parents. 
2 - Plasma level; medicine concentration in plasma 
compared with expected concentration. 
Moderate agreement found between methods (Kappa 
= 0.463, p=0.013). 
Based on self-report 39.4% of children classified as 
non-adherent. 
Based on measuring drug plasma levels 8.9% of 








D. Diabetes   
Two studies measured medicine adherence in patients with diabetes 
(127,139) (Table 2-7). 
Markowitz et al. (127)  used finger-prick blood glucose tests taken at home 
every day by patients/parents as a confirmation of self-report to measure 
adherence rates and reported that self-report was a valid measure of 
adherence rate in research and clinical settings with no difference between 


















Table 2-7 Studies measuring medicines adherence in patients with diabetes 
Study Brief study 
description 








Ages 9-15 years 
1 - Self-report, completed by 338 caregivers 
and 338 children. 
2 - Blood glucose level used as objective 
measure to validate self-report. 
Significant association between blood glucose level 
and adherence rate as measured by self-report 
(p<0.01). 
Self- report valid measure of medicine adherence. 








Mean age 14.96 
years 
daily telephone calls to participants twice daily 
for 10 days to report blood glucose readings and 
missed insulin doses. 
Method provided good information about adherence 
and should be explored in clinical settings. 
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E. Epilepsy   
As shown in Table 2-8, two studies measured medicines adherence in 
patients with epilepsy (125,126).  
Plasma levels were more accurate and reliable than self-reports in assessing 
adherence rates of epileptic patients. Although plasma levels were said to 
be accurate in this study, the authors recommended the use of EMD to 
assess adherence as it can record multiple instances of taking medicines, 
rather than a single test at a later date (126). 
Mohammed Shah et al. found that adherence rates measured by self-report 


















Table 2-8 Studies measuring medicines adherence in patients with epilepsy 
Study Brief study 
description 
Adherence measurement tools Reported outcome 






Ages 2-14 years 
1- Self-report completed by 119 caregivers. 
2- EMD used as objective measure to validate 
self-report. 
Significant associations found between EMD and 
self-report adherence rates (p<0.01). 
Self- report valid measure of medicine adherence. 
 
Mohammed 







Ages 0.9-16 years 
1 - Self-report completed by 100 parents or 
children over 9 years of age. 
2 - Plasma level by chromatographic analysis 
of dried blood spot. 
Self-report appeared to overestimate adherence 
rates, with a reported 94% adherence. 
Dried blood spot analysis useful in estimating 




F. Other diseases  
As shown in Table 2-9, seven studies measured medicines adherence in 
patients with different diseases. 
Although self-reporting appeared to overestimate adherence rates and had 
a potential recall bias, it was inexpensive and reliable (128–132). Chappuy 
et al. (130) reported that adherence rates measured by self-reporting were 
much lower than observed in previous studies because more data were 
taken into account, such as asking families about both the filling of 
prescriptions and their administration. 
Only one study reported that adherence rates measured by self-reporting 
were lower than measured by EMD for patients taking once-daily medicines 
only (128). No explanation was provided for this finding. 
Plasma levels were found to be more reliable and accurate than self-reports 
and pharmacy refill data because self-reports and pharmacy refill data did 










Table 2-9 Studies measuring medicines adherence in patients with different diseases 





Prospective cohort study 
105 participants discharged 
with at least one oral drug 
prescription from a French 
paediatric emergency 
department 
Ages 0.2-12 years 
Self-report, completed by 105 parents. Adherence rate 36.2%. 
Adherence rate much lower than observed in 
previous studies on medicine adherence after 





Retrospective cohort study 
289 participants with malaria 
Ages 2 months-14 years 
1 - Self-report, completed by 289 
caregivers. 
2 - Plasma drug level used as objective 
measure to validate self-report. 
 
Self-reported data good tool in poor countries as 
less expensive than other methods such as EMD. 
 
Nakonazny 





31 participants with major 
depressive disorder 
Ages 7-17 years 
1 - Self-report, completed by parents or 
children. 
2 - Pill count, calculating percentage of 
pills taken over dispensing period. 
3 - EMD used as objective measure to 
validate others measures. 
Self-reporting and pill counts overestimated 
adherence rates. 
Adherence rate differed significantly between 
methods (p=0.0002).  
Adherence rates: EMD 87.51%, pill count 
90.55%, self-report 93.28%. 
Agreement between pill count and EMD reference 
standard stronger than agreement between EMD 
and self-report. 
 











Retrospective cohort study 
93 participants with sickle cell 
disease 
Mean age 7 years 
1 - Pharmacy refill data. 
2 - Plasma level used as confirmation of 
measure of adherence. 
Pharmacy refill data appeared to overestimate 
adherence rate. 
Adherence rate measured by pharmacy refill 
data correlated with plasma level. 













164 participants with 
thalassemia 
Ages 12-19 years 
1 - Self-report, completed by 164 
adolescents. 
2 - Plasma level compared with expected 
concentration. 
3 - Medical records checking attendance 
at 10 follow-up appointments. 
 
Adherence rates: plasma level 47%, medical 
records 57%, self-reporting 73%. 
Plasma level more accurate method to assess 
adherence. 
Self-reporting least accurate but less expensive 
and easier to obtain. 






56 participants with migraine 
Ages 11-17 years 
1 - Self-report, completed by 56 
adolescents. 
2 - EMD. 
 
Self-reported adherence rates lower than 
measured by EMD for patients taking once-daily 
medicine only. 
Self-reported adherence rates higher than 










33 participants with kidney 
transplant 
Ages ≤ 18 years 
1 - Self-report, completed by 33 children. 
2 - Pharmacy refill data. 
14.8% of children non-adherent based on self-
report. 
24.2% of children non-adherent based on 











Knowing the degree of medicines adherence in children is important in order 
to provide information on the consequences of non-adherence and to 
develop strategies to improve adherence (50). By appropriately assessing 
and understanding medicines adherence in children, we may be able to 
improve health outcomes and reduce healthcare costs (99). We performed 
a systematic review to identify the measures of medicines adherence that 
have been used in children and to explore the strengths and weaknesses of 
those measures. Seven methods to measure adherence were identified: 
self-report, EMD, dose count, canister weight, plasma level, medical record 
or pharmacy refill data and daily telephone calls.  
Self-reports have been suggested to be the most practical measure of 
adherence in children and were the most commonly used (115,127). In 
addition, self-report is the only measure that asks patients directly about 
adherence (115). Some self-reporting questionnaires also collected 
information on the beliefs of children and caregivers that may affect 
adherence, such as medicine-taking behaviour and barriers to medicines 
adherence (116,120,131).  
Most self-report tools contained three primary parts, including the question 
type, the recall period (x days, x weeks or x months), and the answer 
options (open-ended questions, closed questions or multiple choices 
questions). Each self-report tool used these parts differently.  In the 
64 
 
included studies the recall period varied from 3 days to 6 months i.e. 
participants were asked to state their adherence over these time periods. 
Some tools used validated scales and others used different questions to 
assess this adherence (114,116,121,129). It has been suggested that self-
report tools that require accurate recall data should focus on shorter periods 
(such as the last three days), whereas self-reports that only require 
estimated recall data can rely on longer time periods (114).  
Each self-report had a different number of questions. In the included 
studies, the number of questions varied from a single question to multiple 
questions (118,129). Moreover, the self-report tools used in the included 
studies varied in their subjects (healthcare professionals, caregivers or 
patients) and their context (e.g., for a specific disease or for multiple 
diseases) (29,117,130).  
Anonymous self-reporting (completed by caregivers) was found in one 
study to be a more accurate method of assessing adherence than regular 
self-reporting, possibly indicating that children/caregivers are more 
comfortable reporting poor adherence anonymously (122). However, this is 
not a useful method in the practical clinical setting (122).  
We found three validated self-report tools which were used to assess 
adherence in children in the studies included in our search. The MARS 
questionnaire was used in one asthma study and one epilepsy study, the 
MAM questionnaire in one IBD study, and the DSMQ was used in one 
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diabetes study (123,124,126,127). The MARS questionnaire assesses both 
beliefs and barriers to medicines adherence. The results of this 
questionnaire were compared to plasma level measure and EMD to assess 
adherence and suggested that adherence was overestimated by the MARS 
(123,126). In one of the included studies the MAM questionnaire was 
compared with pill counts and plasma level to assess adherence in children 
with IBD and no significant correlation was found between the results (p 
>0.05), suggesting that the MAM is not accurate to assess adherence (124). 
However, the adherence rate in children with diabetes, as measured by the 
DSMQ, appeared to be significantly associated with the adherence rate 
measured by EMD, pill count, plasma level, and pharmacy refill data ( 
p<0.05) (127).   
Patients diaries were also used to measure adherence in two of the included 
studies (31,132), and these were the only self-report tools that daily 
reported how children used their medicine regimens (31,132). However, 
some factors may still have led to unreliable reporting. For example, 
patients may have reported incorrect adherence rates or forgot to return 
the diaries (132).  
The accuracy of self-reporting differed in the included studies. Only one 
study with children with HIV found that there was no significant difference 
in the adherence rates as measured by self-report (single question), EMD, 
and pharmacy refill data (p > 0.05) (120).  However, self-reporting was 
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suggested to overestimate adherence levels in ten studies when compared 
with other measures (29,31,117,118,122–124,126,129,132). In nine of 
these studies, the self-reports were completed by parents or caregivers 
(31,117,118,122–124,126,129,132). The suggested overestimated 
adherence rate measured by self-reporting could be caused by two major 
biases. The first is error in self-observation, or memory bias, which can 
result in both under- and over-reporting (31,118). The second is social 
desirability bias, which can occur when questions focus on an undesirable 
behaviour or on the most recent period (31,37,118). In contrast, two of the 
included studies found that adherence rates reported by participants were 
lower than those measured by EMD and drug plasma level (128,134). This 
unusual result may be explained by the self-reports in these studies being 
answered by children, who  are perhaps more likely to answer the questions 
honestly because of their naive nature (128,134). Such findings suggest 
that the precision of self-report depends on the type of self-report used, the 
recall period and who is completing the self-report. 
Our review indicates that the accuracy of self-reports may be strengthened 
by using a self-report scale validated for the same group of patients 
whenever possible; taking steps to reduce social desirability concerns (e.g. 
by writing questions carefully to assure the participant that their responses 
will not adversely affect their health care), and using clinical outcomes or 
other measurement methods to validate self-reports such as pill count, 
pharmacy refill data, or EMD (28,113,116–119). 
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One of the methods reported to be highly accurate in several studies is the 
use of EMDs (28,29,117,120,122,128). User-friendly EMDs that promote 
time efficiency and require minimal technical expertise are important 
facilitators in the clinical setting (117). They require a collaborative effort 
between healthcare professionals and patients to achieve accuracy (117). 
Feedback about medicines use provided by using EMDs may improve 
patients’ medicines taking behaviour (128). EMDs help to identify if the non-
adherence is consistent or sporadic (20,116,118). These features make 
EMDs more useful than self-report and plasma level measures 
(20,116,118).  Additionally, when using EMDs, the tendency to deceive is 
lower than when using dose counts. In dose counts patients can manipulate 
the data by throwing pills away, but with EMDs if patients want to throw 
away the medicine they need to open the bottle at the same time every day 
to guarantee that the same adherence rate is reported (125,135,140). 
Our review showed that several different types of EMDs have been used in 
children including MEMS, eCAP, DOSER, and Smartinhaler devices (28,116–
118,120). From our review MEMS was the most commonly used and was 
most often used as a standard to validate other measures (123,125,132). 
MEMS is strongly associated with results from pharmacy refill data and 
plasma levels (120,135). MEMS also showed high correlation between lower 
viral loads in HIV patients and higher level of adherence rates 
(116,120,135,141). Data downloaded from MEMS can provide details 
related to medicines taking, such as delayed dosing, over dosing, under 
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dosing, and drug holidays (117). However, due to their expense, MEMS are 
only suitable in funded clinical research settings and may not be feasible for 
routine clinical use (117).  
eCAP is very similar to MEMS, and is available for use in commercial packing 
and clinical trials (29). DOSER and Smartinhaler devices are used to 
measure inhaled medicines adherence and have similar weaknesses and 
strengths (31,122). It is difficult for young patients to press the DOSER 
device with enough force to register a puff, and the DOSER device cannot 
register double puffs because one second is required between puffs (31). 
Significant correlation (p<0.05) between adherence rates measured by 
canister weight and DOSER (DOSER showed 51% adherence while canister 
weight showed 46.3% adherence) has been seen suggesting that canister 
weight could be used as an alternative to DOSER (31). 
The EMDs method have some limitations, including that they have not been 
used in large studies because of the amount of support required, mechanical 
malfunctions and their high equipment costs (120). In addition, patients 
may open the medicine bottle or puff a dose from an inhaler device without 
taking any medicine, which would result in overestimation of adherence 
rates (28,29,34,125,128,132,135). The EMD method is very time-
consuming, particularly for staff, who must download data from a device for 
each patient (28). Finally, the presence of a EMD device may remind 
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patients that they are under surveillance, which may affect their medicine-
taking behaviour, thereby inflating their adherence rates (34,116).  
This review showed that dose counting was used to assess medicines 
adherence in HIV, IBD, and major depressive disorder patients 
(28,29,114,124,132,136). For medicines that are taken on as needed basis 
however, dose counts are not suitable (124). When patients are aware that 
the healthcare professional suspects non-adherence, they may be more 
likely to throw doses  away resulting in overestimated adherence rates 
(132). In an adherence assessment study of 42 adolescents with IBD using 
oral medicines, both self-report and dose counts overestimated adherence 
as compared to assessments by plasma level (124). The reliability of dose 
counts could be improved by explaining to families the importance of 
bringing all medicine bottles to each visit and by calling them before each 
visit to remind them to do so (28).  
The pharmacy refill data or medical record data have been used to measure 
adherence for chronic diseases, but they are not useful for medicines taken 
for a short period (31,119–121). Pharmacy refill data methods require 
computerised systems that can provide research scientists or clinicians with 
the information they need to measure adherence (101). Seven of the 
included studies used medical records or pharmacy refill data to measure 
adherence (31,119–121,129,133,137). This method is becoming more 
70 
 
widely used in research with children, especially in hospitals that can 
provide the information that is needed to measure adherence (120).  
Pharmacy refill data has been reported to be a highly accurate method of 
measuring adherence in adults (142). However, two of the included studies 
have pointed out that pharmacy refill data may overestimate medicines 
adherence in children, possibly due to the different practise of dispensing 
for pills versus syrups (120,121). Dispensing and monitoring the use of 
exact amount of syrups is more complicated than pills because some of a 
liquid medicine may be lost during administration (121). Additionally this 
method has been found to overestimate adherence rates because it does 
not guarantee the actual ingestion of medicines (120,137). Furthermore, it 
does not account for the timing of the doses, which is important in assessing 
adherence (137). In addition, to use this method researchers should bear 
in mind that medicine cessation may have been verbally advised by 
healthcare professionals; otherwise, the patient may be incorrectly 
considered non adherent (143). 
Measuring medicine concentration in plasma can provide a direct and 
accurate measurement of adherence and was most commonly used in 
several of the included studies to validate other measures of medicines 
adherence (22,115,124,126,129,135,136). Viral load assessments for HIV 
patients have also been used and recommended in several studies to 
validate other measures of medicines adherence (28,114,116,117,119–
121,136). However, these methods can only detect whether the patient has 
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taken a medicine during a certain interval before the analysis. Bias can 
occur if a patient takes the medicine only during this time period  (126,135). 
Other disadvantages of the plasma-level method are that it cannot provide 
data on dose timing, it is invasive, is expensive and is difficult to perform, 
requiring various professionals and technicians to conduct the tests and to 
interpret the results (126,135). Results may also be affected by food or 
drug interactions, half-life of the drugs and dosing schedule (126). The costs 
of tests to measure adherence to more than one medicine may be 
prohibitive, further limiting the feasibility of this method (126,135).  
In measuring medicines adherence, a multimethod approach is often 
recommended (126,144). Since there is no ideal method to measure 
adherence, it would be appropriate to use two or more measures when 
researchers want to have more precise results (144). Using a single method 
to measure adherence in children with a low to moderate level of adherence 
may lead to an incorrect assessment (116,140). The use of another 






2.5  Limitations 
All titles and abstracts of the search results ideally should have been 
screened according to the inclusion criteria by two researchers. Due to 
the limited resources of our department, one researcher (Aldosari M) 
screened all titles and abstracts, but only 5% of titles and abstracts were 
assessed independently by another researcher from our group (Coral S). 
In addition, the term ‘paediatric*’ was omitted from the search and 
conference abstracts and the grey literature were not searched. It is 
therefore possible that studies have been missed.  
2.6 Conclusion 
This systematic review was performed to identify the measures of medicines 
adherence which have been used in children and to explore the strengths 
and weaknesses of those measures. An ideal measure of medicines 
adherence should be easy to carry out and practical, inexpensive, user 
friendly, flexible, and highly reliable. However, we found no single standard 
method that met all these criteria. This review should provide useful 
information for researchers and clinicians to choose the most useful 
methods for their objectives. The selection of suitable measures of 
adherence depends on the aims of each study, the resources available to 
the study and the properties of each measure. In a resource-limited clinical 
setting self-reports may be preferred. Balancing cost and accuracy, 
pharmacy refill data is more favourable for large studies than EMD. 
Measuring medicine plasma levels is a rarely used approach because it is 
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invasive, and the costs are often too high for both researchers and patients. 
Since there is no single ideal method to measure adherence, research 
groups need to recognise that multiple measures may minimise 
discrepancies and support their findings. Further research is required to 
discover a single method that can accurately measure medicines adherence 





























Chapter 3: Barriers and facilitators to medicines 















Medicines are an important aspect of treatment for many paediatric 
diseases (17). As mentioned previously, enhancing medicines adherence for 
chronic conditions may create significant health and economic benefits 
(7,50). To improve adherence, the multifactorial causes of poor adherence 
should be understood. As previously discussed, the World Health 
Organisation (WHO) classifies these factors into five categories: condition-
related, social and economic related, healthcare team and system-related, 
therapy-related, and patient-related factors (7). Also, it is important to 
recognise that factors influencing a patient’s adherence may change over 
time (14). In addition, because there is no single cause of non-adherence 
to medicines, it is unlikely that a single facilitator can improve adherence 
(14). 
We searched for a systematic review in order to establish what is currently 
known about barriers and facilitators to medicines adherence in children 
and found a review from the Talking About Medicines study (TABS) 
published seven years ago (85). This review was a critical evidence 
synthesis of research to examine the factors influencing non-adherence to 
medicines in children with chronic diseases from 1970 to  2008 (85). We 
therefore performed a systematic review to update the TABS work and to 





This systematic review was registered in PROSPERO, registration number: 
CRD42019116334. 
3.2.1  Search strategy 
A systematic literature search was performed to identify all papers 
describing barriers and facilitators of medicines adherence in children. Six 
databases were searched from November 2008 to July 2020 in order to 
update the TABS study work. The initial search was performed using the 
Healthcare Databases Advanced Search (HDAS) platform, which allows the 
combination of several databases.  




• Cumulative Index to Nursing and Allied Health Literature (CINAHL) 
The search was also conducted separately using the Cochrane library and 
International Pharmaceutical Abstracts (IPA). 
A hand search of the bibliographies of relevant papers was also performed 
in order to identify all studies related to our inclusion criteria. 
The resulting studies were exported to Endnote and combined together to 
remove duplications.  
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The databases were searched for all studies which identified barriers and 
facilitators of medicines adherence that included paediatric patients aged 
≤18 years of age. The following keywords were used: ‘barrier* or factor* 
or reason* or cause* or determinant* or predict* or challeng* or 
facilitator* or motivat* AND adhere* or complian* or nonadhere* 
or noncomplian* or patient compliance* or medication adherence* 
AND children* or child* or  pediatrics* or paediatric* or adolescent* 
or infant* or newborn*or neonate*’. 
3.2.2  Justification of search strategy 
In this systematic review, the specific keywords above were selected to 
integrate a wide variety of terms to meet our aims and purposes.  
The first part of the search covered the barriers and facilitators of medicines 
adherence that we wanted to explore. Terms were selected to cover 
different permutations of plural, noun, singular and adjective using 
asterisks (*). The keywords selected were ‘barrier* or factor* or reason* 
or cause* or determinant* or predict* or challeng* or facilitator* or 
motivat*’. These terms were a combination used in previously published 
peer-reviewed systematic reviews related to the subject of barriers and 
facilitators of medicines adherence including the TABs study (85,145–151). 
The terms covering medicines adherence and children were the same as 
those used in the previous chapter. 
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3.2.3  Inclusion criteria 
Inclusion criteria were original research studies with stated objectives of 
identifying barriers and/or facilitators of medicines adherence in children 
aged from birth to 18 years. The search was conducted to cover studies 
published since the TABs study in order to focus on more recently described 
barriers and facilitators to medicines adherence.  
All countries and all languages were included. To be included, the barriers 
and facilitators of medicines adherence in each study needed to be 
described in some detail.  
3.2.4  Exclusion criteria 
Exclusion criteria included: 
• Review articles, editorials, conference papers, reports. 
• Studies that identified barriers and facilitators to medicines adherence in 
adults, or in both adults and children with no separate information about 
children being provided. 
3.2.5  Data collection  
One reviewer (Aldosari M) screened all titles and abstracts identified by the 
search according to the inclusion and exclusion criteria. Where it was not 
clear from the title or abstract, full papers were obtained and reviewed to 
find relevant papers. As a reliability measure, 5% of titles and abstracts 
were assessed independently by another researcher from our group 
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(Abramson J) and after discussion, Aldosari M and Abramson J reached full 
consensus on which studies were relevant.  
3.2.6  Quality assessment 
Quality assessment was done in order to identify studies with a high risk of 
bias. The quality of the included studies was assessed by one researcher 
(Aldosari M). As a reliability measure, 5% of the included studies were also 
quality assessed independently by another researcher from our group 
(Abramson J) and any discrepancies were resolved by discussion. The 
quality of observational studies was assessed using the Strengthening the 
Reporting of Observational studies in Epidemiology (STROBE) checklist 
(108). STROBE is a comprehensive quality tool which is designed to assess 
the quality of cohort, case series, and cross-sectional studies (108). The 
maximum STROBE score is 100% and the score required for inclusion was 
70% as used in a previous systematic review by our research group 
published in a peer reviewed reputable journal (109).  
The quality of the included RCT studies was assessed using the Cochrane 
Collaborations tool for assessing risk of bias in randomised controlled trials 
(110). The Cochrane process involves assessing the article against seven 
criteria and if the study shows a high risk of bias on two or more criteria 
then it should be excluded. 
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3.2.7  Data analysis 
All included studies were analysed and the following data were extracted 
into a table:  
• Name of authors. 
• Publication year. 
• Country where study was completed. 
• Type of study.  
• Number and age of participants. 
• Type of tools used to explore barriers and facilitators of medicines 
adherence. 
• Type of disease. 
• Reported barriers and facilitators. 
3.3 Results 
3.3.1  Number of studies 
9360 studies were identified after searching the six databases. After 
removing duplication, 6522 papers remained. Aldosari M screened these 
studies and in total 6345 of them were excluded. One hundred and seventy-
seven articles met the inclusion criteria and were included (Figure 3-1). All 
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3.3.2  Quality of studies 
A. Observational studies 
Quality assessment of the one hundred and seventy-five observational 
studies identified was done using the STROBE checklist. One hundred and 
sixty-eight studies scored ≥ 70% and therefore met the standard for 
inclusion. Three studies scored <70%, and were therefore excluded from 
the results (152–154). 
B. RCT 
Quality assessment for the five RCT studies were done using the Cochrane 
collaboration tool. All studies met the standard for inclusion.  
3.3.3  Countries 
The studies identified came from thirty nine different countries, including 
both high economically developed countries (HEDCs) and less economically 
developed countries (LEDCs) (155). This classification allows for comparison 
as to what factors are reported to be barriers or facilitators to medicines 







A. Studies from HEDCs (n=130)  
• United States (n=76)  
• United Kingdom (n=12) 
• Canada (n=6)  
• Australia (n=5)  
• Brazil (n=5)    
• Netherlands (n=5) 
• South Africa (n=4)  
• Jordan (n=3)   
• Spain (n=2) 
• Two studies conducted in Jordan and Northern Ireland. 
• One study conducted in the United Kingdom, Canada, Germany and 
France.  
• Nine studies conducted in each of Belgium, Denmark, France, Germany, 
Japan, New Zealand, Lebanon, Saudi Arabia and Sweden. 
B. Studies from LEDCs (n=47)  
• Uganda (n=9) 
• Ethiopia (n=7) 
• Kenya (n=3)   
• India (n=3) 
• Iran (n=3)     
• Cambodia (n=2)   
• Nigeria (n=2) 
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• Peru (n=2)  
• Tanzania (n=2) 
• Zimbabwe (n=2) 
• One study conducted in Kenya, Uganda and Tanzania.  
• Eleven studies conducted in each of Congo, Cuba, Ghana, Guatemala, 
Jamaica, Mozambique, Pakistan, Thailand, Vietnam, Zambia and Togo. 
3.3.4  Study design 
One hundred and seventy-two studies were observational studies (95 
cohort, 74 cross-sectional and three case series), and five were randomised 
controlled trial studies. 
3.3.5 Tools used to identify barriers and facilitators 
Various tools were used in the included articles, which are described in the 
following sections. 
A. Patients’ medical data 
Nine studies with patients with HIV, kidney diseases, psychotropic disease, 
IBD, different chronic diseases and patients with high cholesterol level were 
based on patients’ medical records or pharmacy refill data to assess factors 
associated with medicines adherence, such as age, gender, education level, 





One hundred and sixty-three studies used self-report tools to identify 
barriers and facilitators. These self-reports were divided into validated 
questionnaires and individually designed questionnaires. The validated 
questionnaires were used for thirty-two studies. Table 3-1 provides a 
summary of validated questionnaires used to identify barriers and 























kidney or liver 
diseases (169–
172). 
Medical Adherence Measure (MAM) questionnaire 
scale. 
 
Adherence across 4 domains assessed: adherence 
behaviour, knowledge, barriers to medicine adherence 
and organisational system. 
Asthma (68,173–








Beliefs about Medicines Questionnaire-Specific 
(BMQ) scale. 
 
Ten questions, five on necessity and five on concerns 
about taking medicines. 
Questions involving concerns assess patients’ concerns 
about taking the medicines prescribed; questions about 










Brief Medication Questionnaire scale. 
 
Three domains: belief screen (to assess patients’ beliefs 
in the need to take medicines), regimen screen (number 
of missed doses within the previous week) and recall 





Diabetes Family Responsibility Questionnaire. 
 
Assesses child and parent perceptions about responsibility 
for treatment adherence. 
Higher scores indicate lower level of parental involvement 
in treatment. 
 
HIV (183) Beck Depression Inventory to assess depression. 
 
21 items, participant picks item describing how they have 
been feeling in last 14 days. 
Results categorised to: severe depression; moderate 








Name of validate questionnaire Details of validated questionnaires used 
HIV (184) Conners’ Parent Rating Scale to evaluate 
children’s behavioural functioning. 
 
Questionnaire consists of 48 descriptors of behaviour 
including learning problems, conduct problems, general 
hyperactivity, anxiety, psychosomatic problems, and 
impulsivity-hyperactivity.  
Parent picks the one that they observed in the last month. 
 
 
HIV (185) Beliefs about Medication Scale. 
 
Questionnaire consists of 59 items to assess positive and 
negative outcome expectancy, perceived threat of illness, 
and intent to adherence. 
 
Asthma (186) Asthma Knowledge Questionnaire. 
 
25 items about childhood asthma. Any score ≤ 11 rated 
as poor knowledge about asthma. 
 
 
Asthma (187) Asthma Expectation Questionnaire Scale. 
 




Adolescent Medication Barriers Scales. 
 
Designed to assess barriers to adherence in adolescent 
transplant recipients. 
Questionnaire consists of 16 questions about barriers and 





Child & Adolescent Adherence to Medication 
Questionnaire. 
 
To identify emotionality and variables that affect 
adherence. 
Two questions about demographic information, one about 
diagnosis, seven open ended questions on participants 
opinions about treatment and adherence, and nine closed 
questions. 
 
Epilepsy (177) Morisky Medication Adherence Scale. 
 
Questionnaire with four items about forgetting, severity of 
disease, feeling better, and absence of symptoms with 
answer of yes=0 and No=1. 






Name of validate questionnaire Details of validated questionnaires used 
Epilepsy (190) Paediatric Epilepsy Medication Self-
Management Questionnaire scale (PEMSQ). 
 
27 items to evaluate medicine self-management in 
children with epilepsy. 
Four scales (adherence to medicines, barriers to 
adherence, epilepsy and treatment knowledge and beliefs 
about medicines efficacy). 
Epilepsy (190) Paediatric Epilepsy Side Effects Questionnaire 
scale. 
 
19 items to assess side effects of antiepileptic medicines 
for epilepsy. 
Epilepsy (190) Parental Environment Questionnaire scale. 
 
42 items to assess parent-child relationship. 
Answers ranging from “definitely true” to “definitely 
false”. 





Disease Management and Barriers Interview-
Sickle Cell Disease scale. 
 







The remaining 131 studies used individually designed questionnaires. The 
questionnaires consisted of multi-item questions to explore the barriers and 
facilitators to medicines adherence in children during a previous period of 
time. The questionnaire items differed in their formats and questions, 
depending on which diseases and populations were being targeted.  
3.3.6  Types of diseases 
The studies identified barriers and facilitators to medicines adherence for 
several diseases, which in order of frequency were: 
• HIV/AIDS (n=60) 
• Asthma (n=25) 
• Kidney or liver diseases and solid organ transplant (n=19) 
• Psychiatric disorders (n=13) 
• Inflammatory bowel disease (IBD) (n=11) 
• Epilepsy (n=10) 
• Multiple chronic diseases (n=6) 
• Sickle cell disease (n=5) 
• Cystic fibrosis (n=4) 
• Diabetes (n=4) 
• Tuberculosis (n=4) 
• Chronic rheumatic disease (n=3) 
• Multiple sclerosis (n=3) 
• Cancer (n=2) 
• Growth hormone deficiency (n=2)  
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• Thalassemia (n=2) 
• Patients taking antibiotics (n=1) 
• Adolescent smoking cessation (n=1) 
• Cystinosis (n=1) 
• Patients with high cholesterol level (n=1) 
Information on barriers and facilitators to medicines adherence were 
extracted from the studies for each disease based on the World Health 
Organisation (WHO) classification of patient-related factors, healthcare 
professional-and system-related factors, condition-related factors, 
medicine-related factors, and socioeconomic-related factors. 
A. HIV/AIDS 
As shown in Table 3-2, sixty studies identified barriers and facilitators to 
medicines adherence in HIV/AIDS patients (61,62,156,157,181,183–
185,192–195,69,196–205,70,206–215,71,216–225,73,226–
235,74,86,93,116). 
• Patient-related factors 
The most common barriers to medicines adherence in HIV patients were 
patient-related factors reported in thirty three studies (61,62,193–
197,199–
203,69,205,210,213,214,218,219,221,228,230,233,70,73,86,93,116,184,
192). Twenty six studies reported that forgetting to take the medicine was 
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the most common barrier to medicines adherence in children (61,62,193–
197,199–
201,205,213,69,214,218,219,221,228,230,70,73,86,93,116,184,192). 
Forgetfulness appeared more common among adolescents, who receive less 
parental supervision (61,62,228,70,93,184,192,194,200,201,218). Efforts 
to avoid forgetfulness to take medicines, such as using reminder tools, 
integrating medicine into daily routines and taking medicines at a specific 
time each day, were associated with medicines adherence 
(62,69,228,73,93,184,193,194,199,205,214). 
Patient age was related to adherence in five studies 
(202,203,210,214,233). Three of these studies found that patients aged > 
12 years are more likely to have  poor adherence to treatment than younger 
patients (203,210,233). Factors linked to decreased adherence with 
increasing age included close relationship with peers, less parental 
involvement and breakdown of family routines (203,210,233). By contrast, 
two studies reported that children aged < 5 years are less likely to be 
adherent than those aged > 5 years (202,214). Wadunde et al. also found 
that patients aged < 10 years are more likely to have poor adherence than 
older children (p = 0.002) (199).  
Suboptimal relationships between children and their parents and families 
are reported as barriers to medicines adherence (62,73,93,196,205,210). 
Factors such as a ‘bad home life’ and ‘family stress’ were associated with 
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medicine non-adherence (62,73,205,210). Children with alcoholic parents 
appeared less likely to adhere to treatments (196,205).  
Knowledge of a disease and its treatment varied among patients and their 
families. Good knowledge of the disease and its treatment was associated 
with good adherence to medicines (70,86,192,196,199,221). Parents and 
children with good knowledge of the disease and its treatment recognised 
the severity of the disease and the necessity for medicine (70). 
• Socioeconomic-related factors 
The second most common barrier to medicines adherence among HIV 
patients were socioeconomic-related factors reported in twenty six studies 
(61,62,196–199,201,203,204,206,214,215,71,217–
221,223,224,231,232,235,73,74,86,93,156,193,194). Among these 
factors, fear of stigma and discrimination was reported in sixteen studies 
(62,71,218,219,221,224,231,232,73,86,93,193,194,201,206,217). Galea 
et al. found that children hid their antiretroviral therapy medicines when 
going out with friends (73). Fetzer et al. reported that children were 
frustrated with their HIV medicine regimens because they compared 
themselves to their peers and found that other children were not 
administered such medicine regimens (93).   
Failure of parents to tell their children about their condition lead to poor 
adherence as reported by twelve studies 
(61,93,231,235,196,198,203,204,217,218,221,224). Reasons for non-
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disclosure included: the child being too young, the child would tell others or 
the child would suffer negative consequences (204,217). Nine of these 
studies showed that patients who knew about their HIV condition were more 
likely to adhere to medicines compared with individuals not aware 
(93,194,196–198,214,218,223,235). Bulali et al. found that good 
adherence is significantly associated with HIV disclosure (p<0.05) (235).   
Economic problems may also influence medicines adherence, such as when 
medicines are not free or when patients live far from healthcare facilities 
and may need to pay for travel expenses. Twelve studies conducted in 
LEDCs reported that financial problems, limited access to healthcare 
facilities, long distance from medical centres and lack of transportation 
result in poor adherence to medicines 
(71,73,220,232,74,86,156,193,196,199,203,215). 
• Medicine-related factors  
The third most common barrier to medicines adherence for patients with 
HIV were medicine-related factors reported in 22 studies 
(62,70,200,201,203,208,210,213–
216,218,71,226,227,74,86,192,193,196–198). Experiencing side effects of 
medicines was one of the most common barriers reported in ten studies 
(70,86,198,200,201,214,216,218,226,227). In addition, five studies have 
showed an association between the fear of the side effects of medicines and 
poor adherence (71,192,196,197,203).  
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Medicines characteristics, such as bad taste or large pill size, were 
associated with non adherence. Six studies showed that children could not 
swallow bad-tasting medicines (193,197,198,208,213,215). Pills that were 
too large and could become stuck in a child’s throat or cause vomiting 
resulted in poor adherence (61,193,195,215,216). Five studies showed that 
the administration of multidrug regimens was associated with poor 
adherence (62,70,74,210,216).  
• Condition-related factors  
The fourth most common barriers in HIV patients were condition-related 
factors reported in nine studies (61,70,71,192,196,216,221,229,232). 
Decreased HIV severity was reported to be associated with poor 
adherence. When patients began to feel better and their symptoms 
decreased, they stopped taking daily medicines (61,71,221). By contrast, 
greater disease severity increased patient adherence (70,196). However, 












Table 3-2  Studies reporting barriers and facilitators to medicines adherence in HIV/AIDS patients. For 
barriers and facilitators numbers are reported as % or significant association (if no numbers given numbers 
not reported in study). 
Study Design Tools used  Barriers identified  Facilitators identified  








months to 18 
years. 
Completed by children and caregivers 
54-item questionnaire: caregiver/child 
health status, sociodemographic 
characteristics, knowledge of disease 
and therapy, and concerns about side 
effects. 
Adherence rate assessed by self-report. 
 Forgetting (35.1%)  
 Change in caregiver (35.1%) 
 Parents busy (27%) 
 Child outside home 27%. 
 Medicines unavailable at 
pharmacy 18.9%. 
 Child depressed 16.2%. 
 Fear of side effects 16.2%. 
 Can’t swallow pills 16.2%. 
 Sleeping 13.5%. 
 Feel too ill 13.5%. 
 Medicines taste bad 13.5%. 
 Caregivers having good 
















aged 8 to 18 
years. 
Questionnaire completed by caregivers 
to evaluate adherence to treatment. 
Participants given list of barriers to 
adherence and asked to tick factors 
they have faced. 
Adherence rate assessed by self-report. 
 Out of stock medicines 43%. 
 Forgetting 22%. 
 Vomiting 14%. 
 Child’s refusal 11%. 








aged ≥ 15 
years. 
Diabetes Family Responsibility 
Questionnaire (DFRQ) completed by 
children and parents (see table 3.1.). 
Adherence rate assessed by self-report. 
 
Did not report barriers.  Caregivers reported youth 
with greater responsibility 
for treatment have better 
adherence (p=0.004). 
 Adolescents reported 
degree of responsibility for 
treatment was not 




et al. 2009, 
Brazil (201) 
Cohort study, 9 
children aged 
12 to 18 years. 
Questionnaire completed by children 
and caregivers about treatment 
aspects, disease experience, family 
support, and daily routine. 
Adherence rate assessed by self-report. 
 Forgetting. 
 Non-acceptance of disease. 
 Experience of side effects. 
 Fear of stigma and 
discrimination. 
Did not report facilitators. 
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Study Design Tools used  Barriers identified  Facilitators identified  







aged ≥ 8 
weeks. 
Questionnaire completed by caregivers. 
At each visit, caregivers asked 
questions about medicines 
administration difficulties. 
Adherence rate assessed by self-report. 
 Children aged < 4 years old. 
 Children in house with large 
number of people. 





 Children aged > 4 years 
old. 
 Children in small 
household. 











of children aged 
up to 14 years. 
Questionnaire completed by caregivers 
and parents open-ended questions 
related to knowledge of disease and 
therapy, factors associated with 
adherence, barriers and facilitators of 
adherence. 
Adherence rate assessed by self-report. 
 Children aged > 10 years. 
 Child’s refusal. 
 Greater child responsibility for 
medicines-taking. 
 Difficult relations between child 
and caregiver. 
 Lack of transportation. 
 Fear of side effects. 
 Lack of financial resources. 
 Non-disclosure HIV status to 
household members. 
 Children aged < 10 years. 
 Caregiver solely responsible 
for medicine. 
 Disclosure HIV status to 

















Questionnaire completed by caregivers 
open-ended questions related to 
knowledge of disease and therapy, 
factors associated with adherence. 
Adherence rate assessed by self-report. 
 Leaving home to visit relatives. 
 Nondisclosure of patient HIV 
status. 
 Lack of transportation and 
economic problems. 
 Lack of food (fear of taking 
medicines on empty stomach). 
 Fear of stigma and 
discrimination. 
 Patient dislike of taking the 
medicine. 
 Patient spitting out the 
medicine. 
 Time of administration. 
 Presence of medicines 
reminders. 
 Good relationship between 
health workers and 
caregivers. 











aged 14 to 22 
years. 
Questionnaire completed by 
adolescents about religious beliefs and 
practises. 
 Lower religious belief (p<0.05). 
 Lower religious practise (not 
significant due to small sample 
size). 
Did not report facilitators. 
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Study Design Tools used  Barriers identified  Facilitators identified  
Standardised depression questionnaire 
(BDI-II) completed by adolescents 
(table 3.1). 
Adherence rate assessed by self-report. 
 Higher depression score (not 
significant due to small sample 
size). 
 






aged 12 to 24 
years. 
Questions completed by patients to 
investigate environment factors that 
may influence adherence. 
Adherence rate assessed by self-report.  
 Problems with medical 
insurance (p<0.04). 
 Problems dealing with family or 
taking care of children 
(p<0.04). 
 Low self-efficacy (p<0001). 
 
 
 High self-efficacy 
associated with good 
adherence (p<0.001). 
 






aged 3 to 16 
years. 
Questionnaire completed by caregivers 
to explore factors associated with 
adherence to medicines: psychosocial 
(factors external to family, family 
environment, characteristics of 
caregiver), and factors related to 
therapy. 
Adherence rate assessed by self-report.  
 Fear of stigma or discrimination. 
 Children aged > 11 years. 
 Absence of both parents 
associated with poor adherence. 
 Psychosocial factors, such as 
parents suffering with his or her 




 Psychological adaptation by 
families. 
 Reducing dose frequencies 












aged 0 to 18 
years. 
Questionnaire completed by physicians 
to explore physicians’ perception about 
factors that caused medicines 
discontinuation.  
Medicine discontinuation assessed by 
medical record. 
 Ritonavir was the least palatable 
medicine associated with 
medicine discontinuation 
(p=0.01). 
 Male gender associated with 
medicine discontinuation 
(p=0.001). 











Questionnaire completed by nurses and 
elderly caregivers (grandparents) 
covered experiences of AIDS, personal 
background, stigma and challenges 
faced with adherence to treatment. 
Adherence rate assessed by self-report.  
 
 Poverty. 
 Immobility of caregivers. 
 Deteriorating memory of 
caregivers. 




Did not report facilitators. 
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Study Design Tools used  Barriers identified  Facilitators identified  






aged 3 to 17 
years. 
Conners’ Parent Rating Scale (CPRS) 
completed by parents or caregivers 
(table 3.1). 
Adherence rate assessed by self-report.  
 
 Learning problems 22%. 
 Somatic complaints 22%. 
 Impulsivity-hyperactivity 20%. 
 
 Use of daily activities as an 
adherence support. 
 Adult responsible for 
medicine administration 
 





aged 8 to 17 
years. 
Questionnaire completed by children 
and caregivers - questions about 
children/caregiver relationships, then 
open-ended questions to explore beliefs 
on ART and HIV and factors related to 
adherence. 
Adherence rate assessed by self-report. 
 Forgetting. 
 Frustrated with medicine 
regimen. 
 Lack of food (fear of taking 
medicines on empty stomach). 
 Lack of assistance from family. 
 Medicine characteristics (high 
dose frequencies, large 
quantity, and bad taste). 






 Presence of medicines 
reminder such as, 
Electronic Monitoring 
Devices (EMDs). 
 Living with two parents. 
 Belief itself that medicine 
was helping. 
 Having strategy or routine 
related to medicine 
administration. 
 Patient disclosed HIV 
status. 
 Convince or motivate 
children to be committed to 











aged 4 to 17 
years. 
Questionnaire completed by caregivers 
covering socio-demographic, marital 
status, level of education, and reasons 
for non-disclosing HIV status. 
Adherence rate assessed by self-report. 
 Non-disclosure was reason for 
not adhering to medicine 39%. 
 Reasons for non-disclosure 
include child too young (72%), 
child would tell others about 
disease (21.1%), child would be 
socially rejected (18.6), fear of 






Did not report facilitators. 
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aged 2 to 10 
years. 
Questionnaire completed by caregivers. 
Open-ended questions covered socio-
demographic, behavioural, and factors 
with potential to affect adherence. 
Adherence rate assessed by pill count 
and EMDs. 
 Hospitalisation of children in last 
three months. 
 Use liquid formulations. 
 Caregiver’s use of alcohol. 
 Caregivers had depression. 
 Caregivers ashamed of child’s 
diagnosis. 
 
 Well-established medicine 
taking routine (e.g. take 
medicine before school). 











aged 15 to 24 
years. 
Questionnaire completed by 
adolescents. 
Open-ended questions to explore HIV 
related stigma, depression, social 
support, and health care satisfaction. 
Adherence rate assessed by self-report. 
 Fear of stigma and 
discrimination caused poor 
adherence but was not 
significantly associated with 
poor adherence. 
 
Did not report facilitators. 
Chandwani 






aged 13 to 17 
years. 
Questionnaire completed by children. 
Open-ended questions identified 
predictors of medicines adherence. 
Adherence rate assessed by self-report. 
 
 Forgetting. 
 Complexity of medicine 
regimen. 
 Busy and varying schedules. 
 Feeling better. 
 Fear of stigma and 
discrimination. 
 Nondisclosure. 
 Unstable housing. 
 
 
 Have someone to remind. 
 Educating children about 












aged 8 to 18 
years. 
Questionnaire completed by children 
and parents. 
Open-ended questions identified 
medicine use, quality of life, 
demographic information, stressful life 
events, and children-parents 
relationship. 
Adherence rate assessed by self-report 
and pill count. 
 
 Child aged > 12 years 
(p<0.05). 
 Greater child responsibility for 
medicines-taking (p<0.05). 
 Poor relationships with parents 
(p<0.05). 





Did not report facilitators. 
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aged 8 to 18 
years. 
Children and parents asked: “People 
may miss their medications for various 
reasons. In the past month, how often 
have you/your child missed taking 
medication because of the following 
reasons?” 
Adherence rate assessed by self-report. 
 
 Forgetting. 
 Delaying taking medicine in 
front of others. 
 Feeling well. 
 Sleeping. 
 Pill burden. 
 Depressed. 
 Did not refill. 
 Change daily routine. 
Did not report facilitators. 





on 4 adults and 
one adolescent 
aged 14 years. 
Questionnaire completed by 
participants to collect medical history, 
patient information, and personal 
barriers to medicines adherence. 




 Lack of family support. 
 Orphan. 













≤ 10 years. 
Questionnaire completed by caregivers 
to obtain demographic information, 
treatment information, and family 
status. 
Adherence rate assessed by self-report 
and pill count. 
 Two or less children in 
household (OR 6.26). 
 Two or less adults in the 
household (OR 3.73). 
 








aged 12 to 24 
years. 
Questionnaire completed by 
participants. 
Participants given list of barriers to 
adherence and asked to tick factors 
they have faced. 
Adherence rate assessed by self-report. 
 Forgetting 73.6%. 
 Did not feel like taking 
medicines 30%. 
 Taking medicines reminds of 
disease 28.9%. 
 Bad taste 20.5%. 
 Ran out of prescription 20.5 %. 






Did not report facilitators. 
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Study Design Tools used  Barriers identified  Facilitators identified  








aged 3 months 
to 18 years. 
Questionnaire completed by caregivers 
and children. 
Open-ended questions covered socio-
demographic, level of education, age, 
sex, and duration of treatment. 
Participants given list of barriers to 
adherence and asked to tick factors 
they have faced. 
Adherence rate assessed by self-report. 
 Forgetting 55.2% of caregivers. 
 Travelling 25.3% of caregivers. 
 Medicines finished 18.4% of 
caregivers. 
 Child reused to take medicines 
11.5% of children. 
 Sleeping 9.2% of children. 
 Vomiting 9.2% of children. 
 Younger than 5 years (OR 
2.62). 
 
 Having medicine strategy 
or reminder (OR 6.34). 
 Regular clinic visits (OR 
8.55). 









aged 7 to 15 
years. 
Questionnaire completed by children 
and parents. 
Participants given list of barriers to 
adherence and asked to tick factors 
they have faced. 
Adherence rate assessed by self-report. 
 Difficulty in going to hospital 
61.7%. 
 Difficulty in swallowing drugs 
12.6%. 
 Bad taste 7.6%. 
 Lack of money 7.1%. 
 








aged 13 to 24 
years. 
Beliefs about Medication Scale (BAMS) 
completed by adolescents (table 3.1). 
Adherence rate assessed by self-report. 
 Adolescents with low level of 
literacy   
 (p<0.05). 
 Adolescents with higher 
negative expectancy. 
 
 Adolescents with higher 
positive expectancy (OR 
1.07). 







mean age 7.8 
years. 
Questionnaire completed by caregivers 
covered socio-demographic, factors 
related to adherence, and reasons for 
missing doses. 
Participants given list of barriers to 
adherence and asked to tick factors 
they have faced. 






 Child feels depressed 24.4%. 
 Experienced side effects 16.3%. 
 Multi-drugs 15.5%. 
 Difficulty in swallowing 
medicines 13.3%. 
 Child too ill 8.9%. 
 
 Orthodox religion 
caregivers (OR 4.15). 
 Married caregivers (OR 
3.75). 




Study Design Tools used  Barriers identified  Facilitators identified  






aged 10 to 19 
years. 
Questionnaire completed by 
adolescents focused on sexual needs 
and experiences of disclosure. 
Questionnaire completed by health care 
providers to explore barriers to 
disclosure HIV status. 
Adherence rate assessed by self-report. 
 Non-disclosure was reason for 
non-adherence to medicine. 
 Reasons for non-disclosure 
included: presumption that 
children would not understand 
consequences of HIV disclosure 
on their lives, fear of stigma and 
discrimination, child would be 
socially rejected. 
 
Did not report facilitators. 







aged 2 months 
to 15 years. 
Questionnaire completed by caregivers. 
Participants given list of barriers to 
adherence and asked to tick factors 
they have faced. 
Disease disclosure and knowledge also 
assessed. 
Adherence rate assessed by self-report. 
 Forgetting 52.3%. 
 Medicine fatigue 26.2%. 
 Fear of stigma and 
discrimination 14.3% 
 Caregivers’ illness 11.9%. 
 Disclosure of the child’s HIV 
status to the child. 











aged 10 to 16 
years.  
Questionnaire completed by children 
including questions about medicine 
handling, interactions around 
medicines, cultural context of HIV 
treatment, and barriers to adherence. 
Adherence rate assessed by self-report. 
 
 Forgetting. 
 Delaying taking medicine in 
front of others. 
 Feeling well. 
 Sleeping. 
 Pill burden. 
 
Did not report facilitators. 







aged 2 months 
to 14 years. 
Questionnaire completed by caregivers, 
questions about most common barriers 
including medicines factors, 
socioeconomic factors, and patient 
factors. 
Participants given list of barriers to 
adherence and asked to tick factors 
they have faced. 
Adherence rate assessed by self-report. 
 
 Forgetting 28.5%. 
 Refused to take medicines 
19.3%. 
 Lack of transportation 19.1%. 
 Run out of pills 13.2%. 
 Illness of the caregivers 5.5%. 
 Pill burden 4.3%. 
 Fear of side effects of medicines 
4.3%. 
 Illness of child 3.2%. 
 Taste of medicines 1.8%. 
 Caregivers have good 
knowledge of disease and 
therapy. 
 Disease severity motivated 
patient’s adherence. 
 Higher education level. 
 Short distance between 
home and hospital. 







Study Design Tools used  Barriers identified  Facilitators identified  







aged < 15 
years. 
Questionnaires were completed by 
caregivers to explore factors associated 
with ART therapy adherence. 
Participants given list of barriers to 
adherence and asked to tick factors 
they have faced. 
Adherence rate assessed by self-report. 
 
 Illness of the child 23.8%. 
 Fear of side effects 23.8%. 
 Child refusal 14.3%. 
 Busy caregiver 14.3%. 
 Forgetting 9.5%. 
 Lack of trust in the treatment 
9.5%. 
 Taste of the drug 4.8%. 
 
 Patients disclosed their HIV 
status. 
 Male were more likely to 
adherent than female. 
 Patients who are on first 
line ART are more adherent 









aged ≤ 5 years 
old. 
Questionnaires completed by 
caregivers including open-ended 
questions to explore parents’ 
understanding of treatment and 
barriers to adherence. 
Adherence rate not assessed. 
 
 Lack of food (fear of taking 
medicines on empty stomach). 
 Non-disclosure. 
 Lack of knowledge about 
treatment. 
 Lack of transportation and 
economic problems. 
 Experienced side effects 
(vomiting). 
 Good relationship between 
child and caregivers. 
 Sweet tasting medicines. 
 Patients disclosed their HIV 
status 







aged 12 to 24 
years. 
Questionnaire completed by 
adolescents to explore treatment 
adherence information. 
Participants given list of barriers to 
adherence and asked to tick factors 
they have faced. 
Adherence rate assessed by self-report. 
 
 Forgetting 23.9%. 
 Fatigue 10.1%. 
 Stigma 9%. 
 Experienced side effects 7.5%. 
 Self-motivation 33.4%. 








aged 15 to 24 
years. 
Questionnaires completed by 
caregivers including open-ended 
questions to explore barriers of 
adherence including, socioeconomic 
factors and medicines factors. 
Adherence rate not assessed. 
 
 
 Fear of stigma. 
 Non-disclosure. 
 High transportation costs. 
 Fear of side effects. 
 Lack of disease’ symptoms. 





Did not report facilitators. 
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Study Design Tools used  Barriers identified  Facilitators identified  






children aged 2 
to 10 years. 
Questionnaires completed by 
caregivers including open-ended 
questions to explore barriers and 
facilitators of adherence including, 
patient factors, socioeconomic factors 
and medicines factors. 
Adherence rate assessed by self-report. 
 
 Lack of money, food, and 
transportation. 
 Lack of social support. 
 Weak relationship between 






 Good relationship between 
caregivers and their 
children. 
 Greater responsibility of 
children for their treatment 
(who were cognitively 
mature). 
 Good social support. 
 







aged 2 to 19 
years. 
Questionnaires completed by children 
and caregivers to identify predictors of 
adherence such as, parental status, 
awareness of disease, duration of 
treatment, and knowledge about 
disease and treatment. 
Adherence rate assessed by pill count. 
 
 Living with non-parental 
caretakers (p=0.042) 
 Fear of stigma and 
discrimination. 
 Forgetting. 
 Lack of knowledge about 
disease and treatment. 
 Feeling better. 
 Non-disclosure HIV status. 
 Treatment longevity. 
 
 Good knowledge about 
disease and treatment. 














aged 10 to 19 
years old. 
Factors associated with poor adherence 
like age, sex, medicine regimen, age at 
last visit, distance to hospital, date of 
medicine initiation were extracted from 
medical records. 
Adherence rate assessed by self-report.  
 
 Male sex (OR 1.38) (p=0.048). 
 Rural location (OR 2.67) 
(p=0.000). 
 Less than one year on 
treatment (OR 1.45) (p=0.022). 







aged 10 to 16 
years. 
Questionnaire completed by children 
and caregivers. 
Different economic and social variables 
assessed such as, caregiver 
employment status, available cash, 
material housing value, food security, 
distance to health care services, and 
social support. 
Adherence rate assessed by self-report.   
Did not report barriers.  Adolescents with caregiver 
employment (OR 1.70). 
 Greater familial asset 
ownership (OR 1.69). 




Study Design Tools used  Barriers identified  Facilitators identified  






aged 12 to 18 
years. 
Questionnaires completed by 
adolescents to explore perceptions of 
disclosure, reaction to disclosure, and 
association between adherence and 
HIV disclosure. 
Adherence rate assessed by self-report. 
 
 
Did not report barriers.  Disclosure HIV status. 












aged 12 to 19 
years. 
Questionnaires completed by 
adolescents. 
Open-ended questions to identify 
barriers and facilitators of medicines 
adherence. 
Adherence rate assessed by self-report. 
 
 Forgetting. 
 Fear of stigma and 
discrimination. 
 Financial barriers. 
 Experienced side effects. 
 
 
 Family support. 
 Health care providers 
support. 
 Good knowledge about 
disease and treatment. 
 







Questionnaire completed by health care 
providers. 
Open-ended questions to explore 
barriers to medicines adherence in 
adolescents and adults. 
Adherence rate assessed by self-report. 
 Unstructured treatment 
holidays. 
 Fear of stigma. 
 Non-disclosure HIV status. 
 Lack of family support. 
 
 
Did not report facilitators. 






aged 2 to 12 
years. 
Questionnaires completed by 
caregivers to identify predictors of 
adherence such as, relationship with 
the child, functional status, medicines 
problems and family’s income. 
Adherence rate assessed by self-report. 
 
 High family income was 
associated with poor adherence 
(p<0.05). 
 Liquid formulation. 
 Mothers with HIV who did not 
adhere to their treatment. 
 
 
Did not report facilitators. 






aged > 18 
years. 
Questionnaires completed by 
caregivers to explore barriers to 
adherence such as medicine related 
factors, patients or caregivers related 
factors, and health care related factors. 
Adherence rate assessed by self-report. 
 Experienced side effects 
(p=0.01). 
 Child refused to take medicines 
(p=0.01). 
 Running out of medicines 
(p=0.02). 
Did not report facilitators. 
106 
 







aged 0 to 14 
years old. 
Questionnaires completed by 
caregivers including open-ended 
questions to assess adherence and 
identified barriers to adherence. 
Adherence rate assessed by self-report 
and EMDs. 
 Forgetting. 
 Child refusal to take medicine. 
 Caregivers not being around to 
give the medicines. 
 Fear of stigma. 
 
Did not report facilitators. 






aged 13 to 21 
years old. 
Questionnaires completed by 
adolescents.  
Open-ended questions to assess 
adherence, self-efficacy, and medicines 
symptoms. 
Adherence rate assessed by self-report. 
 Lower self-efficacy. 




 Higher self-efficacy. 











aged 14 to 22 
years old. 
Questionnaires completed by 
adolescents.  
Open-ended questions to assess 
adherence, and behavioural and 
psychological factors that influenced 
adherence. 




 Poor adherence was associated 
with weekend days. 
 Lack of routine. 






 Higher self-efficacy. 
 Having a strategy or 














aged 12 to 24 
years old. 
Questionnaires completed by 
adolescents.  
Open-ended questions to assess 
adherence, self-efficacy, motivation for 
adherence, depression and social 
support. 
 





 Lower self-efficacy. 
 Lower level of social support. 







 Higher self-efficacy. 

















aged ≤ 15 
years. 
Questionnaires completed by 
caregivers and included four main 
parts: clinical markers in children, 
sociodemographic characteristics, 
medicine taking behaviour, and access 
to care. 




 Younger children more likely to 
be non-adherent. 
 Child with a caregiver who 
works was more likely to be 
non-adherent. 





 Using medicines reminder 
or diary reminder. 
 Children in early stage of 
HIV were more likely to 
adhere to medicine. 









< 15 years old. 
Questionnaire completed by children, 
asked a single question about reasons 
for missing doses.  
Reasons options given to patients to 
choose which one caused missing dose. 
Also factors that may lead to good 
adherence were assessed. 
Adherence rate assessed by pill count. 
 Forgetting 37.1%. 
 Travel 14%. 
 Missed appointment 13%. 
 Experienced side effects 12%. 
 Pill burden 10%. 
 Lack of knowledge and 
motivation 10%. 
 Education of caregiver. 
 Disease severity. 
 Caregivers have good 












aged 12 to 19 
years. 
Questionnaire completed by 
adolescents. 
Open-ended questions to explore 
barriers of medicines adherence. 




 Weak relationships with 
caregivers. 
 Fear of disclosing disease status 
to others. 
 Large household. 
 
 
Did not report facilitators. 







children aged 0 




Caregivers were asked “What are the 
challenges you experience when caring 
for a child on ARV treatment?” 
Adherence rate not assessed. 
 
 
 Financial burden. 
 Fear of stigma. 
 Non-disclosure. 
 Lack of family support. 




Did not report facilitators. 
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Study Design Tools used  Barriers identified  Facilitators identified  









Questionnaire completed by caregivers. 
Participants given list of barriers to 
adherence and asked to tick factors 
they have faced. 
Adherence rate not assessed. 
 Financial burden 69%. 
 Lack knowledge of disease and 
treatment 68%.  
 Depression 41%. 





Did not report facilitators. 





aged 7 to 16 
years. 
Questionnaire completed by caregivers 
and professionals. 
Open-ended questions identified 
medicine adherence, responsibility, and 
executive function. 
Adherence rate assessed by self-report. 
 Children aged >12 years. 
 Greater children responsibility 
for medicine. 







 Younger child age. 
 Caregiver solely responsible 
for medicine. 










aged 13 to 17 
years. 
Questionnaire completed by caregivers 
and professionals. 
Open-ended questions identified 
barriers and facilitators to medicines 
adherence. 





 Lack of knowledge about 
disease. 
 Fear of stigma and 
discrimination. 
 Family’s economic problems. 
 Weak relationship with 
caregivers. 




 Personal strategies. 
 Peer support. 
 Living with two parents. 












aged 0 to 14 
years. 
Questionnaire completed by caregivers 
assessing: child-related factors, 
caregiver-related factors, and drug 
regimen related factors that may affect 
adherence. 
 
Adherence rate assessed by self-report. 
 Children aged < 10 years more 
likely to be non-adherent to 
medicine (p=0.002). 
 Lack of transportation and 
economic problems. 
 Forgetting. 
 Parents busy. 
 
 Older children were more 
likely to adhere. 
 Using medicines reminder. 
 Caregivers have good 















aged 0 to 13 
years. 
Demographic factors that may affect 
adherence such as, clinical factors, 
duration of treatment, family status, 
and medical regimen factors were 
identified from, medical records. 
Adherence rate assessed by self-report 
and pill count. 
 
 
 Orphan children were more 
likely to have lower adherence 
rate (OR 0.78). 
 Longer duration on 
medicines was associated 
with higher adherence rate 
(OR 1.10, p<0.001). 







aged 15 to 17 
years. 
Questionnaires completed by 
adolescents to identify predictors of 
adherence such as, parental and 
caregiver information, social support, 
duration of treatment, and knowledge 
about disease and treatment. 
Adherence rate assessed by self-report. 
 
 Longer duration on medicines 
more than 9 years (AOR 0.35). 
 Main caregiver was a relative 
(OR 0.37). 
 Did not belief there is a cure for 
disease (OR 0.40) 





study, 2 health 
care providers, 
4 patients aged 
14 to 24 years. 
Questionnaire completed by health care 
providers and patients. 
Open-ended questions identified 
barriers to medicine adherence. 
Adherence rate assessed by self-report. 
 Poverty. 
 School attendance limited 
patients’ privacy. 
 Lack family support. 




Did not report facilitators. 







aged 6 to 17 
years. 
Parents asked:” Does the child know 
his/her HIV status?” 
Association between adherence rates 
and disclosure status was tested. 
Adherence rate assessed by medication 
possession ratio (MPR) calculation. 
 HIV disclosure was less among 
male and children aged <10 
years (p<0.05). 
 
 HIV disclosure was 
associated with good 
adherence (p<0.05). 
 HIV disclosure was high 
among female, children 
aged >10 years, and those 





As shown in Table 3-3, twenty five studies identified barriers and facilitators 
to medicines adherence in patients with asthma (68,87,187,236–
244,88,245–249,90,94,122,173–175,186). 
• Patient-related factors  
The most common barriers to medicines adherence in patients with asthma 
are patient-related factors reported in twelve studies 
(87,88,246,249,90,122,186,240–243,245). Eight of these studies reported 
that children and their parents who lack knowledge about asthma and its 
treatment are more likely to have poor adherence 
(87,88,90,186,240,242,246,249). Conversely, children and their parents 
who have good knowledge about asthma and its treatment are more likely 
to have good adherence (87,88,240). Another common barrier to 
adherence in this group is forgetting (87,88,122,241,243,245). Factors 
affecting forgetting include being away from home and changes in daily 
routines (243). Measures taken to avoid forgetting to take medicines 
include the use of reminders, such as notes on the refrigerator and the use 
of an alarm clock; these efforts were associated with good adherence 
(87,122,241,243). 
• Medicine-related factors 
The second most common barriers to medicines adherence in patients with 
asthma are medicine-related factors reported in nine studies 
(122,173,175,236,240,242,245,247,248). Some patients and their parents 
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are concerned about side effects, and they considered medicines as 
unnecessary in an attempt to avoid any side effects 
(173,175,242,245,247,248). Children and parents who have weak beliefs 
on the necessity of medicines use are more likely to have poor adherence 
(173,175,245,247). Fear of side effects is also associated with poor 
adherence (242,248). Moreover, complex medicine regimens, such as high 
dosing frequencies, multidrug administration and evening doses, are 
associated with poor adherence (122,236,240,245). 
• Condition-related factors 
Condition-related factors were reported in four studies (68,173,174,240). 
The severity of asthma is associated with adherence to medicines. For 
instance, patients with mild asthma are more likely to have poor adherence 
(68,173,174,240). Klok et al. reported that for patients with mild asthma 
and parents who believe that medicines may cause harm are less likely to 
adhere because they do not believe that their child needed treatment (173). 
• Healthcare professional and system-related factors  
Healthcare professional and system-related factors were reported in four 
studies (87,88,236,240). A weak relationship between healthcare providers 
and patients may lead to lack of confidence in healthcare providers and lack 
of patients’ knowledge about their disease and its treatment. Poor 
communication between healthcare professionals and patients and their 
parents has been shown to result in non-adherence to medicines 
(87,88,236,240). According to Mirsadraee et al. if healthcare professionals 
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fail to provide sufficient information to patients and their parents about their 
disease and about the efficacy of the treatment, this can result in poor 
adherence (240). The same study also showed that being visited by several 
doctors due to an unavailability of doctors or a lack of confidence in doctors 

















Table 3-3 Studies reporting barriers and facilitators to medicines adherence in patients with asthma. For 
barriers and facilitators numbers are reported as % or significant association (if no numbers given, 
numbers not reported in study). 
Study Design Tools used  Barriers identified 
 
Facilitators identified  





Aged 1 to 12 
years 
Last appointment clinical 
symptoms, adherence rate, 
morbidity features, factors that 
may influence adherence and 
knowledge about disease were 
recorded. 




 Mother’s low education 
level 
 High frequency doses, (> 
two sprays/day) 
 Poor communication with 
healthcare providers 
 Absence of allergic rhinitis 
 
Did not report facilitators. 
Orrell-Valente 






children, aged 4 
to 19 years. 
Questionnaires completed by 
parents about socio-demographic 
information, educational level, 
family status, symptom control 
and extent of child responsibility. 
Association of adherence rates 
with different factors assessed. 




 Males less likely to adhere 
to medicines than females. 
 Non-white parents reported 
to have significantly 
(p<0.05) lower adherence 
than white parents. 
 Adolescents had lower 




 Parents solely 
responsible for 
medicines. 
 Females more likely to 








Cohort study, 51 
participants, 
aged 18 months 
to 7 years.  
Questionnaire completed by 
caregivers covered asthma 
symptoms, medicine usage, who 
was responsible for remembering 
to take medicine and barriers to 
adherence. 




 High frequency doses. 




 Using medicines 
reminder. 
 Using child-friendly 
spacer device. 




Study Design Tools used  Barriers identified 
 
Facilitators identified  







aged 7 to 17 
years. 
Questionnaires completed by 
children and caregivers: asked 
about asthma knowledge, 
motivational factors, 
socioeconomic information and 
self-management. 
Association of adherence rates 
with different factors assessed. 
Adherence rate assessed by MPR 
calculation and self-report. 
 
 
 Less parent motivation to 
use inhaled corticosteroids. 








 Positive motivation. 








Bracken et al. 
2009, United 
Kingdom (238) 
Cohort study, 71 
participants, 
aged 4 to 18 
years. 
Questionnaires completed by 
children and parents about: home 
life, asthma treatment, 
understanding of treatment and 
how these factors affect 
adherence. 
Adherence rate assessed by self-
report. 
 Child depression 28%. 
 Parental depression 28%. 
 Inappropriate inhaler 
devices 15%. 
 
Did not report facilitators. 






aged 3 to 15 
years. 
Questionnaire completed by 
parents asked about concerns and 
worries about use of medicine and 
if they had been educated about 
asthma and its treatment.  
Adherence rate not assessed. 
 Fear of side effects 56%. 
 Parents worried that inhaler 
may cause addiction 48%. 
 Low socioeconomic status. 
 Lack of knowledge about 
asthma and treatment. 
 Complex medicine regimen. 
 Weak communication 
between physician and 
patient. 





Did not report facilitators. 
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Study Design Tools used  Barriers identified 
 
Facilitators identified  






aged 4 to 12 
years. 
Beliefs about Medicines 
Questionnaire (BMQ) scale 
completed by parents (table 3.1). 
Adherence rate assessed by self-
report. 
 
 Low parental education 
level. 
 Weak parental necessity 




 High parental 
education level. 
 Strong parental 
necessity beliefs about 
medicine use. 






Cohort study, 26 
participants, 
aged 12 to 20 
years. 
Questionnaires completed by 
children about treatment and 
disease knowledge and barriers to 
adherence. 
Adherence rate assessed by self-
report. 
 Lack of knowledge about 
asthma and treatment. 
 Incorrect assumptions 
about asthma. 







importance of daily 
medicine. 
 Family support. 




Riekert  et al. 
2011, United 
States (244) 
Cohort study, 37 
participants, 
aged 10 to 15 
years. 
Questionnaires completed by 
children and parents about 
adherence, motivation, self-
efficacy, knowledge and 
responsibility for treatment. 
Study assessed adherence before 
and after motivational interviewing 
intervention. 
Adherence rate assessed by self-
report. 
 

















aged 2 to 6 
years. 
Beliefs about Medicines 
Questionnaire (BMQ) scale 
completed by parents (table 3.1). 
Adherence rate assessed by EMDs. 
 Parents of children with 
mild asthma expected high 
harm of inhaled 
corticosteroids (ICS). 
 Parental perceived 
medicine necessity was 
low. 
 Parental perceived 
medicine necessity 
was high. 
 Parental expected little 




Study Design Tools used  Barriers identified 
 
Facilitators identified  






aged 2 to 6 
years. 
Questionnaires completed by 
parents about family and personal 
history of asthma, asthma 
symptoms, and reasons for non-
adherence. 
Adherence rate assessed by EMDs. 
 Forgetting. 
 Child refusal. 
 Too busy. 
 Thought the child not need 
medicine. 
 Evening doses. 
 
Did not report facilitators. 
Mirsadraee et 





aged ≤ 15 years. 
Children asked single question 
about reasons for missing doses.  
Options given to patients to 
choose which caused missing 
dose. 
Caregivers’ knowledge about 
asthma and treatment, asthma 
symptoms and education level 
assessed. 
Adherence rate assessed by self-
report. 
 
 Long term treatment 
76.7%. 
 Patients visited several 
doctors because lack of 
confidence in doctor 
75.3%. 
 Complex regimen 72%. 
 Delayed therapeutic 
response 43.3%. 
 Concern about medicine 
dependency 38.7%. 
 Costs of medicines 34.7%. 
 Caregivers’ poor knowledge 
about disease and therapy. 
 Children with mild asthma 
symptoms. 
 High educational level 
of caregivers. 
 Caregivers have good 
knowledge of disease 
and therapy.  













aged 12.01 to 
17.25 years. 
Adolescents asked to assess 
factors that associated with 
adherence and family support. 
Adherence rate assessed by self-
report. 
Did not report barriers.  Family routines around 
asthma care. 










aged 6 to 15 
years. 
Questionnaires completed by 
caregivers about educational level 
of caregivers, family size, family 
status, and other factors that may 
affect adherence. 
Adherence rate assessed by EMDs. 
 
 Forgetting. 
 Male sex. 
 Large household size. 
 
 
 Medicines reminder 







Study Design Tools used  Barriers identified 
 
Facilitators identified  






aged 12 to 16 
years. 
Participants asked to describe 
thoughts about asthma, reasons 
for not using medicines, role of 
parents, and solutions to improve 
adherence. 
Adherence rate assessed by self-
report. 
 Feeling of being different 
from other children. 






 Parents support. 
 Use of medicine 
reminder. 
 Having strategy to 
remember medicine 









Pelaez et al. 
2015, Canada 
(88) 
Cohort study, 8 
participants, two 
adolescents ages 
15 and 18 years 
and six parents 
of children aged 
2 to 12 years. 
Questionnaire completed by 
children and parents to explore 
use of asthma medicines, patients’ 
perceptions of their asthma, self-
management, and patient-doctor 
relationship. 
Adherence rate assessed by self-
report. 
 Lack of knowledge about 
asthma and treatment. 
 Forgetting. 
 Lack of motivation. 




 Having established 
routines for taking 
medicine. 
 Perceiving the 
necessity of medicine. 
 Good knowledge about 
disease and treatment. 
 
 






aged 2 to 12 
years. 
Beliefs about Medicines 
Questionnaire (BMQ) scale 
completed by children and parents 
(table 3.1). 
Adherence rate assessed by EMDs. 
 Patients with poor 
adherence had mild asthma 
symptoms. 
 Child’s age not associated 
with adherence. 
 Parent perceived 
medicine necessity 
was high. 
 Parents expected little 
harm of ICS. 
 






aged 11 to 16 
years. 
Questionnaires completed by 
children asked about treatment 
and disease knowledge and 
barriers to adherence. 
Adherence rate assessed by MPR 
calculation. 
 
 Older age. 
 Male. 
 Lack of knowledge about 
asthma and treatment. 
 
Did not report facilitators. 
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Study Design Tools used  Barriers identified 
 








aged 5 to 18 
years. 
Questionnaires completed by 
caregivers about asthma 
medicines, asthma control, 
medicine technique and caregiver 
depressive symptoms. 
Adherence rate assessed by self-
report. 
 
 Weak parent-child 
relationships. 
 Patient perception of need. 
 Family beliefs. 
 Belief that medicine is not 
necessary. 
 Cost of medicine. 
 
Did not report facilitators. 






aged 6 to 11 
years. 
Beliefs about Medicines 
Questionnaire (BMQ) scale 
completed by children and parents 
(see table 3.1). 





 Patients with poor 





 Children beliefs about 
treatment efficacy. 
 Parents expected little 
harm of ICS. 
 






mean age 0f 6.4 
years. 
Caregivers were asked: “How 
worried or concerned about your 
child’s asthma medications and 
side effects?” 
Adherence rate not assessed. 





Did not report facilitators. 
RK et al. 
2017, India 
(249) 
Cohort study, 53 
participants, 
aged > 5 years. 
Questionnaire completed by 
children and parents. 
Gender of participants, age, 
distance from hospital, located in 
rural or urban area, knowledge 
about disease, concerns about side 
effects, treatment duration 
assessed. 




 Younger age. 
 Lack of knowledge about 







 Older age children had 
a better adherence  
 (p<0.005). 
 Good knowledge about 





Study Design Tools used  Barriers identified 
 
Facilitators identified  





aged 2 to 14 
years. 
Asthma Knowledge Questionnaire 











 Low socioeconomic status. 
 Poor caregivers’ knowledge 







Did not report facilitators. 
Holley et al. 
2018, United 
Kingdom (87) 
Cohort study, 75 
participants, 
aged 12 to 18 
years. 
Children and parents asked 
several questions to explore 
barriers and facilitators to 
adherence. 
Adherence rate not assessed. 
 
 Forgetting. 
 Burden of treatment. 
 Lack of knowledge about 
asthma and treatment. 
 Feeling embarrassed. 
 Lack of motivation. 
 Difficult communication 
with healthcare 
professionals. 
 Routines and 
medicines reminder. 
 Acceptance of asthma 
and medicine. 
 Good knowledge about 
asthma and treatment. 
 Support from friends. 
 Good communication 
with healthcare 
professionals. 





aged 12 to 20 
years. 
Asthma expectation questionnaire 
scale completed by adolescents 
(table 3.1). 
Adherence rate assessed by self-
report. 
 Younger adolescents. 
 Lower self-efficacy. 
 Higher barrier perceptions. 
 
 
 Older adolescents. 
 Higher self-efficacy. 









C. Kidney or liver diseases and solid organ transplant patients  
Table 3-4 shows the nineteen studies which identified barriers and 
facilitators to medicines adherence in patients with kidney or liver diseases 
and solid organ transplants (79,91,189,250–257,133,158,159,169–
172,188). 
• Patient-related factors  
The most common barriers to medicines adherence in patients with kidney 
or liver disease and solid organ transplant were patient-related factors 
reported in eight studies (91,169,170,172,189,252,254,256). Six of these 
studies reported that forgetting to take medicine was the most common 
barrier to medicines adherence (91,169,170,189,254,256). Two studies 
showed that to avoid forgetting to take medicines, patients used reminders 
(e.g. alarm watch and notes posted on their fridge door), integrated taking 
medicines into their daily routines and used a medicines checklist. These 
practices were associated with good adherence (91,189). Lack of knowledge 
about a disease and its treatment were associated with poor adherence 
(170,172,252). 
• Medicine-related factors  
The second most common barriers to medicines adherence in these patients 
were medicine-related factors, such as high dosing frequencies (159,169), 
multidrug regimen (79,188), bad taste (170,254) and difficulty of 
swallowing medicine (171). In addition, having had an experience of side 
effects of medicines resulted in non-adherence (171,250,254). 
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• Socioeconomic-related factors  
Other barriers reported in patients with kidney or liver disease and solid 
organ transplant were socioeconomic-related factors. In the US, patients 
with public health insurance were less likely to adhere to treatment 
compared with those who had private health insurance (158,253,257). 
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Table 3-4 Studies reporting barriers and facilitators to medicines adherence in patients with kidney or liver 
diseases or solid organ transplant. For barriers and facilitators numbers are reported as % or significant 
association (if no numbers given numbers not reported in study). 
Study Design Tools used  Barriers identified 
 
Facilitators identified  
Simons et al. 
2008, United 
States (169) 
Cohort study, 80 
children with solid 
organ transplant, 
aged 11 to 21 years. 
Medical Adherence Measure 
(MAM) questionnaire scale 
completed by adolescents and 
parents (table 3.1). 
Adherence rate assessed by self-
report and EMDs. 
 Forgetting. 
 Scheduling problems. 
 Poor planning. 
 Time and number of dose 
frequencies. 
 Attempts to be normal. 
 





Cohort study, 56 
children with end-
stage renal disease, 
aged 11 to 18 years. 
Medical Adherence Measure 
(MAM) questionnaire scale 
completed by adolescents (table 
3.1). 
Adherence rate assessed by self-
report and EMDs. 
 Poor knowledge of disease 
and treatment. 
 Forgetting. 
 Not at home. 
 Interferes with activity. 
 Bad taste. 
 
Did not report facilitators. 
Van Herzeele 




Cohort study, 744 
children with 
nocturnal enuresis, 
aged 5 to 17 years. 
Questionnaires completed by 
children and parents-open-ended 
questions to assess medicine 
efficacy and factors related to 
poor adherence to medicine. 
Adherence rate assessed by pill 
count. 
 Long duration of treatment. 






Did not report facilitators. 
Simons et al. 
2010, United 
States (171) 
Cohort study, 82 
children with solid 
organ transplant, 
aged 11 to 20 years. 
Medical Adherence Measure 
(MAM) questionnaire scale 
completed by adolescents (table 
3.1). 
Adherence rate assessed by self-
report. 
 Disease frustration. 
 Concerns regarding peers. 
 Tired of taking the 
medicine. 
 Difficulty of swallowing 
medicine. 
 Experienced of many side 
effects. 
 
Did not report facilitators. 
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Study Design Tools used  Barriers identified 
 
Facilitators identified  
Wu et al. 
2010, United 
States (251) 
Cohort study, 55 
children with liver or 
kidney transplant, 
aged ≤ 18 years. 
Questionnaires completed by 
children and parents-open-ended 
questions to assess psychological 
function, anxiety, and depression 
symptoms and their influence on 
adherence. 
Adherence rate assessed by 
EMDs. 
 




















Cohort study, 71 
children with liver 
transplant, aged 11 
to 20 years. 
Questionnaire completed by 
adolescents-open questions about 
self-management, regimen 
knowledge, demonstrated skills, 
and psychosocial adjustment. 
Adherence rate assessed by 
medicine plasma level and 
medical records. 
 
 Patients being monitored 
less by parents. 
 Lack of knowledge of 









Cohort study, 34 
children with chronic 
kidney diseases, 
aged 10 to 21 years. 
Child & Adolescent Adherence to 
Medication Questionnaire 
(CAAMQ) completed by children 
(table 3.1). 





 Bad tasting medicine. 
 Interfere with daily routine. 
 
 
 Using reminder. 
 Pill boxes. 






et al. 2014, 
Canada (159) 
Cohort study, 558 
children with chronic 
kidney diseases, 
aged 7 to 14 years. 
Study based on medical history 
data, including, sex, age, drug, 
doses, age of disease, and annual 
household income. Effect of these 
on adherence assessed. 
Adherence rate assessed by self-
report. 
 Older age. 





Did not report facilitators. 
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Study Design Tools used  Barriers identified 
 
Facilitators identified  
Javalkar et al. 
2014, United 
States (253) 
Cohort study, 52 
children with chronic 
kidney diseases, 
aged 13 to 21 years. 
Questionnaire completed by 
adolescents and parents-open 
questions about socioeconomics 
factors related to medicines 
adherence. 
Adherence rate assessed by self-
report and MPR calculation. 
 
 Younger adolescents. 
 Patients had public 
insurance. 




 Older adolescents. 
 Patients had private 
insurance. 








Cohort study, 22 
children receiving 
dialysis, aged 13 to 
21 years. 
Adolescent Medication Barriers 
Scales (AMBS) completed by 
adolescents (table 3.1). 
Adherence rate assessed by self-
report. 
 Male. 






 Did not report 
facilitators. 




study, 18 children 
had received a liver 
or kidney transplant, 
aged ≤ 18 years. 
Questionnaire completed by 
caregivers asked about medicine 
management in view of time of 
administration and preparation, 
regimen complexity and factors 
negatively or positively affecting 
medicine intake (barriers and 
facilitators). 
Adherence rate assessed by self-
report. 
 
 Forgetting 70%. 
 Vomiting 70%.   
 Bad taste 60%. 
 Interfering in routine 60%.  
 Refusing medicine 50%. 
 Using alarms to avoid 
forgetfulness.  
 Using a medicine 
checklist. 
 Medicine box for 
medicine storage. 
 Having a reliable 
babysitter.  
 Guidance from health 
care workers.  
 Preparing medicine in 
advance.  
 Having spare medicine 
bottle. 
Danziger-




study, 368 children 
with solid organ 
transplant, aged 6 to 
21 years. 
Brief Medication Questionnaire 
(BMQ) scale completed by 
children and parents (table 3.1). 
Adherence rate assessed by self-
report. 




 Lack of supervision by 
family. 
 Poor family cohesion. 
Did not report facilitators. 
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Study Design Tools used  Barriers identified 
 
Facilitators identified  





study, 103 children 
with chronic kidney 
diseases, mean age 
13.5 years. 
Questionnaire completed by 
children-open-ended questions to 
explore barriers and facilitators to 
medicines adherence. 
Adherence rate assessed by self-
report. 
 Lower socioeconomic 
status. 
 Difficulty with access to 
healthcare services. 
 Lower educational level of 
parents. 
 
 Higher educational 
level of parents. 
 Higher reported 
income. 




Mehta et al. 
2017, United 
States (91) 





Did not report age. 
Questionnaire completed by 
healthcare providers to evaluate 
clinical practice, transplant 
providers’ attitudes, and beliefs 
regarding adherence among 
children. 
Adherence rate assessed by self-
report. 
 Forgetting 94%. 
 Desire to be normal 86%. 
 Lack of support 86%. 
 Poor parental monitoring 
79%. 
Did not report facilitators. 
Varnell et al. 
2017, United 
States (256) 
Cohort study, 97 
children with kidney 
transplant, aged 1 to 
24 years. 
Questionnaires completed by 
patients and caregivers-open 
questions about barriers to 
treatment adherence. 
Adherence rate assessed by self-
report. 
 Forgetting. 
 Bad taste. 




Did not report facilitators. 
Lee et al. 
2017, United 
States (172) 
Cohort study, 78 
children waiting solid 
organ transplant, 
aged 0 to 20 years 
Medical Adherence Measure 
(MAM) questionnaire scale 
completed by caregivers (table 
3.1). 







 Greater time since patient’s 
diagnosis. 




Did not report facilitators. 
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Study Design Tools used  Barriers identified 
 
Facilitators identified  
Killian et al. 
2017, United 
States (257) 
Cohort study, 105 
children heart and 
lung transplant 
recipients. 
Aged 0 to 18 years. 
Psychological and family 
demographic information collected 
through first year post-transplant 
treatment notes. Effect on 
adherence assessed. 
Adherence rate assessed by 
medicine plasma level. 
 Older age. 
 Experience of childhood 
maltreatment. 
 Families with psychosocial 
problem. 
 Difficulties with familial 
communication. 
 
 Parental education of a 
college degree or 
more. 
 Two parents in home. 
 Families had at least 
adequate financial 
resources. 








Cohort study, 400 
children with liver 
transplant, aged 1 to 
17 years. 
Study based on patient medical 
chart to assess adherence, 
socioeconomic factors, and effect 
of age and length of treatment on 
adherence. Effect on adherence 
assessed. 
Adherence rate assessed by 
medicine plasma level. 
 Older age. 
 One parent households. 
 Patient who had public 
health insurance. 




 Younger age. 
 Two parent 
households. 














33 participants with 
kidney transplant 
Ages ≤ 18 years 
Beliefs about Medicines 
Questionnaire (BMQ) scale was 
completed by children and parents 
(table 3.1). 
Adherence rate assessed by self-
report and pharmacy refill data. 
 Presence of side effects. 
 Males were more likely to 
be non-adherent. 
 
 Females were more 





D. Psychiatric disorders 
As shown in Table 3-5, thirteen studies identified barriers and facilitators to 
medicines adherence in patients with psychiatric disorders (81,89,263–
265,160,161,179,258–262). 
• Medicine-related factors  
The most common reported barriers to adherence in patients with 
psychiatric disorders were medicine-related factors in nine studies 
(81,89,161,258,259,261–264). Low beliefs on the necessity of medicine 
were associated with poor adherence in three studies (81,259,264). 
Conversely, high beliefs on the necessity of medicine were associated with 
good adherence (89,258,259,261,264).  
Poor adherence to treatment was associated with  complex medicine 
regimens, such as multidrug administration and high dosing frequencies  
(81,89,161,262), and bad taste (259). Fear of side effects (89,263) or 
having had an experience of side effects (262) also resulted in non-
adherence to medicine. 
• Socioeconomic-related factors  
The second most common barriers to medicines adherence in patients with 
psychiatric disorders were socioeconomic-related factors. Patients may be 
ashamed if other people know that they are taking psychiatric medicines 
(263). Three studies showed that fear of stigma and discrimination was 
associated with poor adherence (81,89,263).  
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• Patient-related factors  
Medicines taking responsibilities are different among children, which affects 
adherence. Two studies showed that children were less likely to adhere to 
medicines when they are responsible for medicine taking without their 






Table 3-5 Studies reporting barriers and facilitators to medicines adherence in patients with psychiatric 
disorders. For barriers and facilitators numbers are reported as % or significant association (if no numbers 
given numbers not reported in study). 
Study Design Tools used  Barriers identified 
 
Facilitators identified  
Munson et al. 
2010, United 
States (258) 
Cohort study, 70 
adolescents receiving 
psychotropic medicines, 
aged 12 to 17 years. 
Adolescents’ demographic and 
clinical characteristics 
assessed. 
Questionnaire completed by 
adolescents to assess 
perceptions toward disease and 
treatment. 
Adherence assessed by self-
report. 
 Younger adolescents 
(p<0.05). 
 Low family income 
(p<0.01). 
 
 High education level 
(p<0.01). 
 Positive attitudes towards 
treatment (p<0.05). 
 Perception that their 
disease may have serious 
consequences (p<0.05). 
Dean et al. 
2011, 
Australia (179) 
Cohort study, 27 
children receiving 
psychotropic medicines, 
aged 6.9 to 18.9 years. 
Brief Medication Questionnaire 
(BMQ) scale completed by 
children and parents (table 
3.1). 
Adherence assessed by self-
report. 
 Lack of parental 





 Involvement of a parent 








Cohort study, 27 
children diagnosed with 
depression, aged 5 to 
17 years. 
Demographic factors, clinical 
factors, and medical regimen 
factors identified from medical 
records and effect on 
adherence assessed. 
Adherence assessed by MPR 
calculation. 
 Older age. 
 Ethnic disparities in 
access to and quality of 
mental health care for 
minority population. 
 Adequate dosing of 
antidepressants. 
 Children in foster care 








Cohort study, 27 parent 
of children diagnosed 
with ADHD, aged 5 to 
12 years. 
Questionnaire completed by 
parents. Open-ended questions 
identified barriers and 
facilitators. 
Adherence assessed by self-
report. 
 Fears of personality 
changes. 
 Fears of side effects. 
 Complex medicine 
regimen. 
 Fear of stigma and 
discrimination. 
 High levels of self-
efficacy. 
 Parent beliefs that 
treatment was imperative 




Study Design Tools used  Barriers identified 
 
Facilitators identified  
Hebert et al. 
2013, Canada 
(259) 
Cohort study, 33 
children with ADHD, 
mean age 8.7 years. 
Questionnaire completed by 
children and parents to assess 
severity of disease symptoms, 
and attitudes towards 
medicine. 
Adherence assessed by self-
report. 
 Lower parental beliefs 
about necessity of 
medicine. 
 Lower child’s beliefs 
about necessity of 
medicine. 
 Fear of stigma and 
discrimination. 




 Higher parental beliefs 
about necessity of 
medicine. 
 Higher child’s beliefs 






Logan et al. 
2014, United 
States (161) 




Age not reported. 
Study based on medical records 
of patients to determine 
predictor of adherence to 
medicines. 
Adherence assessed by MPR 
calculation. 
 
 Medicine regimen 
complexity most 




 Male sex. 
 Non-Hispanic whites more 
adherent than minorities. 
 




30 children with 
psychiatric disorders, 
aged 7 to 17 years. 
Questionnaire completed by 
children and parents assessed 
children’s trust in their parents 
and parents’ trust in their 
children’s medicine and effect 
on adherence.  





Did not report barriers  Parent felt that their 
child’s condition improved 
with medicines. 









children diagnosed with 
first episode psychosis. 
Age not reported. 
Questionnaire completed by 
healthcare professionals 
identified barriers and 
facilitators. 
Participants given a list of 
barriers and facilitators to 
 Fear of side effects 
87%. 
 Children were 
responsible for medicine 
taking 78%. 
 Medicines will make them 
better 93%. 
 Good relation with staff 
85%. 




Study Design Tools used  Barriers identified 
 
Facilitators identified  
adherence and asked to tick 
factors that may affect 
adherence. 
Adherence assessed by self-
report. 
 Not trusting treatment 
71%. 
 Fear of stigma 59%. 
 Family do not think their 
child is ill 58%. 





Cohort study, 21 
adolescents with bipolar 
disorder. Aged 12 to 22 
years. 
Questionnaire completed by 
adolescents to assess: illness 
specific factors, patient factors, 
treatment factors, provider 
factors and developmental 
factors that may cause poor 
adherence. 
Adherence assessed by self-
report and EMDs. 
 Greater disease 
severity. 
 Adolescents who 
weighed more. 
 Experienced side effect. 





Did not report facilitators. 




101 children with 
ADHD, mean age 15.6 
years. 
Beliefs about Medicines 
Questionnaire (BMQ) scale 
completed by children (table 
3.1). 







 Longer duration on 
treatment. 
 Dosage alterations. 
 Experienced side effects. 
 Lower of belief in 
necessity of medicine. 
 
Did not report facilitators. 
Ahmed et al. 
2017, 
Australia (263) 
Cohort study, 16 
parents of children with 
ADHD. 





Questionnaire completed by 
parents to assess adherence to 
medicine and explore impact of 
positive and negative 
experience on adherence. 
Adherence rate not assessed. 
 Experienced side effects. 
 Concern about long-
term consequences of 
medicine. 





Did not report facilitators. 
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Study Design Tools used  Barriers identified 
 
Facilitators identified  
Zehgeer et al. 
2018, United 
States (264) 
Cohort study, 349 
children with anxiety 
disorder. Aged 7 to 17 
years. 
Questionnaire completed by 
children and parents to discuss 
anxiety symptoms, treatment 
response, functioning, side 
effects, and influences on 
adherence. 
Adherence assessed by self-
report. 
 Children living with 
single parent. 
 Lower parental beliefs 
about necessity of 
medicine. 
 Lower child’s beliefs 




 Children living with two 
parents. 
 Higher parental beliefs 
about necessity of 
medicine. 
 Higher child’s beliefs 
about necessity of 
medicine. 
 




118 children with 
ADHD, aged 6 to 12 
years. 
Beliefs about Medicines 
Questionnaire (BMQ) scale 




Adherence rate assessed by 
self-report. 
 Low paternal education 
level. 
 Low socioeconomic 
status. 
 History of 
psychopharmacologic 
treatment in family. 
Did not report facilitators. 
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E. Inflammatory bowel diseases (IBD) 
As shown in Table 3-6, eleven studies identified barriers and facilitators to 
medicines adherence in patients with IBD  (34,134,268,164–
168,176,266,267). 
• Medicine-related factors  
The most common barriers to medicines adherence in patients with IBD 
were medicine-related factors reported in eight studies (164–168,266–
268). Low beliefs on the necessity of medicine were associated with poor 
adherence (164–167,267). Two studies showed that poor adherence to 
treatment is associated with complex medicine regimens, bad taste and 
large pill size (266,268). Reed-Knight et al. reported that a long duration of 
treatment was significantly associated with poor adherence (p<0.05) (168). 
• Patient-related factors  
The second most common barriers to medicines adherence in patients with 
IBD were patient-related factors. Six studies reported that forgetting and 
being outside the home resulted in poor adherence to medicines (164–
167,266,268). 
• Condition-related factors  
Condition-related factors such as the severity of IBD were reported as a 
common barrier to adherence. Five studies showed that patients who feel 




Table 3-6 Studies reporting barriers and facilitators to medicines adherence in patients with IBD. For 
barriers and facilitators numbers are reported as % or significant association (if no numbers given numbers 
not reported in study). 
Study Design Tools used  Barriers identified 
 
Facilitators identified  






age 13.2 years. 
Questionnaire completed by 
children. 
Participants given list of barriers 
to adherence and asked to tick 
factors they have faced. 
Adherence rate assessed by self-
report. 
 
 Forgetting 56%. 
 Too busy 55.6%. 
 Uncomfortable with prescribed 
enemas 18.2%. 
 Difficult to swallow medicine 
17.8%. 
 Too many medicines 13.4%. 
Did not report facilitators. 
Ingerski et al. 
2009, United 
States (164). 
Cohort study, 74 
participants, aged 
13 to 17 years. 
Medical Adherence Measure 
(MAM) questionnaire scale 
completed by caregivers (table 
3.1). 
Adherence rate assessed by self-
report and pill count. 
 
 
 Forgetting 87.8%. 
 Outside home 47.3%. 
 Interference with activity 
44.6%. 
 Refused to take medicine 
17.6%. 
 Didn’t fill/ran out 16.2%. 
 Feeling sick 16.2 %. 
 Belief that medicine is not 
necessary 14.9%. 
Did not report facilitators. 
Hommel et al. 
2009, United 
States (165). 
Cohort study, 16 
participants, aged 
13 to 17 years. 
Medical Adherence Measure 
(MAM) questionnaire scale 
completed by caregivers (table 
3.1). 
Adherence rate assessed by self-
report and pill count. 
 
 
 Forgetting 87.5%. 
 Was not in home 75%. 
 Interference with activity 
68.8%. 
 Refusal/defiance 25%. 
 Feeling sick 25%. 
 Didn’t fill/ran out 18.8%. 
 Belief that medicine is not 
necessary 12.5%. 
 
Did not report facilitators. 






11 to 18 years. 
Questionnaire completed by 
adolescents and parents. 
 Lack of time 33% of adolescents 
and 32% of parents. 
 Feeling sick 16% of adolescents 
and 7% of parents. 
Did not report facilitators. 
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Study Design Tools used  Barriers identified 
 
Facilitators identified  
Participants given list of barriers 
to adherence and asked to tick 
factors they have faced. 
Adherence rate assessed by self-
report. 
 
 Experienced side effects 14% of 
adolescents and 20% of 
parents. 
 Medicine was ineffective 14% of 
adolescents and 13% of 
parents. 
Reed-Knight 






11 to 18 years. 
Questionnaire completed by 
adolescents to explore factors 
affecting adherence and test 
association to adherence rates. 
Adherence rate assessed by self-
report. 
 Long duration of treatment 
(p<0.01). 
 Parent-adolescent conflict 
(p<0.001). 
 Lack of motivation (p=0.02). 
 Higher perceived 
disease severity 
(p=0.01). 
 Maternal involvement 
in the treatment 
(p<0.01). 






13 to 17 years. 
Questionnaire completed by 
children and parents to explore 
factors affecting medicines 
adherence. 
Adherence rate assessed by self-
report. 
 Forgetting. 
 Complex regimen. 
 Weak parent-child relationship. 
 Lack knowledge about disease 
and treatment. 
 
 Family support. 
 Good parent-child 
relationship. 




Hommel et al. 
2011, United 
States (166) 
Cohort study, 62 
participants, aged 
13 to 17 years. 
Medical Adherence Measure 
(MAM) questionnaire scale 
completed by caregivers (table 
3.1). 
Adherence rate assessed by self-
report. 
 
 Forgetting 85.5%. 
 Not at home 43.5%. 
 Interfere with activity 38.7%. 
 Feeling sick well 14.5%. 
 Ran out/didn’t fill 14.5%. 
 Bad taste 12.9%. 
Don’t think necessary 12.9%. 
Did not report facilitators. 
Gray et al. 
2012, United 
States (167). 
Cohort study, 79 
participants, aged 
13 to 17 years. 
Medical Adherence Measure 
(MAM) questionnaire scale 
completed by caregivers (table 
3.1). 




 Forgetting 84.8%. 
 Was not in home 43%. 
 Interference with activity 
34.2%. 
 Didn’t fill/ran out 15.3%. 
 Hate taste 12.7%. 
 Feeling sick well 12.7%. 
 Refusal/defiance 11.4%. 
Do not think necessary 10.1%. 
Did not report facilitators. 
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Study Design Tools used  Barriers identified 
 
Facilitators identified  
LeLeiko et al. 
2013, United 
States (34) 
Cohort study, 62 
participants, aged 
8 to 17.5 years. 
Demographic factors, clinical 
factors, and medical regimen 
factors were identified, based on 
medical records. 
Adherence rates are compared 
with different factors. 
Adherence rate assessed by 
EMDs. 
 Only older age was significantly 
associated with poor adherence 
(p<0.05). 
 







12 to 25 years. 
Beliefs about Medicines 
Questionnaire (BMQ) scale 
completed by children (table 
3.1). 
Adherence rate assessed by self-
report. 
 Young adults (12-18 years) had 
lower adherence than 
transitioned patients (18- 25 
years). 
 More concerns about medicines 
in young adult patients. 
 
Did not report facilitators. 







Ages 13-17 years 
Beliefs about Medicines 
Questionnaire (BMQ) scale 
completed by children and 
parents (table 3.1). 
Adherence rate assessed by self-
report and plasma level. 
 Higher scores in the concern-
necessity differential. 






Table 3-7 shows the ten studies which identified barriers and facilitators to 
medicines adherence in patients with epilepsy (126,177,190,269–275). 
• Socioeconomic-related factors  
The first most common barriers to medicines adherence in patients with 
epilepsy were socioeconomic-related factors as reported in nine studies 
(126,177,190,269–274). Economic status could affect therapy depending 
on the level and the type of therapy, especially when medicines were not 
free (271). Five studies conducted in the US, Uganda and Pakistan showed 
that lack of money was a common barrier to adherence (190,269–272). 
Several other social factors were reported to be associated with poor 
adherence including divorce of parents (177,269), parental depression 
(126), large family size (177) and fear of stigma and discrimination 
(273,274). 
• Medicine-related factors  
The second most common barrier to adherence in patients with epilepsy 
were medicine-related factors as reported in six studies 
(126,177,270,271,273,274). Three of these studies showed that fear of 
side effects was associated with poor adherence (177,270,271). In addition, 
Shah et al. found that patients and their parents with low beliefs on the 
necessity of medicine were more likely to have poor adherence to medicines 
(OR 1.08-1.57) (126). Two studies showed that poor adherence to 
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treatment was associated with multidrug administration (177,271), bad 
taste and large pill size (273,274).  
• Patient-related factors  
Patient-related factors such as forgetting were shown in four studies to 
result in non-adherence (177,270,273,274). Among these studies, one 
study showed that the use of medicine reminders, such as an alarm watch, 










Table 3-7  Studies reporting barriers and facilitators to medicines adherence in patients with epilepsy. For 
barriers and facilitators numbers are reported as % or significant association (if no numbers given numbers 
not reported in study). 
Study Design Tools used  Barriers identified 
 
Facilitators identified  
Modi et al. 
2008, United 
States (269) 
Cohort study, 35 
participants, aged 2 to 
12 years. 
Questionnaire completed by 
parents: child’s age, gender, 
socioeconomic status, parent’s 
age, occupation, and 
composition of family. 
Effect of these on adherence 
assessed. 
Adherence rate assessed by 
EMDs. 
 Children of divorced 
parents. 









 Children of married 
parents. 










Shah et al. 
2013, United 
Kingdom (126) 
Cohort study, 100 
participants, aged 0.9 
to 16 years. 
Beliefs about Medicines 
Questionnaire (BMQ) scale 
completed by children and 
parents (table 3.1). 
Adherence rate assessed by 
EMDs, self-report, and 
medicine plasma level. 
 Older age (OR 1.03-1.4). 
 Parent depressed (OR 
1.16-11.41). 
 Lower belief on medicine 
necessity (OR 1.08-1.57). 
 
Did not report facilitators. 




122 participants, aged 
6 months to 16 years. 
Questionnaire completed by 
children-open-ended questions 
to explore barriers and 
facilitators. 
Adherence rate assessed by 
self-report, and medicine 
plasma level. 
 Caregivers having a job 
(did not have time to care 
for children). 
 Lack of money. 
 Forgetting. 
 Fear of side effects. 
 
 
 Having a primary 
caregiver other than the 
mother. 
 Medicine reminder such 





Gaber et al. 
2014, Saudi 
Arabia (177) 
Cohort study, 116 
participants, aged 13 to 
18 years. 
Beliefs about Medicines 
Questionnaire (BMQ) and 
Morisky Medication adherence 
Scale (MMAS) completed by 
 Forgetting. 
 Fear of side effects. 
 High number of 
medicines. 
Did not report facilitators. 
140 
 
Study Design Tools used  Barriers identified 
 
Facilitators identified  
adolescents (table 3.1). 
Demographic information 
obtained. 
Adherence rate assessed by 
EMDs, self-report. 
 Divorced parents. 
 Large family size. 
 Stronger concern about 
medicine consequences. 
 





120 participants, aged 
≤ 18 years. 
Questionnaire completed by 
caregivers and professionals. 
Open-ended questions 
identified barriers and 
facilitators. 




 Fear of side effects. 
 Lack of continuous supply 
of antiepileptic drugs 
because family did not 
have enough money. 
 Lower socioeconomic 
status. 
 Multi-drug. 
 Caregivers and children 
have poor knowledge of 
adherence and therapy. 
 Monotherapy. 
 Caregivers and children 
have good knowledge of 
adherence and therapy. 










146 participants, aged 
1 to 12 years. 
Questionnaire completed by 
parents-open-ended questions 
related to adherence, missed 
doses, missed appointment, 
seizure frequency, 
socioeconomic status, and 
health literacy. 
Adherence rate assessed by 
self-report. 
 Inadequate parent health 
literacy  
 Lack of money. 
 Older children. 





Did not report facilitators. 
Ramsey et al. 
2017, United 
States (273) 
Cohort study, 48 
participants, aged 2 to 
12 years. 
Questionnaire completed by 
caregivers and children-open-
ended questions identified 
barriers to adherence. 
Adherence rate assessed by 
EMDs. 
 Taste of medicine. 
 Forgetting. 
 Child refusal. 
 Difficulty getting to 
pharmacy. 
 Fear of stigma and 
discrimination. 
 Difficulty swallowing 
medicines. 
 
Did not report facilitators. 
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Study Design Tools used  Barriers identified 
 
Facilitators identified  
Smith et al. 
2018, United 
States (190) 
Cohort study, 48 
participants, aged 13 to 
17 years. 
Paediatric Epilepsy Medication 
Self-Management 
Questionnaire scale completed 
by adolescents and Paediatric 
Epilepsy Side Effects 
Questionnaire scale completed 
by adolescents (table 3.1).  
Parental Environment 
Questionnaire scale completed 
by parents (table 3.1).  
Adherence rate assessed by 
EMDs. 
 Family conflict. 
 Lower socioeconomic 
status. 
 Experienced with side 
effects. 








 Less family conflicts. 















colina et al. 
2018, United 
States (274) 
Cohort study, 77 
participants, aged 5 to 
25 years. 
Questionnaire completed by 
caregivers and adolescents-
open-ended questions identified 
barriers to adherence. 
Adherence rate assessed by 
EMDs. 
 Taste of medicine. 
 Forgetting. 
 Child refusal. 
 Difficulty getting to 
pharmacy. 
 Fear of stigma and 
discrimination. 
 Difficulty swallowing 
medicines. 
Did not report facilitators. 




63 participants, aged 
1.5 to 18 years. 
Beliefs about Medicines 
Questionnaire (BMQ) scale 
completed by parents (table 
3.1). 
Adherence rate assessed by 
self-report. 
 More concern about side 
effects. 
 Low beliefs of medicine 
necessity. 
 
Did not report facilitators. 
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G. Studies conducted with patients with different diseases 
As shown in Table 3-8, six studies identified barriers and facilitators to 
medicines adherence in patients with different diseases  (85,92,162,276–
278). 
Medicine-related factors were the most common barriers to medicines 
adherence including fear of side effects (85), bad taste of medicine (85,92) 
and difficulty with inhaler medicine devices (277). Venables et al. reported 
that patients who were taking medicines with bad taste or with high dose 
frequencies were more likely to refuse their medicines and have poor 














Table 3-8  Studies reporting barriers and facilitators to medicines adherence in patients with different 
diseases. For barriers and facilitators numbers are reported as % or significant association (if no numbers 
given numbers not reported in study). 
Study Design Tools used  Barriers identified 
 
Facilitators identified  
Fischer  et al. 
2010, United 
States (162) 
Cohort study, 9417 
children with various 
diseases, aged 0 to 18 
years. 
E-prescribing data of patients 
included information on prescribing 
clinician, patient, prescription date, 
dosage form, medicine name and 
insurance plan. 
Adherence rate assessed by MPR 
calculation. 
 Medicines were 
prescribed by general 
physician (not 
paediatrician). 
Poor adherence was 
common for newly 
prescribed medicines. 
Did not report facilitators. 
Elliott et al. 
2013, United 
Kingdom (85) 
Cohort study, 18 
children with asthma, 
heart disease, diabetes, 
and epilepsy, aged 10 
to 17 years. 
Questionnaires completed by 
professionals, children, and 
caregivers about issues around 
medicine-taking in children. 
Adherence rate not assessed. 
 Forgetting. 
 Interference with 
routine. 
 
 Reminder device. 




Bryson et al. 
2014, United 
Kingdom (276) 
Cohort study, 70 
children with various 
diseases, aged 3 to 11 
years. 
Questionnaires completed by 
children, professionals, and 
caregivers about issues around 
medicine-related factors. 
Adherence rate assessed by MPR 
calculation. 
82% of children who took ≤ two 
different medicines each week were 
adherent. 
73% of children who took ≥ three 
medicines each week were non-
adherent. 
 
 Taste of medicine 
especially in younger 
children. 






 Medicines with good 
taste. 










Study Design Tools used  Barriers identified 
 





Cohort study, 57 
children aged 12-18 
years and 221 
carers/parents of 




13-item questionnaire completed by 
children and parents with questions 
to explore barriers to adherence. 
 
Adherence rate assessed by self-
report. 
 Bad taste (p<0.001) 
 Volume or quantity of 
medicine (p<0.001). 
 Texture of medicine (p 
= 0.017). 
 Difficulty with 
swallowing. 
 Smell and colour of 
medicine. 





Cohort study, 27 
healthcare providers. 
Focus groups to discuss barriers to 
medicine adherence (oral 
formulations barriers). 
Information recorded during 
sessions. 
Adherence rate not assessed. 
 Bad taste. 
 Texture of medicine. 
 Difficulty with 
swallowing. 
 Smell and colour of 
medicine. 





Cohort study, 29 
children diagnosed with 
different diseases and 
administered non-oral 
formulations, aged 0 to 
17 years. 
13-item questionnaire completed by 
children and parents with questions 
to explore barriers to adherence. 
Adherence rate assessed by self-
report. 
 Difficulty with spacer 
for inhaled devices in 
patients with asthma 
38%. 
 Disliking parenteral 
formulations 38%. 
 Greasy texture of 
topical medicines. 
 Large dose of nasal 
medicines. 
 Difficulty with an 
ocular ointment. 




H. Sickle cell disease 
As shown in Table 3-9, five studies identified barriers and facilitators to 
medicines adherence in patients with sickle cell disease (180,191,279–
281). 
Patient-related factors were the most common barriers to medicines 
adherence. Three studies reported that forgetting or lack of time are 
reasons for non-adherence to medicines (191,279,280). In addition, three 
studies reported that patients using medicine reminders such as receiving 
daily text messages and established daily routines related to medicine 
taking were more likely to have good adherence (191,280,281). Klitzman 
et al. reported that having an established routine related to medicine taking 
















Table 3-9 Studies reporting barriers and facilitators to medicines adherence in patients with sickle cell 
disease. For barriers and facilitators numbers are reported as % or significant association (if no numbers 
given numbers not reported in study). 
Study Design Tools used  Barriers identified 
 
Facilitators identified  




71 participants, aged 6 
to 18 years. 
Disease Management and 
Barriers Interview-Sickle Cell 
Disease scale completed by 
adolescents and caregivers 
(table 3.1). 
Adherence rate assessed by 
self-report. 
 Fear of stigma 57%. 
 Multiple medicines 43%. 
 Forgetting 29%. 
 Treatment discomfort 
29%. 
 Lack of time 29%. 
 Medicine reminder 38%. 
 Physician emphasis 
25%. 
Inoue et al. 
2016, United 
States (279) 
Cohort study, 19 
participants, aged 2 to 
21 years. 
Questionnaire completed by 
caregivers or patients about 
disease knowledge, barriers to 
adherence, and beliefs about 
treatment. 
Adherence rate assessed by 
EMDs. 
 Absence of medicine 
delivery to the home 
74%. 
 Forgetting 68%. 
Did not report facilitators. 




80 participants, aged 
12 to 22 years. 
Questionnaire completed by 
patients-4 items of questions 
were about daily medicines and 
barriers to adherence. 
Adherence rate assessed by 
self-report. 
 Forgetting 67%. 
 Lack of time 23%. 
 Being overwhelmed 
23%. 
 Medicine reminder 94%. 
 Disease education 89%. 
 Medicine education 
88%. 
 




34 participants, aged 
12 to 22 years. 
Brief Medication Questionnaire 
(BMQ) scale completed by 
children and parents (table 
3.1). 
Adherence rate assessed by 
self-report. 
 
 Worse pain (p=0.02). 
 Fatigue (p=0.05). 
 Depression (p=0.05). 
Did not report facilitators. 
147 
 
Study Design Tools used  Barriers identified 
 
Facilitators identified  




85 participants, aged 8 
to 18 years. 
Questionnaire completed by 
patients and parents to assess 
family communication, child 
routines, family problem-
solving, and demographic 
information. 
Adherence rate assessed by 
self-report. 
Did not report barriers  Established routine 
related to medicine 
administration 
(p<0.05). 











I. Cystic Fibrosis 
As shown in Table 3-10, four studies identified barriers and facilitators to 
medicines adherence in patients with cystic fibrosis diseases (178,282–
284). 
• Medicine-related factors  
The most common barriers to medicines adherence in patients with cystic 
fibrosis were medicine-related factors. Low beliefs on the necessity of 
medicine were reported to be associated with poor adherence 
(178,283,284). In addition, two studies reported that high beliefs on the 
necessity of medicine were associated with good adherence (178,284). 
• Patient-related factors  
The second most common barriers to medicines adherence in patients with 
cystic fibrosis were patient-related factors. Two studies reported that lack 
of time and forgetting were reasons for non-adherence to medicine 
(282,284). Sawicki et al. reported that having a routine related to medicines 









Table 3-10 Studies reporting barriers and facilitators to medicines adherence in patients with cystic fibrosis 
diseases. For barriers and facilitators numbers are reported as % or significant association (if no numbers 
given numbers not reported in study). 
Study Design Tools used  Barriers identified 
 




Cohort study, 146 
participants, aged 
14 to 25 years. 
Questionnaire completed by 
participants and parents to 
explore reasons for non-
adherence, and family status. 
Adherence rate assessed by self-
report. 
 Forgetting 35%. 
 Lack of time 35%. 
 Too tired to take medicine 
22%.  
Did not report facilitators. 







≤ 18 years. 
Beliefs about Medicines 
Questionnaire (BMQ) scale 
completed by parents (table 3.1). 
Adherence rate assessed by self-
report and MPR calculation. 
 Older age. 
 More concern about side 
effects. 













controlled trial, 128 
participants, aged 
16 and older. 
Questionnaire completed by 
participants assessing: medicine 
beliefs, motivation, self-efficacy, 
and perceived importance. 
Adherence rate assessed by MPR 
calculation. 
 High depressive symptoms. 
 Low beliefs of medicine 
necessity. 
 Less self-efficacy. 
 Less motivation. 
 
 






Sawicki et al. 
2015, United 
States (284) 
Cohort study, 18 
participants, aged 
16 to 21 years. 
Questionnaire completed by 
participants focused on: readiness 
of self-care, living with disease as 
an adult, barriers, and facilitators 
to adherence. 
Adherence rate assessed by self-
report. 
 Lack of time. 
 Being too busy. 
 Fear of stigma and 
discrimination. 





 High beliefs of medicine 
necessity. 
 Good relationship with 
care provider. 
 Being treated as adult. 






As shown in Table 3-11, four studies identified barriers and facilitators to 
medicines adherence in patients with diabetes (95,182,285,286). 
Patient related factors were the most common barriers to medicines 
adherence. Three studies reported that lack of family support was 
associated with poor adherence (95,182,285). In addition, good family 
















Table 3-11  Studies reporting barriers and facilitators to medicines adherence in patients with diabetes. For 
barriers and facilitators numbers are reported as % or significant association (if no numbers given numbers 
not reported in study). 
Study Design Tools used  Barriers identified 
 
Facilitators identified  
Saletsky et al. 
2014, United 
States (285) 
Cohort study, 137 type 
2 diabetes diagnosed 
children, aged 10 to 17 
years. 
Questionnaire completed by 
children and parents. 
Open-ended questions to 
assess diabetes self-care, 
parent-youth conflict, and its’ 
effect on adherence. 
Adherence rate assessed by pill 
count. 
 Parents using more 
controlling style to their 
child towards diabetes. 
















Cohort study, 53 type 1 
diabetes diagnosed 
children, aged 8 to 18 
years. 
Diabetes Family Responsibility 
Questionnaire (DFRQ) 
completed by children and 
parents (table 3.1). 
Adherence rate assessed by 
glucose plasma level. 





 Child-parent agreement 
regarding treatment 
responsibility. 
 Family support. 
 
 
Katz  et al. 
2016, United 
States (286) 
Cohort study, 699 type 
2 diabetes diagnosed 
children, aged 10 to 17 
years. 
At each consultation visit, study 
staff discussed and evaluated 
adherence and factors that may 
affect adherence with the 
participant. 
Adherence rate assessed by pill 
count. 
 Depression symptoms 
(p<0.05). 
Did not report facilitators. 
Venditti et al. 
2018, United 
States (95). 
Cohort study, 525 type 
2 diabetes diagnosed 
children, aged 10 to 17 
years. 
Questionnaire completed by 
caregivers and professionals. 
Open-ended questions 
identified barriers and 
facilitators. 
Adherence rate assessed by pill 
count. 
 Forgetting. 
 Being outside home. 
 Interference with activity. 
 Pill burden. 
 Lack of family support. 
 
 
 Family help and support. 
 Uses routine or schedules. 
 Reminder device. 
 Caregivers and children 
have good knowledge of 





As shown in Table 3-12, four studies identified barriers and facilitators to 
medicines adherence in patients with tuberculosis (287–290). 
Medicine-related factors were the most common barriers to medicines 
adherence. Several factors related to medicine were reported to cause poor 
adherence such as experienced side effects (p<0.05) (287), fear of side 
















Table 3-12  Studies reporting barriers and facilitators to medicines adherence in patients with tuberculosis. 
For barriers and facilitators numbers are reported as % or significant association (if no numbers given 
numbers not reported in study). 
Study Design Tools used  Barriers identified 
 
Facilitators identified  





aged 0 to 18 
years. 
Questionnaire completed by children 
and parents. 
Factors associated with failure to 
adherence including side effects, sex, 
age, and reasons for missing doses 
assessed. 
Adherence rate assessed by pill 
count. 
 Aged 15-18 years (p<0.05). 
 Development of hepatitis 
(p<0.05). 
 Experienced side effects 
(p<0.05). 
Did not report facilitators. 





children, aged < 
16 years. 
Study based on retrospective data 
conducted by reviewing patient 
medical chart and patient’s 
registration book. 
Adherence rate assessed by MPR 
calculation. 
 Fear of side effects 28.6% of 
participants. 
 Feeling better 16.48% of 
participants. 
 Forgetting 4.39% of 
participants. 
 Weak physician-patient 
communication. 
 Caregivers and 




 Good physician-patient 
communication. 
 High quality of service. 
Lopez-Varela 
et al. 2016, 
Mozambique 
(289) 
Cohort study, 50 
children, aged < 
3 years. 
Clinical data obtained at every clinical 
visit. 
Other socio-demographic data 
obtained by patient medical records. 
Adherence rate assessed by MPR 
calculation. 
 Malnutrition (p<0.05). 
 History of migrant mother 
(p<0.05). 
Did not report facilitators. 
Chiang et al. 
2017, Peru 
(290) 




children aged 0 
to 19 years. 
Questionnaire completed by 
healthcare providers and parents to 
identify barriers to treatment. 
Adherence rate assessed by self-
report. 
 Dosing errors. 
 Time, preparation, and 
administration of medicines. 
 Providers concern that 
isoniazid resistance may 
result from isoniazid 
preventive therapy. 
Did not report facilitators. 
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L. Chronic rheumatic diseases 
As shown in Table 3-13, three studies identified barriers and facilitators to 
medicines adherence in patients with chronic rheumatic disease (291–293). 
Patient-related factors were the most common barriers to medicines 
adherence. Several factors related to patients were reported to cause poor 
adherence such as forgetting (291,292), children being responsible for 
medicines management (293) and children refusing to take medicine 
(291,292). In addition, other factors were associated with good adherence 
such as using medicine reminders (291) and  caregivers being responsible 













Table 3-13  Studies reporting barriers and facilitators to medicines adherence in patients with chronic 
rheumatic disease. For barriers and facilitators numbers are reported as % or significant association (if no 
numbers given numbers not reported in study). 
Study Design Tools used  Barriers identified 
 
Facilitators identified  









disease, aged 13 
to 20 years. 
Questionnaire completed by 
adolescents to explore reasons for 
missing medicines. 
Adherence rate assessed by self-
report. 
 
 Forgetting 54%. 
 Running out of medicine 
10%. 
 Child refused the medicine 
10%. 
 Using medicines 
reminder 80%. 






study conducted in 
two sites, 76 
children with 
arthritis, 50 in Rio 
de Janeiro and 27 
in Boston aged 1 
to 17 years. 
Questionnaire completed by children > 
12 years and parents to identify 
barriers to adherence. 
Participants given list of barriers to 
adherence and asked to tick factors 
they have faced. 
Adherence rate assessed by self-
report. 
 
 Child refused the medicine 
50% in Boston. 
 Fear of side effects 25% in 
Boston and 16% in Rio de 
Janeiro. 
 Forgetting 25% in Boston 
21% in Rio de Janeiro. 
 Inability to go to hospital 
26% in Rio de Janeiro. 
 Medicine not available in 
pharmacies 21% in Rio de 
Janeiro. 





study, 90 children 
with chronic 
rheumatic disease, 
with mean age 
14.1 years. 
Questionnaire completed by caregivers 
and children aged >10 years to collect 
sociodemographic information such as, 
caregivers’ education level, age, family 
composition, and responsibility for 
medicines administration. 
Adherence rate assessed by self-
report. 
 Older children (p<0.0001). 
 Older caregivers (p=0.011). 
 Caregivers with lower 
education level (p=0.031). 
 High number of patients per 
caregiver (p=0.004). 
 Child was responsible for 
medicine management 
(p<0.0015). 
 Caregivers have depression 
(p=0.028). 
 Caregiver together 




 Younger children 
(p<0.0001). 




M. Multiple Sclerosis 
As shown in Table 3-14, three studies identified barriers and facilitators to 
medicines adherence in patients with multiple sclerosis (294–296). 
• Medicine related factors  
The most common barriers to medicines adherence in patients with multiple 
sclerosis were medicine-related factors. Several factors related to medicines 
have been reported to cause poor adherence such as experienced side 
effects (294,296), intolerance to injections and lack of treatment efficacy 
(294). 
• Patient related factors  
Other barriers to medicines adherence in these patients were patient-
related factors. Two studies reported that forgetting was a reason for non-
adherence to medicines (295,296). Using medicines reminders such as a 










Table 3-14  Studies reporting barriers and facilitators to medicines adherence in patients with multiple 
sclerosis. For barriers and facilitators numbers are reported as % or significant association (if no numbers 
given numbers not reported in study). 
Study Design Tools used  Barriers identified 
 
Facilitators identified  
Thannhauser 
et al. 2009, 
Canada (294) 
Cohort study, 17 
adolescents, mean age 
15.8 years. 
Questionnaire completed by 
adolescents to explore reasons 
for discontinuing treatment. 
Adherence rate assessed by 
self-report. 
 Intolerance to injections 
37.5%. 
 Experienced side effects 
37.5%. 
 Lack of treatment efficacy 
12.5%. 
Did not report facilitators. 




30 participants, mean 
age 15.8 years. 
Questionnaire completed by 
adolescents and parents to 
explore reasons for 
discontinuing treatment. 
Adherence rate assessed by 
self-report. 
 Forgetting 50 % of 
patients. 
 Children wanted to ignore 
their disease (p=0.008). 
Did not report facilitators. 
Yeh et al. 
2018, United 
States (296) 
Cohort study, 28 
participants, aged 10 to 
18 years. 
Questionnaire completed by 
children. Open-ended questions 
identified barriers and 
facilitators to adherence. 
Adherence rate assessed by 
self-report. 
 Forgetting. 
 Experienced with fatigue. 




 Using medicines 
reminder. 








As shown in Table 3-15, two studies identified barriers and facilitators to 
medicines adherence in patients with cancer (297,298). 
• Patient-related factors  
Factors related to patients were reported to cause poor adherence such as 
forgetting (297,298), patients refusing to take medicine (297), and patients 
being away from home (298). 
• Medicine-related factors  
Factors related to medicines were also reported to cause poor adherence 
such as bad taste, difficulty swallowing (298), experienced side effects and 













Table 3-15  Studies reporting barriers and facilitators to medicines adherence in patients with cancer. For 
barriers and facilitators numbers are reported as % or significant association (if no numbers given numbers 






Study Design Tools used  Barriers identified 
 
Facilitators identified  
Lehrnbecher 
et al. 2008, 
Germany (297) 
Cohort study, 216 
children with cancer, 
aged 1 month to 27 
years. 
Questionnaire completed by 
children and parent evaluated 
factors with potential impact on 
adherence: knowledge, side 
effects, efficacy of treatment, 
personal belief and medical 
care. 
Adherence rate assessed by 
self-report. 
 Forgetting 25.9%. 
 Patient refused to take 
medicine 25.5%. 
 Experience of side effects 
11.1%. 
 Fear of potential side 
effects 2.8%. 
 Inadequate supply of 
medicine 1.4%. 





Cohort study, 103 
children with cancer, 
aged 13 to 19 years. 
Questionnaire completed by 
children and parents evaluated 
factors with potential impact on 
adherence: self-efficacy, side 
effects and medicine related 
factors. 
Adherence rate assessed by 
self-report. 
 Forgetting 37.9%. 
 Not being at home 11.7 %. 
 Hard to swallow pills 
10.7%. 
 Hating the taste 9.7%. 
 Not feeling well 6.8%. 
Did not report facilitators. 
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O. (GH) deficiency 
As shown in Table 3-16, two studies identified barriers and facilitators to 
medicines adherence in patients with growth hormone deficiency 
(299,300). 
GH treatment is expensive, and its’ cost has an effect on adherence, 
especially when the medicine is not free. Moheseni et al. in Iran reported 
that GH cost is the most common cause of non-adherence (300). A long 
duration of GH injections has also been reported to be associated with poor 
adherence (p=0.001) (299), because patients may become exhausted from 

















Table 3-16  Studies that reported barriers and facilitators to medicines adherence in patients with GH 
deficiency. For barriers and facilitators numbers are reported as % or significant association (if no numbers 
given numbers not reported in study). 
Study Design Tools used  Barriers identified 
 
Facilitators identified  
De Pedro et 
al. 2016, 
Spain (299) 
Cohort study, 158 
children, aged 4 to 
16 years. 
Questionnaire completed by 
children and parents about: 
duration of treatment, 
socio-economic status, level 
of education, and parental 
employment status. 
Adherence rate assessed by 
self-report. 
 Long treatment duration (P=0.001) 
 Lower mother’s education level 
(P=0.007). 
Did not report facilitators. 





children, aged 2 to 
12 years. 
Questionnaire completed by 
children and parents. 
Participants given a list of 
barriers to adherence and 
asked to tick factors they 
have faced. 
Adherence rate assessed by 
self-report. 
 
 Cost (65.7% child, 55.6% 
adolescent). 
 Inaccessibility to growth hormone 
distributing pharmacy (64.7% child, 
38.9% adolescent). 
 Growth hormone shortage (64.7% 
child, 38.9% adolescent) 
 Exhausted from long-term injections 
(54.3% child, 48.6% adolescent). 
 Concern about long-term 
complications (54.3% child, 51.4% 
adolescent). 
 Dissatisfaction with treatment results 
(37.1% child, 32.4% adolescent). 
 Being away from home (34.4% child, 
18.9% adolescent). 
 Forgetting (22.9% child, 18.9% 
adolescent). 




Table 3-17 shows two studies which identified barriers and facilitators to 
medicines adherence in patients with thalassemia (129,301). 
Patient related factors were the most common barriers to medicines 
adherence. Factors such as being aged over 16 years (p<0.05) (129,301), 
low parent education level (p<0.05) and large family size (p=0.01) (129) 


















Table 3-17  Studies reporting barriers and facilitators to medicines adherence in patients with thalassemia. 
For barriers and facilitators numbers are reported as % or significant association (if no numbers given 





Study Design Tools used  Barriers identified 
 
Facilitators identified  






12 to 19 years. 
Questionnaire completed by 
adolescents to explore 
sociodemographic information, 
disease knowledge, 
psychosocial impairment, and 
its’ effect on treatment 
adherence.  
Adherence rate assessed by 
self-report and medicine 
plasma level. 
 
 Psychosocial impairment was 
significantly associated with 
low adherence rate (p<0.05). 
 Older age over 16 years was 
significantly associated with 
low adherence rate (p<0.05). 
Did not report facilitators. 






12 to 19 years. 
Questionnaire completed by 
adolescents to explore 
sociodemographic information, 
disease knowledge, 
psychosocial impairment, and 
its’ effect on treatment 
adherence. 
Adherence rate assessed by 
self-report, medical record and 
medicine plasma level. 
 
 Older age over 16 years 
(p<0.05). 
 Low parent education level (p 
=0.04). 
 Large family size (p=0.01). 
 Presence of sibling with 
thalassemia (p=0.02). 
Did not report facilitators. 
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Q. Other diseases 
As shown in Table 3-18, the four remaining studies identified barriers and 
facilitators to medicines adherence in patients with other different diseases 
(163,302–304).  
Medicine-related factors were the most common barriers to medicines 
adherence. Two studies reported that experience of side effects was 
associated with poor adherence (303,304). Multidrug treatment and high 
dose frequencies (303) were also reported to cause poor adherence. In 
addition, factors such as good taste (302), fewer daily doses, fewer pills 
and using a medicines combination (302–304) were reported to result in 
good adherence. Healthcare professional and system-related factors 
included healthcare professionals providing sufficient information to 
patients about the disease and its treatment (302) and frequent 
consultation visits (163), both were reported to cause good adherence. 
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Table 3-18 Studies reporting barriers and facilitators to medicines adherence in patients with other 
diseases. For barriers and facilitators numbers are reported as % or significant association (if no numbers 
given numbers not reported in study). 
Study Design Tools used  Barriers identified 
 
Facilitators identified  








antibiotics, aged 0 
to 18 years. 
Questionnaire completed by 
caregivers. 
Participants given list of facilitators 
to adherence and asked to tick 
factors they have faced. 
Adherence rate not assessed. 
Did not report barriers.  Physician explanation of 
indication 85%. 
 Physician explanation of 
medicine 75%. 
 Physician explanation of side 
effects 72%. 
 Less daily dosing 42%. 
 Short duration 37%. 
 Good taste of medicine 20%. 
Ariceta  et 
al. 2015, 
Spain (303) 
Cohort study, 34 
cystinosis 
diagnosed children. 
Age not reported. 
Questionnaire completed by 
children and parents - 21 multiple 
choice questions covering: 
knowledge of disease, adherence 
to treatment, and measures to 
improve adherence. 
Adherence rate assessed by self-
report. 
 Patients complained of 
unpleasant smell (side 
effect of cystamine) 44%. 
 Multidrug 44% 
 High number of daily 
doses 35%. 
 Gastrointestinal side 
effects 24%. 
 
 Dose reminder or alarms 65%. 
 Fewer pills, less frequency 
doses, or reduced pill size 
60%. 
 Additional education about the 
disease 42%. 





Cohort study, 8710 
patients with high 
cholesterol level, 
Aged 8 to 20. 
Study based on medical records of 
patients to determine predictors of 
adherence to medicines. 
Adherence rate assessed by MPR 
calculation. 
 Older adolescents. 
 Obesity patients. 
 ≤2 inpatient visits in last 
year. 
 ≤5 outpatient visits in last 
year. 
 
 Younger adolescents. 
 3+ inpatient visits in last year. 
 6+ out-patient visits in last 
year. 








Cohort study, 312 
participants used 
bupropion to quit 
smoking. Aged 14 
to 17 years. 
Questionnaire completed by 
adolescents about symptoms of 
smoking withdrawal, adherence to 
medicine and abstinence. 
Adherence rate assessed by self-
report and pill count. 
 Race other than 
white/Caucasian. 








Our search for a systematic review of barriers and facilitators to medicines 
adherence in children identified only the TABS review that was done in 
August 2008 and published in 2013 (85). This review was a critical evidence 
synthesis of research to examine reasons for non-adherence to medicines 
in children with chronic diseases (85). It analysed 197 studies identifying 
barriers and facilitators to medicines adherence in children (85). More than 
70% of these studies were conducted in the US, and less than 10% were 
conducted in the UK (85). About 50% of these studies focused on patients 
with asthma, whereas the others focused on patients with HIV, arthritis, 
diabetes, epilepsy, kidney diseases and other diseases (85). The review 
found that factors potentially affecting adherence in children were related 
to the medicine, patient, condition and patient healthcare provider 
relationships (85). Specifically, this review showed that the most common 
barriers to adherence included parents’ fear of side effects, forgetting, lack 
of family support, medicine responsibility among adolescents, regimen 
complexity and perceptions regarding the necessity of medicine (85). 
Adherence rates were positively correlated with income when patients paid 
for their medicine. Although providing clear information about a disease and 
its treatment was thought essential, provision of such information did not 
guarantee good medicines adherence. Moreover, regimen complexity was 
associated with poor adherence, but reducing dosing frequency did not 
always increase adherence rate (85).  
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We performed a systematic review to update the TABS work and to identify 
the barriers and facilitators to medicines adherence in children in studies 
published since then. Most studies (75%) in our review were conducted in 
HEDCs similar to those in the TABs review including the US (76), the UK 
(11), and Canada (6) (over 70% of the included studies in TABs were from 
the US, and fewer than ten percent from the UK). Only 25% of the studies 
were conducted in LEDCs, including Uganda (9), Ethiopia (7) and Kenya (3) 
(no such information was reported in the TABs). The studies included in this 
review included 50% focusing on patients with HIV or asthma, 30% on 
patients with kidney disease, epilepsy, psychiatric disorders or IBD, and the 
remaining 20% focussing on patients with other diseases including sickle 
cell disease, diabetes and cystic fibrosis. Our review identified studies of 
more diseases than those identified by the TABS review including GH 
deficiency, thalassemia, multiple sclerosis, psychiatric disorders and cancer. 
Our review included eight studies identifying only facilitators to adherence, 
86 studies identified only barriers to adherence and the remaining 83 
studies identified both barriers and facilitators to medicines adherence. The 
TABs study did not specify which studies reported barriers only, facilitators 
only, or both together.  
3.4.1  Barriers to medicines adherence in children 
Our findings are consistent with that of the TABS review about most 
common barriers and facilitators to medicines adherence in children. Here 
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we will discuss barriers to medicines adherence in children found in our 
review according to the WHO classification. 
A. Patient-related factors 
The patient-related factor that is the most commonly reported barrier to 
medicines adherence was forgetting. Reasons such as, ‘just forget’ , 
‘interferes with activity’ and ‘wasn’t home’  were the causes of poor 
adherence in patients with HIV, IBD, kidney diseases, asthma, cystic 
fibrosis, chronic rheumatic disease and diabetes 
(95,164,170,189,192,243,254,284,291). This finding shows that 
everyday life activities have a large impact on whether patients take their 
medicines or not (189). We could infer that caregivers and children do 
not have a systematic procedure related to their medicines taking (243). 
Moreover, a study that assessed potential barriers to medicines 
adherence in HIV-infected children showed that 41% of children and 33% 
of caregivers reported that forgetting was the main reason for non-
adherence (61). This finding suggests that even in severe diseases, 
forgetting affects the rate of medicines adherence.  
Another patient–related factor that is considered to be a barrier to 
medicines adherence is the patient’s age. Younger children with HIV and 
asthma tended to have lower rates of medicines adherence than older 
children (69,199,240,249). Older children with HIV or asthma tended to 
have better awareness and appreciation of the negative effects of poor 
medicines adherence, especially if their disease status was disclosed to 
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them (199,240). This may suggest that when children aged 11 years and 
older are informed about their condition, they tend to become more 
responsible; therefore, their adherence rate is higher than younger 
children (69,199,240). This is probably due to the fact that younger 
children are fully dependent on their parents to take their medicines 
because they do not have the cognitive understanding or physical 
capacity to take their medicines by themselves (69). In addition, younger 
children who are usually reminded by their parents to take their 
medicines may forget about their doses when their parents or caregivers 
are absent or busy (199).   
By contrast several studies have reported that adolescents with HIV, 
asthma, chronic rheumatic disease, psychiatric disorder, thalassemia and 
kidney diseases tend to have lower adherence rates than younger 
children because taking medicines is a responsibility that is likely to have 
been transferred from parents to children 
(129,160,176,181,194,197,246,253,293). There are a few sociological 
explanations for this finding. First,  is that parents who were responsible 
for their adolescent’s treatment may be in conflict with their child’s desire 
to develop competence and independence (197). Another possible reason 
is that adolescents who are given full responsibility may not believe they 
need medicines to control their disease or perhaps they are not yet ready 
for this responsibility (129,194). Moreover young children are dependent 
on their parents for taking their medicine, and since parents carry this 
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responsibility many of them ensure to set alarms or visual reminders 
(181).  
B. Socioeconomic-related factors 
Fear of stigma and discrimination is a social-related factor that is reported 
to result in poor adherence. Some conditions, such as HIV disease are 
particularly linked to social stigma. Galea et al. reported that children 
with HIV hid their medicine when going out with friends (73). This pattern 
suggests that being around others could cause children stress, and it 
increases their likelihood of not taking their medicines as they feel the 
need to act just like their peers (73,74). In relation to this, MacCarthy et 
al. reported that school attendance limits patients’ privacy, resulting in 
poor medicines adherence (74). When children attend school, they spend 
less time with their family at home and they may feel ashamed to take 
their medicines in front of their peers (74).  
Another socioeconomic-related factor considered to be a barrier to 
medicines adherence is non-disclosure of the children’s health status. 
Studies have shown that children with HIV who are unaware of their 
condition are more likely to have poor adherence to antiretroviral therapy 
(61,73,93,196,198). There are two possible reasons for this pattern. 
First, patients who were aware of their condition were more health aware 
and believed their medicines to be helpful (196). Second, patients who 
were unaware of their condition refused to take their medicines as they 
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did not understand the rationale behind the treatment while they felt 
apparently healthy (196). 
Some of the most important reasons for medicines non-adherence in 
patients with HIV, asthma, psychiatric disorder, IBD and diabetes include 
family conflict, stability, parental marital status, family size, and stress 
for children and parents (210,211,224,241,247,264,268,285). Low 
family support and a lack of adult support tends to be a barrier to 
medicines adherence, as the children/adolescents feel uncared for and 
thus they do not see the need for adherence (211,224,285). In addition, 
suboptimal relationships with caregivers may affect a child’s adherence 
and attendance to appointments, a pattern more common in older 
children (210,247,268). 
Children who live in a single parent household tend to have less family 
support, which may contribute to low medicines adherence rates (264). 
According to Chan et al., adherence may also be poor in larger families 
as there are more matters to attend to, reducing the time spent to care 
for an ill child in the family (241). 
C. Medicine-related factors 
Complexity of drug regimens (such as high dosing frequency or 
administering multiple drugs) has been associated with poor medicines 
adherence in patients with HIV, IBD, asthma, kidney diseases, epilepsy 
(70,79,122,167,170,177,210,236,270). When the number of medicines 
prescribed increased or when changes in administration schedule were 
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made, the possibility that medicines or doses were missed increased, 
leading to poor adherence (70,79,177,236). 
Long duration of treatment has been reported to cause poor adherence 
in patients with HIV, psychiatric disorders, epilepsy, asthma, IBD, kidney 
diseases and growth hormone deficiency (81,162,168,190,202,299). For 
example, where medicines are administered over a long period, 
adherence may significantly decline over time (168,299). Adherence 
drops when patients do not perceive therapeutic effectiveness, and their 
motivation to take medicines decreases (168,299). In addition, the fear 
of a lack of efficacy of certain medicines can affect adherence, especially 
with regard to chronic diseases, such as HIV and multiple sclerosis, where 
medicines are prescribed to control the disease and do not make the 
patients feel better (197,294). 
Medicines are administered in various ways. The oral route is preferred 
and is the most frequently used route of medicine administration in 
children (92). However, the bad taste of some medicines has been seen 
to negatively affect the adherence of patients with HIV, psychiatric 
disorders and kidney diseases (70,85,92,193,208,254,259). Bad-tasting 
medicines discouraged younger children to willingly take their prescribed 
medicine, increasing non-adherence (70,85,92,193,208,254,259). 
Moreover, fear of the unknown adverse effects of medicines has been 
reported as a reason for discontinuing daily medicines in patients with 
173 
 
HIV, asthma, epilepsy, chronic rheumatic disease, tuberculosis and 
psychiatric disorders (70,85,193,196,197,240,254,270,288,292). For 
example, when an asthmatic child begins to feel better, some parents 
stop administering daily inhaled steroids, believing this will prevent the 
medicine’s side effects (173,240). However, this behaviour may worsen 
the condition which the patient is suffering from. 
Poor adherence has also been reported in children with HIV, psychiatric 
disorders, multiple sclerosis and kidney disease who have experienced 
the side effects of medicines (171,198,254,262,296). For example, 
children have been shown to often struggle with Lopinavir/Ritonavir 
syrup, which can cause vomiting. This side effect disrupts the dosing if 
the medicine is not re-administered after vomiting (198). This side effect 
reduces adherence because other barriers may arise; for instance, 
children may develop a negative perspective towards taking medicines if 
they feel it will make them feel worse (198). 
D. Condition related factors 
Studies with patients with HIV and asthma have shown that when the 
symptoms of the disease are few or had disappeared, the absence of 
symptoms became a barrier for patients to follow their treatment regimen 
as patients did not see the need to continue taking their medicine and 
thus their adherence decreased (61,195,240).  
Disease severity and rate of progression may affect medicines adherence 
in different ways. For example, when the severity of HIV is high, 
174 
 
medicines adherence may decrease if patients lose trust in their 
treatments, or because parents prefer nonmedical options such as the 
use of holy water (religious practices) (61,69,70,195). This behaviour has 
been attributed to reduced trust in healthcare providers and the 
effectiveness of the treatments given (61,69,70,195). By contrast, some 
studies have reported that low severity of HIV and asthma is associated 
with poor adherence (68,70,173,196,240). There are two possible 
reasons for this pattern: first, when disease severity decreases, patients 
tend to stop taking medicines because they think they are no longer 
necessary (68,173,240). Second, high severity of a disease motivates 
patients to take medicines as prescribed to avoid condition complications 
(70,196). 
E. Healthcare professional- and system-related factors 
These factors have been seen to particularly influence patients with 
asthma (87,88,236,238,240). Several studies have shown that 
inadequate communication between healthcare providers and their 
patients or their parents can contribute to poor adherence 
(87,88,236,238,240). In some cases, the parents did not have the same 
views about their children’s condition as their healthcare provider. For 
example, the parents did not always view asthma as a chronic disease 
that requires constant administration of medicine, nor did they 
necessarily believe that inhaled corticosteroids are safe (240). In 
addition, a healthcare provider’s failure to explain the side effects and 
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benefits of medicines, failure to demonstrate how to use inhaler devices 
or failure to explain the need for a complex medicine regimen may 
contributes to non-adherence (238,242). 
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3.4.2  Facilitators to medicines adherence 
In contrast to the above-mentioned barriers to medicines adherence, 
numerous factors contribute to high adherence rates. These factors 
include integrating taking medicines into daily routines or using medicines 
reminders to avoid forgetfulness. In addition, the practices that 
effectively prevent forgetting include taking medicines at the same time 
each day (e.g., before a meal), marking a calendar, setting an alarm 
clock, or using note reminders (70,87,91,122,189,193,241,243).  
Other factors that have been associated with high rates of adherence in 
patients with HIV, asthma, kidney disease and psychiatric disorders 
involve a higher level of caregivers and parental education 
(175,196,240,255,258). Educated parents or caregivers had a better 
understanding and knowledge about certain diseases and treatment, 
which in turn helped them to improve the adherence rates of their 
children (196,240).  
Factors that promote good relationships between patients (and their 
parents) and healthcare providers have also been associated with high 
rates of adherence in patients with HIV, tuberculosis and epilepsy 
(193,271,288,302). These factors included discussing with the patients 
and their parents the different formulations of medicines (e.g., some 
patients prefer syrup formulation with a good taste over tablets) 
(193,302). Other important matters, such as the safety of medicines, 
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treatment rationale and benefits of adherence, are also associated with 
high rates of medicines adherence (193,271,288). 
3.4.3 HEDC vs LEDC 
One hundred and twenty six studies were conducted in HEDCs including 
the US (76), UK (11), and Canada (6), and only forty six studies were 
conducted in LEDCs, including Uganda (9), Ethiopia (7) and Kenya (3). 
Forgetting was a common barrier to adherence in both HEDC and LEDC  
(95,164,170,189,192,243,254,284,291) and measures taken to avoid 
forgetting to take medicines include the use of reminders, such as notes 
on the refrigerator and the use of an alarm clock; these efforts were 
associated with good adherence in both HEDC and LEDC 
(87,122,241,243). Medicines related-factors such as experienced and 
fear of side effects, complexity of drug regimens and bad taste of 
medicines were associated with poor adherence in both HEDCs and LEDCs 
(70,79,210,236,254,259,270,85,92,122,167,170,177,193,208).  
In LEDCs poor adherence has been reported to be due to low 
socioeconomic status and limited access to healthcare facilities, such as 
long distances from medical centres (74,86,196,199,203).  Arage et al. 
reported that patients who needed to travel more than 10 kilometres 
were 2.3 times more likely to show poor adherence to medicines 
compared with patients who had to travel less distance (196). This mainly 
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refers to families with a low income and who live in LEDC such as Ethiopia 
(196). 
Two studies conducted in Iran (LEDC) revealed an association between 
high medicine costs and poor adherence of patients with asthma and GH 
deficiency and without health insurance (240,300). In some cases, these 
patients tried to reduce the cost of medicines by decreasing their dosage 
and/or the frequency of a recommended treatment (240,300).  Moreover, 
lack of knowledge about the disease and its treatment in patients with 
HIV, asthma, kidney diseases, tuberculosis and epilepsy has been 
reported to be associated with poor understanding regarding medicines 
regimens and poor adherence (61,70,71,73,170,221,242,270,271,288). 
Many of the studies that support this idea were conducted in LEDCs, 
where the level of education is often low (70,71,73,221,270,271,288). 
Given the low level of education in LEDCs, medicines adherence is also 
low as parents may be unaware of the impact of following medicine 
prescriptions on their children’s overall health (71,221).   
In contrast, countries such as the US and the UK generally provide high-
quality education, which helps facilitate good communication among 
healthcare professionals, patients and parents. Such communication 
helps to ensure that the patients are more aware of their condition and 
that parents gain a wider knowledge about the treatments given and their 




3.4.4  Limitations 
All titles and abstracts of the search results should have been screened 
according to the inclusion criteria by two researchers. Due to the limited 
resources of our department, one researcher (Aldosari M) screened all 
titles and abstracts, but only 5% of titles and abstracts were assessed 
independently by another researcher from our group (Abramson J). The 
quality of all included studies should also have been assessed 
independently by two researchers. Given the high numbers of included 
studies and the limited resources of our department, one researcher 
(Aldosari M) quality assessed all of the included studies but, only 5% of 
the included studies were quality assessed independently by another 
researcher from our group (Abramson J). In addition, conference 
abstracts and the grey literature were not searched therefore it is 
possible that studies have been missed. 
3.5 Conclusion 
This systematic review identified the barriers and facilitators to medicines 
adherence in children reported in the literature in the last 12 years. We 
found that children faced many different barriers to medicines adherence 
which varied with different diseases and that no single facilitator could 
improve medicines adherence. Rates of adherence are influenced by 
children’s or caregiver’s beliefs about the treatment. Forgetfulness and fear 
of side effects were the most common barriers to medicines adherence. The 
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range of barriers to adherence included family conflict, weak patient-
provider relationships, stigma and discrimination, drug regimen complexity, 
and lack of support from families. The most frequent facilitators of 
medicines adherence included using reminders to avoid forgetfulness, high 
parental education levels and good patient-provider relationships. To 
achieve optimal adherence, healthcare providers need to be aware of these 
barriers and to consider the most appropriate facilitators to encourage 











Chapter 4: Exploratory study on the barriers and 
facilitators of medicines adherence in a Saudi 




We have already completed a systematic review on the barriers and 
facilitators of medicines adherence in children (Chapter 3). This systematic 
review highlighted that forgetfulness and fear of side effects were the most 
common barriers to medicines adherence. The most frequent facilitators of 
medicines adherence included using reminders to avoid forgetfulness, high 
parental education levels and good patient-provider relationships.  
Most of the included studies in our systematic review focussed on patients 
with a limited number of specific diseases. Just one of these studies was 
conducted in Saudi Arabia and explored barriers of medicines adherence in 
children with epilepsy (177). This study reported that forgetfulness, fear 
from side effects, high numbers of medicines, divorced parents, lack of 
family support and strong concerns about medicine consequences were the 
most common barriers of medicines adherence in children with epilepsy in 
Saudi (177). It focused only on barriers and did not explore facilitators of 
adherence.  
This chapter describes the first study to explore both barriers and facilitators 
of medicines adherence in children with any chronic disease in Saudi Arabia 
to our knowledge. Saudi is my home country which is the reason why we 
wished to conduct a study there in order to fill the gap in knowledge by 




This study aims were to: 
• Measure medicines adherence in children with chronic diseases 
attending the King Fahad Medical City (KFMC) in Saudi Arabia.  
• Explore the barriers and facilitators to medicines adherence in these 
children. 
4.2 Method 
Both the Institutional Review Board (IRB) in the KFMC and the Head of 
Pharmacy in the KFMC approved our research protocol to conduct this 
study (Appendix 1).  
This study was conducted between 24th July 2019 and 10th October 2019 
at King Fahad Medical City (KFMC), a tertiary hospital and one of the 
largest medical facilities in Saudi Arabia, containing 246 beds for children.  
4.2.1  Inclusion criteria 
• Paediatric patients ≤ 18 years receiving long-term medicines who were 
inpatients or attending outpatient clinics at the KFMC Hospital.  
o If a child was too young to complete the study questionnaires, 
then their parent would assist the child by completing the 
questionnaires in the child’s own words i.e. reading questions 
out to the child and writing the answers down.  
• Parents of children taking long-term medicines who were too young to 
provide their own opinions on the questionnaires. 
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4.2.2  Exclusion criteria 
• Patients over 18 years old. 
• Patients/ Parents who were too distressed/ ill to approach. 
• Patients/ Parents who did not speak English or Arabic. 
4.2.3  Recruitment 
The researcher (MA) worked under the supervision of the hospital pharmacy 
supervisor during the data collection in KFMC. Participants were recruited 
from the waiting area at the outpatient pharmacy and from the paediatric 
in-patient wards in the hospital. Participant information sheets and consent 
forms were available in English and Arabic (Appendix 2).  
The researcher (MA) asked the pharmacists in the waiting area of the 
outpatient pharmacy and the nurses in the paediatric in-patient wards which 
families would be suitable to be approached in terms of age of the patient, 
medicines prescribed and ability to speak English or Arabic. We received 
approval from the IRB in KFMC to access the pharmacy refill records for 
each patient. The researcher checked if the patient was taking long-term 
medicines from pharmacy refill records.  
After eligibility for inclusion in the study was confirmed, the patients and 
their parents or guardians were asked to participate in the study. They were 
provided with written and verbal information about the study in age-
appropriate language by the researcher (English and Arabic).  
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In all cases, written informed consent was obtained from the parent/legal 
guardian or the child if ≥16 years of age. The patient or parent were asked 
to answer all questions in the Beliefs about Medicines Questionnaire (BMQ) 
and our own designed questionnaire form (Appendices 3 and 4) which 
are explained below. The participants’ personal information was recorded 
on the consent forms only, and the researcher coded the questionnaires 
with a number corresponding to each participant’s consent form.  
From the pharmacy refill records for each patient we could establish the 
total number of days’ supply of medicines dispensed and the number of 
days that the patient should have been taking the medicines. This 
information allowed us to calculate the Medication Possession Ratio (MPR) 
to assess medicines adherence (as described in more detail on page 184). 
The completed questionnaires and consent forms were stored separately in 
locked facilities in the KFMC during the data collection period in Saudi 
Arabia. Data were entered on University password-protected computers. 
Data were analysed using SPSS version 26. 
4.2.4  Justification of the questionnaires 
Most of the studies included in our systematic review used purpose designed 
questionnaires to explore barriers and facilitators of medicines adherence 
in children and studied only a single specific disease (Chapter 3). We also 
found that sixteen studies used validated questionnaires e.g. the Morisky, 
and the Paediatric Epilepsy Medication Self-Management Questionnaire 
Scales. These were used only in studies involving children with epilepsy 
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(177,273). The Diabetes Family Responsibility Questionnaire was used only 
in studies with children with diabetes (182), the Medication Adherence Rate 
Scale (MARS) was used only in studies with children with asthma and 
epilepsy (123,126), and the Medical Adherence Measure was used only in 
studies with children with inflammatory bowel disease and organ 
transplantation (164,169).  
Only one of the validated questionnaires was used in studies in children with 
several different chronic diseases. This validated questionnaire was the 
Beliefs about Medicines Questionnaire (BMQ) (42).  
A. Beliefs about Medicines Questionnaire (BMQ)  
The BMQ was originally developed and validated by Professor Robert Horne 
and colleagues to use in adult patients, and parents and guardians of 
children with chronic diseases (42). A 2017 review shows that this 
questionnaire has been used successfully in studies about medicines 
adherence across a broad range of clinical conditions in adults, including 
asthma, HIV, diabetes, liver transplant, inflammatory bowel disease, 
cardiovascular disease, mental disorders, haemophilia, hypertension, and 
patients after stroke events (305). The BMQ questionnaire was also used 
by eight studies identified by our own systematic review (Chapter 3) 
including studies in children with asthma, inflammatory bowel disease, 
attention deficit hyperactivity disorder, epilepsy, and cystic fibrosis 
(68,81,126,173–176,178). An Arabic translation of the BMQ has also been 
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validated for use in children and their parents (306).  We therefore used 
the BMQ in our study using the English and Arabic translations. 
The BMQ (Appendix 3) aims to assess patient’s concerns and beliefs about 
medicines (42,307). It consists of 18 questions and is divided into two 
sections, the BMQ-General (8 questions) which assesses beliefs about 
medicines in general and the BMQ-Specific (10 questions) which assesses 
beliefs about medicines prescribed for personal use (42,307). The two 
sections can be used separately or in combination (42,307). As our 
objective was to explore barriers and facilitators of children’s adherence to 
their prescribed medicines, we used the BMQ-Specific questionnaire only. 
This was also the case with all nine studies in our systematic review that 
used the BMQ (68,81,126,173–178).  Four of these studies utilised the 
BMQ-Specific only for the parents because they included children aged 
under 7 years of age (68,173,175,178), three studies utilised the BMQ-
Specific only for adolescents (81,176,177), and only one study utilised the 
BMQ-Specific for both parents and children aged over 6 years (126,174). 
The BMQ-Specific questionnaire consists of ten questions: five on people’s 
concerns about taking medicines and five on people’s beliefs about medicine 
necessity (42). The questions involving concerns assess patients’ concerns 
about taking the medicines prescribed (e.g., “I sometimes worry about the 
long-term effect of my medicines”). The questions involving necessity 
assess patients’ beliefs in the necessity of taking the medicines prescribed 
(e.g. “my life would be impossible without my medicines”) (42). All items 
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are rated on a five-point scale ranging from 5 = strongly agree to 1 = 
strongly disagree (i.e., the overall score range is from 5-25 for each 
section).  A score of 15 to 25 is defined as high concern or high necessity. 
A differential score between necessity and concern is calculated by 
subtracting the results of the concern scores from those of the necessity 
scores. Therefore, a negative score indicates stronger concerns about the 
consequences of the medicine than beliefs in the necessity of taking the 
medicine.  By contrast, a positive differential score indicates stronger beliefs 
in the necessity of taking the medicine (42).  
By also measuring adherence using our separate purpose designed 
questionnaire (described below) and in addition, by using the Medication 
Possession Ratio (MPR) (calculated as described below), we assessed the 
relationship between adherence rates and beliefs in the necessity of 
children’s medicines and concerns about consequences. 
B. Purpose-designed questionnaire  
The BMQ only assesses participant’s beliefs about medicines in terms of 
necessity and concerns. Our aim was to explore all factors that affect 
medicines adherence in children. To achieve this aim, we therefore designed 
our own questionnaire to use in addition to the BMQ to explore other 
barriers and facilitators of medicines adherence in children. 
From our systematic review (Chapter 3), we found that most of the 
included studies used questionnaires that were designed for each individual 
study to identify the barriers and facilitators of medicines adherence in 
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children. Taking these findings into account, we developed our purpose-
designed questionnaire (Appendix 4) by including questions modified from 
various previous studies to make it suitable for children with different 
diseases and their parents.  
Our purpose-designed questionnaire consists of: 
• Most common barriers and facilitators to medicines adherence 
The first question consisted of lists of ten barriers and seven facilitators of 
medicines adherence. The lists included the most frequent barriers and 
facilitators of medicines adherence that were reported in our systematic 
review. The children, children with parent’s help when needed or parents 
when their children were too young were asked to either tick (✓) the “agree” 
box if they had encountered this barrier or facilitator or tick the “disagree” 
box if they had not.  
The participants’ answers to this part of the questionnaire enabled us to 
report the percentage of participants who have faced each barrier or 
facilitator and to identify the most common barriers and facilitators in our 
participant population in a similar way to those reported in previous studies 
(70,164,167,192,196,197,240,254,288). 
• Measures of adherence 
From our systematic review on measuring medicines adherence in children 
(Chapter 2) we found that there is no known ideal method to measure 
adherence but that it is more reliable to use two or more adherence 
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measures together. We therefore used self-report through our 
questionnaire and also the MPR method to measure medicines adherence 
in our participants.  
Our systematic review on measuring medicines adherence (Chapter 2) 
showed that a single question (i.e., How do you rate your medicine taking 
in the last month from 0% to 100%?) was used by six studies to measure 
adherence in children (116–118,120,122,129). We therefore used this 
question as a self-report tool to estimate patients’ adherence rates in our 
own questionnaire.  
The participants were asked:  
‘Plot on the line from 0% (none) to 100% (all) how many of the prescribed 
doses of medicines you/your child managed to take in the last four weeks’.  
The MPR is the most common measure of medicines adherence using 
prescription refill records. It measures the percentage of time a patient has 
access to their medicines. The MPR is calculated by dividing the total 
number of days’ supply of medicines dispensed by the number of days that 
the patient should have been taking the medicines and multiplying this by 
100.  
The MPR equals 100, representing the highest adherence, when the total 




We therefore used two methods to measure the medicine adherence rate, 
the MPR and self-report methods. Both provided the medicine adherence 
rate as a percentage which allowed us to compare the two results. 
The remaining questions explored the areas listed below (Appendix 4). 
Our systematic review of the barriers and facilitators to medicines 
adherence identified previous studies that used similar questions. We 
modified the questions from those studies to be suitable for different 
diseases. 
a) Forgetfulness 
As our systematic review (Chapter 3) suggested that forgetfulness is one 
of the most common barriers to adherence, one question elucidated 
participants’ own thoughts about why they might forget to take their 
medicine and how they could manage this barrier (85,93,195).  
b) Side effects of medicines 
Two questions explored whether the children/parents worry about or have 
experienced any side effects from taking medicines in order to determine 
whether this concern affects medicines adherence. All medicines have 
possible side effects, and we wanted to know the most frequent side effects 




c) Responsibility for medicines adherence 
One question asked who is responsible for administering the medicines and 
explored how this affects medicines adherence. The transition age of 
children as they become responsible for their own actions is an important 
issue in assessing medicines adherence (176). We wanted  to compare the 
adherence rates of children whose parents were responsible for 
administering their medicines to adherence rates of children who are 
responsible for administering their medicines (85,195,244,254).  
d) Fear of stigma or discrimination 
One question was about whether the child/family experience any concerns 
about taking medicines in front of others. In particular, we wanted to assess 
whether stigma affects medicines adherence in children (85,93,193).  
e) Problems with regimen 
Two questions were about the medicines regimen and how it affects 
adherence. For children, there are different dosage forms and different 
methods of administration e.g. a liquid formulation is the preferred and 
most frequently used form for many children (76). Each medicine regimen 
has different forms and different dosage frequencies. We wanted to explore 
whether the child had difficulties with their medicine regimen and how it 




f) Participants’ thoughts that may improve adherence 
One question asked for thoughts and suggestions that the children and their 
families may have to help improve medicines adherence in children. With 
this question, we intended to gather ideas from the children and their family 
which would help with this. 
Both questionnaires (BMQ and our own designed questionnaire) were tested 
by the researcher (MA) and the Chief Investigator (Dr Sharon Conroy) in 
the Derby Children’s Hospital before the study started. 
4.2.5  Thematic analysis 
Three questions in our purpose designed questionnaire were open ended 
(Q2, Q6 and Q10) (Appendix 4). The participants’ answers to these 
questions (qualitative data) were analysed using thematic analysis 
(308,309).  
Thematic analysis is one of the most commonly used analysis methods for 
qualitative research (308,310). According to Braun and Clarke, thematic 
analysis identifies, organises and links participants’ answers into themes 
within a data set. It also interprets different aspects of the research topic 
(310). This analysis allows a researcher to identify participants’ answers in 
relation to a specific topic, and it can identify numerous topics in a data set 
(308,310). Many researchers use this method for its accessibility and 
flexibility (it can be used for interviews and questionnaires) (308,310); 
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however, this flexibility can make it difficult for a researcher to decide what 
aspect of their data to focus on (310). Therefore, a researcher should be 
aware of how to generate themes that serve to focus on the issues being 
studied (310). We decided to use thematic analysis because its flexibility 
allowed us to analyse the answers to the open questions and also extract 
defined themes from the participants’ answers (308,310).  
In this study, to undertake the thematic analysis manually, Braun and 
Clarke’s six-phases framework was followed (310). This framework is one 
of the most commonly used methods to conduct thematic analysis and 
provides a clear step-by-step process: 
1- Familiarisation 
I read the participants’ answers text, generally looking through the 
participants’ answers to get familiar with it. 
2- Generating initial codes 
I highlighted sections of participants’ answers (phrases or words) and wrote 
codes to describe their content (examples are shown in Table. 4-1). At this 







Table 4-1  Examples of coding 
3- Searching for themes 
I looked over the codes that had been created, identified patterns among 
them, and started to generate themes. In this method, themes are 
generally intended to be broader than codes. Most codes became themes in 
their own right. Sometimes however, I combined several codes into a single 
theme. Table 4-2 shows examples of turning codes into themes. 
Table 4-2  examples of turning codes into themes 
Codes Themes 
• Setting an alarm 
• Writing notes 
Using reminders. 
• Multidrug 
• Many doses 
Many doses each day. 
• Medicine tastes bad 
• Painful injection 
• Difficulty with inhaler device 
Medicine difficult to take due to size, 
poor taste/smell/pain/device. 
• Family help/support Family support. 
 
4- Reviewing themes 
After generating themes for all the participants’ answers, I re-read each 
answer and the initial code and chosen theme for each question to ensure 
the selected themes were appropriate.  
Question Participants’ answers codes 
can you think of anything that 
could help you to remember? 
1- We set a phone alarm to 
remind us of the time of 
doses. 
 




can you think of anything that 
could help you to remember? 
1- Writing notes. 
 





5- Defining and naming themes 
I identified more precisely what each theme is about and described how it 
helps us understand the data. 
6- Producing the report 
In this final phase, I wrote the analysis and provided examples of the 
participants’ answers that related to each theme. 
Therefore, by applying Braun and Clarke’s six-phases framework, I have 
been able to identify, analyse, and generate themes.  
As a reliability measure, all the participants’ answers, codes and themes 











4.2.6  Statistical analysis 
To express the adherence rate as a binary variable, the defined cut-off value 
was 80% (as used in several previous studies) of the continuous data for 
the two adherence assessment methods (68,160,161,178,292). Patients at 
80% and above were defined as adherent, patients below as non-adherent. 
For statistical analysis, data was analysed descriptively to determine the 
agreement between the two assessment methods for the adherence rate 
(the Questionnaire and the MPR). Kappa (κ) testing was conducted to 
compare the adherence rates measured by the two methods. The strength 
of agreement between the two methods was described as poor if κ <0.2, 
fair if 0.2 < κ ≤ 0.4, moderate if 0.4 < κ ≤ 0.6, substantial if 0.6 < κ ≤ 0.8, 
and almost perfect if 0.8 < κ ≤ 1 (311,312). 
We also used chi-square testing to assess the correlation of medicine 
adherence rates (good adherence ≥ 80% and poor < 80%) with child age, 
child sex, parents’ education level, and child’s/parents’ beliefs in the 
necessity and their concerns about consequences of their medicines 
(assessed by the BMQ-Specific). 
4.2.7  Sample size and justification 
The estimated sample size was 96 patients. We calculated this sample size 
with the help of a University of Nottingham statistician using nQuery Sample 
Size Software. It was computed based on the precision approach that we 
would need a sample size of 96 to estimate the proportion adhering with a 
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good level of precision, which was defined as a 95% confidence interval 
width of 0.1, assuming the rate of adherence is no less than 50%. If the 
proportion of adherence were higher, the precision would be better (width 
higher than 0.1). 
The sample size of 96 also provided 90% power to detect a kappa of 0.35 
or higher. In the chi-squared analysis, this sample size of 96 would also 
provide 80% power to detect a difference in adherence proportions between 




4.3.1  Demographic and clinical characteristics 
In total, 100 children were recruited to the study. Thirty-nine children 
answered questions alone, 35 children answered questions with the help of 
their parents and 26 parents answered questions for their children. Twenty-
nine participants did not answer every question. This is described below for 
each section. Appendix 5 shows a summary table with the gender, age, 
disease, medicines, adherence rates and BMQ results for each participant. 
Previous studies used the mean or median age as a cut-off point to compare 
two different age groups (older and younger age group) (129,178,233). The 
mean age of the participants in our study was 9.35 ± 4.50 years (range: 1-
18) and the median was ten years. Ten years was chosen based on the 
median as the cut-off point to compare the two age groups.  
Fifty-two children (52%) were ≥10 years of age (26 male, 26 females) (27 
with parents with low education level and 25 with parents with high 
education level) and 48 (48%) were under 10 years of age (30 male and 
18 female) (21 with parents with low education level and 27 with parents 
with high education level). Most of the children were males (56%). Slightly 
more than half of the children's parents (52%) had a university education 
and 48% had a secondary education or less. One-fifth of the study 
population (19%) had epilepsy, 17% had asthma and 14% were diabetic 
children (Table 4-3). 
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Table 4-3 Demographic and clinical characteristics of the study population (n = 
100) 







   Male 




Level of Parent Education 
   Secondary or less 








Growth Hormone Deficiency 
Heart Disease 
End-Stage Renal disease 
Anaemia 
Leukemia 
Psychiatric Disorder  
Gastrointestinal Disorder 



























4.3.2 Barriers to medicines adherence 
The answers to the first part of our purpose designed questionnaire are 
summarised in Table 4-4. The most frequently perceived barrier of 
medicines adherence was ‘I worry about possible side effects’ as reported 
by 79 (79%) of the participants. This was followed by ‘I forget to take my 
medicine’ reported by 62 (62%) and ‘I worry about what other people would 
think of me if they knew I took medicine’ reported by 62 (62%).  
Forty-seven participants ticked “not certain” for Q2 ‘My medicine tasted bad’ 
(Table 4-4). Thirteen of these participants were taking non-oral medicines. 
Eight patients with GH deficiency, two with diabetes and one with 
haemophilia B were taking injections only; one with a GI disorder was taking 
medicines via a feeding tube; and one with cancer was having their 
medicines administered intravenously. The remaining 34 participants were 
taking oral medicines. 
Twenty-six participants ticked on “agree” for ‘I don’t know enough about 
the illness and treatment’. Twenty-one of these participants were with 
parents with a secondary-level education. 
Fourteen participants ticked on “agree” for ‘I don’t have enough family 












Not answered  
n (n%) 
Q.1: I forget to take my medicine. 62 (62%) 36 (36%) 1 (1%) 1 (1%) 
Q.2: My medicine tastes bad. 24 (24%) 29 (29%) 47 (47%) 0  
Q.3: I worry about possible side effects. 79 (79%) 19 (19%) 1 (1%) 1 (1%) 
Q.4: I don’t have enough family support. 14 (14%) 85 (85%) 0 1 (1%) 
Q.5: I don’t know enough about the illness and treatment. 26 (26%) 74 (74%) 0 0  
Q.6: The medicine makes me feel sick. 19 (19%) 76 (76%) 5 (5%) 0  
Q.7: We weren’t given enough information about the illness and 
treatment. 
19 (19%) 79 (79%) 2 (2%) 0  
Q.8: I have to take lots of medicine or many doses per day. 57 (57%) 40 (40%) 3 (3%) 0  
Q.9: I worry about what other people would think of me if they knew I 
took medicine. 
62 (62%) 37 (37%) 1 (1%) 0 
Q.10: I don’t need to take my medicine as my symptoms have gone. 25 (25%) 73 (73%) 2 (2%) 0 
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4.3.3  Facilitators to medicines adherence 
All questions exploring perceived facilitators to medicines adherence were 
answered by all participants except Q4 which was answered by 97 
participants (Table 4-5). 
The highest perceived facilitator of medicines adherence, as reported by 96 
(96%), was ‘I have good family support’. In addition, 81 (81%) agreed that 
‘I use a medicine reminder or routine about my medicine’, and 80 (80%) 
agreed that ‘We were given enough information about my illness and the 
importance of treatment’. Seventy-five percent of the participants ticked on 
“not certain” for Q7 ‘My doctor gives me medicine which taste ok’ and 
thirteen of them were on non-oral medicines as described previously (Table 
4-5). The remaining 34 participants were taking oral medicines. 
Fifteen participants ticked on “disagree” for ‘I have good knowledge about 
my disease and treatment’. Thirteen of these participants were with parents 

















Q.1: I use a medicine reminder or routine about my medicine (e.g. 
taking medicine before school). 
81 (81%) 19 (19%) 0 0 
Q.2: We were given enough information about my illness and the 
importance of treatment. 
80 (80%) 18 (18%) 2(2%) 0 
Q.3: I have good family support. 96 (96%) 4 (4%) 0 0 
Q.4: I have good knowledge about my disease and treatment. 76 (76%) 15 (15%) 6 (6%) 3(3%) 
Q.5: The doctor has prescribed medicine which can be taken once 
or twice a day. 
37 (37%) 41 (41%) 22 (22%) 0 
Q.6: My medicine schedule is quite simple. 33 (33%) 48 (48%) 19 (19%) 0 





4.3.4  Adherence rates 
Fifty-six patients took two medicines, 27 patients took one medicine, 14 
patients took three medicines and only three patients took four medicines 
(Appendix 5).  
All patients taking more than one medicine reported the same adherence 
rate to each medicine. In addition, the MPR percentages were the same for 
each medicine. 
Twenty-six parents reported the adherence rate for their children and 74 
children reported their own adherence rate. Adherence rates reported by 
parents were higher than those reported by children. The mean percentage 
of medicines adherence as reported by parents was 97.12, while the mean 
percentage as reported by children was 95.13.  
The mean percentage of medicines adherence as reported by the study 
population overall was higher than the mean percentage of medicines 
adherence measured by the MPR (Table 4-6). 
Table 4-6  Medicines adherence, as reported by the study population and 
measured by the MPR 
Medicines adherence [Min-Max] Mean ±SD 
Self-reported Adherence 70-100 95.41±8.63 
 
 






A score of ≥80% adherence was considered the cut-off for good medicines 
adherence. Based on the MPR 85 participants had good medicines 
adherence, while 15 participants had poor adherence. Based on the self-
report 91 participants had good medicines adherence, while nine 
participants had poor adherence.  
Two children (7.4% of children who took a single medicine) who took a 
single medicine displayed poor adherence (by MPR and self-report), while 
among children who took multiple medicines, seven children (9% of children 
who took multiple medicines) (self-report) and 13 children (18% of children 
who took multiple medicines) (MPR) displayed poor adherence. 
According to both adherence measures, 85 participants displayed good 
medicines adherence and nine participants displayed poor medicines 
adherence (Table 4-7). For six participants (four males and two females), 
the two measures showed conflicting medicines adherence ratings with 
good adherence being self-reported but the MPR showing poor adherence. 
These included two patients with asthma, one with end-stage renal disease, 
one with diabetes, one with epilepsy and one with anaemia. 
The Kappa test (κ) was run to determine whether there was an agreement 
between the two medicines adherence measures (self-reported vs. MPR). 
There was substantial agreement between the two medicine adherence 
measures, κ = 0.718, p<0.001. The confidence interval gives us 95% 
confidence that the true kappa falls between 0.509 and 0.928; in other 
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words, the agreement between the two methods was between moderate 
and almost perfect (Table 4-7). 
 
Table 4-7 Self-reported vs. MPR level of agreement of medicines 
adherence. 
 Medicine Possession 
ratio (MPR) 











<80% 9 0 9 
<0.001*** 0.509-0.928 
≥80% 6 85 91 
Total 15 85 100  











Most of the children had good medicines adherence (≥ 80%) across all 
diseases except asthma, where eight (47%) showed poor adherence by MPR 
and five of them (29.5%) showed poor adherence by MPR and self-report.  
Two of five patients with anaemia showed poor adherence when measured 
by MPR and one of them showed poor adherence when measured by self-
report and MPR.  
One of three patients with sickle cell anaemia showed poor adherence when 
measured by MPR and self-report.  
Five of six children with end-stage renal disease had good adherence by 
MPR, and all of them had good adherence by self-report.  
Children with diabetes, cancer, heart disease, and growth hormone (GH) 
deficiency had complete medicines adherence. Further details of adherence 
are displayed in Table 4-8.  
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Table 4-8. Distribution of children’s adherence to medicines by disease 















Epilepsy 3 (15.8%) 16 (84.2%) 2 (10.5%) 17 (89.5%) 
Asthma 8 (47.1%) 9 (52.9%) 5 (29.5%) 12 (70.5%) 
Diabetes 0 14 (100%) 0 14 (100%) 
Growth Hormone Deficiency 0 8 (100%) 0 8 (100%) 
Heart Disease 0 7 (100%) 0 7 (100%) 
End-Stage Renal disease 1 (16.7%) 5 (83.3%) 0 6 (100%) 
Anaemia 2 (40%) 3 (60%) 1 (20%) 4 (80%) 
Leukemia 0 4 (100%) 0 4 (100%) 
Psychiatric Disorder 0 3 (100%) 0 3 (100%) 
Gastrointestinal Disorder 0 3 (100%) 0 3 (100%) 
Sickle Cell Anaemia 1 (33.3%) 2 (66.7%) 1 (33.3%) 2 (66.7%) 
Cystic Fibrosis 0 3 (100%) 0 3 (100%) 
Hypothyroidism 0 3 (100%) 0 3 (100%) 
Hypertension 0 2 (100%) 0 2 (100%) 
Hyperactivity 0 1 (100%) 0 1 (100%) 
Haemophilia B 0 1 (100%) 0 1 (100%) 





4.3.5  Statistical analysis 
Table 4-9 shows the stratification of the study participants’ characteristics 
and their adherence to medicines as assessed by MPR. The only statistically 
significant association was that children whose parents had a university-
level education had good adherence measured by the MPR compared with 
children whose parents had a secondary-level education or less. Forty-nine 
children whose parents had a university-level education showed good 
adherence compared to only 36 children of parents with a secondary-level 
education or less (p = 0.007). There was no statistically significant 
association between age and gender with the MPR. However, a non-
significant result does not mean that there is no association. Our study was 
only powered to detect a difference of more than 18% in the adherence 
rates of the two exposure groups. The findings suggest that children who 
were adherent to medicines were younger than non-adherent children. 
Eighty-seven per cent of children aged < 10 years had good adherence to 
medicines, while almost 83% of children aged ≥ 10 years had good 
medicines adherence. Eighty-six per cent of females had good adherence 





Table 4-9 Stratification of the study participants’ characteristics and 















































6 (12.5%)  










9 (16%)  
6 (13.7%)  
 
0.735 
Level of Education ¥ 






12 (25%)  






Table 4-10 shows the stratification of the study participants’ characteristics 
and their adherence to their medicines as assessed by self-report. Again, 
only the children with parents with university-level education were 
significantly associated with good adherence when compared with children 
with parents with secondary-level education or less (p = 0.01).  
Again, there was no statistically significant association between age and 
gender with the reported adherence. The findings suggest similar results to 
those measured by the MPR (Table 4-9); younger children, females and 
children of parents with a university-level education had a higher adherence 
rate. Forty five  children aged <10 years had good adherence to medicines 
(21 parents reported their children’s adherence rate and 24 children 
reported their own adherence rate), while forty six children aged ≥10 years 
reported good medicines adherence (four parents reported their children’s 









Table 4-10. Stratification of the study participants’ characteristics and 
self-report adherence to medicine 













< 10 years 
≥ 10 years 
 













50 (89.3%)  
41 (93.2%)  
 
6 (10.7) 
3 (6.8%)  
 
0.499 
Level of Education ¥ 




51 (98.1%)  
 
8 (16.7%)  


















4.3.6  Barriers and facilitators to medicines adherence  
Questions Q2 to Q10 in the second part of our purpose designed 
questionnaire (Appendix 4) explored barriers and facilitators to medicines 
adherence in more detail. Four of these questions were open-ended 
questions (Q2a, Q2b, Q6 and Q10a) and the free text answers will be 
discussed later in the thematic analysis section. Appendix 5 shows a 
summary table with the gender, age, disease, medicines, adherence rates 
and BMQ results for each participant. 
The responses to these questions are summarised in Table 4-11. Most were 
answered by 99 participants, except Q5, which was answered by 97 
participants and Q10, which was answered by 95 participants  
Three questions about the barriers to medicines adherence from the first 
part of the questionnaire (Table 4-4 (Q1, Q8 and Q9)) were repeated to 
confirm the participants’ answers and to explore further details of these 
barriers. Only one question, which was about forgetfulness, received 
different answers to the same question in the first and second parts (Table 
4-4 and Table 4-11). Forty-five per cent of patients reported forgetting to 
take their medicines in the second part of the questionnaire, a lower 
percentage than that reported in the first part (Table 4-4 (Q1)) which was 
62%. This difference may have occurred because an answer of Yes to Q2 in 
the second part of the questionnaire would require the patient to answer an 
open-ended question. This open-ended question was at the end of the 
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questionnaire. Because participants often wanted to complete the 
questionnaire quickly, some patients may have answered No to finish more 
quickly. It has been reported that response rates are lower for longer 
questionnaires (313).    
The majority (77%) were worried about the side effects of the medicine, 
despite 76% not having experienced any side effects. One participant who 
had end-stage renal disease reported that he did not take his medicine 
because he was worried about the gastro-intestinal side effect of 
mycophenolate. Also, two participants reported that they did not take their 
medicines because they had experienced side effects. One experienced dry 
cough as a side effect of captopril and one experienced weakness and 
dizziness as side effects of levetiracetam.  
Thirty-four children were responsible for measuring and taking their 
medicines by themselves (31 of these children were aged ≥ 10 years, and 
three were aged < 10 years old) (Q5). The mean percentage of adherence 
rates by MPR when the children were responsible for taking their medicines 
was 94.02% with a range of 63%-100%, while the mean percentage of 
adherence rates by self-report was 96.2% (all adherence rates were 
reported by children) with a range of 75%-100%. 78.5% children with 
diabetes, 64.5% of children with asthma and 50% of children with GH 
deficiency were responsible for taking their medicines (Appendix 5). All 
patients with diabetes and GH deficiency showed good adherence rates (by 
MPR and self-reporting). However, eight patients with asthma showed poor 
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adherence rates by MPR, and five of the eight reported poor adherence rates 
(for four of these patients, their parents were responsible for administering 
the medicine and all of them showed poor adherence by the MPR and self-
report). Nineteen of the children responsible for measuring and taking their 
own medicine had parents with a university-level education, and all of them 
showed good adherence rates by MPR and self-reporting, while the other 
15 children had parents with a secondary-level or less education; six of the 
15 showed poor adherence by MPR and four of the 15 reported poor 
adherence rates (None of these were analysed statistically because the 
sample size was small). 
The mean adherence rate by MPR when the parents were responsible for 
measuring and administering medicine to their children was 90.78%, with 
a range of 50%-100%, while the mean percentage of self-reported 
adherence rates was 94.6% (26 parents reported the adherence rates and 
40 children reported the adherence rates) with a range of 70%-100%.  
Most participants who used medicines reminders had good adherence rates 








Table 4-11  Questions about barriers and facilitators to medicines adherence 
 Yes 
n (n%) 
No n (n%) Not 
answered n 
(n%) 
2. Do you ever forget to take your medicine? 
a. If so can you think of anything that makes this happen? 
 










3. Do you worry about side effects of any of your medicine? 
a. Does this ever put you off taking your medicines?      









4. Have you experienced side effects of any medicine? 
a. Did this ever put you off taking the medicines?   
    









5. Do you measure and take your medicine by yourself? 34 (34%) 63 (63%) 3 (3%) 
6. Is there anything that makes it harder for you to take your medicine? 
 
62 (62%) 37 (17%) 1 (1%) 
7. Do you ever feel concerned about taking your medicine when other people are around? 59 (59%) 40 (43%) 1 (1%) 
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8. Do you have any worries about the number of medicine doses that you need to take or the 
time of the doses? 










9. Do you have any worries about the size of tablets that you need to take or the taste of your 
medicine? 
a. Does this ever put you off taking your medicine? 
    











10. Have you tried or do you use any methods to help you with medicine taking? 
a. If yes, please describe them and how well they work. 







4.3.7  Thematic analysis  
Further information on barriers and facilitators to medicines adherence was 
explored in the study participants’ answers to open-ended questions in the 
second part of the questionnaire and shown in Table 4-11 (Q 2, Q6 and 
Q10). Questions 2a (answered by 41 participants) and Q6 (answered by 62 
participants) explored barriers to medicines adherence and Q2b (answered 
by 52 participants) and Q10a (answered by 60 participants) explored 
facilitators of medicines adherence.  
The participants’ answers about the barriers to medicines adherence were 
grouped into seven themes and the answers regarding the facilitators of 
medicines adherence were grouped into six themes (Table 4-12).  
Table 4-12 Barriers and facilitators themes. 
Barriers themes Facilitators themes 
Many doses each day Using reminder 
Changes in usual routine Established routine 
Feeling better so not needing 
medicines 
Masking poor taste/pain of 
medicine/big tablet 
Fear of stigma Family support 
Medicine difficult to take due to size, 
poor taste/smell/pain/device 
More acceptable medicinal product/ 
device provided 
Fear of side effects Medicines organiser 




A. Barriers to medicines adherence 
The study participants’ answers about the barriers to medicines adherence 
(Q2a and Q6 in Table 4-11) were grouped into seven themes and 17 
codes as shown in Table 4-13.  
Table 4-13 Barriers to medicines adherence as reported by study 
participants 
Barriers themes n Codes (n) 
1. Many doses each day 50 • Many doses each day (n= 24) 
• Many doses each day and multiple 
medicines (n=18) 
• Night doses (n=5) 
• Multiple medicines (n=3) 
2. Changes in usual 
routine 
33 • Changes in usual routine (n=17) 
• Not at home (n=11) 
• Forget at weekends (n=3) 
• Holiday/Travelling (n=2) 
3. Medicine difficult to take 
due to poor 
taste/smell/pain/device 
 
18 • Poor taste (n=12) 
• Painful injection (n=4) 
• Difficulty with inhaler devices 
(n=2) 
4. Fear of side effects 12 • Fear of side effects (n=12) 
5. Being busy  7 • Busy (n=5) 
• Rushing (n=2) 
6. Feeling better so not 
needing medicines 
3 • Feeling better so not needing 
medicines (n=3) 
 
7. Fear of stigma  2 • Embarrassed to take medicine in 
front of others (n=1) 
• Hates people knowing (n=1) 
 
Theme 1: Many doses each day 
This was the strongest theme reported by many participants (n = 50). This 
theme was reported by 36 children and 14 parents. This theme describes 
aspects of the dose frequency, which may affect medicine taking or 
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potentially hinder adherence. Fifty of the participants reported that many 
doses, multiple drugs or night doses made it hard for them to give or take 
their medicines. 
‘My medicines doses are too many because I need to take them every 
six hours, and sometimes I missed the night doses when I was 
sleeping’ (Child: 16-year-old boy, asthma, Q6). 
‘I have to take many doses every day’ (Child: 14-year-old boy, heart 
disease, Q6). 
‘Our child needs many doses every day, which may cause some doses 
to be forgotten sometimes’ (Mother: four-year-old girl, epilepsy, Q2a). 
Theme 2: Change in daily routine  
This theme describes how a change in daily routine may lead to forgetting, 
which affects medicine adherence (n = 33). This theme was reported by 17 
parents and 16 children. 
‘During the holiday time, I did not give my child her medicines as much 
as I should. We travel a lot, so our schedule was changing every day 
and sometimes we missed one or more doses’ (Mother: five-year-old 
girl, anaemia, Q6). 
‘Change in routine’ (Mother: three-year-old boy, anaemia Q2a). 
‘On weekends, we may go out and forgot to take the medicines with 
us’ (Mother: five-year-old girl, epilepsy, Q2a). 
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Theme 3: Medicine difficult to take due to poor 
taste/smell/pain/device 
This theme describes the effects of poor taste of medicines, pain caused by 
injections and difficulty with inhaler devices on medicine adherence (n = 
18). This theme was reported by seven children and 11 parents. All the 
participants who reported that the bad taste of the medicine made it hard 
for them to take their medicine belonged to the younger group (aged < 10 
years old). Some participants who reported poor taste showed poor 
adherence (five by MPR and three of them by self-report also). 
‘Some of her medicines taste badly, so we mix them with good 
flavoured juice’ (Mother: seven-year-old girl, epilepsy, Q10a).  
‘I take an insulin injection twice daily, and it is painful’ (Child: 16-year-
old boy, diabetes, Q6). 
‘I have to take 3 puffs of salbutamol every 4 hours/Difficulty with 
inhalers devices’ (Child: 14-year-old boy, asthma, Q6). 
Theme 4: Fear of side effects 
Some participants (n = 12) linked adherence with their concern about the 
expected side effects of the medicine. This theme describes that the 
participants’ fear of side effects made it hard for them to take their 
medicine. This theme was reported by three children aged ≥ 10 years old 
and nine parents. 
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‘I fear of steroids side effects’ (Child: 17-years-old girl, asthma, Q6).  
‘I have some concerns about the long effect of his medicine’ (Mother: 
five- year-old boy, GH deficiency, Q6).  
‘Possible side effects of his medicines’ (Mother: one-year-old boy, 
cancer, Q6). 
Theme 5: Being busy 
This theme describes the effect of children’s or parents’ preoccupation with 
other life matters on their medicine adherence (n = 7). This theme was 
reported only by parents. 
‘Busy with other children’ (Mother: five-year-old boy, diabetes, Q2a). 
‘Rushing in morning’ (Mother: seven-year-old boy, diabetes, Q2a). 
Theme 6: Feeling better so not needing medicines 
This theme describes that some of the participants felt their condition had 
improved, so they no longer needed to take their medicine (n = 3). This 
theme was reported by one child and two parents.  
“Sometimes, I felt that, I did not need to take my inhaler when asthma 
symptoms disappeared” (Child:15 years old girl, asthma, Q6).  
‘The biggest thing that made it hard to give him medicines was that 
when he felt better, he thought that he didn’t need his medicines 
anymore’ (Mother: 10-year-old boy, asthma, Q6). 
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‘Sometimes he refused to take his medicines because he thought that 
he felt better and didn’t need the medicines’ (Mother: nine-year-old 
boy, asthma, Q6). 
Theme 7: Fear of stigma 
This theme describes that some children fear being stigmatised because of 
their medicine, and this may affect their adherence (n = 2). Both 
participants who reported that a fear of being stigmatised made it hard for 
them to take their medicine were female. 
‘She hates people knowing about her medicines’ (Mother: eight-year-
old girl, epilepsy, Q6). 
‘Sometimes I ashamed to take my inhaler in front of my friends and 









B. Facilitators of medicines adherence 
The answers of the study participants (Q2b, Q10a in Table 4-11) regarding 
the facilitators of medicines adherence were grouped into six themes: and 
14 codes as shown in Table 4-14. 
Table 4-14 Facilitators of medicines adherence as reported by study 
participants 
Facilitators themes n Codes (n) 
1. Using reminders 56 • Phone alarm (n=31) 
• Writing notes (n=14) 
• Clock alarm (n=11) 
2. Established routine 29 • Established routine (n=18) 
• Taking medicine on waking 
and before sleeping (n=6) 
• Linking medicine taking with 
meals (n=5) 
 
3. Masking poor taste/pain of 
medicine/big tablet  
17 • Mix with drink (n=9) 
• Takes with drink (n=2) 
• Ice helps (n=2) 
• Mix with yoghurt (n=2) 
• Change injection site (n=2) 
 
4. Family support 8 • Family help/support (n=8)  
5. Medicines organiser 4 • Pillbox (n=4) 
 
6. More acceptable medicinal 
product/device provided 










Theme 1: Using reminders 
Fifty-six of the participants’ answers were grouped under the theme of 
using reminders, such as a phone alarm (n = 31), writing notes (n = 14) 
and an alarm clock’ (n = 11). This theme was reported by 29 children and 
27 parents. Most of these participants showed good adherence (55 by 
self-report and 53 by the MPR). 
‘We set a phone alarm to remind us of the time of doses’ (Father: 
three-year-old boy, epilepsy, Q10a). 
‘I use clock alarm to help me remember’ (Child: 10-year-old girl, lupus 
erythematous, Q2b).  
‘Writing notes to remember my medicines’ (Child: 13-year-old girl, 
asthma, Q10a).  
Theme 2: Established routine 
Twenty-nine of the participants’ answers were grouped under the theme of 
established routine. The participants reported that establishing a routine 
helped them remember to take their medicine. Four of these participants 
used medicine reminders with an established routine, and all of them 
showed good adherence by MPR and self-report. This theme was reported 
by 15 children and 14 parents. All participants who reported that they linked 
medicine taking with meals were diabetic patients. 
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‘It was easy to remember to take medicine when I link it with the meals 
times’ (Child: 18-year-old boy, diabetes, Q2b). 
‘I take my medicine when I wake up every morning’ (Child: 12-year-
old girl, hypothyroidism, Q2b). 
‘Set phone alarm and establish routine’ (Mother: five-year-old girl, 
epilepsy, Q2b). 
Theme 3: Masking poor taste/pain of medicine/big tablet 
Seventeen of the participants’ answers were grouped under the theme of 
masking the poor taste/pain of medicine. Thirteen participants reported that 
they mixed or took their medicine with juice, a drink or yoghurt to make its 
taste more acceptable. Four participants reported that they put ice on the 
injection site, or they changed the injection site to relieve injection pain. 
This theme was reported by one child and 16 parents. 
‘She did not like her medicine’s taste, and we mixed with juice’ 
(Mother: six-year-old boy, epilepsy, Q10a). 
‘We give her medicine with yoghurt’ (Mother: 11-year-old girl, sickle 
cell anaemia, Q10a). 
‘We put ice on the injection site to relieve the pain’ (Mother: 10-year-
old girl, GH deficiency, Q10a). 
‘Change injection site’ (Mother: seven-year-old boy, diabetes, Q10a). 
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Theme 4: Family support 
Eight of the participants’ answers were grouped under the theme of family 
support. The participants reported that family support was important for 
encouraging children to take their medicine. This theme was reported only 
by children. 
‘When I was first diagnosed, I had difficult times that I could not have 
overcome without my family’s support and help’ (Child: 16-year-old 
boy, end-stage renal disease, Q6). 
‘My family reminds me to take my medicine if I forgot it’ (Child: 14-
year-old girl, anaemia, Q2b). 
‘My mother reminds me to take my medicine’ (Child: 13-year-old girl, 
GORD, Q2b).  
Theme 5: Medicines organiser 
Four of the participants’ answers were grouped under the theme of 
medicines organiser. The participants reported that the use of an 
organisational tool, such as a pillbox, helped them organise multiple 
medicines by day and dose. This theme was reported by three children and 
one parent. 
‘With a pillbox, it became easy for us to organise our multiple medicines 
and doses’ (Mother: 10-year-old girl, cancer, Q10a). 




Theme 6: More acceptable medicinal product/device provided 
Only one participant reported that using a more acceptable medicinal device 
helped her with medicine taking. 
‘My doctor changed my insulin needle to new pen injection device which 



















4.3.8  Beliefs about Medicines Questionnaire (BMQ)  
All questions were answered by all 100 participants except Q3 and Q7 
answered by 99 participants and Q5 and Q6 answered by 98 participants. 
On the necessity scale (Q1, Q3, Q4, Q7 and Q10), Table 4-15 shows that 
82 participants agreed or strongly agreed that, ‘My health at present 
depends on my medicine’. Also, 81 participants agreed or strongly agreed 
that, ‘My medication protects me from becoming worse’.  
On the concern scale (Q2, Q5, Q6, Q8 and Q9), 76 participants agreed or 
strongly agreed that, ‘I sometimes worry about the long-term effects of my 
medication’. Furthermore, 61 participants agreed or strongly agreed that, 
‘I sometimes worry about becoming too dependent on my medication’. More 
than two-thirds of the participants disagreed or strongly disagreed that, ‘My 








Strongly Agree Agree Uncertain Disagree Strongly 
Disagree 
Q.1: My health at present depends on my medicine 34  48  8  7  3  
Q.2: Having to take medication worries me 8  36  21  33  2  
Q.3: My life would be impossible without my medication 27  28  20  20  4  
Q.4: Without my medication I would be very ill 26  37  17  16  4  
Q.5: I sometimes worry about the long-term effects of my 
medication 
18  58  6  14  2  
Q.6: My medication is a mystery to me 2  12  18  58  8  
Q.7: My health in the future will depend on my medication 18  38  24  16  3  
Q.8: My medication disrupts my life 5  29  19  41  6  
Q.9: I sometimes worry about becoming too dependent on 
my medication 
7  54  10  28  1  





Twenty-six parents and 74 children answered the BMQ. The mean necessity 
score of the parents was 19 and the mean concerns score was 13.6. The 
mean necessity score of the children was 17.2 and the mean concerns score 
was 15.45. Children appeared to have less necessity beliefs and more 
concern beliefs than parents (Table 4-16).    
Children with parents with secondary-level education or less appeared to 
have less necessity beliefs and more concern beliefs than children with 
parents with university-level education level (Table 4-16).     
Table 4-16 Mean BMQ necessity and concerns scales in different groups. 
 Mean BMQ 
necessity score 














Children with parents with 
university-level education  

















The mean necessity score of all the study population was 18 and the mean 
concerns score was 15. A positive mean necessity-concerns differential of 3 
was calculated. Most of the participants (74%) had a higher necessity than 
concern score and 26% had a higher concern than necessity score (Table 
4-17). 
The participant who had the highest positive differential score reported 
100% adherence rate by MPR and self-report and the participant who had 
the highest negative differential score reported 75% adherence rate and 
had 67% adherence rate by MPR. 
Table 4-17. Mean BMQ necessity and concerns scales 
 n [Min-Max] Mean ± SD 
BMQ Necessity Scale (mean 
±SD) 
100 [7-25] 18.00±4.25 
BMQ Concerns Scale (mean 
±SD) 
100 [5-25] 15.00±3.4 
Necessity-Concerns differential 
    Positive or equal differential  



















Table 4-18 shows that patients’ necessity beliefs about medicines exceeded 
their concerns in 67 participants with good adherence as assessed by MPR 
and seven participants with poor adherence. Eight patients with strong 
concern belief scores had poor adherence, six of them with asthma, one 
with epilepsy and one with diabetes.  
The chi-square test showed a statistically significant association between 
the BMQ differential score and the MPR (p = 0.009). This suggests a positive 
relationship between good medicines adherence and a positive BMQ 
differential score, where participants have greater belief in the necessity of 
taking medicines than concern about the medicines.  


















belief score (0* 
or positive 
differential) 
67 (90.5%) 7 (9.5%) 74 




18 (69.2%) 8 (30.8%) 26 
Total 85 15 100 






Table 4-19 shows that medicine necessity beliefs exceeded concerns in 70 
participants with good adherence to medicines as assessed by self-report 
and four participants with poor adherence. Five patients with higher concern 
belief scores had poor adherence, four with asthma and one with epilepsy. 
The chi-square test showed a statistically significant association between 
the BMQ differential score and the reported adherence rate (p = 0.034). 
This means there is a relationship between medicines adherence rates 
measured by self-report and the BMQ differential score. 





















belief score (0 
or positive 
differential) 







21 (80.8%) 5 (19.2%) 26 
Total 91 9 100 







As stated at the beginning of this chapter, from our systematic review 
(Chapter 3) we found only one study conducted in Saudi Arabia that 
explored the barriers to medicines adherence in children with epilepsy 
(177).  
The current study is the first to measure medicines adherence and to 
explore the barriers and facilitators in children with a variety of chronic 
diseases in Saudi Arabia. It demonstrated a substantial agreement between 
the two adherence measurement methods (self-report and the MPR). 
Furthermore, this study found a statistically significant association between 
the BMQ differential score and adherence rates. This suggests a positive 
relationship between good medicines adherence and a positive BMQ 
differential score, indicating that participants with a greater belief in the 
necessity of taking a medicine than concerns about the medicine are more 
likely to be adherent. 
We also found a statistically significant association between good adherence 
rates and the children of parents with a university-level education. 
No statistically significant associations between adherence rates and age 
and gender were found. 
Additionally, this study identified that many doses each day, changes in 





taste/smell, causing on pain on administration or difficult to use devices and 
fear of side effects were the most common barriers to medicines adherence.  
Using reminders, established routine for taking medicines, measures to 
address poor taste, pain caused by administration or taking big tablets and 
family support were the most common facilitators for medicines adherence 
in children.  
4.4.1  Adherence rates 
Patients with ≥ 80% adherence were defined as having good adherence and 
patients below that level as having poor adherence. This study showed that 
most participants displayed good medicines adherence using the two 
medicines adherence measures, self-reporting (95%) and the MPR (92%). 
This result is consistent with previous studies conducted in the UK, the USA, 
India, Sweden, Saudi Arabia and Thailand in which mean adherence rates 
were ≥ 80% among children with chronic diseases, including asthma, 
ADHD, epilepsy and HIV (81,87,177,230,246,249).  
This study also showed a substantial agreement between adherence 
measured by participants’ self-reports and the MPR (κ = 0.718). Similar to 
this result, Muller et al. conducted a study in South Africa with children with 
HIV and reported that there were no significant differences between 
adherence rates measured by self-report and MPR (p > 0.1) (120). 
However, in the current study, adherence rates measured by self-report 





previous studies conducted among children with thalassemia and chronic 
kidney disease (129,253). The high self-reported adherence rate may be 
the result of participants’ tending to provide socially desirable responses 
(314). 
In the current study the mean percentage of medicines adherence as 
reported by parents was slightly higher than the mean percentage reported 
by children. Parents appear to overestimate their children’s adherence to 
medicines, possibly to avoid being accused of failing to give their children 
their medicines as prescribed (31,37,118). In addition, in Goodfellow et al.’s 
(178) study with children with cystic fibrosis, they noted that the parents 
reported higher adherence rates than the children. They justified this by 
proposing that the parents may have thought their children had taken their 
medicine when they had not (178). 
Both methods were found to be inexpensive and easy to use, but they do 
not guarantee medicines’ taking/administration as highlighted in previous 
studies (120,129,132). 
The free education system in Saudi Arabia has encouraged Saudi people to 
continue their studies and obtain a high level of education (315,316). In 
addition, the Saudi government gives stipend to postgraduate students to 
help them with the cost of living (315). In this study, half of the children’s 
parents had a university degree, which reflects the support available from 





education. The adherence rate (measured by MPR and self-report) was 
significantly (p<0.05) associated with the level of parental education, 
meaning that good adherence was positively associated with a high parental 
education level. This result is consistent with reports in previous studies 
conducted with children in Jordan, Iran, US and Brazil 
(129,233,240,253,293). This finding suggests that parents with higher 
education levels are more likely to understand the necessity of adherence 
and the effects that poor adherence can potentially have on their child 
(240). 
4.4.2  Barriers to medicines adherence  
Many barriers to medicines adherence were identified from the quantitative 
and qualitative analyses in the current study.  
The quantitative results of this study reported that the top four perceived 
barriers to medicines adherence amongst children with chronic diseases in 
Saudi Arabia were ‘I worry about possible side effects’ as reported by 79 
(79%) of the participants followed by ‘I forget to take my medicine’ reported 
by 62 (62%). ‘I worry about what other people would think of me if they 
knew I took medicine’ was reported by 62 (62%) of patients and ‘I take lots 
of medicine or many doses per day’ reported by 57 (57%). Previous studies 
conducted in patients with IBD, epilepsy, asthma and HIV support these 
findings (167,177,196,240). For example, Gabr et al. found the primary 
reasons for poor adherence in patients with epilepsy in Saudi Arabia were a 





The qualitative results of this study reported that the most common barriers 
to medicines adherence were many doses each day, changes in daily 
routine, medicines being difficult to take due to large tablet size, poor 
taste/smell, causing on pain on administration or difficult to use devices and 
fear of side effects. Each barrier is discussed separately below. 
In this study, multiple drugs, doses and night doses were the most common 
reported barrier. These findings are supported by previous research 
(122,162,177,210,236,240,245). A study conducted in the USA with 
children with HIV reported that complexity of medicine regimen was 
significantly associated with poor adherence (p<0.05) (210). Two studies 
conducted in Australia and Iran with children with asthma found that taking 
many medicines at different times of the day may affect adherence to timing 
of the medicines’ administration, which could result in missed or delayed 
doses (122,240). Having to take multiple medicines a day or the same 
medicine multiple times a day is a barrier to many patients (122,240). In 
the current study, evening doses are seen as a separate barrier as children 
normally go to sleep earlier than most adults so taking their medicines at a 
late hour could affect their adherence.  
In this study, the answers reported by children and parents revealed that 
changing a daily routine (being outside the home, holidays/travelling) was 
the most common cause of forgetfulness. Likewise, previous studies showed 





poor adherence in patients with HIV, IBD, kidney diseases, asthma, cystic 
fibrosis, chronic rheumatic disease and diabetes 
(95,164,170,189,192,243,254,284,291). Everyday life activities have a 
large impact on whether patients take their medicines as prescribed (189). 
We could infer that parents, or perhaps even children, do not always follow 
a daily routine when taking medicine (243). 
The third most common barrier that reported by the participants in the 
current study was ‘medicine difficult to take due to poor 
taste/smell/pain/device’ (n = 18). Taste-masking is a major barrier to the 
development of medicines as oral liquid formulations (317). The bad taste 
of some medicines has been associated with poor medicines adherence in 
patients with ADHD, psychiatric disorders and kidney diseases 
(85,92,254,259). In the current study, some participants who reported poor 
taste showed poor adherence (three by self-report and five by MPR). 
Venables et al. found that the bad taste of medicine was significantly 
associated with medicine refusal in children and poor adherence (p<0.001) 
(92). Some evidence indicates that mixing the medicine with drinks or food 
to make the taste more acceptable may reduce the delivered dose and 
affect the effect of medicine (92). 
Fear of medicine side effects was the fourth most common barrier reported 
by 12 participants in the current study. Eight of them showed poor 
adherence by MPR and five of them showed poor adherence by self-report. 





effects is the reported reason for discontinuing daily medicine for patients 
with HIV, asthma, epilepsy, chronic rheumatic disease, tuberculosis and 
psychiatric disorders (70,85,193,196,197,240,254,270,288,292). This fear 
may greatly impact medicine adherence, especially if the patient believes it 
is not necessary to take their medicine (173,240).  
In our study, the BMQ was used to assess patients’ and parents’ beliefs 
about the necessity of medicines and concerns about their long-term use. 
Substantial evidence from children suffering a wide range of chronic 
diseases and their parents demonstrates that these beliefs have a major 
impact on adherence to medicines (68,81,126,173–176,178). Our study’s 
results revealed that most participants perceived the necessity of medicines 
outweighs concerns about their long-term use. Significantly, there was 
higher adherence among those with lower concern about their medicines 
use and with stronger beliefs in the necessity of medicines. Patients with 
negative necessity-concern differential scores were less adherent compared 
to patients with positive scores. These results are supported by several 
studies conducted in Saudi Arabia, the USA and Sweden among children 
with asthma, epilepsy and ADHD that found statistically significant 
associations between the BMQ differential score and the reported adherence 
rate (81,174,177). For example, Gabr et al. conducted a study involving 
children with epilepsy in Saudi Arabia using the BMQ and reported that 
patients who believed that medicines do more harm than good were less 





Overall, these results suggest that the BMQ differential score is a robust 
indicator of medicines adherence and shows that adherence in children may 
be influenced by their beliefs about their medicines.   
Our results showed that most children had good medicines adherence 
(≥80%) across all diseases except asthma, in which 47% of children 
showed poor adherence by MPR and 30% showed poor adherence by self-
report. Klok et al. measured adherence rates by EMD and found that 41% 
of asthmatic children demonstrated poor medicines adherence (68). Koster 
et al. measured adherence rate by self-report and concluded that 43% of 
children with asthma had poor medicines adherence (243).  
The low adherence rates of children with asthma could be explained by 
differences in asthma severity. Low severity of asthma together with low 
patients’ beliefs about the necessity of taking medicines and greater 
concern about medicines have been associated with poor medicines 
adherence (68,173,174). In our study, all patients with asthma who 
reported poor adherence had greater concerns about the medicines than 
their beliefs about the necessity of taking them. Several studies conducted 
with children with asthma and IBD found that children who experienced a 
reduction of symptoms may not take their medicines in order to avoid 
expected side effects (90,239,267). 
Our study suggested that when children were given full responsibility to 
take their medicines, they displayed a slightly higher adherence rate (94% 





(90% by MPR, 94% by self-report). Several studies similarly reported that 
when children with HIV and asthma were responsible for taking their 
medicines, they showed a higher adherence rate than children whose 
parents were responsible for administering the medicines to their children 
(69,196,199,240,249). This could be because when children are responsible 
for taking their medicines, they sense their importance and rely on 
themselves to take them, even in the absence of their parents (196,199). 
The transition of the responsibility to take medicines from parents to 
children is an important area and there are some points that it is suggested 
should be taken into account (61). Children must be aware of the 
importance of their medicines and how to use them (318). In addition, 
during this transition, it is recommended that parents and children have a 
discussion with their healthcare providers regarding medicines adherence 
and any factors that might affect adherence (61,318). If a child is not yet 
ready to take full responsibility, it is preferable for their parents to continue 
to support them until it is confirmed that the child has the ability to take 
responsibility for himself (61). 
4.4.3  Facilitators of medicines adherence  
Our study found that the most common perceived facilitator of medicines 
adherence, as reported by 96 (96%), was ‘I have good family support’. In 
addition, 81 (81%) agreed that ‘I use a medicine reminder or routine about 
my medicine’, and 80 (80%) agreed that ‘We were given enough 





only focused with children, having good family support was the highest 
rated facilitator as many children rely on their parents for help with their 
medicines’ administration.  
Additionally, as our systematic review (Chapter 3) suggested that 
forgetfulness is one of the most common barriers to adherence, setting 
reminders or a routine is a way to overcome this barrier, as it seems to 
highly be an effective facilitator. In our study most participants who used 
medicines reminders had good adherence (by MPR and self-report). 
Moreover, patients who are more aware of why they are taking their 
medicines and what effects they may experience if they do not take their 
prescribed medicines are more likely to have good adherence. 
The qualitative results of this study revealed the most commonly reported 
facilitator for medicines adherence was ‘using reminders’ such as setting 
alarms on phone or clock and making notes, which agrees with  findings 
from previous studies conducted with children with HIV, asthma, kidney 
disease, solid organ transplant and chronic diseases 
(70,85,87,91,122,189,193,241,243) and using these tools  was associated 
with good adherence (87,122,241,243). Using a phone or clock alarm was 
the most common technique among the current study’s participants to 
avoid forgetfulness, as it provides patients (or patients’ parents) with 





Another facilitator to medicines adherence reported by participants was 
established routine with the dose times. Twenty-nine participants reported 
that integrating medicine into daily routines (e.g., meals, morning, and 
bedtime) and taking medicine at a specific time each day helped them to 
avoid forgetfulness. Similarly, previous studies reported that using a 
scheduled routine corresponded to good adherence 
(70,87,91,122,189,193,241,243). Some participants in our study however, 
reported that having an established, scheduled routine is challenging when 
away from home and or when there are changes in daily routines.   
Medicines administered to children have different tastes and smells. 
Children may be hesitant to take bad-tasting medicines, or they may vomit 
or spit out the dose, resulting in an inappropriate use of medicines, because 
the child is not receiving the full dose. A bad drug taste has been extensively 
reported as a factor associated with poor medicines adherence 
(170,193,197,198,208,213,215,254). In this study, 13 participants’ 
answers were grouped under the ‘Masking poor taste’ (e.g., mixing 
medicine with water or juice, taking it with yoghurt or water). Masking the 
taste of medicines and parent counselling about a medicine’s flavour could 
have a positive impact on adherence.  El Rachidi et al. reported that 
techniques like using flavours and oral syringes for drug administration can 





4.4.4  Implications for practice 
Healthcare providers who are interested in medicine adherence should 
consider the difficulties faced by with children and their parents. Finding 
ways to flexibly address the various causes of non-adherence and 
empower children and their parents to honestly disclose their medicine 
adherence are essential.   
Children may have important opinions about their medicine; therefore, it 
is critical that healthcare providers address and include children when 
discussing matters related to medicines. 
The adherence measures of MPR and self-report used in this study were in 
substantial agreement, which suggests that both are reliable. Calculation 
of the MPR requires sufficient time and information from the patients’ 
records. Self-report is inexpensive and easy to use. Doctors could assess 
their patients’ medicine adherence in a short time by using a single 
question self-report. 
Children’s and parents’ beliefs about the necessity of medicine and their 
concerns about their use significantly impact their medicine adherence. To 
improve medicine adherence, healthcare professionals in Saudi Arabia can 
help develop patients’ and parents’ beliefs by explaining the importance of 






The BMQ differential score is a robust indicator of medicines adherence and 
suggests that adherence in children may be influenced by their beliefs 
regarding their medicines. It was easy for participants (parents and 
children) to answer the BMQ because of the options of available answers 
and answering the BMQ did not take a long time (from two to five minutes). 
These advantages may make the BMQ easy to use during medical 
appointments, while patients wait to meet with their healthcare providers. 
Alternatively, it may be better to send it to patients’ homes before 
appointments so that they can bring it with them already answered. 
4.4.5  Limitations  
There were some limitations to this study. We had sufficient statistical 
power to detect only quite large differences in adherence rates between 
exposure groups (e.g. differences greater than 18% of adherence rates 
between two different groups). Therefore, smaller differences would have 
been missed in this study. A larger sample size would be needed in future 
studies to detect smaller differences. 
In this study, we could not conduct statistical comparisons between sub-
groups (e.g. the medicine-taking responsibility of the child vs his/her 
parents) because the sub-group sample sizes were too small. However, 
we compared the adherence rates between these sub-groups by looking at 





differences between them. In future research, it would be interesting to 
conduct such comparisons by increasing the sample sizes.  
Neither adherence measure guaranteed that the patients actually took their 
medicines. For all patients who took more than one medicine they reported 
the same adherence rate to each medicine. Additionally, the MPR 
percentages were the same for each medicine. Some patients may have a 
different adherence rate for each medicine. Hence, further research is 
required to discover a method that can accurately measure medicines 
adherence in children and guarantee that patients took their medicine. 
In addition, while some patients refused to participate in our study, we did 
not document their numbers. We have no way to discern why they refused 
or whether they may be different from our sample in terms of adherence. 
In a future study, it would be useful to document the numbers of patients 
who refuse to participate and to explore their reasons for refusal if possible. 
 
4.5 Conclusions 
This study found good agreement between the two adherence 
measurements MPR and self-report. Parental education level and BMQ 
differential scores were found to be factors that were significantly 





The study has shown for most participants a positive necessity–concern 
differential, which indicates that these participants cared more about the 
necessity of administering medicines than the anticipated harm.  
The most common barriers to medicines adherence identified were many 
doses each day, changes in daily routine, medicine difficult to take due to 
poor taste/smell/pain/device and fear of side effects  and the most common 
facilitators were using reminders, established routine for taking medicines, 
masking poor taste/pain of medicine/big tablet and family support.  
This study was the first such study in children with chronic diseases in Saudi 
Arabia and its’ findings will add to the understanding of the barriers to and 
























Chapter 5: Exploratory study on the barriers and 
facilitators of medicines adherence in a UK 


















Our systematic review (Chapter 3) showed that twelve studies had been 
conducted in the United Kingdom 
(85,87,277,278,92,126,178,219,228,238,261,276) to explore the barriers 
and facilitators to medicines adherence in children, seven of which were 
conducted with patients with specific diseases: two with patients with HIV 
(219,228), two with patients with asthma (87,238), one with patients with 
psychiatric diseases (261), one with patients with epilepsy (126) and one 
with patients with cystic fibrosis (178). Only five studies were conducted 
with patients with diverse diseases (85,92,276–278). Four of the five 
studies with patients with diverse diseases did not address all barriers and 
facilitators to medicines adherence in children: three explored only 
formulation factors affecting adherence (92,276,278) and one explored only 
barriers to administering non-oral formulations in a paediatric population 
(277).  
Only one study addressed all barriers and facilitators to medicines 
adherence in children with diverse diseases (85). This study focused mainly 
on parental reporting rather than child reporting and excluded younger 
children and the parents of older children from discussions. It examined the 
barriers and facilitators of adherence only in four specific diseases including 
diabetes, asthma, epilepsy, and heart disease (85) and was conducted over 
ten years ago. This study suggested that future research should include the 





In our study, we proposed to take this work further by measuring medicines 
adherence and examining the barriers to and facilitators of medicines 
adherence in children by including all parents and all children in the 
discussions. We also recruited children with a wider variety of long-term 
conditions than had previously been studied.  
5.1.1  Aims 
Our study aims were to: 
• Measure medicines adherence in children with chronic diseases 
attending the Derbyshire Children’s Hospital in the UK. 
• Explore the barriers and facilitators to medicines adherence in these 
children. 
5.2 Method 
The study was approved by the NHS Health Research Authority (HRA) and 
Health and Care Research Wales (HCRW). It was also approved by the 
Research and Development (R&D) Department of the University Hospitals 
of Derby and Burton NHS Trust and was conducted in the Derbyshire 
Children’s Hospital in the UK (Appendix 6).  
As part of the approval processes the researcher completed a Research 






This study was conducted between 1 December 2019 and 18 January 2020 
at the Derbyshire Children’s Hospital, which provides healthcare for 94,000 
children annually (319).  
5.2.1  Inclusion criteria 
• Paediatric patients ≤ 18 years receiving long-term medicines who were 
inpatients or attending outpatient clinics at the Derbyshire Children’s 
Hospital.  
o If a child was too young to complete the questionnaires but was 
willing to take part then their parent would assist the child by 
completing the questionnaires in the child’s own words i.e. 
reading questions out to the child and writing the answers 
down.  
• Parents of children taking long-term medicines who were too young to 
provide their own opinions on the questionnaires. 
5.2.2  Exclusion criteria 
• Patients over 18 years old. 
• Patients/ Parents who were too distressed/ ill to approach. 
• Patients/ Parents who did not speak English or Arabic. 
5.2.3  Recruitment 
Participants were recruited from the waiting area of the outpatients’ clinics 





The researcher asked the nurses in the waiting area of the outpatients 
clinics and in the paediatric inpatient wards about which families would 
be suitable to approach in terms of the age of the patients, the medicines 
prescribed and the ability to speak English or Arabic.  
In compliance with the requirements of the NHS Health Research 
Authority to recruit participants, the researcher needed to be introduced 
to participants by a member of Trust staff. The researcher was therefore 
introduced to the participants by the clinic or ward nurses, the Chief 
Investigator (Sharon Conroy, Paediatric Pharmacist) or a nurse from our 
research group (Coral Smith) (also employed by the Trust). Participant 
information sheets and consent forms were available in English and Arabic 
(Appendix 3).  
After eligibility for inclusion in the study was confirmed by the Trust staff 
and the researcher had been introduced to the family, the patients and 
their parents or guardians were asked to participate in the study. They 
were provided with written and verbal information about the study in age-
appropriate language by the researcher (MA).  
In all cases, informed consent was obtained from the parent/legal guardian 
or the child if ≥16 years of age. The patients and parents were asked to 
answer the questions in the BMQ and our own designed questionnaire form 
(Appendices 3 and 4). The participants’ personal information was 
recorded on the consent forms only, and the researcher coded the 





participant’s consent form. Some participants expressed a preference to 
complete the questionnaires at home and for these participants, a stamped 
addressed envelope was provided to post the questionnaires back.   
We sought and received approval from the HRA, HCRW and the Trust R&D 
department) to view the patient’s Summary Care Records in order to find 
information on prescription refills so that we could calculate the Medication 
Possession Ratio (MPR). The researcher and the Chief Investigator viewed 
the initial patient’s Summary Care Records and found unfortunately that the 
information available in this was not enough to calculate the MPR. 
Therefore, the adherence rates in this study were assessed by self-report 
only.  
The questionnaires and consent forms were stored separately in locked 
facilities in the University Medical School. Data were entered on University 
password-protected computers and analysed using SPSS version 26. 
5.2.4  Justification of the questionnaires 
We used the same questionnaires as previously described and justified in 
the Saudi study in Chapter 4 (BMQ and our designed questionnaire). 
5.2.5  Thematic analysis 
As mentioned in Chapter 4, Braun and Clarke’s six-phases framework was 
followed to conduct thematic analysis of the free text data obtained from 





As a reliability measure, all the participants’ answers, codes and themes 
generated were checked and agreed between the Chief Investigator and the 
researcher. 
5.2.6  Statistical analysis 
As described in Chapter 4. 
5.2.7  Sample size and justification 
As described in Chapter 4. 
5.3 Results 
5.3.1  Demographic and clinical characteristics 
In total, 108 families were asked to join the study. Five parents did not 
consent to participate, with two of them saying that they did not have time 
and the other three not providing a reason. Four participants agreed to 
answer the questionnaires at home and post them back in the envelope 
provided, however only one of these participants returned their 
questionnaires to us.  
One hundred children/parents therefore participated in the study. Forty-
four children answered the questions themselves, 29 answered the 
questions with the help of their parents and 27 parents answered the 
questions for their children. Nine participants did not answer every 
question. This is described below for each section. 
Appendix 8 shows a summary table with the gender, age, disease, 





As explained in the last chapter, previous studies used the mean or median 
age as a cut-off point to compare two different age groups (older and 
younger age groups) (129,178,233). The mean age of the participants in 
our study was 10.03 ± 4.85 years (range: 1-18 years), and the median age 
was ten years. Therefore, ten years was chosen as the cut-off point to 
compare the two age groups. Fifty-six children (56%) were ≥ ten years of 
age and 44 (44%) were under 10 years of age. Fifty-three (53%) of the 
children were female. Slightly more than half of the children’s parents 
(54%) had a university or college education, and 46% had a secondary 
education. One-fifth of the study population (22%) had asthma, 12% had 
epilepsy and 10% had acne (Table 5-1). 
Table 5-1 Demographic and clinical characteristics of the study 
population (n = 100) 







   Male 




Level of Education 
   Secondary 

















Attention Deficit Hyperactivity Disorder 
Gastroesophageal reflux disease (GORD) 





















































5.3.2  Most common barriers to medicines adherence 
The answers to the first part of our purpose designed questionnaire are 
summarised in Table 5-2. All questions exploring perceived barriers to 
medicines adherence were answered by all participants except Q8 which 
was answered by 99 participants. 
The most frequently perceived barrier of medicines adherence was ‘I forget 
to take my medicine’ as reported by 52 (52%) of the participants. This was 
followed by ‘I worry about possible side effects’ reported by 50 (50%) and 
‘I have to take lots of medicine or many doses per day’ reported by 50 
(50%) (Table 5-2).  
Forty-seven participants ticked “agree” for ‘My medicine tasted bad’. Thirty-
nine of these participants were belonged to the younger age group. Twelve 
participants ticked “not certain” for ‘My medicine tasted bad’ (Table 5-2). 
Five of these participants were taking non-oral medicines; three participants 
with diabetes and one with GH deficiency were taking injections only, while 
one participant with GORD was taking medicines via a feeding tube 
(percutaneous endoscopic gastrostomy (PEG) tube). The other seven 
participants were taking oral medicines. 
Twenty-one participants ticked on “agree” for Q7 ‘I don’t know enough 
about the illness and treatment’. Nineteen of these participants were with 
















Q.1: I forget to take my medicine. 52 (52%) 46 (46%) 2 (1%) 0 
Q.2: My medicine tastes bad. 47(47%) 41 (41%) 12 (12%) * 0  
Q.3: I worry about possible side effects. 50 (50%) 45 (45%) 5 (5%) 0 
Q.4: I don’t have enough family support. 8 (8%) 91 (91%) 1 (1%) 0 
Q.5: I don’t know enough about the illness and treatment. 21 (21%) 71 (71%) 8 (8%) 0  
Q.6: The medicine makes me feel sick. 12 (12%) 78 (78%) 10 (10%) 0  
Q.7: We weren’t given enough information about the illness and 
treatment. 
10 (10%) 88 (88%) 2 (2%) 0  
Q.8: I have to take lots of medicine or many doses per day. 50 (50%) 43 (43%) 6 (6%) 1 (1%)  
Q.9: I worry about what other people would think of me if they knew I 
took medicine. 
24 (24%) 68 (68%) 8 (8%) 0 
Q.10: I don’t need to take my medicine as my symptoms have gone. 
 
6 (6%) 87 (87%) 7 (7%) 0 





5.3.3  Most common facilitators to medicines adherence 
All questions exploring perceived facilitators to medicines adherence were 
answered by all participants (Table 5-3). 
The highest perceived facilitator of medicines adherence, as reported by 94 
(94%), was ‘I have good family support’. In addition, 88 (88%) agreed that 
‘My medicine schedule is quite simple’, and 85 (85%) agreed that ‘The 
doctor has prescribed medicine which can be taken once or twice a day’ 
(Table 5-3). 
Thirteen participants ticked on “disagree” for ‘I have good knowledge about 
my disease and treatment’. All these participants were with parents with a 
secondary-education level. 
Twenty-eight participants ticked on “disagree” for ‘My doctor gives me 
medicine which taste ok’. Twenty-five of these participants were belonged 





















Q.1: I use a medicine reminder or routine about my medicine (e.g. 
taking medicine before school). 
60 (60%) 40 (40%) 0 0 
Q.2: We were given enough information about my illness and the 
importance of treatment. 
82 (82%) 13 (13%) 2(2%) 0 
Q.3: I have good family support. 94 (94%) 4 (4%) 2 (2%) 0 
Q.4: I have good knowledge about my disease and treatment. 75 (75%) 13 (13%) 12 (12%) 0 
Q.5: The doctor has prescribed medicine which can be taken once or 
twice a day. 
85 (85%) 11 (11%) 4 (4%) 0 
Q.6: My medicine schedule is quite simple. 88 (33%) 10 (48%) 2 (2%) 0 







5.3.4  Adherence rates 
Twenty-seven parents reported adherence rates for their children, and 73 
children reported their own adherence rates. The adherence rates reported 
by parents (89.62%) were almost the same as those reported by children 
(89.02%).  
Forty-four patients took one medicine, 37 took two medicines, 18 took three 
medicines and one patient took five medicines (Appendix 6). Most 
participants who took more than one medicine reported the same 
adherence rate to each medicine.  
Only 14 participants who took more than one medicine reported different 
adherence rates for each medicine; their adherence rates for the different 
medicines differed only slightly (Table 5-4). This group included seven 
participants (two with epilepsy, one with asthma, one with ADHD, one with 
acne, one with heart disease and one with end-stage renal disease), who 
reported (in their answers to Q4a) that the side effects they experienced 
deterred them from taking some of their medicines (Table 5-4).  
Among the other seven participants reporting different adherence rates for 
their different medicines (six with asthma and one with acne), five 
participants with asthma reported (in their answers to Q8a) that their 
complex medicine regimens, which involved many doses and night doses, 
put them off from taking their medicines. Additionally, one participant with 





that the size of the tablet or the taste of the medicine put them off from 
taking their medicines. 
Table 5-4 Adherence rate for 14 participants who took more than one 
medicine and reported different adherence rates. 








Atenolol, furosemide 80,90 (C) (good adherence) 
12 Epilepsy Sodium valproate, Carbamazepine 100,85 (C) (good adherence) 
9 Asthma Symbicort, Azithromycin 60,70 (C) (poor adherence) 
8 Asthma Salbutamol, Seretide 90,100 (C) (good adherence) 




Lisinopril, Prednisolone, Azathioprine 90,100,100 (C) (good adherence) 
14 ADHD Atomoxetine, Sertraline 90, 80 (C) (good adherence) 
14 Asthma Salbutamol, Montelukast 90,85 (C) (good adherence) 
4 Asthma Salbutamol, Seretide, Montelukast 80,100,90 (P) (good adherence) 
8 Asthma Salbutamol, Seretide, Montelukast 85,100,90 (C) (good adherence) 
7 Asthma Salbutamol, Desloratadine 80,90 (C) (good adherence) 
6 Epilepsy Sodium Valproate, Clobazam 100, 80 (P) (good adherence) 









The mean percentage of medicines adherence reported by the study 
population overall was 89.31% (range: 47-100). A score of ≥80% 
adherence was considered the cut-off for good medicines adherence as 
reported in several studies (68,160,161,178,292). Overall, 82 participants 
exhibited good medicines adherence, while 18 participants had poor 
medicines adherence based on their self-reported scores (Table 5-5).  
Table 5-5. Self-reported adherence rates 
 Participants n (n%) 
Poor adherence <80% 18 (18%) 
Good Adherence ≥80% 82 (82%) 
Total 100 (100%) 
 
Four participants with asthma, four with acne, two with constipation, two 
with GORD, two with epilepsy, one with ADHD, one with heart disease, one 
with psoriasis and one with diabetes showed poor adherence. Further details 



















Asthma 4 (18.1%) 18 (81.9%) 
Epilepsy 2 (16.6%) 10 (83.3%) 
Acne 4 (40%) 6 (60%) 
Constipation 2 (28.5%) 5 (71.5%) 
ADHD 1 (16.6%) 5 (83.3%) 
GORD 2 (40%) 3 (60%) 
End-Stage Renal disease 0 5 (100%) 
Autism 0 3 (100%) 
Heart disease 1 (33.3%) 2 (66.7%) 
Diabetes 1 (33.3%) 2 (66.7%) 
Eczema 0 3 (100%) 
Anaemia 0 3 (100%) 
IBD 0 2 (100%) 
Bronchitis 0 2 (100%) 
Cystic Fibrosis 0 1 (100%) 
Hypothyroidism 0 1 (100%) 
GH deficiency 0 1 (100%) 
Cystic fibrosis 0 1 (100%) 
Extreme Prematurity 0 1 (100%) 
Migraine 0 1 (100%) 
Nocturnal enuresis 0 1 (100%) 
Thalassemia 0 1 (100%) 
Pseudohypoaldosteronism 0 1 (100%) 
Psoriasis 1 (100%) 0 
Chronic urticaria 0 1 (100%) 
Scleroderma 0 1 (100%) 
Juvenile dermatomyositis 0 1 (100%) 
Chronic bullous disease of 
childhood 
0 1 (100%) 






5.3.5  Statistical analysis 
Table 5-7 shows the stratification of some of the study participants’ 
characteristics that affect their adherence to medicines. Almost 80% of 
children aged <10 years and almost 84% of children aged ≥10 years had 
good medicines adherence. Eighty-three per cent of females and almost 
81% of males had good adherence to medicines.  More children of parents 
with a university-level education adhered to their medicine compared to 
those with parents with a secondary education. There was no statistically 
significant association between age and gender (p>0.05) with the 
adherence rates. Only parental university-education was significantly 
associated with good adherence when compared with parental secondary-
level education (p=0.014). However, a non-significant result does not mean 
that there is no association. Our study was only powered to detect a 











Table 5-7 Stratification of the study participants’ characteristics and 
children’s adherence to medicine  

























< 10 years 
≥ 10 years 
 













38 (80.9%)  
44 (83%)  
 
9 (19.1%) 
9 (17%)  
 
0.778 






49 (90.7%)  
 
13 (28.3%)  







5.3.6 Barriers and facilitators to medicines adherence  
Questions Q2 to Q10 in the second part of our purpose-designed 
questionnaire explored further barriers and facilitators to medicines 
adherence. Four of these questions were open-ended questions (Q2a, Q2b, 
Q6 and Q10a) and the free text answers will be discussed later in the 
thematic analysis section. 
These questions are summarised in Table 5-8. Most questions were 
answered by each of the 100 participants, except Q4 and Q6, which were 
answered by 99 participants and Q3a, Q7 and Q10 which were answered by 
98 participants. 
Table 5-8 shows the percentages of participants who answered Yes or No 
and their answers to some open-ended questions (Q2, Q6 and Q10).  
Three questions about the barriers to medicines adherence already 
discussed in the first part of the questionnaire (Table 5-2) (Q1, Q8 and Q9) 
were repeated in the second part (Table 5-8) (Q2, Q3 and Q7) to confirm 
the participants’ answers and to explore further details about these barriers. 
No participants gave different answers to these questions in the different 
sections.  
The children reported forgetting their medicine (Q2) more than parents. 
Seventy-four per cent of children reported that they sometimes forgot to 
take their medicine, while 43% of parents reported that they sometimes 





Thirty-nine children were responsible for measuring and taking their 
medicine by themselves (Q5). Thirty-eight of them were aged ≥ 10 years 
and one aged < 10-years-old. The mean reported adherence rates when 
the children were responsible for measuring and administering their own 
medicines was 90.7%, with a range of 60%-100% (all adherence rates were 
reported by the children). Seven of the children responsible for measuring 
and administering their own medicine reported poor adherence. Three had 
acne, two had asthma, one had constipation and one had diabetes. Twenty-
five of the children responsible for measuring and taking their own medicine 
had parents with a university-level education, 24 of them reported good 
adherence and one reported poor adherence. The other 14 children had 
parents with a secondary-level education; six of them reported poor 
adherence.  
The mean adherence rate when the parents were responsible for measuring 
and administering medicines to their children was 88.4% with a range of 
47%-100% (adherence rate were reported by 34 children and 27 parents). 
Eleven of the children whose parents were responsible for measuring and 
administering their medicine reported poor adherence. Two of them had 
asthma, two had epilepsy, two had GORD, one had heart disease, one had 
constipation, one had ADHD, one had acne and one had psoriasis. 
Two participants reported that they stopped taking their medicines because 





that he did not take montelukast because of the large size of the tablet. 
Another participant with acne reported that he did not take doxycycline 





Table 5-8 Questions about barriers and facilitators to medicines adherence 







2. Do you ever forget to take your medicine? 
a. If so can you think of anything that makes this happen? 
 










3. Do you worry about side effects of any of your medicine? 
a. Does this ever put you off taking your medicines?  
     









4. Have you experienced side effects of any medicine? 
a. Did this ever put you off taking the medicines?   
    
b. If yes please write the name of the medicines causing side effects and what side 








5. Do you measure and take your medicine by yourself? 39 (39%) 61 (61%) 0 
6. Is there anything that makes it harder for you to take your medicine? 69 (69%) 30 (30%) 1 (1%) 
7. Do you ever feel concerned about taking your medicine when other people are around? 











8. Do you have any worries about the number of medicine doses that you need to take or 
the time of the doses? 










9. Do you have any worries about the size of tablets that you need to take or the taste of 
your medicine? 
a. Does this ever put you off taking your medicine? 
    











10. Have you tried or do you use any methods to help you with medicine taking? 
a. If yes, please describe them and how well they work. 
52 (52%) 
 









Half of the participants (50%) were worried about the side effects of the 
medicine, despite 75% not having experienced any side effects. Eight 
participants reported that experienced side effects put them off taking their 
medicines. For example, one participant who had psoriasis reported that he 
did not take adalimumab because he experienced migraines as a side effect. 
Additionally, one participant who had epilepsy reported that he did not take 
carbamazepine because he experienced weight gain and motor tics as side 
effects. Further details are shown in Table 5-9. These participants provided 
no further information about whether they refused to take the medicine or 
if it had been agreed with the doctor that it would no longer be prescribed. 
Table 5-9  Examples of experienced side effects. 
Age  Disease Medicine Experienced side effects 
8 Asthma Salbutamol Hallucination 
6 Epilepsy Clobazam Very tired 
14 ADHD Sertraline Feel sick and loss of appetite 
17 End stage renal disease Prednisolone Tiredness 
15 Psoriasis Adalimumab Migraine 
18 Acne Doxycycline Sickness 
12 Epilepsy Carbamazepine Weight gain and motor tics 








5.3.7  Thematic analysis  
Further information on barriers and facilitators to medicines adherence was 
explored in the study participants’ answers to the open-ended questions in 
the second part of our questionnaire (Table 5-8) (Q 2, Q6 and Q10). 
Questions 2a and Q6 explored barriers to medicines adherence and Q2b and 
Q10a explored facilitators of medicines adherence. The participants’ 
answers about the barriers to medicines adherence were grouped into ten 
themes and the answers regarding the facilitators of medicines adherence 
were grouped into seven themes (Table 5-10).  
 Table 5-10 Barriers and facilitators themes. 
Barriers themes Facilitators themes 
many doses each day using reminder 
changes in usual routine established routine 
feeling better so not needing 
medicines 
masking poor taste/pain of medicine/big 
tablet 
fear of stigma family support 
medicine difficult to take due to size, 
poor taste/smell/pain/device 
more acceptable medicinal product/ device 
provided 
fear of side effects medicines organiser 
feeling ill or tired more acceptable medicine route of 
administration 
complex manipulations needed  
autism symptoms and understanding  





A. Barriers to medicines adherence 
The study participants’ answers about the barriers to medicines adherence 
(Q2a and Q6 in Table 8) were grouped into ten themes and 21 codes as 
shown in Table 5-11.  
Table 5-11  Barriers to medicines adherence as reported by study 
participants 
Barriers themes n Codes (n) 
1. Medicine difficult to take due 
to size/ poor 
taste/smell/pain/device 
 
40 • Poor taste (n = 15) 
• Big tablet (n = 13) 
• Difficulty with inhaler devices (n 
=7) 
• Painful injection (n = 5) 
 
2. Many doses each day 36 • Many doses each day (n = 19)  
• Multiple medicines (n = 14) 
• Night doses (n = 3) 
3. Changes in usual routine 27 • Changes in usual routine (n = 
10) 
• Not at home (n = 9) 
• Holiday/Travelling (n = 6) 
• Forget at weekends N = 2) 
4. Being busy 20 • Busy (n = 13) 
• Rushing (n = 7) 
5. Feeling ill or tired  6 • Tired (n = 4) 
• Feeling sick (n = 2) 
6. Fear of side effects  5 • Fear of side effects (n = 5) 
7. Fear of stigma  2 • Embarrassed to take medicine in 
front of others (n =1) 
• Bullying with inhaler use (n =1) 
8. Feeling better so not needing 
medicines 
1 • Symptoms disappeared (n = 1) 
 
9. Complex manipulations 
needed 
 
1 • Dilution & small volume 
measurement (n = 1) 
 
10. Autism symptoms and 
understanding 
1 • Autism symptoms and 





Theme 1: Medicine difficult to take due to size/poor 
taste/smell/pain/device 
This was the most commonly mentioned theme reported by forty 
participants. This theme describes the effects of poor taste, tablet size, pain 
caused by the injection of medicine and difficulty with inhaler devices on 
medicines adherence. This theme was reported by 21 children and 19 
parents.  
All of the participants who reported that the bad taste of a medicine made 
it hard for them to take belonged to the younger group (<10 years old), 
except one child who was aged ≥10 years old. Out of this group, five 
participants had end-stage renal disease, three had epilepsy, three had 
GORD, two had acne, two had constipation and the remaining had other 
diseases. 
All participants who reported that the big size of a tablet or capsule was a 
barrier to taking their medicine belonged to the older group (≥ 10 years 
old), except three children aged < 10 years old.  
Five parents and two children reported that difficulty with inhaler devices 
made it harder for them to administer or take their medicine.  
Four children and one parent reported that pain caused by the injection of 
medicine made it harder for them to administer or take their medicine. 
‘Sometimes, he refuses to take the medicine because of its taste’ 





‘It is difficult to swallow a big pill’ (Child: 11-year-old girl, epilepsy, 
Q6). 
‘It is not easy to use inhalers’ (Child: 11-year-old boy, asthma, Q6). 
‘Thought of sting when injecting’ (Child: 15-year-old girl, psoriasis, 
Q6). 
Theme 2: Many doses each day 
This theme describes aspects of the dose frequency, which may affect 
medicine taking or potentially hinder adherence. Thirty-six of the 
participants reported that many doses, multiple drugs or night doses made 
it hard for them to give or take their medicines. This theme was reported 
by 23 children and 13 parents. Out of this group, nine participants had 
asthma, seven epilepsy, four acne, three end-stage renal disease, two 
diabetes and 11 other diseases.  
‘Baby was on Nifedipine, which needed dilution + small volume 
measuring + also Ranitidine, both 3 times daily, which was much 
harder’ (Mother: one-year-old boy, extremely premature, Q6). 
‘I might not wake up for the night doses’ (Child: 14-year-old girl, 
asthma, Q6). 
‘He takes more than one medicine several times every day’ (Mother: 






Theme 3: Change in usual routine  
This theme describes how a change in daily routine may lead to forgetting, 
which affects medicine adherence (n = 27). This theme was reported by 16 
parents and 11 children. 
‘I forget to take my medicines when I have to go out somewhere’ 
(Child: 17-year-old girl, acne, Q2a). 
‘Sometimes, I’m out of the house and don’t get back until after my 
scheduled time to take them so I end up forgetting’ (Child: 18-year-
old girl, diabetes, Q2a). 
‘Change of routine, e.g. weekend/holidays’ (Mother: three-year-old 
boy, asthma, Q2a). 
‘It was Christmas and we were out of routine’ (Child: 14-year-old boy, 
acne, Q2a). 
Theme 4: Being busy 
This theme describes the effect of children’s or parents’ preoccupation with 
other life matters on their medicine adherence (n = 20). This theme was 
reported 18 by parents and two children. 
‘Being late for school rushing’ (Mother: eight-year-old girl, asthma, 
Q2a). 





‘I forget at school, too busy with friends’ (Child: 16-year-old girl, acne, 
Q2a). 
Theme 5: Feeling ill or tired 
Six participants reported that feeling ill or tired made it hard for them to 
administer or take their medicine. This theme was reported by two parents 
and four children. 
‘When she was feeling sick’ (Mother: eight-year-old girl, asthma, Q6). 
‘When being tired’ (Child: 12-year-old girl, epilepsy, Q6). 
‘Overtired’ (Child: 15-year-old boy, epilepsy, Q2a). 
Theme 6: Fear of side effects 
Some participants (n = 6) linked medicine adherence with their concern 
about the expected side effects of the medicine. This theme describes that 
the participants’ fear of side effects made it hard for them to give or take 
their medicine. This theme was reported by two children and four parents. 
‘I worry about possible side effect of lamotrigine’ (Mother: seven-year-
old boy, epilepsy, Q6)  
‘Sometimes, I feel concern about the side effects of medications’ 
(Child: 14-year-old boy, asthma, Q6).  
‘My concern is about the effect of medicines on my child’ (Mother: Six-





Theme 7: Fear of stigma 
This theme describes that some children fear being stigmatised because 
their medicine, and this may affect their medicine adherence (n = 2). Both 
participants who reported that a fear of being stigmatised made it hard for 
them to administer or take their medicine were female. 
‘I feel embarrassed to take my medicines in front of others’ (Child: 18-
year-old girl, diabetes, Q6). 
‘At school, she was bullied by an older child who was laughing at her 
while she used her inhaler’ (Mother: eight-year-old girl, asthma, Q6). 
Theme 8: Feeling better so not needing medicines 
One participant reported that when the symptoms of her condition 
disappeared, it made it difficult for her to take her medicine because she 
felt her condition had improved, so she no longer needed to take her 
medicine (n = 1). This theme was reported by one child.  
‘When symptoms disappeared’ (Child: 11-year-old girl, asthma, Q6). 
Theme 9: Complex manipulations needed 
One mother reported that she had to perform complex manipulations to her 





‘Baby was on Nifedipine, which needed dilution + small volume 
measuring + also Ranitidine, both 3 times daily, which was much 
harder’ (Mother: one-year-old boy, extremely premature, Q6). 
Theme 10: Autism symptoms and understanding 
One mother reported that her child’s autism symptoms and difficulty in 
understanding the importance of the medicine made it hard for her to give 
him the medicine.  














B. Facilitators of medicines adherence 
The answers of the study participants (Q2b, Q10a in Table 5-9) regarding 
the facilitators of medicines adherence were grouped into seven themes and 
23 codes as shown in Table 5-12. 
Table 5-12 Facilitators of medicines adherence as reported by study 
participants 
Facilitators themes n Codes (n) 
1. Using reminders  58 • Phone alarm (n = 18) 
• Alarm (n = 16) 
• Using reminder (n = 10) 
• Writing notes (n = 10) 
• Using Alexa reminder (n = 2) 
• Using chart (n = 1) 
• Using iPad/iPod reminder (n = 1) 
2. Masking poor taste/pain of 
medicine/ big tablet 
25 • Mix with drink (n =10) 
• Mix with yoghurt (n = 4) 
• Dissolve in drink (n = 3) 
• Ice helps (n =2) 
• Takes with drink (n = 2) 
• Change injection site (n = 1) 
• Walk around after injections (n = 1) 
• Take medicine with milk and biscuit 
(n = 1) 
• Mix medicine with honey (n = 1) 
3. Family support 11 • Family help/support (n = 11) 
4. Established routine  9 • Established routine (n = 7) 
• Taking medicine on waking or before 
sleeping (n = 2) 
5. Medicine organiser 4 • Pillbox (n = 2) 
• Organiser box (n = 2) 
6. More acceptable medicinal 
product/device provided 
1 • Administered medicine via syringe (n 
= 1) 
7. More acceptable route of 
administration. 








Theme 1: Using reminders 
Fifty-eight of the participants’ answers were grouped under the theme of 
using reminders. This theme was reported by 25 children and 33 parents. 
In addition, this theme was reported by 21 children aged > 10 years and 
for 37 children aged ≤ 10 years (reported by four children and 33 parents). 
‘Chart to tick every day with rewards’ (Mother: five-year-old boy, 
kidney disease, Q2b). 
“Writing it on the calendar /reminder on the phone” (Child: 10-year-
old girl, asthma, Q2b). 
“an alarm/reminders or poster” (Child: 16-year-old boy, 
hyperthyroidism, Q2b). 
Theme 2: Masking poor taste/pain of medicine/big tablet 
Twenty-five of the participants’ answers were grouped under the theme of 
masking the poor taste/pain of medicine/big tablet. Twenty-one 
participants reported that they mixed, dissolve or take their medicine with 
juice, a drink, honey or yoghurt to make its taste more acceptable. Out of 
this group, five participants had asthma, three constipation, three anaemia, 






Four participants reported that they put ice on the injection site, or they 
changed the injection site to relieve injection pain. This theme was reported 
by nine children and 16 parents. 
‘I walk around after I injected the insulin’ (Child: 18-year-old girl, 
diabetes, Q10a). 
‘We crush the tablets into honey due to the taste’ (Child: 10-year-old 
girl, asthma, Q10a). 
‘Takes a fizzy drink to help make it go down’ (Child: 11-year-old girl, 
asthma, Q10a). 
Theme 3: Family support 
Eleven of the participants’ answers were grouped under the theme of family 
support. Family support has many meanings to different people. The 
participants explained what this meant to them, stating that their family 
supported them by reminding them what times to take their medicine, 
helping them to take their medicine, motivating them to take their medicine 
and rewarding them when they took their medicine as prescribed. This 
theme was reported by nine children and two parents. 
‘My family help me to take my medicines when I feel sick’ (Child: 16-





‘I give him a reward if he takes medicine’ (Mother: five-year-old boy, 
asthma, Q10a). 
‘By using clock alarm/telling my parents to remind me’ (Child: 11-year-
old boy, epilepsy, Q2b). 
Theme 4: Established routine 
Nine of the participants’ answers were grouped under the theme of 
established routine. The participants reported that establishing a routine 
helped them remember to take their medicine. Three of these participants 
used medicine reminders with an established routine, and all of them 
reported good adherence. This theme was reported by two children and 
seven parents.  
‘I made medicine taking a part of my routine’ (Child: 13-year-old girl, 
epilepsy, Q2b). 
‘I take my medicine same time daily’ (Child: 10-year-old boy, heart 
disease, Q2b).  
‘Phone /start routine’ (Mother: five-year-old boy, hyperactivity, Q2b). 
Theme 5: Medicines organiser 
Four of the participants’ answers were grouped under the theme of 





organisational tool such as a pillbox, helped them organise multiple 
medicines by day and dose. This theme was reported by four children. 
‘Using an organiser box (pillbox) to organise each day doses’ (Child: 
14-year-old boy, epilepsy, Q10a).  
‘I have a box labelled from Monday-Sunday filled with tablets’ (Child: 
16-year-old boy, hyperthyroidism, Q10a). 
Theme 6: More acceptable medicinal product/device provided 
Only one participant reported that using more acceptable medicinal device 
helped them with medicine taking. 
‘Liquid medication via syringe’ (Mother: one-year-old girl, epilepsy, 
Q10a). 
Theme 7: More acceptable route of administration 
Only one participant reported that giving medicines via a more acceptable 
route of administration helped them with medicine-taking. 
‘We give them via a PEG (feeding tube) – makes it easier – It’s less 









5.3.8  Questionnaire (BMQ) 
As described in Chapter 4, the BMQ aims to assess patient’s worries and 
beliefs about medicines (42,307). A differential score between necessity 
and concern is calculated by subtracting the results of the concern scores 
from those of the necessity scores. Therefore, a negative score indicates 
stronger concerns about the consequences of the medicine than beliefs in 
the necessity of taking the medicine.  By contrast, a positive differential 
score indicates stronger beliefs in the necessity of taking the medicine (42). 
All questions were answered by all 100 participants.  
On the necessity scale (Q1, Q3, Q4, Q7 and Q10), Table 5-13 shows that 
83 participants agreed or strongly agreed that, ‘My medication protects me 
from becoming worse’. Also, 66 participants agreed or strongly agreed that, 
‘My health at present depends on my medicine’.  
On the concern scale (Q2, Q5, Q6, Q8 and Q9), 45 participants agreed or 
strongly agreed that, ‘I sometimes worry about the long-term effects of my 
medication’. Furthermore, 33 participants agreed or strongly agreed that, 
‘I sometimes worry about becoming too dependent on my medication’. On 
the other hand, 44 disagreed/strongly disagreed that, ‘I sometimes worry 
about becoming too dependent on my medication’, which means more 
participants understood the need for adhering to their medicines and 
disagreed with being concerned about becoming dependent on them. More 
than two-thirds of the participants disagreed or strongly disagreed that, ‘My 






Table 5-13  Beliefs about Medicines among participants. 
 
 
 Strongly Agree Agree Uncertain Disagree Strongly 
Disagree 
Q.1: My health at present depends on my medicine 29  37  22 9  3  
Q.2: Having to take medication worries me 7  18  13  41  21  
Q.3: My life would be impossible without my medication 15 26  29  24  6 
Q.4: Without my medication I would be very ill 20  26  28  18  8 
Q.5: I sometimes worry about the long-term effects of my 
medication 
16  29 13 26  16  
Q.6: My medication is a mystery to me 5 13 22  44  16 
Q.7: My health in the future will depend on my medication 21  30  29 15  5 
Q.8: My medication disrupts my life 5  19  12  42  22  
Q.9: I sometimes worry about becoming too dependent on my 
medication 
11 22  23  31  13 





Twenty-seven parents and 73 children answered the BMQ.  Parents had 
slightly lower necessity scores and slightly higher concern scores than 
children (Table 5-14).  The children aged ≥ 10 years had slightly higher 
necessity scores and slightly higher concern scores than children aged <10 
years. The children with parents with secondary-level education had slightly 
lower necessity scores and slightly higher concern scores than children with 
parents with university-level education (Table 5-14).    
Table 5-14 Mean BMQ necessity and concerns scales in different groups. 
 Mean BMQ 
necessity score 














Children with parents with 
university-level education  



















The mean necessity score of all the study population was 18 and the mean 
concerns score was 13. A positive mean necessity-concerns differential of 5 
was calculated. Most of the participants (81%) had a higher necessity than 
concern score and 19% had a higher concern than necessity score (Table 
5-15). 
The participant who had the highest positive differential score reported 
100% adherence rate, and the participant who had the highest negative 
differential score reported a 60% adherence rate. 
Table 5-15. Mean BMQ necessity and concerns scales 
 n [Min-Max] Mean ± SD 
BMQ Necessity Scale  
 
100 8-25 18±4.25 
BMQ Concerns Scale  100 5-23 13±4.66 
Necessity-Concerns differential 
























Table 5-16 shows that participants’ necessity beliefs about medicines 
exceeded concerns in 74 participants with good adherence and seven 
participants with poor adherence. Eleven participants with strong concern 
belief scores (negative differential) reported poor adherence, three of them 
with asthma, two with constipation, two with GORD, two with acne, one 
with epilepsy, and one with diabetes. 
Eight participants had experienced side effects of their medicines; six of 
them reported poor adherence rates and had higher concerns than 
necessity score. The other two participants reported poor adherence rates 
despite having a higher necessity than concern score. 
The chi-square test showed a statistically significant association between 
the BMQ differential score and the self-reported medicines adherence rate 
(p = 0.0001). This suggests that there is a relationship between self-
reported medicines adherence rates and the BMQ differential score. For 
example, there seems to be a positive relationship between good medicines 
adherence and a positive BMQ differential score, by which participants have 
greater belief in the necessity of taking the medicine than concern about 


























Higher necessity belief 
score (0* or positive 
differential) 
74 (91.4%) 7 (8.6%) 81 
0.0001*** 
Higher concern belief 
score (Negative 
differential 
8 (42.1%) 11 (57.9%) 19 
Total 82 18 100 



















As mentioned at the beginning of this chapter, from our systematic review 
(Chapter 3), we found that only one study (the TABS study (85)) explored 
all barriers and facilitators to medicine adherence in children suffering from 
a wide diversity of diseases in the UK (85). This study reported that parents 
appeared to lack confidence in trusting their children to take responsibility 
for taking medicines, that schools provided good support to optimise 
medicine use and that the most common barriers to medicine adherence 
appear to be related to forgetfulness and routine, rather than stigma or side 
effects (85). It examined the barriers and facilitators of adherence only in 
four specific diseases including diabetes, asthma, epilepsy, and heart 
disease (85) and was conducted over ten years ago. This study suggested 
that future research should include the parents of older patients and also 
younger patients in the discussion (85). 
Our study took this work further by including all parents and all children in 
the discussion and recruiting children with a wider variety of long-term 
conditions than have previously been studied. 
This study is the first to use the BMQ with children with a diversity of 
diseases in the UK. Specifically, it revealed that there was a statistically 
significant association between the BMQ differential score and adherence 
rates. This suggests a positive relationship between medicines adherence 





necessity of taking medicines are greater than their concerns about the 
medicine are more likely to be adherent.  
In addition, this study is also the first in the UK to explore the relationship 
between adherence rates in children and the education level of their 
parents. Notably, it was found that there was also a statistically significant 
association between adherence rates and parents having university-level 
education, but there were no statistically significant associations between 
good adherence rates, age and gender. 
We also identified that medicines being difficult to take due to large tablet 
size, poor taste/smell, causing on pain on administration or difficult to use 
devices; requiring many doses each day plus changes in usual routine and 
being busy were the most common barriers to medicines adherence. In 
addition, this study identified that using reminders or measures to address 
poor taste, pain caused by administration or taking big tablets, family 
support, and following a scheduled routine for taking medicines were the 
most common facilitators for medicines adherence in children.  
5.4.1 Adherence rates 
Patients reporting ≥ 80% adherence were defined as having good 
adherence, and patients below that level were defined as having poor 
adherence. Most of our participants (89.3%) self-reported good medicines 
adherence. This result is consistent with previous studies in which the mean 
adherence rates was ≥80% among children with chronic diseases, including 





In our study, 80% of children aged <10 years reported good adherence to 
medicines, while 84% of children aged ≥10 years reported good medicines 
adherence, the difference was very small. Some studies however have 
found larger differences in adherence rates between younger and older 
children with HIV and asthma where adherence rates were also measured 
by self-report (69,199,240,249). The difference in the adherence rates 
between young and old children may be due to most younger children being 
fully dependent on their parents to take their medicines as they do not have 
the cognitive understanding or physical capacity to take their medicines by 
themselves (69). In addition, younger children who are usually reminded 
by their parents to take their medicines may forget about their doses when 
their parents or caregivers are absent or busy (199).   
In our study, 54% of the children’s parents had a university education, 
which represents a high level of education. Based on the report from the 
Office for National Statistics analysis data from July 2017 to September 
2017, 42% of the population aged between 21 to 64 years in the UK who 
were not enrolled in any educational course were university graduates 
(320), which is a little lower than the percentage found in this study 
suggesting that our participant parents were quite highly educated overall. 
Children whose parents had a university education were significantly more 
likely to have good adherence compared with children whose parents had a 
secondary-level education (p=0.014), meaning that good adherence may 





consistent with reports in previous studies (129,233,240,253,293). In 
addition, our study suggested that the mean necessity score for children 
with parents with a secondary-level education was less than that for 
children with parents with a university-level education. Also, the mean 
concerns of children with parents with a secondary-level education was 
higher than those for children with parents with university-level education.  
Most of our participants believed the necessity of medicines outweighed 
their concerns about long-term use with a statistically significant positive 
association between the BMQ differential score and the self-reported 
medicines adherence rate. These results are paralleled by those of several 
studies conducted in Saudi Arabia, the USA and Sweden among children 
with asthma, epilepsy and ADHD that also found a statistically significant 
association between the BMQ differential score and  self-reported adherence 
rates (81,174,177). Overall, these results suggest that the BMQ differential 
score is a robust indicator of medicines adherence and that adherence in 
children may be influenced by their beliefs regarding their medicines.  
5.4.2  Barriers to medicines adherence  
The quantitative results of this study illustrated that the most frequently 
perceived barrier of medicines adherence was ‘I forgot to take my medicine’ 
as reported by 52 (52%) of the participants. Children reported forgetting 
their medicine more than parents. Elliott et al. conducted a study with 





forgetting more than their parents and suggested that parents may have 
tended to provide the more socially desirable answer (85). Forgetting may 
have more of an impact with children who depend on themselves to take 
their medicine. Some children stated that they were more likely to forget 
their morning dose because they were rushing to school (85). Moreover, a 
study that assessed 19 potential barriers to medicines adherence in HIV-
infected children showed that 41% of children and 33% of caregivers 
reported that forgetting was the main reason for non-adherence (61).  This 
finding suggests that even in severe diseases, forgetting affects the rate of 
medicines adherence. 
The qualitative results of this study reported that the most common barriers 
to medicines adherence were medicines being difficult to take due to large 
tablet size, poor taste/smell, causing on pain on administration or difficult 
to use devices, many doses each day, changes in usual routine and being 
busy. Each barrier is discussed separately below. 
Most of our participants who reported that the bad taste of the medicine 
made it hard for them to take belonged to the younger group (<10 years 
old). This may be because oral liquid formulations are the preferred and 
most frequently used form for many younger children (76). Previous studies 
with patients with ADHD, psychiatric disorders and kidney diseases reported 
that the bad taste  of some medicines was associated with poor medicines 





children with chronic disease in the UK and reported that good adherence 
was associated with a positive response to medicine taste and conversely 
poor adherence was associated with a negative response (276). Some 
children refuse to take medicines that have a bad taste or may vomit or spit 
out some of the dose (58). Bad-tasting medicines also discourage younger 
children from willingly taking their prescribed medicine, increasing non-
adherence (85,92,254,259). Some evidence indicates that mixing 
medicines with drinks or food to make the taste more acceptable may 
reduce the delivered dose and affect the effect of medicine (92).  
In our study, the large size of tablets/capsules was reported as a barrier by 
13 participants, most of who were older children. Previous studies with 
patients with epilepsy and IBD also reported that poor adherence to 
treatment was associated with a large pill size (266,268,273,274). The 
ability of children to swallow capsules or tablets depends on the size of these 
tablets and the age of the child (321). Some patients who have difficulty 
swallowing large tablets may have to crush the tablet or open the capsule 
and dissolve it in a drink, which may affect the actual dose of the medicine 
delivered (322). 
In our study, multiple drugs, doses and night doses were the second most 
common reported barrier. These findings are supported by previous 
research (122,162,177,236,240,245,276,303). Multidrug treatment or 





missed (276,303). A study conducted with children with chronic diseases 
found that 82% of children who took two or less different medicines each 
week were adherent, while 73% of children who took three or more different 
medicines each week were non-adherent (276). Previous studies conducted 
with children with chronic disease, epilepsy and asthma reported that when 
the number of medicines prescribed increases or when changes in the 
administration schedule are made, the possibility that medicines or doses 
are missed increases, leading to poor adherence (177,236,276). In general, 
a simpler regime reduces confusion, is more easily understood, and 
facilitates adherence (276). In our study, evening doses were seen as a 
barrier as most of the children were used to taking their medicine before 
going to sleep, in cases where they returned home late, children often went 
to sleep, forgetting to take their medicine (85). 
Another common reported barrier in the current study was being busy and 
rushing. This factor was particularly noticed in children who were dependent 
on their parents to measure and administer their medicine. The findings of 
some previous studies conducted with children with asthma and HIV were 
consistent with those of our study, reporting that parents being busy was a 
barrier to adherence (122,192,199,245). In addition, some participants in 
the current study reported that their children being busy was a barrier to 
adherence. The preoccupation of some children with other matters is a 






Some of our participants reported that experiencing side effects put them 
off taking their medicines. Smith et al. reported that poor adherence in 
children with epilepsy was significantly associated with experiencing side 
effects (190). In addition, previous studies conducted with children with 
tuberculosis, ADHD, HIV, IBD, multiple sclerosis and cancer also found that 
experiencing side effects was a reason for poor adherence  
(81,226,267,287,296). The experience of side effects may greatly impact 
medicines adherence, especially if the patient believes it is not necessary 
to take their medicine (81). Of the eight patients who experienced side 
effects in our study, six reported poor adherence rates and had a higher 
concerns than necessity score. Emilsson et al. reported that children with 
ADHD who experienced fewer side effects, who had a higher necessity 
score, and who had a lower concern score on the BMQ were more likely to 










5.4.3  Facilitators of medicines adherence  
The quantitative results of our study showed that the highest perceived 
facilitator of medicines adherence, as reported by 94 (94%), was ‘I have 
good family support’. Family support has many meanings to different 
people. The participants in the current study explained what this meant to 
them, stating that their family supported them by reminding them what 
times to take their medicine, helping them to take their medicine, 
motivating them to take their medicine and rewarding them when they took 
their medicine as prescribed. Previous studies conducted with children with 
psychiatric disorders, asthma, HIV and sickle cell disease support this 
finding (86,90,261,281). Klitzman et al. conducted a study with children 
with sickle cell disease in the USA and reported that family support was 
associated with good adherence (p<0.05) (281). In addition, low family 
support and a lack of adult support tends to be a barrier to medicines 
adherence, as the children can feel uncared for and thus not recognise the 
need for adherence (211,224,285). 
The qualitative results of our study revealed the most commonly reported 
facilitator for medicines adherence was ‘using reminders’. Fifty-eight 
participants reported that they used tools such as setting an alarm on a 
phone and writing notes. Such tools have also been reported as facilitators 
in previous studies (70,87,91,122,189,193,241,243), and have been 





alarm was the most common technique among our study participants to 
avoid forgetfulness, as it provided patients (or patients’ parents) with 
automatic reminders to take their medicines. Although there are many new 
smartphone reminder applications, the use of either a phone or clock alarm 
is a more commonly used technique among patients to remember their 
medicines (323). 
A medicine tasting bad has been extensively reported as a factor associated 
with poor medicines adherence (170,193,197,198,208,213,215,254). As 
discussed previously in Chapter 4, children may be hesitant to take bad-
tasting medicines, or they may vomit or spit out the dose, resulting in an 
inappropriate use of medicines, because the child is not receiving the full 
dose. In this study, 25 participants’ answers were grouped under the 
‘masking poor taste/pain of medicines/big tablet’ (e.g., mixing medicine 
with water or juice, taking it with yoghurt or water). Masking the taste of 
medicines and parent counselling about a medicine’s flavour may have a 
positive impact on adherence. Some techniques such as using flavours and 
oral syringes for drug administration can conceal or minimise an unpleasant 
taste (58). In the current study one mother reported that using an oral 






5.4.4 Implications for practice 
Finding ways to flexibly identify and address the various causes of non-
adherence and to empower children and their parents to honestly disclose 
their challenges with medicines adherence is essential. Healthcare providers 
should be aware of the importance of talking to both children and their 
parents when discussing matters related to medicines and not neglect the 
child. 
The bad taste of medicine was reported by some participants in this study 
as a barrier to adherence. Careful consideration of alternatives available by 
the healthcare provider (by asking the patient if they prefer a particular 
flavour if it is available) may be helpful as may lobbying of pharmaceutical 
companies to carefully consider the taste of medicines. 
Although medicines adherence rates in this study was high for most 
participants, some demonstrated low adherence. Healthcare providers 
should consider assessing their patients’ medicines adherence over a short 
time period by using a single question self-report. 
Children’s and parents’ beliefs about the necessity of medicines and their 
concerns about their use significantly impact their medicines adherence. To 
improve medicines adherence, Healthcare professionals could help to 
develop patients’ and parents’ beliefs by explaining the importance of the 





It is useful for healthcare providers to be aware that parents may have low 
education levels and ensure that they explain the treatment and the 
importance of adherence in suitable language adjusted to the child and 
parents’ capacity to understand. 
The BMQ differential score is a robust indicator of medicines adherence and 
that adherence in children may be influenced by their beliefs regarding their 
medicines. It was easy for participants (parents and children) to answer the 
BMQ because of the options of available answers. In addition, answering 
the BMQ did not take a long time (from two to five minutes). These 
advantages may make the BMQ easy to use during medical appointments, 
while patients wait to meet with their healthcare providers. Alternatively, it 
may be better to send it to the patient’s home before the appointment and 
for them to bring it already completed. 
5.4.5  Limitations 
There were some limitations to this study. We had sufficient statistical 
power to only detect differences greater than 18% adherence between two 
different groups, therefore, smaller differences would have been missed. A 
larger sample size would be needed in future studies to detect smaller 
differences.  
We proposed to measure adherence rates by self-report and MPR. The 
researcher and the Chief Investigator viewed the initial patient’s Summary 





was not enough to calculate the MPR. Therefore, the adherence rates in this 
study were assessed by self-report only. 
We were unable to conduct statistical comparisons between sub-groups 
(such as medicines taking responsibility of child vs parents) because the 
sub-group sample sizes were too small. In future research, it would be 
interesting to conduct such comparisons by increasing sample sizes. 
Although we were able to recruit participants with a good variety of 
conditions (22 different conditions), it was difficult to recruit diabetic 
patients as they and their parents were too busy filling in pre-appointment 
forms. Diabetic patients represent a large proportion of children with 
chronic disease and may have barriers and facilitators of adherence that are 
somewhat different from others. 
In addition, some patients refused to participate in our study. We have no 













In this study, parents’ education level and BMQ differential scores were 
found to be factors that were significantly associated with medicines 
adherence rates as measured by self-report.  
A number of factors such as medicines being difficult to take due to size, 
poor taste/smell, causing pain or a difficult to use device together with the 
need for many doses each day, changes in usual routine and being busy 
were seen to be the most common barriers to medicines adherence.  
Using reminders or finding ways measures to address poor taste or big 
tablets and pain caused by administration together with family support and 
following a scheduled routine for taking medicines were the most common 
facilitators for medicines adherence in children. 
Involving patients and their parents in discussions about medicines and 
their importance and trying to alleviate concerns about potential harm 




















Chapter 6: Barriers to and facilitators of 
medicines adherence in children with diverse 












In Chapter 3 we described a systematic review of the barriers to and 
facilitators of medicines adherence in children that we had conducted. We 
found six studies conducted involving children with diverse diseases. Three 
of these studies explored only formulation factors affecting adherence 
(92,276,278), one identified predictors of non-adherence based on an 
electronic prescription record (162) and one explored only barriers to 
administering non-oral formulations in a paediatric population (277). Only 
one study (TABS study) explored all potential barriers to and facilitators of 
medicines adherence in children with diverse diseases (85). 
In addition, we have conducted two new studies to explore the barriers to 
and facilitators of medicines adherence in children with diverse diseases in 
Saudi Arabia and the UK (Chapters 4 and 5). The aim of this chapter is to 
pull together the information from these eight studies and summarise 
current knowledge about barriers to and facilitators of medicines adherence 
in children with diverse diseases. 
6.2 Methods 
6.2.1  Saudi and UK studies (Chapters 4 and 5) – Key differences 
In both countries, recruitment was carried out as previously described. In 
Saudi Arabia however, it was easy to recruit children with different diseases, 
and there were no obstacles related to any particular disease, whilst in the 





their parents were too busy completing pre-appointment information and 
other study surveys. 
Both self-report and MPR were used to measure medicines adherence in 
children in the Saudi study, while self-report alone was used in the UK study 
as previously explained. Notably, in the Saudi study, a substantial 
agreement was found between self-report and MPR data, providing some 
reassurance that the methods are comparable. 
6.2.2 Previous studies conducted with children with diverse 
diseases 
In our systematic review (Chapter 3), we identified six studies that 
explored barriers to medicines adherence in children with different diseases 
(85,92,162,276–278); two of these studies also explored facilitators of 
medicines adherence in children (85,276).  
6.2.3  Data analysis 
All included studies were analysed and the following data were extracted 
into a table:  
• Name of authors. 
• Publication year. 
• Country where study was completed. 
• Type of study.  





• Type of tools used to explore barriers and facilitators of medicines 
adherence. 
• Type of disease. 
• Reported barriers and facilitators. 
6.3 Results 
6.3.1 Countries 
A total of six studies have now been conducted in the UK (80,87,88,90,91, 
Chapter 5), one in Saudi Arabia (Chapter 4) and one study in the US (162). 
6.3.2 Most common barriers and facilitators in all studies 
As shown in Table 6-1, four studies (including our two studies) explored 
both barriers to and facilitators of medicines adherence in children with 
different diseases (87,91, Chapters 4 and 5) and four studies explored only 
barriers to adherence (92,162,277,278).  
Medicine-related factors were the most common barriers to medicines 
adherence, including the complexity of the medicines regimen (80,87,88, 
Chapters 4 and 5), fear of side effects (91, Chapters 4 and 5), problems 
with size and swallowing of medicines (92,278) and bad taste of medicine 
(80,87,88, Chapters 4 and 5). Venables et al. reported that patients who 
were taking medicines with bad tastes or high dose frequencies were more 
likely to refuse their medicines and have poor adherence (p<0.001) (92). 





medicines each week were adherent, and 73% of children who took three 
medicines or more each week were non-adherent (276).  
Our own studies found that parental education level and patients’ and 
parents’ beliefs about medicines were found to be factors that were 





Table 6-1 Studies reporting barriers and facilitators to medicines adherence in patients with diverse 
diseases. For barriers and facilitators numbers are reported as % or significant association (if no numbers 
given numbers not reported in study). 
Study Participants Tools used  Main barriers identified Main facilitators identified  
Fischer  et al. 
2010, United 
States (162) 







agents), aged 0 to 
18 years. 
E-prescribing data of patients 
including prescribing clinician, 
patient, prescription date, 
dosage form, medicine name 
and insurance plan. 
Adherence rate assessed by 
MPR calculation (87.3% 
children were adherent). 
 Medicines being prescribed 
by general physician (not 
paediatrician). 
 Poor adherence common 







Did not report facilitators. 
Elliott et al. 
2013, United 
Kingdom (85) 
18 children with 
asthma, heart 
disease, diabetes, 
and epilepsy, aged 
10 to 17 years. 
Questionnaires completed by 
professionals, children, and 
caregivers about issues around 
medicine-taking in children. 
Adherence rate not assessed. 
 Forgetting. 
 Interference with routine. 
 Evening doses. 
 Side effects. 
 Being tired. 
 
 
 Reminder device. 
 Having routine related to 
medicine administration. 
 Knowledge about 
consequences of not using 
medicine and necessity of it. 
 




70 children with 
various diseases, 
aged 3 to 11 
years. 
Questionnaires completed by 
children, professionals, and 
caregivers about issues around 
medicine-related factors. 
Adherence rate assessed by 
MPR calculation. 
82% of children who took ≤ 
two different medicines each 
week were adherent. 
73% of children who took ≥ 
three medicines each week 
were non-adherent.  
 Taste of medicine especially 
in younger children. 






 Medicines with good taste. 
















57 children aged 








completed by children and 
parents with questions to 
explore barriers to adherence. 
Question about medicine 
refusal conducted to assess 
adherence. 
Almost one third of 
respondents reported 
medicines refusal.  
 Bad taste (p<0.05). 
 Volume or quantity of 
medicine (p<0.05). 
 Texture of medicine 
(p<0.05). 
 Socioeconomic status 
(p<0.05). 
 Difficulty with swallowing. 
 Smell and colour of 
medicine. 
 Highest incidence of poor 
taste medicines were 
prednisolone, ranitidine and 
trimethoprim. 
 












Focus groups to discuss 
barriers to medicine adherence 
(oral formulations barriers). 
Information recorded during 
sessions. 
Adherence rate not assessed. 
 
 
 Bad taste. 
 Texture of medicine. 
 Problems with size and 
swallowing. 
 Problems with smell and 
colour of medicine. 
 Problems with quantity and 
volume. 











aged 0 to 17 
years. 
13-item questionnaire 
completed by children and 
parents with questions to 
explore barriers to adherence. 
Question about medicine 
refusal conducted to assess 
adherence. 
7% of non-oral formulations 
were refused. 
 Difficulty with spacer for 
inhaled devices in patients 
with asthma 38%. 
 Disliking parenteral 
formulations 38%. 
 Greasy texture of topical 
medicines. 
 Large dose of nasal 
medicines. 
 Difficulty with eye 
ointment. 
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completed by children/parents 
to explore barriers and 
facilitators. 
Adherence rate assessed by 
self-report (91% were 
adherent) and MPR (85% were 
adherent). 
 Many doses each day 50%. 
 Changes in usual routine 
33%. 
 Medicine difficult to take 
due to poor 
taste/smell/pain/device 
18%. 
 Fear of side effects 12%. 
 High concern belief scores 
(p<0.05). 
 Using reminders 56%. 
 Established routine 29%. 
 Masking poor taste/pain of 
medicine/big tablet 17%. 
 Family support 8%. 
 Children with parents with a 
University education level 
(p<0.05). 
















completed by children/parents 
to explore barriers and 
facilitators. 
 
Adherence rate assessed by 
self-report (82% were 
adherent). 
 Many doses each day 36%. 
 Changes in usual routine 
27%. 
 Medicine difficult to take 
due to poor 
taste/smell/pain/device 
40%. 
 Fear of side effects 5%. 
 Being busy 20%. 
 High concern belief scores 
(p< 0.05). 
 Using reminders 58%. 
 Established routine 9%. 
 Masking poor taste/pain of 
medicine/big tablet 25%. 
 Family support 11%. 
 Children with parents with a 








This chapter summarises the main findings of the eight studies (two 
unpublished) conducted to explore medicines adherence with children with 
diverse diseases (six in the UK, one in the USA and one in Saudi Arabia). 
All studies explored barriers to adherence, but only four of them explored 
facilitators. 
Medicine-related factors were the most common barriers to medicines 
adherence in many studies. Poor taste of the medicine was reported as a 
barrier by five studies (80,87,88, Chapters 4 and 5), problems with the size 
of medicine and swallowing was reported by four studies (80,88, Chapters 
4 and 5) and complex medicines regimen was reported by five studies 
(92,162,278). 
Most of the participants in the three studies who reported that the bad taste 
of the medicine made it hard for them to take belonged to the younger 
group (87, Chapters 4 and 5). This may be explained by the fact that 
younger children are more likely to be prescribed oral liquid formulations, 
which often have a bad taste that is more difficult to mask (276). Bryson et 
al. reported that good adherence was associated with a positive response 
to medicine taste, and conversely, poor adherence was associated with a 
negative response (276). Venables et al. also found that the bad taste of a 
medicine was significantly associated with medicine refusal in children and 





incidence of poor taste were prednisolone soluble tablets, ranitidine liquid 
and trimethoprim liquid (92). In our studies (Chapters 4 and 5), most 
participants reporting that their medicine had a poor taste did not report 
which of their medicines tasted poorly. This may have been due to the 
nature of the question in our designed questionnaire (Chapters 4 and 5), 
which asked participants to write the name of medicines with a bad taste 
only if the poor taste of medicine was the reason they avoided or stopped 
taking their prescribed medicine. However, the reporting of the poor taste 
of medicines in many studies suggests that despite the availability of 
medicines with different flavours and different formulations, the poor taste 
of medicines is still a common barrier to medicines adherence in children. 
In addition, participants in three studies (80, Chapters 4 and 5) reported 
manipulating medicines to mask poor taste. Therefore, the taste of 
medicines should be considered by pharmaceutical companies when 
producing new formulations in order to improve medicines adherence in 
children. Furthermore, prescribers are advised to talk with children and 
parents about whether the child prefers a particular flavour of medicine if a 
choice is available. 
Problems with the size of solid dose medicines and swallowing were 
reported by participants in four of the studies (80,88, Chapters 4 and 5). 
Venables et al. reported that problems with the solid dosage forms were 
related to difficulty swallowing and the size of the medicine (92). Swallowing 





medicines are available in a mini-tablet form, the acceptability of which has 
been explored in children aged between six months and six years (324). 
This study found that 46% of children aged two years and 86% of the oldest 
children were able to swallow the mini-tablets (324). Some patients who 
have difficulty swallowing large tablets may have to crush the tablet or open 
the capsule and dissolve it in a drink, which may affect the actual dose of 
the medicine (80, Chapters 4 and 5). Mixing medicine with foodstuffs may 
affect the drug bioavailability by increasing the binding capability of the 
medicine with foodstuff (92). To minimise medicine manipulation, 
prescribers are advised to consider the age of the child and the size of the 
tablets when prescribing the medicine. 
Complex medicine regimens, such as those involving multiple drugs, doses 
(80,87,88, Chapters 4 and 5) and night doses (91, Chapters 4 and 5), were 
also reported as barriers to adherence. In our studies (Chapter 4 and 5), 
some participants reported that high dose frequencies were a reason they 
forgot to take their medicines on time. In addition, night doses were seen 
as a barrier as children tend to go to sleep early and found it difficult to 
wake up every night to take their medicine (Chapter 4 and 5). Elliott et al. 
reported that the night dose was the most frequently missed dose among 
children with chronic diseases (85). 
In general, a simpler regime reduces confusion, is more easily understood, 





regimen of prescribed medicine was more likely to be adhered to (276). 
Some participants in our studies (Chapters 4 and 5) who were taking many 
doses each day (solid formulations) reported that they used an organising 
box to separate each day’s doses and found that useful. Therefore, it is 
suggested that those who must take many doses daily (solid formulations) 
use tools to help them to organise their daily doses, such as an organising 
box. As these boxes are suitable only for solid dosage forms, no participants 
reported methods of organising liquid formulations. Therefore, future 
research may look at how to organise complex medicines regimens 
involving liquid formulations. 
Fear of side effects was reported by participants in three studies (91, 
Chapters 4 and 5). Side effects of medicines may have a large impact on 
adherence, especially if patients believe that it is acceptable to refrain from 
taking their medicines in order to avoid side effects (Chapters 4 and 5). 
Elliot et al. found that knowledge about the consequences of not using 
medicines as prescribed and the necessity of doing so facilitated medicines 
adherence in children (85). Venables et al. also reported that parental 
understanding of the importance of medicines influenced medicines 
adherence (278). 
In our studies (Chapters 4 and 5), we used the BMQ scale to assess patients’ 
beliefs about medicines and determine how they affect children’s adherence 
to medicines. Our studies were the first studies to use the BMQ with children 





parents’ beliefs and their adherence. We found a statistically significant 
association between the BMQ differential score and the adherence rates. 
There was an increase in the adherence rate among those with low concern 
about long-term use and with a stronger belief in the necessity of medicines. 
Patients with negative necessity-concern differential scores were less 
adherent than patients with positive scores. In addition, we found that six 
of eight participants who had experienced side effects of their medicines 
(Chapter 5) reported poor adherence rates and had higher concerns than 
necessity scores. These findings suggest that healthcare providers can help 
to strengthen patient and parents’ beliefs by explaining the importance of 
the medicine and addressing their concerns, and thereby improve 
adherence in children. 
Venables et al. reported that parents have an influence on their children’s 
adherence to medicines (278). The nurses interviewed in this study 
emphasized the need for parental education (278). The studies presented 
in Chapters 4 and 5 were the first to investigate the relationship between 
parental education level and the adherence rate of children with diverse 
diseases statistically (Chapters 4 and 5). In both studies, more than half of 
the children’s parents had a university education, which represents a high 
level of education. Children whose parents had a university education were 
significantly more likely to have a good adherence rate than children whose 
parents had a secondary-level education, meaning that good adherence was 





higher education levels are more likely to understand the vital importance 
of adherence and the effects that poor adherence can potentially have on 
their child (240). This result suggests the importance of ensuring that the 
patient understands the importance of the medicine and the potential 
effects of poor adherence. 
Three studies reported that using reminders or establishing a routine have 
a positive effect on remembering to take medicine (91, Chapters 4 and 5). 
Furthermore, some participants in Chapters 4 and 5 reported that they use 
reminders to take their medicines and they have an established routine to 
help them remember to take their medicines. All of these participants 
showed good adherence rates.  
6.5 Conclusion 
This chapter summarised the most common known barriers to and 
facilitators of medicines adherence in children with diverse diseases rather 
than most previous studies which only examined specific diseases. Poor 
tasting medicines, problems with swallowing medicines, complexity of the 
medicine regimen and fear of side effects were the most common barriers. 
The most common facilitators of medicines adherence were using reminders 
and establishing a routine. Our studies (Chapters 4 and 5) confirmed 
these barriers and facilitators and observed that rates of adherence were 
significantly associated with the child’s and parents’ beliefs about 





and pain caused by administration, together with family support were 
findings added by our studies (Chapters 4 and 5) as facilitators of 
medicines adherence. Furthermore, children whose parents had a university 
education had a significantly better adherence rate compared with children 
whose parents had a secondary-level education. These findings will add to 
the understanding of the barriers to and facilitators of medicines adherence 


















































Non-adherence to medicines is a complex healthcare issue. Patients may 
take their medicine at the wrong time, use less or more than the prescribed 
amounts, or discontinue treatment prematurely (12). Enhancing medicines 
adherence for chronic conditions may create significant economic and 
health benefits (7,50).  
This PhD project first aimed to measure medicines adherence in children 
with chronic diseases and to explore barriers to and facilitators of 
adherence. While there are a number of known medicines adherence 
measures, no previous systematic review has been conducted to evaluate 
their relevance and experience in children. We therefore performed a 
systematic review to identify medicines adherence measures that have been 
used with children and explores the strengths and weaknesses of those 
measures. 
We also searched for a systematic review in order to establish what is 
currently known about barriers and facilitators to medicines adherence in 
children and found a review from the Talking about medicines study (TABS) 
published seven years ago (85). This review was a critical evidence 
synthesis of research to examine the factors influencing non-adherence to 
medicines in children with chronic diseases from 1970 to 2008 (85). We 
therefore performed a systematic review to update this work and to identify 






Based on the information obtained from these systematic reviews, we then 
conducted two studies to measure medicines adherence in children and to 
explore the barriers and facilitators to medicines adherence in two centres: 
Saudi Arabia and the UK. 
7.2 Key findings 
The first systematic review (Chapter 2) aimed to identify medicines 
adherence measures that have been used in children and to explore the 
strengths and weaknesses of those measures. This review identified 31 
articles that met the inclusion criteria. In these articles seven methods to 
measure adherence were identified: self-report, EMD, dose count, canister 
weight, plasma level, medical record or pharmacy refill data, daily 
telephone calls.  
Self-reporting was the most commonly used method to assess adherence 
and was reported to be flexible, inexpensive, and time saving but it was 
the least accurate and overestimated adherence rates. MEMS was the 
most accurate method but was also the most expensive. Dose counting 
was easy to use and inexpensive but adherence was also overestimated 
with this method. Measuring medication plasma levels was more precise 
than self-reporting and dose counting but was costly, time consuming and 
difficult to perform. Pharmacy refill data was more accurate than self-
reporting and less accurate than MEMS and medication plasma levels. 
Mobile phone methods were reported to be very expensive and difficult to 





less expensive but was only applicable to inhalation devices. Currently, no 
gold standard method to measure adherence to medicines in children 
exists as each method has its own advantages and disadvantages.  
The second systematic review (Chapter 3) aimed to identify barriers and 
facilitators to medicines adherence in children as reported over the past 
twelve years. This review identified 177 articles that met the inclusion 
criteria. Most studies were conducted in the US (76), followed by the UK 
(12) and Canada (6), with the remaining 83 studies in various other 
countries. Forgetfulness and fear of side effects were the most common 
reported barriers to medicine adherence. Others reported barriers included 
family conflict, weak patient-provider relationships, stigma and 
discrimination, drug regimen complexity and lack of support from families. 
Factors reported to facilitate high rates of adherence include linking of 
medicine taking with daily life routines, using reminders to avoid 
forgetfulness, a higher level of caregivers and parental education and good 
communication between healthcare professionals, patients and parents.  
The exploratory study (Chapter 4), which aimed to measure medicines 
adherence in children with chronic diseases attending the KFMC in Saudi 
Arabia and to explore related barriers and facilitators to medicines 
adherence, found good agreement between the study’s two adherence 
measurements methods (self-report and the MPR). Additionally, this study 
found a statistically significant association between the BMQ differential 





association between adherence rates and the education level of a patients’ 
parents. Furthermore, this study identified that many doses each day, 
changes in daily routine, medicines being difficult to take due to large tablet 
size, poor taste/smell, causing on pain on administration or difficult to use 
devices and fear of side effects were the most common barriers to 
medicines adherence. Using reminders, having an established routine for 
taking medicines, measures to address poor taste, pain caused by 
administration or taking big tablets and family support were the most 
common facilitators for medicines adherence in children.  
The second exploratory study (Chapter 5) aimed to measure medicines 
adherence and to explore the barriers to and facilitators of adherence in 
children with chronic diseases attending the Derbyshire Children’s Hospital 
in the UK. The findings of this study were similar to those of the Saudi study 
(Chapter 4) and the differences were only in the order of the most common 
barriers to and facilitators of medicines adherence. This study found a 
statistically significant association between the BMQ differential score and 
adherence rates and between adherence rates and the education level of 
the patients’ parents. In addition, this study found that medicines being 
difficult to take due to large tablet size, poor taste/smell, causing on pain 
on administration or difficult to use devices; requiring many doses each day 
plus changes in usual routine and being busy were the most common 
barriers to medicines adherence. Furthermore, this study identified that 





administration or taking big tablets, family support, and following a 
scheduled routine for taking medicines were the most common facilitators 
for medicines adherence in children.  
7.3 Key practice implications 
The aforementioned findings from this project add to the understanding of 
the barriers to and facilitators of medicines adherence in children with 
various diseases. 
• The most common barriers to and facilitators of medicines adherence 
in children with diverse diseases have been identified which will be 
useful to healthcare providers to help them when prescribing 
medicines for children. 
• To achieve optimal adherence, healthcare providers need to be aware 
of the most common barriers for their patients and to consider the 
most appropriate facilitators to encourage them to take their 
medicines as prescribed.  
• Children’s and parents’ beliefs about the necessity of medicines and 
their concerns about their use significantly impact their medicines 
adherence. To improve medicines adherence, healthcare providers 
may help develop patients’ and parents’ beliefs by explaining the 
importance of each medicine and addressing any concerns or 





• Parental education level significantly impacts a child’s drug 
adherence. If possible, healthcare providers should identify parents 
with low education levels in order to explain treatment and the 
importance of drug adherence to them in understandable terms. 
• The bad taste of a medicine was reported by some participants in both 
studies (Chapters 4 and 5) as a barrier to adherence. 
Pharmaceutical companies need to carefully consider the taste of 
medicines when designing new formulations, especially oral liquid 
formulations. Furthermore, prescribers are advised to talk with 
children and parents about whether the child prefers a particular 
flavour of medicine if a choice is available. In addition, techniques 
such as using oral syringes for drug administration may help to 
conceal or minimise an unpleasant taste.  
• None of the medicines’ adherence measures were highly accurate in 
the assessment of adherence. It is therefore important to use a 
combination of multiple measures in order to gain a true picture of 
adherence. 
7.4 Limitations 
There were some limitations to this work as has been highlighted already 
in each chapter. This thesis included two systematic reviews (Chapter 2 
and 3). The main limitations in these reviews were that all titles and 
abstracts of the search results should have been screened according to 





department, one researcher (Aldosari M) screened all titles and abstracts, 
but only 5% of titles and abstracts were assessed independently by 
another researcher from our group. The quality of all included studies 
should have been assessed independently by two researchers. Given the 
high numbers of included studies in the Chapter 3 and the limited 
resources of our department, one researcher (Aldosari M) quality 
assessed all of the included studies but, only 5% of the included studies 
were quality assessed independently by another researcher from our 
group. Finally, conference abstracts and the grey literature were not 
searched, so it is possible that studies were missed. 
For the two exploratory studies, the main limitations were that we only had 
sufficient statistical power to detect quite large differences in adherence 
rates between exposure groups (e.g., differences greater than 18% 
between the two groups), so smaller differences were not detectable in this 
study. Also, neither of the adherence measures in this study guarantees 
that patients took their medicine. Some patients also refused to participate 
in our study, and it is possible that those who chose not to participate varied 
from our sample in terms of adherence. 
7.5 Challenges 
During my PhD, I faced many challenges. As was required at the beginning 
of a PhD, I needed to learn different skills regarding literature search 





took a lot of effort and time to learn these skills and apply them in my 
studies. These skills however will help me in my future research. 
In the second systematic review (Chapter 3), there were numerous studies 
that needed to be carefully read, assessed, and have data extracted from 
them. I learned how to organise many studies, and I gained experience in 
search techniques, quality assessment and data management and analysis. 
In the exploratory studies (Chapters 4 and 5), I also spent a significant 
time at the two hospitals in order to recruit 100 participants at each centre. 
During this time, I improved my confidence and communication skills with 
patients and their parents and with healthcare providers. It became clear 
to me during this time that most children, parents and healthcare providers 
are cooperative and helpful in supporting this type of research. 
7.6 Future research 
Despite the project findings, there are still some areas that require further 
research: 
• The first systematic review (Chapter 2) showed that there is not a 
gold-standard method for measuring children’s medicine adherence. 
Future research should therefore focus on developing a highly 
accurate assessment tool to measure medicines adherence. 
• In the exploratory studies (Chapter 4 and 5), we had sufficient 
statistical power to detect only quite large differences in adherence 





adherence rates between two different groups). Therefore, smaller 
differences would have been missed in these studies. A larger sample 
size would be needed in future studies to detect smaller differences. 
• In the exploratory studies (Chapter 4 and 5), we did not conduct 
statistical comparisons between sub-groups (such as child vs. parents 
having the responsibility for taking or giving medicine) because the 
sub-groups’ sample sizes were too small. Future research could 
increase the sample sizes to conduct such comparisons. 
7.7 Conclusion 
The objectives of this project, to measure medicines adherence in children 
in the UK and Saudi Arabia and to explore to the barriers and facilitators of 
that adherence, were achieved. Previous studies covered a limited number 
of diseases, but in this project, we covered a wider variety of long-term 
conditions than had previously been studied. We also explored all barriers 
to and facilitators of medicines adherence in children with diverse diseases 
in the UK and Saudi Arabia.  
This project found a statistically significant association between the BMQ 
differential score and adherence rates and between the education level of 
patients’ parents and adherence rates in both countries.  
The most common barriers in both countries seem to be medicine-related 
issues and patient-related factors. In addition, this project found that the 
most common facilitators for children’s medicines adherence in both 





flavour, developing a scheduled routine for taking medicine, and having 
family support.  
The findings of this project will add to the understanding of the barriers to 
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9.2 Participant information sheets and consent forms 
 
 
Barriers and facilitators of medicines adherence in children  
Parent / Legal Guardian Participant Information Sheet 
(Final version 2.0 Date: 25/07/2019) 
 
IRAS Project ID: 247581 
 
Title of Study: Barriers and facilitators of medication adherence in children 
 
Name of Chief Investigator: Dr Sharon Conroy 
Local Researcher(s): Mohammed Aldosari  
 
We would like to invite you to take part in our research study. Before you decide we would like you to understand 
why the research is being done and what it would involve for you. One of our team will go through the 
information sheet with you and answer any questions you have. Talk to others about the study if you wish. Ask 
us if there is anything that is not clear. 
 
What is the purpose of the study? 
People have different experiences of trying to take their medicines as prescribed 
by the doctor. We understand that sometimes things can get in the way of 
following your doctor’s instructions about taking medicines.  We are hoping that 
the answers given by people like you in this questionnaire will help us to 
understand more about any difficulties that children and their families may have 
with taking medicines and also tell us what might help make it easier.   
Why have I been invited? 
You are being invited to take part because your child is prescribed medicines and we would like to 
hear your thoughts about this. We are hoping to get about 60 participants including children and 
parents like you to take part. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you don’t wish to take part your and your 
child’s medical care will not be affected in any way. If you do decide to take part you will be given 
this information sheet to keep and be asked to sign a consent form.  If you decide to take part you 
are still free to withdraw at any time and without giving a reason. This would not affect your or your 






What will happen to me if I take part? 
Your child; you on their behalf if they are too young to read and write down their answers; or you 
yourself if your child is too young to take part will be asked to complete two short questionnaires. 
You can do this in the hospital if possible or at home if you would prefer (we will give you an 
envelope to post it back to us if you choose to do this). One questionnaire is about your/your child’s 
thoughts on medicines taking and one is about what makes it easier or harder for your child to take 
their medicines as prescribed. The questionnaires take about 10-20 minutes to complete depending 
on how much you want to tell us.  
Expenses and payments 
Participants will not be paid to participate in the study. 
What are the possible disadvantages and risks of taking part?  
The only disadvantages of this study are the inconvenience of answering our questions about your 
child’s medicines. 
What are the possible benefits of taking part? 
We cannot promise the study will help you and your family but the information we get from this 
study may help in future to develop ways to help children with their medicines taking in future.  
What happens when the research study stops? 
Your and your child’s care will continue as normal. 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researchers who 
will do their best to answer your questions.  The researchers’ contact details are given at the end of 
this information sheet. If you remain unhappy and wish to complain formally, you can do this by 
contacting the Patient Advice and Liaison Service (PALS) at the Royal Derby Hospital (telephone: 
01332 785156 or email: dhft.contactpals@nhs.net). 
 
It is very unlikely that anything will go wrong as a result of taking part in this study as your and your 
child’s treatment will not be affected in any way. If something does go wrong however and you or 
your child are harmed during the research and this is due to someone's negligence then you may 
have grounds for a legal action for compensation against the University of Nottingham but you may 
have to pay your legal costs. The normal National Health Service complaints mechanisms will still be 
available to you. 
Will my taking part in the study be kept confidential? 
 






If you join the study, we will use information collected from you during the course of the research. 
This information (consent form and questionnaires) will be kept strictly confidential; stored in a 
secure and locked office; and the questionnaire answers on a password protected database in the 
University of Nottingham Medical School at the Royal Derby Hospital.  Under UK Data Protection 
laws the University is the Data Controller (legally responsible for the data security) and the Chief 
Investigator of this study (named above) is the Data Custodian (manages access to the data). This 
means we are responsible for looking after your information and using it properly. Your rights to 
access, change or move your information are limited as we need to manage your information in 
specific ways to comply with certain laws and for the research to be reliable and accurate. To 
safeguard your rights we will use the minimum personally – identifiable information possible. 
 




The data collected for the study will be looked at and stored by authorised persons from the 
University of Nottingham who are organising the research. They may also be looked at by authorised 
people from regulatory organisations to check that the study is being carried out correctly. All will 
have a duty of confidentiality to you as a research participant and we will do our best to meet this 
duty. 
 
Where possible information about you which leaves the hospital will have your name and address 
removed and a unique code will be used so that you cannot be recognised from it, however we need 
to ensure that we can recognise your child to link the research data with their medical records so in 
these instances we will need to know their name and date of birth. We will also need this 
information if we need to follow up their medical records as part of the research, where we may 
need to ask the Government services that hold medical information about you (such as your child’s 
GP surgery) to provide this information to us. By signing the consent form you agree to the above. 
 
Your contact information will be destroyed securely by the University of Nottingham when we have 
the information we need from your GP about your medicines. Until then this information will be kept 
separately from the research data collected and only those who need to will have access to it.  All 
other data (research data) will be kept securely for 7 years.  After this time your data will be disposed 
of securely.  During this time all precautions will be taken by all those involved to maintain your 
confidentiality, only members of the research team given permission by the data custodian will have 
access to your personal data. 
 
In accordance with the University of Nottingham’s, the Government’s and our funders’ policies we 





in other countries, for research in health and social care. Sharing research data is important to allow 
peer scrutiny, re-use (and therefore avoiding duplication of research) and to understand the bigger 
picture in particular areas of research. Data sharing in this way is usually anonymised (so that you 
could not be identified) but if we need to share identifiable information we will seek your consent for 
this and ensure it is secure. You will be made aware then if the data is to be shared with countries 
whose data protection laws differ to those of the UK and how we will protect your confidentiality. 
 
Although what you say to us is confidential, should you disclose anything to us which we feel puts 
you or anyone else at any risk, we may feel it necessary to report this to the appropriate persons. 
What will happen if I don’t want to carry on with the study?  
Your participation is voluntary and you are free to withdraw at any time, without giving any reason, 
and without your legal rights being affected. If you withdraw we will no longer collect any 
information about you or from you. However, if you withdraw then the information collected so far 
cannot be erased as we are not allowed to tamper with study records and this information may have 
already been used in some analyses and may still be used in the final study analyses. 
Involvement of the General Practitioner/Family doctor (GP)  
We will not tell your GP about your participation in this study. 
What will happen to the results of the research study? 
At the end of this study, the results of the research will be made available in reports and academic 
papers read by children’s doctors, nurses and pharmacists. A report of the study will be written up as 
part of the researcher’s PhD studies. Direct quotes from you/your child may be used but these will be 
anonymous. 
Who is organising and funding the research? 
This study is organised by the University of Nottingham as part of Mr. Mohammed Al dosari PhD 
studies. 
Who has reviewed the study? 
All research in healthcare is looked at by independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given favourable opinion by 
the London-Stanmore Research Ethics Committee. 
Further information and contact details 
Chief investigator:                   Dr Sharon Conroy, Associate Professor,  
University of Nottingham, Royal Derby Hospital Centre 
Uttoxeter Road, Derby DE22 3DT  
Phone: 01332 724692 
                                       Email Sharon.Conroy@nottingham.ac.uk 
 
Co-investigators:                      Dr Ana Oliveira, Assistant Professor,  
University of Nottingham, Royal Derby Hospital Centre 





Phone: 01332 724621 
E-mail: Ana.Oliveira@nottingham.ac.uk 
 
Mr. Mohammed Al Dosari, Postgraduate student 
University of Nottingham, Royal Derby Hospital Centre 
Uttoxeter Road, Derby DE22 3DT  


















































Barriers and facilitators of medicines adherence in children 
Young Person 11-15 years Participant Information Sheet 
(Final version 2.0 Date: 25/07/2019) 
 
IRAS Project ID: 247581 
 
Title of Study: Barriers and facilitators of medicines adherence in children 
 
Name of Chief Investigator: Dr Sharon Conroy 
Local Researcher(s):  Mohammed Al dosari  
 
We would like to invite you to take part in our project. Before you decide about joining in, we’d like to tell you 
why we’re doing it and what it will involve for you. This leaflet tells you most things that you need to know but 
please talk to your family, friends, doctor, nurse or the researcher if you want to find out more. 
What is the purpose of the study? 
People have different experiences of trying to take their medicines as prescribed 
by the doctor. We understand that sometimes things can get in the way of 
following your doctor’s instructions about taking medicines.  We are hoping that 
the answers given by people like you in this project will help us to understand 
more about any difficulties that children and their families may have with taking 
medicines and also tell us what might help make it easier.   
Why have I been invited? 
You are being invited to take part because you are taking some medicine and we would like to hear 
your thoughts about this. We are hoping to get about 60 people like you to take part. 
Do I have to take part? 
No. It is up to you. We will ask you and your parent’s agreement and your parents will sign a form if 
you are all happy to take part. We will give you a copy of this information sheet and a signed form to 
keep. If you don’t want to take part that’s fine and if you do take part you are free to change your 
mind at any time without telling us why. If you decide not to take part or if you do change your mind, 
this will not affect any of the care that you will be given. 
What will happen to me if I take part? 
You and your parent will be asked to complete two short questionnaires while in the hospital if 
possible or at home if you would prefer (we will give you an envelope to post it back to us if you 





about what makes it easier or harder for you to take your medicines. The questionnaires will take 
about 10-20 minutes to complete depending on how much you want to tell us.  
Expenses and payments 
Sorry but we cannot pay you to take part in the study. 
 
What are the possible disadvantages and risks of taking part?  
Just the few minutes it takes for you to answer our questions about your medicine. 
What are the possible benefits of taking part? 
We cannot promise the study will help you but the information we get from this study may help in 
future to treat children better.  
What happens when the research study stops? 
Your care will continue as normal.  
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researchers who 
will do their best to answer your questions.  Their contact details are at the end of this information 
sheet. If you remain unhappy and wish to complain, you can do this by contacting the Patient Advice 
and Liaison Service (PALS) at the Royal Derby Hospital (telephone: 01332 785156 or email: 
dhft.contactpals@nhs.net). 
Will my taking part in the study be kept secret? 
If you join the study, we will look at your GP prescriptions and keep the forms that you fill in for us. 
Only the form that your parents sign to agree to the study will have your name or address on it, 
everything else will just have a special code. The form with your name and address will be kept 
separate to everything else and everything will be kept under lock and key in our University offices at 
the Royal Derby Hospital and your questionnaire answers on a password protected University 
computer.   
 
We will only keep your personal information (name, address etc) for three months in case we have 
any questions to ask you or your parents. The questionnaires will be kept safely for 7 years.   
What will happen if I don’t want to carry on with the study?  
You can stop taking part at any time, without giving any reasons. It won’t affect anything. 
What will happen to the results of the research study? 
At the end of this study, we will share the results in reports and papers read by children’s doctors, 
nurses and pharmacists and the researcher will write about it in his University project.  





This study is organised by the University of Nottingham as part of Mr. Mohammed Al dosari PhD 
studies. 
Who has reviewed the study? 
A group of people, called an Ethics Committee have looked at the project to make sure that 
everything is ok with it. 
 
Further information and contact details: 
Chief investigator:                   Dr Sharon Conroy, Associate Professor,  
University of Nottingham, Royal Derby Hospital Centre 
Uttoxeter Road, Derby DE22 3DT  
Phone: 01332 724692 
                                       Email Sharon.Conroy@nottingham.ac.uk 
 
 
Co-investigators:                      Dr Ana Oliveira, Assistant Professor,  
University of Nottingham, Royal Derby Hospital Centre 
Uttoxeter Road, Derby DE22 3DT 
Phone: 01332 724621 
E-mail: Ana.Oliveira@nottingham.ac.uk 
 
Mr. Mohammed Al Dosari, Postgraduate student 
University of Nottingham, Royal Derby Hospital Centre 
Uttoxeter Road, Derby DE22 3DT  






















Barriers and facilitators of medicines adherence in children 
Young Person 16-18 Participant Information Sheet 
(Final version 2.0 Date: 25/07/2019) 
 
 
IRAS Project ID: 247581 
 
Title of Study: Barriers and facilitators of medicines adherence in children 
 
Name of Chief Investigator: Dr Sharon Conroy 
Local Researcher(s): Mohammed Al dosari 
 
We would like to invite you to take part in our research study. Before you decide we would like you to understand 
why the research is being done and what it would involve for you. One of our team will go through the 
information sheet with you and answer any questions you have. Talk to others about the study if you wish. Ask 
us if there is anything that is not clear. 
What is the purpose of the study? 
People have different experiences of trying to take their medicines as prescribed 
by the doctor. We understand that sometimes things can get in the way of 
following your doctor’s instructions about taking medicines.  We are hoping that 
the answers given by people like you in this questionnaire will help us to 
understand more about any difficulties that children and their families may have 
with taking medicines also tell us what might help make it easier.   
Why have I been invited? 
You are being invited to take part because you are taking medicines and we would like to hear your 
thoughts about this. We are hoping to get 60 people like you to take part. 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you don’t want to take part that’s fine. If you 
decide to take part you will be given this information sheet to keep and be asked to sign a consent 
form. If you decide to take part you are still free to withdraw at any time and without giving a reason. 
Not taking part at all or changing your mind after starting will not affect your medical care and legal 
rights. 
What will happen to me if I take part? 
You will be asked to complete two short questionnaires while in the hospital if possible or at home if 
you would prefer (we will give you an envelope to post it back to us if you choose to do this). One 





harder for you to take your medicines as prescribed. The questionnaires take about 10-20 minutes to 
complete depending on how much you want to tell us.  
Expenses and payments 
It is not possible to pay anyone to take part in the study. 
 
What are the possible disadvantages and risks of taking part?  
The only disadvantages of this study are the slight inconvenience of answering our questions about 
your medicine. 
 
What are the possible benefits of taking part? 
We cannot promise the study will help you but the information we get from this study may help in 
future to improve medicines adherence in children. 
What happens when the research study stops? 
Your care will continue as normal.  
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researchers who 
will do their best to answer your questions.  The researchers’ contact details are given at the end of 
this information sheet. If you remain unhappy and wish to complain formally, you can do this by 
contacting the Patient Advice and Liaison Service (PALS) at the Royal Derby Hospital (telephone: 
01332 785156 or email: dhft.contactpals@nhs.net). 
 
It is very unlikely that anything will go wrong as a result of taking part in this study as your treatment 
will not be affected in any way. If something does go wrong however and you are harmed during the 
research and this is due to someone's negligence then you may have grounds for a legal action for 
compensation against the University of Nottingham but you may have to pay your legal costs. The 
normal National Health Service complaints mechanisms will still be available to you. 
Will my taking part in the study be kept confidential? 
We will follow ethical and legal practice and all information about you will be handled in confidence. 
 
If you join the study, we will use information collected from you during the course of the research. 
This information (questionnaires and consent form) will be kept strictly confidential, stored in a 
secure and locked office, and your questionnaire answers on a password protected database at the 
University of Nottingham Medical School at the Royal Derby Hospital.  Under UK Data Protection 
laws the University is the Data Controller (legally responsible for the data security) and the Chief 
Investigator of this study (named above) is the Data Custodian (manages access to the data). This 





access, change or move your information are limited as we need to manage your information in 
specific ways to comply with certain laws and for the research to be reliable and accurate. To 
safeguard your rights we will use the minimum personally – identifiable information possible. 
 




The data collected for the study will be looked at and stored by authorised persons from the 
University of Nottingham who are organising the research. They may also be looked at by authorised 
people from regulatory organisations to check that the study is being carried out correctly. All will 
have a duty of confidentiality to you as a research participant and we will do our best to meet this 
duty. 
 
Where possible information about you which leaves the hospital will have your name and address 
removed and a unique code will be used so that you cannot be recognised from it, however we need 
to ensure that we can recognise you to link the research data with your medical records so in these 
instances we will need to know your name and date of birth. We will also need this information if we 
need to follow up your medical records as part of the research, where we may need to ask the 
Government services that hold medical information about you (such as your GP surgery) to provide 
this information to us. By signing the consent form you agree to the above. 
 
Your contact information will be destroyed securely by the University of Nottingham when we have 
the information we need from your GP about your medicines. Until then this information will be kept 
separately from the research data collected and only those who need to will have access to it.  All 
other data (research data) will be kept securely for 7 years.  After this time your data will be disposed 
of securely.  During this time all precautions will be taken by all those involved to maintain your 
confidentiality, only members of the research team given permission by the data custodian will have 
access to your personal data. 
 
In accordance with the University of Nottingham’s, the Government’s and our funders’ policies we 
may share our research data with researchers in other Universities and organisations, including those 
in other countries, for research in health and social care. Sharing research data is important to allow 
peer scrutiny, re-use (and therefore avoiding duplication of research) and to understand the bigger 
picture in particular areas of research. Data sharing in this way is usually anonymised (so that you 
could not be identified) but if we need to share identifiable information we will seek your consent for 
this and ensure it is secure. You will be made aware then if the data is to be shared with countries 






Although what you say to us is confidential, should you disclose anything to us which we feel puts 
you or anyone else at any risk, we may feel it necessary to report this to the appropriate persons.  
 
What will happen if I don’t want to carry on with the study?  
Your participation is voluntary and you are free to withdraw at any time, without giving any reason, 
and without your medical care and legal rights being affected. If you withdraw we will no longer 
collect any information about you or from you. However, if you withdraw then the information 
collected so far cannot be erased as we are not allowed to tamper with study records and this 
information may have already been used in some analyses and may still be used in the final study 
analyses. 
What will happen to the results of the research study? 
At the end of this study, the results of the research will be made available in reports and academic 
papers. A report of the study will be written up as part of the researcher’s PhD studies. Direct quotes 
from you may be used but these will be anonymous. 
Who is organising and funding the research? 
This study is organised and funded by the University of Nottingham as part of Mr. Mohammed Al 
dosari PhD studies. Mohammed Aldosari is a PhD student sponsored by the Saudi Arabia Cultural 
Bureau. 
Who has reviewed the study? 
All research in healthcare is looked at by independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given favourable opinion by 
the London-Stanmore Research Ethics Committee. 
 
Further information and contact details 
Chief investigator:                   Dr Sharon Conroy, Associate Professor,  
University of Nottingham, Royal Derby Hospital Centre 
Uttoxeter Road, Derby DE22 3DT  
Phone: 01332 724692 
                                       Email Sharon.Conroy@nottingham.ac.uk 
 
 
Co-investigators:                      Dr Ana Oliveira, Assistant Professor,  
University of Nottingham, Royal Derby Hospital Centre 
Uttoxeter Road, Derby DE22 3DT 
Phone: 01332 724621 
E-mail: Ana.Oliveira@nottingham.ac.uk 
 
Mr. Mohammed Al Dosari, Postgraduate student 
University of Nottingham, Royal Derby Hospital Centre 
Uttoxeter Road, Derby DE22 3DT  

























9.3 BMQ questionnaire Arabic and English forms 
 
 
 وجهات النظر حول استطالع رأي عن األدوية )إصدار هورني وينمان وهانكينس 1999(. 
 أوالً وجهة نظرك حول األدوية الموصوفة لك.
 أسألك عن وجهة نظرك الشخصية حول األدوية الموصوفة لك.أود أن  •
 هذه عبارة أدلى بها أشخاص أخرون حول أدويتهم.  •
 يرجى اإلشارة إلى مدى موافقتك أو عدم موافقتك عليها بوضع عالمة في المربع المناسب.  •
 ال توجد إجابات صحيحة أو خاطئة، فنحن مهتمون بآرائك الشخصية فقط.  •
 ة في مربع واحد لكل سؤال. يرجى فقط وضع عالم •
 
 تعتمد صحتي في الوقت الحالي على األدوية الخاصة بي  -1
موافق بشدة       
 
موافق        غير متأكد         غير موافق بشدة  غير موافق  
 
 
    
 
 االضطرار إلى تناول األدوية يقلقني. -2
موافق بشدة       
 






    
 حياتي ستكون مستحيلة بدون دوائي. -3
موافق بشدة       
 




    
 بدون دوائي, سأكون مريضاً جداً  -4
موافق بشدة      موافق         غير متأكد         غير موافق بشدة  غير موافق  
     
     








    
 
 أشعر بالقلق أحيانًا بشأن اآلثار الطويلة األجل ألدويتي.  -5
 
موافق بشدة       
 





    
 دوائي غامض بالنسبة لي.  -6
موافق بشدة       
 





    
 ستعتمد صحتي في المستقبل على دوائي. -7
موافق بشدة       
 





    
 دوائي يقلق حياتي  -8
موافق بشدة       
 




    
 
 أشعر بالقلق أحيانًا من اعتمادي على دوائي بشكل كبير جداً.  -9
 
موافق بشدة       
 





    
 الدواء يحميني من أن أصبح أسوأ. -10
     
     
     
     
     





موافق بشدة       
 
موافق        غير متأكد         غير موافق بشدة  غير موافق  
 
 




Beliefs about medicines questionnaire (BMQ) Horne, Weinman, Hankins, (1999)  
BMQ-Specific 
Your views about medicines prescribed to you. 
• I would like to ask you about your personal views about medicines prescribed for you. 
• These are statements other people have made about their medication. 
• Please indicate the extent to which you agree or disagree with them by placing a cross in the 
appropriate box. 
• There are no right or wrong answers. I am interested in your personal views. 
• Please only cross one box per question. 
1) My health at present depends on my medicines 
 
Strongly agree  agree  uncertain  disagree  strongly disagree 
  
     
 
2) Having to take medication worries me 
 




3) My life would be impossible without my medication 
 
Strongly agree  agree  uncertain  disagree  strongly disagree 
 
     
     
     
Code 







4) Without my medication I would be very ill 
 




5) I sometimes worry about the long-term effects of my medication 
 




6) My medication is mystery to me  
 




7) My health in the future will depend on my medication 
 




8) My medication disrupts my life 
 
Strongly agree  agree  uncertain  disagree  strongly disagree 
 
 
     
     
     
     








9) I sometimes worry about becoming too dependent on my medication 
 




10) My medication protects me from becoming worse. 
 



















     









. عبارة، يرجى وضع عالمة في مربع واحد لتعكس مشاعرك حول األشياء التي قد تجعل تناول األدوية أكثر صعوبةلكل   
 لست متأكدا  غير موافق  موافق  العبارة  الرقم 
    الدواء الخاص بي  نسيت أن أتناول 1
    طعم دوائي سيئاً  2
    أنني قلق بشأن اآلثار الجانبية المحتملة  3
    ليس لدي ما يكفي من الدعم األسري  4
    ال أعرف ما يكفي من المعلومات عن مرضي وعالجه  5
    الدواء يجعلني أشعر بالمرض  6
    لم أحصل على معلومات كافية حول المرض والعالج  7
يجب أن أتناول الكثير من الدواء أو العديد من الجرعات  8
 يومياً 
   
أنا قلق بشأن ما قد يفكر به اآلخرون عني إذا علموا أنني  9
 أتناول األدوية. 
   
ال أحتاج إلى تناول األدوية الخاصة بي ألن األعراض قد  10
 زالت. 
   
 
. مشاعرك حول األشياء التي قد تجعل تناول األدوية أكثر سهولةلكل عبارة ، يرجى وضع عالمة في مربع واحد لتعكس   
أستخدم تذكير إلخباري بموعد دوائي أو روتين عن أدويتي  1
 )مثل تناول األدوية قبل المدرسة(. 
   
    تلقيت معلومات كافية عن مرضي وأهمية العالج.  2
    لدي دعم عائلي جيد.  3
وعالجي. لدي معرفة جيدة بمرضي  4     
وصف لي الطبيب األدوية التي يمكن أن تؤخذ مرة أو  5
 مرتين في اليوم. 
   
    جدول أدويتي بسيط للغاية.  6









 يرجى اإلجابة على األسئلة التالية:  
األدوية التي تمكنت من تناولها في األسابيع األربعة يرجى التوضيح على الفراغات أدناه عدد الجرعات الموصوفة من  -1
 الماضية. إذا كنت تتناول عدة أدوية ، فيرجى ذكر كل دواء على خط منفصل. 
% 100----------------%  )ال شيء( 0(:................. 1اسم الدواء رقم )   
% 100----------------%  )ال شيء( 0(:................. 2اسم الدواء رقم )   
% 100----------------%  )ال شيء( 0(:................. 3اسم الدواء رقم )   
% 100----------------%  )ال شيء( 0(:................. 4اسم الدواء رقم )   
 ثانياً : 
 ال نعم العبارة 
هل نسيت أن تأخذ األدوية الخاصة بك؟ -2  
تجعل ذلك يحدث من وجهة نظرك؟ إذا كانت اإلجابة بنعم، فما هي األشياء التي -أ  
 ..................................................................... 
هل يمكنك التفكير في أي شيء يساعدك على التذكر؟ -ب  
 ...................................................................... 
  
الجانبية ألي من األدوية الخاصة بك؟ هل أنت قلق بشأن اآلثار -3    
 هل هذا يمنعك من تناول األدوية؟ 
 إذا كانت اإلجابة بنعم، فيرجى إخبارنا باألدوية وأعطينا مثاالً على اآلثار الجانبية التي تقلقك. 
 ................................................................ 
  
جانبية بشأن أي من أدويتك؟ هل واجهت آثار -4  
 
  
   هل أدى هذا إلى تأجيل تناول األدوية؟
إذا كانت اإلجابة بنعم، فيرجى كتابة اسم األدوية التي تسبب آثاراً جانبية وما هي اآلثار الجانبية 
 التي واجهتها. 
 .................................................... 
  
هل تعاير وتتناول أدويتك بنفسك؟ إذا لم يكن كذلك، فمن يساعدك على تناول األدوية؟ -5  
 ........................................................... 
  
هل هناك شيء يجعل من الصعب عليك تناول ادويتك؟ -6  
 .......................................................................... 
  





   هل هذا جعلك تتوقف عن تناول األدوية؟ 
تناولها أو وقت الجرعات؟ هل لديك أي مخاوف بشأن عدد جرعات الدواء التي تحتاج إلى -8    
   هل هذا يمنعك من أخذ األدوية. 
هل لديك أي مخاوف بشأن حجم األقراص التي تحتاج إلى تناولها أو طعم األدوية؟ -9    
   هل هذا يمنعك من أخذ الدواء ؟ 
 إذا كانت اإلجابة بنعم، يرجى إعطائنا مثاالا 
 .................................................................. 
  
هل جربت أو هل تستخدم أي طرق لمساعدتك في تناول األدوية؟ -10  
























What makes taking medicines easier or harder? 
Date  Sex of child             M/F  
Child’s date of 
birth 






There are no right/wrong answers to our questions, we’re just interested in your 
honest views.  
For each statement please tick the box best reflecting your feelings about things that may 
make taking medicines more difficult. 






1 I forget to take my medicine.    
2 My medicine tastes bad.    
3 I worry about possible side effects. 
 
   
4 I don’t have enough family support. 
 
   
5 I don’t know enough about the illness and treatment.    
6 The medicine makes me feel sick. 
 
   
7 We weren’t given enough information about the illness and 
treatment. 
 
   
8 I have to take lots of medicines or many doses per day. 
 
   
9 I worry about what other people would think of me if they knew I 
took medicines. 












For each statement below please tick the box which best reflects your 
feelings about what may make taking your medicines easier. 






1 I use a medicine reminder or routine about my medicines (e.g. 
taking medicines before school). 
   
2 We were given enough information about my illness and the 
importance of treatment. 
   
3 I have good family support. 
 
   
4 I have good knowledge about my disease and treatment. 
 
   
5 The doctor has prescribed medicines which can be taken once or 
twice a day. 
   
6 My medicines schedule is quite simple. 
 
   
7 My doctor gives me medicines which taste ok. 
 
   
 
Please answer the following questions: 
1. Please plot on the line below how many of the prescribed doses of medicines you think you 
managed to take in the last four weeks. If you take several medicines please plot each 
medicine on a separate line. 
(Name of drug1……………………..…………) 0% (none) ____________________________________________________100% (all) 
(Name of drug 2………………...…………….) 0% (none) ____________________________________________________100% (all) 
(Name of drug 3……………………...……….) 0% (none) ____________________________________________________100% (all) 
(Name of drug 4……………………...……….) 0% (none) ____________________________________________________100% (all) 
 





a. If so can you think of anything that makes this happen? 
 
            b. Can you think of anything that could help you to remember? 
 
3. Do you worry about side effects of any of your medicines?    Yes/ No  
Does this ever put you off taking your medicines?    Yes/ No  
If yes please tell us which medicines and give us an example of side effects that worry you. 
 
 
4. Have you experienced side effects of any medicines?    Yes/ No  
Did this ever put you off taking the medicines?    Yes/ No  




5. Do you measure and take your medicines by yourself? If not, who helps you to take your medicine? 
 
6. Is there anything that makes it harder for you to take your medicines? 
 
7. Do you ever feel concerned about taking your medicines when other people are around?   
Yes/ No 
           Does this ever put you off taking them?  Yes/ No  
 
8. Do you have any worries about the number of medicine doses that you need to take or the time of 
the doses?            
  Yes/ No  







9. Do you have any worries about the size of tablets that you need to take or the taste of your 
medicines?  
Yes/ No  
          Does this ever put you off taking your medicine?   Yes/ No 
          If yes can you please give us an example? 
 
10. Have you tried or do you use any methods to help you with medicines taking? If yes, please 


















9.5 Summary table for Chapter 4 















1 F 8 Epilepsy Fluticasone, Levetiracetam 100 (C) 100 20 14 6 
2 M 7 Epilepsy Levetiracetam, Topiramate, Clobazam, Phenobarbital 95 (C) 95 20 18 2 
3 F 12 Heart Disease Captopril, Digoxin, Furosemide 98 (C) 94 14 10 5 
4 F 4 Epilepsy Levetiracetam, Clobazam, Baclofen, Topiramate 100 (P) 100 22 21 1 
5 M 3 Epilepsy Levetiracetam, phenobarbital 100 (P) 100 17 16 1 
6 F 9 Epilepsy Valproate, Levetiracetam 90 (C) 100 15 12 3 
7 M 6 Epilepsy Rufinamide, Lamotrigine 90 (P) 88 17 20 -3 
8 F 12 Diabetes Insulin, Levothyroxine, Growth Hormone 100 (C) 100 18 14 4 
9 F 5 Epilepsy Levetiracetam, Baclofen 98 (P) 91 17 16 1 
10 M 1 Heart Disease Furosemide, Captopril, Salbutamol, Propranolol 100 (P) 96 20 13 7 
11 M 16 haemophilia B Factor 9 100 (C) 100 22 10 12 
12 M 7 Hyperactivity Methylphenidate 70 (C) 56 18 14 4 
13 F 8 Asthma Fluticasone, Salbutamol 100 (C) 83 21 12 9 
14 F 10 Lupus Erythematous Nitrofurantoin, Omeprazole, Metoclopramide 90 (C) 91 25 21 4 
15 M 3 Anaemia Ferric Hydroxide 98 (P) 95 18 15 3 
16 F 13 Asthma Salbutamol 80 (C) 66 14 15 -1 
17 F 16 Epilepsy Levetiracetam, Baclofen 90 (C) 100 20 18 2 
18 F 14 Anaemia Ferric Hydroxide, Multivitamins 90 (C) 100 14 17 -3 
19 M 11 Epilepsy Levetiracetam 75 (C) 67 11 17 -6 
20 F 13 Epilepsy Levetiracetam, Rufinamide, Clobazam 100 (C) 100 18 17 1 
21 M 16 End-stage renal disease Solifenacin 90 (C) 81 18 14 4 
22 F 6 Epilepsy Valproate 99 (P) 98 18 14 4 
23 M 4 Epilepsy Levetiracetam 90 (P) 100 16 18 -2 




















25 F 3 Heart Disease Captopril, Digoxin 100 (P) 100 20 14 6 
26 F 12 Growth hormone 
deficiency 
Growth Hormone 99 (C) 85 10 14 -4 
27 M 5 Asthma Fluticasone, Salbutamol 100 (P) 92 15 12 3 
28 M 5 Diabetes Insulin degludec, Insulin aspart 90 (P) 80 24 13 11 
29 M 5 Growth hormone 
deficiency 
Growth Hormone 100 (P) 96 13 15 -2 
30 F 11 Asthma Fluticasone, Salbutamol 100 (C) 87 19 14 5 
31 F 13 Diabetes Insulin aspart, Insulin glargine 100 (C) 100 18 14 4 
32 M 9 Asthma Fluticasone, Salbutamol 100 (C) 70 14 16 -2 
33 M 4 Anaemia Ferric Hydroxide, Ranitidine 80 (P) 62 20 16 4 
34 M 4 Epilepsy Levetiracetam 100 (P) 100 14 16 -2 
35 M 8 Sickle cell anaemia Penicillin, Hydroxyurea 79 (C) 78 19 16 3 
36 M 10 Asthma Salbutamol, Fluticasone 100 (C) 100 14 17 -3 
37 M 12 Asthma Fluticasone, Salbutamol 70 (C) 55 16 17 -1 
38 M 13 Diabetes Insulin aspart, Metformin 99 (C) 99 15 16 -1 
39 F 7 Epilepsy Levetiracetam 100 (C) 100 16 11 4 
40 F 5 Anaemia Ferric Hydroxide, Levothyroxine 100 (P) 100 14 16 -2 
41 M 6 End-stage renal disease Prednisolone, Vitamin D 100 (C) 100 10 13 -3 
42 M 1 Cancer Methotrexate, Prednisolone, Mercaptopurine 100 (P) 100 22 13 9 
43 M 11 Epilepsy Valproate, Rufinamide, Clobazam 100 (C) 100 17 15 2 
44 M 7 Asthma Salbutamol, Fluticasone 100 (C) 88 14 11 3 
45 F 8 Epilepsy Levetiracetam, Vitamin D 75 (C) 68 14 20 -6 
46 M 7 Diabetes Multivitamins, Insulin aspart 100 (C) 100 18 17 1 
47 M 10 Epilepsy Rufinamide, Clobazam, Lacosamide 100 (C) 100 22 20 2 




















49 F 17 Asthma Salbutamol, Fluticasone 70 (C) 50 12 17 -5 
50 M 8 Diabetes Multivitamins, Insulin aspart 100 (C) 99 17 12 5 
51 F 2 Gastrointestinal 
Disorder 
Omeprazole 100 (P) 100 19 19 0 
52 F 10 Cancer Methotrexate, Dexamethasone, Mercaptopurine 100 (C) 100 21 15 6 
53 M 16 Asthma Fluticasone/Salmeterol, Salbutamol 70 (C) 53 14 18 -4 
54 F 13 Gastrointestinal 
Disorder 
Sodium bicarbonate 100 (C) 100 17 19 -1 
55 M 18 Diabetes Insulin aspart, Metformin 100 (C) 95 18 14 4 
56 M 3 Epilepsy Valproate, Levetiracetam 100 (P) 89 23 20 3 
57 F 7 Growth hormone 
deficiency 
Growth Hormone 100 (C) 100 22 13 9 
58 M 12 Diabetes Insulin aspart, Metformin 100 (C) 100 19 17 2 
59 M 16 Asthma Fluticasone, Salbutamol 75 (C) 69 19 15 4 
60 F 11 Cystic fibrosis Prednisolone, Levofloxacin 100 (C) 100 19 16 3 
61 F 12 Growth hormone 
deficiency 
Growth Hormone 100 (C) 100 11 13 -2 
62 M 15 Diabetes Insulin aspart, Metformin 100 (C) 96 12 16 -4 
63 F 12 Hypothyroidism Levothyroxine 100 (C) 100 22 14 8 
64 M 1 Gastrointestinal 
Disorder 
Omeprazole 100 (P) 100 24 22 2 
65 M 13 Asthma Fluticasone, Salbutamol 75 (C) 60 19 17 2 
66 M 15 Growth hormone 
deficiency 
Growth Hormone 100 (C) 99 25 19 6 
67 M 14 Heart Disease Digoxin, Enalapril maleate, Furosemide 100 (C) 100 22 15 7 
68 M 1 Hypertension Ranitidine, Captopril, Furosemide 100 (P) 100 21 18 3 
69 M 12 Epilepsy Levetiracetam 100 (C) 99 24 21 3 
70 F 15 Anaemia Ferric Hydroxide, Multivitamins 75 (C) 75 19 19 0 




















72 M 14 psychiatric disorder Escitalopram, Diazepam 100 (C) 100 16 20 -4 
73 M 15 psychiatric disorder Escitalopram, Fluoxetine 100 (C) 100 20 17 3 
74 F 2 Cystic fibrosis Salbutamol, Levofloxacin 90 (P) 90 21 19 2 
75 M 9 Asthma Fluticasone, Salbutamol 90 (C) 88 18 15 3 
76 F 12 Growth hormone 
deficiency 
Growth Hormone 95 (C) 89 13 13 0 
77 M 14 Diabetes Insulin aspart, Metformin 100 (C) 94 24 16 8 
78 M 1 Hypothyroidism Levothyroxine 100 (P) 100 20 17 3 
79 F 12 Diabetes Insulin aspart, Metformin 100 (C) 100 19 17 2 
80 M 11 Cystic fibrosis Salbutamol, Tobramycin 100 (C) 100 20 18 2 
81 F 13 Hypothyroidism Levothyroxine 100 (C) 100 18 13 5 
82 F 6 End-stage renal disease Prednisolone, Furosemide 100 (C) 100 22 16 6 
83 F 11 Sickle cell anaemia Hydroxyurea, Folic acid 100 (C) 100 20 16 4 
84 M 7 Sickle cell anaemia Hydroxyurea, Folic acid, Ferric Hydroxide 100 (C) 92 20 16 4 
85 F 12 Asthma Fluticasone/Salmeterol, Salbutamol 100 (C) 100 19 16 3 
86 F 4 Heart Disease Digoxin, Captopril 100 (P) 100 23 15 0 
87 M 13 Diabetes Insulin aspart, Metformin 100 (C) 100 21 19 2 
88 M 11 Hypertension Captopril 100 (C) 94 19 17 2 
89 F 12 End-stage renal disease Prednisolone, Furosemide 80 (C) 72 15 19 -4 
90 M 16 Asthma Prednisolone, Salbutamol 100 (C) 96 20 15 5 
91 M 9 Cancer Prednisolone, Methotrexate 100 (C) 100 23 18 5 
92 F 7 Psychiatric disorder Escitalopram 100 (C) 100 19 18 1 
93 F 14 Growth hormone 
deficiency 
Growth Hormone 100 (C) 100 20 19 1 
94 F 12 Heart Disease Valsartan, Furosemide, Multivitamins 100 (C) 100 23 19 4 
95 M 6 Cancer Prednisolone, Methotrexate 100 (C) 100 17 20 -3 




















97 F 13 Growth hormone 
deficiency 
Growth Hormone 100 (C) 100 16 16 0 
98 F 9 Heart Disease Digoxin, Captopril, Furosemide 100 (C) 100 24 19 5 
99 M 5 End-stage renal disease Furosemide, Prednisolone 100 (P) 100 21 19 2 











9.6 Ethical approval in the UK (Chapter 5) 
   
Dr Sharon Conroy    
Medical School  Email: hra.approval@nhs.net  
HCRW.approvals@wales.nhs.uk  
Royal Derby Hospital Centre   
Uttoxeter Road, Derby  
DE22 3DT  
  
30 July 2019  
  
Dear Dr Conroy    
  
HRA and Health and Care  
  
Research Wales (Letter  
    
Study title:  Exploratory study on the barriers and facilitators of 
medicines adherence in a UK children’s hospital and in a 
Saudi Arabia children’s hospital.  
IRAS project ID:  247581   
Protocol number:  19038  
REC reference:  19/LO/1250    
Sponsor  University of Nottingham  
  
I am pleased to confirm that HRA and Health and Care Research Wales (HCRW) Approval 
has been given for the above referenced study, on the basis described in the application form, 
protocol, supporting documentation and any clarifications received. You should not expect to receive 
anything further relating to this application.  
  
Please now work with participating NHS organisations to confirm capacity and capability, in line with 
the instructions provided in the “Information to support study set up” section towards the end of this 
letter.  
  






HRA and HCRW Approval does not apply to NHS/HSC organisations within Northern Ireland and 
Scotland.  
  
If you indicated in your IRAS form that you do have participating organisations in either of these 
devolved administrations, the final document set and the study wide governance report (including 
this letter) have been sent to the coordinating centre of each participating nation. The relevant 
national coordinating function/s will contact you as appropriate.  
 
Please see IRAS Help for information on working with NHS/HSC organisations in Northern Ireland and 
Scotland.   
  
How should I work with participating non-NHS organisations?  
HRA and HCRW Approval does not apply to non-NHS organisations. You should work with your non-
NHS organisations to obtain local agreement in accordance with their procedures.  
  
What are my notification responsibilities during the study?   
   
The document “After Ethical Review – guidance for sponsors and investigators”, issued with 
your REC favourable opinion, gives detailed guidance on reporting expectations for studies, including:  
• Registration of research  
• Notifying amendments  
• Notifying the end of the study  
The HRA website also provides guidance on these topics, and is updated in the light of changes in 
reporting expectations or procedures.  
  
Who should I contact for further information?  
Please do not hesitate to contact me for assistance with this application. My contact details are 
below.  
Your IRAS project ID is 247581. Please quote this on all correspondence.  
  
Yours sincerely,  
  
Thomas Fairman  
HRA Approvals Manager  
Email: hra.approval@nhs.net     





List of Documents  
The final document set assessed and approved by HRA and HCRW Approval is listed below.    
Document    Version    Date    
Covering letter on headed paper [covering letter]   1.0   25 June 2019   
Evidence of Sponsor insurance or indemnity (non NHS Sponsors only) 
[Evidence of sponsor insurance]   
1.0   31 July 2018   
IRAS Application Form [IRAS_Form_25072019]      25 July 2019   
Letter from sponsor [Sponsor letter]   3.0   27 June 2019   
Non-validated questionnaire [Study questionnaire]   1.0   24 June 2019   
Organisation Information Document [Organisation information document]   2.0   25 July 2019   
Other [Delegation log]   1.0   24 June 2019   
Other [Sponsor letter re insurance renewal]   1.0   19 July 2019   
Participant consent form [Consent form parent]   1.0   24 June 2019   
Participant consent form [Consent form parent participant]   1.0   24 June 2019   
Participant consent form [Consent form 16yrs +]   1.0   24 June 2019   
Participant information sheet (PIS) [PIS 2-5yrs]   2.0   25 July 2019   
Participant information sheet (PIS) [PIS 11-15yrs]   2.0   25 July 2019   
Participant information sheet (PIS) [PIS 16-18yrs]   2.0   25 July 2019   
Participant information sheet (PIS) [PIS 6-10yrs]   2.0   25 July 2019   
Participant information sheet (PIS) [Parent PIS]   2.0   25 July 2019   
Research protocol or project proposal [Protocol]   1.0   24 June 2019   
Schedule of Events or SoECAT [Schedule of events]   1.0   24 June 2019   
Summary CV for Chief Investigator (CI) [Chief investigator CV]   1.0   25 June 2019   
Summary CV for student [CV PhD student]   1.0   25 June 2019   
Summary CV for supervisor (student research) [PhD supervisor CV]  1.0   26 June 2019   






Information to support study set up  
  
The below provides all parties with information to support the arranging and confirming of capacity and capability with participating NHS organisations in England 





Expectations related to confirmation of capacity and 
capability  
Agreement to be 
used  
Funding 
arrangements   
Oversight 
expectations  
HR Good Practice Resource Pack 
expectations  
 All sites will 
perform the same 
research activities 
therefore there is 
only one site type.  
Organisations will not be required to formally confirm 
capacity and capability, and research procedures may begin 
35 days after provision of the local information pack, provided 
the following conditions are met.   
• You have contacted participating NHS organisations 
(see below for details)  
• HRA and HCRW Approval has been issued  
• The NHS organisation has not provided a reason as to 
why they cannot participate  
• The NHS organisation has not requested additional 
time to confirm.  
  
You may start the research prior to the above deadline if HRA 
and HCRW Approval has been issued and the site positively 
confirms that the research may proceed.  
You should now provide the local information pack for 
your study to your participating NHS organisations. A 
current list of R&D contacts is accessible at the NHS RD 




Document has been 
submitted and the 
sponsor is not 
requesting and 
does not expect any 
other site 
agreement to be 
used.  
No study funding 
will be provided to 
sites as per the  
Organisational 
Information  




appointed at study 
sites of this type  
Where arrangements are not already in 
place, researchers undertaking any of 
the  
research activities listed in A18 of the 
IRAS form would be expected to 
obtain a Letter of Access.   
  
This would be on the basis of a 
Research Passport (if university 
employed) or an NHS to NHS 
confirmation of pre-engagement 
checks letter (if NHS employed). These 
should confirm DBS checks and 






 Other information to aid study set-up and delivery  
This details any other information that may be helpful to sponsors and participating NHS organisations in England and Wales in study set-up.  
The applicant has indicated that they do not intend to apply for inclusion on the NIHR CRN Portfolio.  
this purpose. The password to access the R&D contact 












9.8 Summary table for Chapter 5 













1 M 8 Asthma Salbutamol, Seretide, Montelukast 100 (C) 25 8 17 
2 M 1 Extreme Prematurity Abidec, Sodium feredetate, Omeprazole 100 (P) 14 10 4 
3 M 6 Epilepsy Sodium Valproate, Clobazam 100, 80 (P) 17 13 4 
4 M 12 Cystic Fibrosis Cortisone, Antibiotic 100 (C) 23 12 11 
5 M 13 Autism Melatonin 100 (C) 16 11 5 
6 M 10 Epilepsy Circadin, Lamotrigine 70 (C) 16 17 -1 
7 F 18 Diabetes Insulin 75 (C) 16 19 -3 
8 F 7 Asthma Salbutamol, Desloratadine 80,90 (C) 20 17 3 
9 M 3 Asthma Salbutamol, Seretide, Montelukast 100 (P) 19 5 14 
10 M 12 Nocturnal enuresis Desmopressin 90 (C) 12 6 6 
11 F 13 Migraine Amitriptyline 98 (C) 18 5 13 
12 F 3 Anaemia Iron 90 (P) 19 17 2 
13 M 15 Acne Antibiotic 100 (C) 14 11 3 
14 M 11 Autism Circadin 55 (P) 18 16 2 
15 M 5 Hyperactivity Sleeping medicine 100 (P) 17 9 8 
16 F 6 Asthma Salbutamol, Montelukast, 100 (P) 25 5 20 
17 F 11 Asthma Salbutamol, Seretide 95 (C) 17 14 3 
18 M 14 Asthma Salbutamol, Montelukast 100 (C) 24 12 12 
19 F 16 Asthma Salbutamol 100 (C) 15 11 4 
20 F 8 Asthma Salbutamol, Seretide, Montelukast 85,100,90 (C) 25 18 7 
21 M 11 Epilepsy Baclofen, Mebeverine 100 (C) 21 19 2 
22 M 12 Asthma Salbutamol, Seretide, Montelukast 70 (C) 20 16 4 
23 F 1 Epilepsy Levetiracetam 100 (P) 21 14 7 


















25 M 4 Asthma Salbutamol, Seretide, Montelukast 80,100,90 (P) 17 22 -5 
26 M 7 Constipation Movicol, Rifampicin 80 (P) 21 19 2 
27 M 15 Acne Isotretinoin 90 (C) 25 15 10 
28 F 13 Acne Doxycycline 80 (C) 19 10 9 
29 F 14 Asthma Salbutamol, Montelukast 90,85 (C) 20 10 10 
30 M 14 Constipation Movicol, Lactulose 100 (C) 17 16 1 
31 F 9 GORD Omeprazole, Laxido 100 (C) 17 13 4 
32 M 5 Autism Melatonin 100 (C) 17 18 -1 
33 M 11 Asthma 
Salbutamol, Chlorphenamine, Fluticasone 
propionate 
85 (C) 20 13 7 
34 M 9 
Attention Deficit 
hyperactivity disorder 
Medikinet, Bisacodyl 100 (C) 20 10 10 
35 F 14 
Attention Deficit 
hyperactivity disorder 
Atomoxetine, Sertraline 90, 80 (C) 16 10 6 
36 M 4 Asthma Salbutamol, Budesonide 90 (P) 18 12 6 
37 M 10 Pseudohypoaldosteronism Sodium chloride, Sodium bicarbonate 100 (C) 22 22 0 
38 F 14 Kidney disease Prednisolone 100 (C) 25 9 16 
39 F 17 Kidney disease Lisinopril, Prednisolone, Azathioprine 90,80,100 (C) 23 15 8 
40 M 9 
Inflammatory bowel 
disease 
Folic acid, Ursolic acid 100 (C) 13 14 -1 
41 F 5 Chronic urticaria Loratadine, Montelukast 85 (P) 16 12 4 
42 F 15 Psoriasis Imraldi 80 (C) 18 10 8 
43 F 13 Kidney disease Calcium carbonate, Darbepoetin, Vit D 90 (C) 25 10 15 
44 F 3 Constipation Lactulose 95 (P) 12 9 3 
45 F 16 Acne Isotretinoin 97 (C) 8 6 2 


















47 F 1 GORD Gaviscon 70 (P) 15 16 -1 
48 F 3 Asthma Salbutamol, Seretide 80 (P) 18 19 -1 
49 M 15 Epilepsy Carbamazepine 80 (C) 16 10 6 
50 F 13 Acne Doxycycline 75 (C) 9 5 4 
51 F 6 Asthma Salbutamol, Seretide, Montelukast 100 (P) 18 13 5 
52 M 18 Acne Doxycycline, Steroid cream 40,70 (C) 13 20 -7 
53 F 16 
Inflammatory bowel 
disease 
Budesonide, Omeprazole, Vit D 100 (C) 20 10 10 
54 F 5 
Persistent bacterial 
bronchitis 
Azithromycin 90 (P) 17 13 4 
55 M 8 
Attention Deficit 
hyperactivity disorder 
Medikinet 70 (C) 19 18 1 
56 F 3 
Chronic bullous disease of 
childhood 
Dapsone 100 (P) 13 14 -1 
57 F 18 Acne Isotretinoin 60 (C) 8 11 -3 
58 F 10 GORD Gaviscon, Movicol, Omeprazole 80 (C) 17 20 -3 
59 M 14 Epilepsy Sodium valproate, Circadin 100 (C) 22 9 13 
60 F 11 Thalassemia Folic acid, Iron 100 (C) 20 23 -3 
61 F 16 Acne Doxycycline, Budesonide 90,100 (C) 15 13 2 
62 M 1 Bronchitis Montelukast 100 (P) 12 10 2 
63 M 14 Asthma Salbutamol, Seretide 100 (C) 23 7 16 
64 F 8 Asthma Salbutamol, Seretide 90,100 (C) 19 19 0 
65 F 7 Constipation Movicol, Sodium picosulfate 70 (C) 16 20 -4 
66 F 15 Having period Contraceptive 100 (C) 9 5 4 
67 M 3 Asthma Salbutamol, Seretide 100 (P) 22 16 6 
68 M 14 Acne Isotretinoin 90 (C) 18 12 6 


















70 F 9 Asthma Symbicort, Azithromycin 60,70 (C) 12 19 -7 
71 M 15 Hyperthyroidism Carbimazole 90 (C) 21 12 9 
72 F 15 Hypothyroidism Levothyroxine 85 (C) 16 11 5 
73 M 12 Epilepsy Sodium valproate, Carbamazepine 100,85 (C) 21 14 7 
74 M 8 Anaemia Iron, Folic acid, Vitamin 100 (C) 20 14 6 
75 F 11 Epilepsy Levetiracetam, Circadin, Carbamazepine 100 (C) 25 20 5 
76 F 8 Constipation Movicol 100 (C) 18 5 13 
77 F 5 Epilepsy Baclofen 80 (P) 16 15 1 
78 F 18 
Growth hormone 
deficiency 
Growth hormone 80 (C) 18 12 6 
79 F 10 
Attention Deficit 
hyperactivity disorder 
Medikinet 70 (C) 18 10 8 
80 M 14 Constipation Movicol, Bisacodyl 100 (C) 19 8 11 
81 M 14 Epilepsy Sodium valproate 90 (C) 25 23 2 
82 F 15 Heart disease Atenolol, furosemide 80,90 (C) 14 11 3 
83 F 8 Diabetes Insulin aspart, Insulin glargine 100 (C) 24 22 2 
84 F 15 Eczema Fexofenadine, Loratadine, Doxycycline 60 (C) 16 11 4 
85 M 7 Asthma Salbutamol, Budesonide 47 (P) 13 14 -1 
86 F 12 Epilepsy Circadin, Sodium valproate 88 (C) 17 18 -1 
87 F 12 Acne Acnecide gel 80 (C) 11 10 1 
88 M 14 
Attention Deficit 
hyperactivity disorder 
Lisdexamfetamine 100 (C) 13 11 2 
89 F 9 Eczema 
Mometasone, Tacrolimus cream, Cetirizine, 
Salbutamol, Fluocinolone acetonide 
70 (C) 21 15 6 
90 M 10 Heart disease Propranolol 99 (C) 17 5 12 
91 M 18 Asthma Salbutamol, Seretide, Fexofenadine 90 (C) 20 11 9 


















93 M 12 Constipation Movicol 60 (C) 15 18 -3 
94 F 9 Kidney disease Trimethoprim 96 (C) 17 16 1 
95 F 15 GORD Omeprazole, Folic acid 100 (C) 16 12 4 
96 M 5 Kidney disease Tolterodine, Movicol 100 (P) 24 11 13 
97 M 3 Asthma Salbutamol, Budesonide, Cetirizine 60,75,75 (P) 13 19 -6 
98 F 4 GORD Ranitidine 55 (P) 14 15 -1 
99 M 15 Scleroderma Mofetil 100 (C) 17 12 5 
100 F 4 Juvenile dermatomyositis Hydroxychloroquine, Methotrexate 100 (P) 20 14 6 
 
 
 
 
 
